<SEC-DOCUMENT>0001576280-23-000060.txt : 20230509
<SEC-HEADER>0001576280-23-000060.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509170024
ACCESSION NUMBER:		0001576280-23-000060
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Guardant Health, Inc.
		CENTRAL INDEX KEY:			0001576280
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				454139254
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38683
		FILM NUMBER:		23903108

	BUSINESS ADDRESS:	
		STREET 1:		3100 HANOVER STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		855-698-8887

	MAIL ADDRESS:	
		STREET 1:		3100 HANOVER STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gh-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433,d:d1808bc5647e45c0b487ecea2e9e50b0--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:gh="http://guardanthealth.com/20230331" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gh-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8xLTEtMS0xLTY4MDIy_823ab805-2e29-4c4e-a2e0-a58919aa9cdd">false</ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8yLTEtMS0xLTY4MDIy_e16aaedd-bde9-4e02-94fa-10f18e5911de">2023</ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8zLTEtMS0xLTY4MDIy_b466da8c-94d7-45ca-93b9-9eedd0018a29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl80LTEtMS0xLTY4MDIy_2178446d-7509-4a1b-b5f9-f73946382204">0001576280</ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl81LTEtMS0xLTY4MDIy_88ef61b3-0497-49c4-8331-8febc4a64dcd">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4a3c1288310f43a4abefc9f3326e5f24_D20201101-20201130" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82Ny9mcmFnOmEwN2RiMjA5N2Q3ZjRhMjhiOGY2NjU5NjAxZjllNmFkL3RleHRyZWdpb246YTA3ZGIyMDk3ZDdmNGEyOGI4ZjY2NTk2MDFmOWU2YWRfMTA5_6a036bc5-dd78-4844-9fae-f6bc09ce9254">0.0071523</ix:nonFraction><ix:nonNumeric contextRef="iad577482d6c44d62a1d8638eab07b300_D20200501-20200531" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYxNw_60b18dda-66c2-4999-b9be-3ed7aa5e2977">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gh-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic63eda5373a64e0b98a90b18ccae37eb_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6506cad5ab63497db74f92ba4f91d108_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id314243f2ead4456aa30110c9be601cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b4fdb150214c56afcbdbb322033b7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i061c59efe2d945519dfb0e5134ddbbfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08422884f60b4434b3801e044a34720c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65627937720c45f5af483254a1fe5f4b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia281fcd22cc54accbefe8d9b460bd5cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9eaada43ef4cfd925883681dcbc4c2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234915b13fca42879cd971070e15ee06_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f8f14dc64d49c6be419158cec74a14_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23b9007cc9d4791bd36771afacf5634_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c902d77713c48f9b6c55bb637b64351_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004e4666a5184be996fa4c7ddf054bc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b965e37113409d8d7d5afef90e67b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bad5d6e63649409643e7d759322b03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837fd30e88e14cca94ef2ffcde2af73e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6340409bc504436ca385dbfa0f3ec40c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61824cd12b914964a5a603b514d2a3de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ecdc52faa648b9851cd7fd4d341e4d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaeefd32a5fc49089e432e6ef771b042_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10781cf49c274a30b77473e1ab3caaa8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2401cae2c40e42969858a2d39f106f28_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gh:segment</xbrli:measure></xbrli:unit><xbrli:context id="idd26156a544941a48ee279e2b62c8c3f_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id35cadfe3a234269bcb1f5e099b19840_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f9229bf0864d9e814f7520f6d69d7d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f93c12cead4d2c895bca577a25be67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfb22333f754690bd602bfaec6d0504_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f4f6ec0d8c49d09f2cbdc348b5a7c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966b9062789c40178998266340270e67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb596e53d6d4e77aa67b76c30c717a5_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251adc25d68b484abdc116bdcad141c8_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6502eac62f4edfbd8f440e52695d9f_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ecc6c83a29450f8f6715df23f4d2d3_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85a3adbc9da44018010d9f2fcd08a6c_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5caeb66ee94198aa9cd342c3f706e3_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6691016ad5b34d59883ed1923b33bed4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604eb9f9835e4c13814c14e8654cb3e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a86681777f4f5a97cdce262db9a555_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7810d83be2d148339c6e185649dcccc3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17dac8c118b84995ab3b80232dab1573_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="seat"><xbrli:measure>gh:seat</xbrli:measure></xbrli:unit><xbrli:context id="ia536ff2c58f1448390655c51b679d617_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40dd21d206c406fb998d0a9b6cd895f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd08dde4eb843418c0ae87833fedcdf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbcb14cec5f44c8289340eb8d4348692_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1670651f92b400b9f911d06867002b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic021058209134f95a1e8e10b009c7ace_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246a5d493f5c473b88cd065c03268005_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a29ac54766d4a0f8b2b24b51cdb55b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b5561c4b114d22bafce063538c856e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d186d3354934b5a8f8bbe42c4c14495_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bdcfada3cd4a2cbbe095e2aa5e702a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca178fdb5534ed4b35053a5ba325f0d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2f9a0766ce44c6af97879837c1db9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5c289384e245aa892095bbc5f2ab2b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f279ce6f9246c4848f2a4e3e17128a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc566dc53fa4e07bf56f8a8aabdb279_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3168dac582d49e69c1516251fd3e0dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e3cdcf1bbe4a9b81b4b8bdc2e6ab64_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3214563d103944fcad24fe9145d19d95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f02aa3d8ed8418682e04a58b2a857df_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a924e51c984ac7b0fbc1fd9ad60d4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb852a9ed67d4316a04d75194f6818e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b835cd88e044426b718c40c4b445c18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a5558266daa4fd5803cd22934821259_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af15fbc37d84fa1955e0848cbda5aaa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d01132e1c54427979eb175a61dff09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1963c0481247479c9f779e03f6b467ab_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i698a971f2120433494d66c1f389aa846_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i645a895f548a4ff28015517f297d96a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c5fb94fc744d39b9304cf6183f81e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie641c330319e42cb920c03007560f205_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfd089f28904d93b229f01b003d873a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d21756670fa4cdd8e4365d35747d8c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58665cb260e34ed2974fba4c7d288b91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63bc9236559423696b0059bb44368a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cc878b77cc41ffae86c8b04609a610_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a34db6e72349e9af6fc43f300a4276_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6d2513d70d4e718e77e46a90e3914f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ed47738cd74c8e8c229d9ce44342ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c04821a302247519fa063baf7a9e04a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c4a003031e4fc18e276dd67fb04ae3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293edf8bd4704d8884ce7ede54eb1f69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b77f5413426453b85bf391a9398dbb7_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967d903179d741649abf3b3123b84ae7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d8629622e1d44fb9a12b229ec47a1f7_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib473620977be4b178565e23e78583e12_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9f5b8c565a4dca904ac822c40abf74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7491d2ac94a0486e8c65beb38d59a2ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cd2d2a717f448ca58407271970c8e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f16d72a05843cbbd0a5e1691d4c754_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb285d391a2d4b938bbb5a745115ea97_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379830d644434dba8ff6a21e1c68f858_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebfefb0eb874a23853e2e48b2069dc0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1e2b5f8f4a47bca104f021c60c4860_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d73083e0eca473a97a807ca5c0d2592_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926f66c4f4dc49b7a001e9143083c137_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc2aa61097449da810dfe20cd6df079_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482b6cd7778c438ba3a971ad9a5511c0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8dad0b65c142c5b15551bf9029a808_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d00e5d8314401f9793acf9cd87f30d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3add32afcf0e47928bccc0d9a1e4ab89_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c2c3e9fc144decaddb722e0a2f7ce2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ffab5486f140f2bc284e765264afc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d450e08fff545ebb9a7c77e00ca86e1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ad0ce630064286a222741120078585_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef1b08124ca422d8c5fde0b52484dbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2ed04947454c96b49ed77c531cc5bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20def10aa5d14802a5363d3f0e99bcb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ad1fbc3dfd4b90ba560b118b576125_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4afdaf1a32649acbb00d349e86393cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7530b179b2482daf26e93a3433f2d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06cffa6cd1640db8649a5e4f20e89f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputQuotedPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd5c38886184fd6af5573e63dd61acd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8b26b7ee69436e81522ee5db3fb810_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a0869ad8ec4e6aa0ab8611139bf5b8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73765d8c5b9c47e49e769314e9a95216_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6e61cb42a24541ada6ecb600b9aafe_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3c1288310f43a4abefc9f3326e5f24_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e94bdae869e4b2a9849b1c8d02651a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6cdfb5a23124fe8acf8a056dc1ce503_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gh:patent</xbrli:measure></xbrli:unit><xbrli:context id="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7c95d575374df5873ad5d340d429dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471e1119a5c84de99cc7a66a9091e4b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e6708f9c264d729a87143b05a29523_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5419e29cd3674106abc793e0ae7a5a7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6c755d9322493ea937d75411cca741_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b801579905e486f9d16da0424368dea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67005148159d4de98f4625a633c07616_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3f42809445495ba7ea570bf865bb5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12acc1844c7547209359a2ebd3bbac18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2888bc5ff0cd47c1b681eb96ef6bc6c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b85720538549e793c0ea411f6d2926_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4744fe70bd24460bded39c69c9e72eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bde5cb1e9146c78e36910bd9edc42c_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167512a61ade446cb826830cb9b48a43_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id371f8b5f52a447a988f5108d595d824_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79268d66ccd4c498d88b492e67d4b78_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f4b6d3e1a44b50bca2cfe317198cd9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>gh:tranche</xbrli:measure></xbrli:unit><xbrli:context id="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad577482d6c44d62a1d8638eab07b300_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ae71f8bf884fe38ffe82c44c115460_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a0dc3163854d6cb56d919865f28f0f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8355f22e8d444065acdca383af614973_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie817ff3c12124b78a03fdb6de0e8038d_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8405ea1a894bd49c95fae94c570714_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9210d17c359d4a029aa0d629f68b0d32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia06f00d018a84185bf63dbd26b8fcf13_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="grantee"><xbrli:measure>gh:grantee</xbrli:measure></xbrli:unit><xbrli:context id="i5f314cba04f147aaa5a0130ab210f819_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e84c2df8114b2ca174af7f12413df9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22845a3df5054db690d00e20e26e9de7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa36b882d6a4a99b4d65b78a2f7f31f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:CostOfDevelopmentServicesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb41fcfde104edeb7f180200c669ff1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:CostOfDevelopmentServicesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257ec7f3adfd447980af46db25d249da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525b368da8b94090b710ab4a0286430d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e6b4f53ad9427188ba1f105f093cba_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0babdde2fcb4400f8a4240d151c2273f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f08d30f39d4fd18d425c922f9e450a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5740f52d90ea487290d3e3b20b00fe62_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic749eee03b16467aa70909df615b2c86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf899f29153c4ae48025cc44a9774ca0_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e087e17e0e420b8c053b525bbb7093_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d35aee771524865b1b3cd4a8ec1d0ac_D20230302-20230302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07e4ec43ccf4868a95b7cba38569e07_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8405bc3396f043d38ac107f7e621ea0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1dfcb8b82cc435bafa0737693ff7b95_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a7782cf20244b492722ced02d556d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018eca720b2b4bee988fdb517bb09d46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784a2015beb447b480ff240ec2998829_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b84667fc3047d39ba495dfdb6af2a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c434d2375a64859af229e0a8a1a79c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f00602410084027a24ca5b4c50e87c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436487de8e484b5891dc7aaa105cc2dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d27c009cdc4d3c997e7de9fc339551_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5f7a63f9954f08adb2cdcc6eafb151_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d27e6a526f14a71b27f8d0b9f9a0f23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9213a2532134ae5b9a645905cc1fbad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3794fca71da4bfdaa6a037250b08ea1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a0c4f0823b457fb2f4cda5edce7d8f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e06c37d3dbd437d892d43f95983c3c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25302361b67443c4a5fa5c0994f68a46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cbb23a4c4404fd09cf2220d10bbfd76_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI0_a0f72873-3919-4722-a106-338df7f27a32">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMw_f8f0c47a-eb29-4f66-a997-710f6a43adaf">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yNjQ_f6b47afb-c54d-426c-820f-c678408bbb42">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM3_1ac216ce-c9ac-44be-843d-df60f45ac2f6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMx_7712473a-d9ab-480c-ab34-acafc0a02efd">001-38683</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI1_e9c084d9-67b9-4ef5-9f2c-064f71b0b357">GUARDANT HEALTH, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6OTAzYzY3OGE2YTc0NDdhOTg5MjFjNGQ3NjhjNDI3ZTQvdGFibGVyYW5nZTo5MDNjNjc4YTZhNzQ0N2E5ODkyMWM0ZDc2OGM0MjdlNF8wLTAtMS0xLTY4MDIy_d421a498-f56b-4c13-a2c5-c61ef063cf19">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6OTAzYzY3OGE2YTc0NDdhOTg5MjFjNGQ3NjhjNDI3ZTQvdGFibGVyYW5nZTo5MDNjNjc4YTZhNzQ0N2E5ODkyMWM0ZDc2OGM0MjdlNF8wLTItMS0xLTY4MDIy_feeb1c7b-d6c7-4aea-a42e-3570a4f1936d">45-4139254</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI3_0efb6352-3142-433e-8c16-93fdc36a926c">3100 Hanover Street</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMy_d4cd0699-7ee3-4590-9885-cfb4380b6d11">Palo Alto</ix:nonNumeric>, <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMz_50d8c7d3-e527-459b-8ff6-cdea8a35ee0b">California</ix:nonNumeric>, <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI4_1d5226be-709f-4d59-b65a-45a631301a88">94304</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI2_5cbb83bd-62d3-4005-ab0e-d3af23caf2f8">855</ix:nonNumeric>) <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM0_8377b53d-3c4d-4f84-8961-c8d8b70bb97f">698-8887</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTAtMS0xLTY4MDIy_87d98880-1345-4bd7-a9d9-71f2a319cd9d">Common Stock, $0.00001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTEtMS0xLTY4MDIy_9f688192-8be6-46d6-9c96-f6b67e78ae9b">GH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTItMS0xLTY4MDIy_7096c3a9-1755-4385-800f-ac6ca41e564d">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI5_d879cd72-23f1-4e63-b551-e3d357dd0a14">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM1_02b58445-87cb-43a4-979d-de2c1f38e67c">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.887%"><tr><td style="width:1.0%"></td><td style="width:28.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl8wLTAtMS0xLTY4MDIy_86b677ef-a603-4dd6-852b-7b601a915a34">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl8yLTMtMS0xLTY4MDIy_b30a6818-4801-4ae8-8117-d71f96489f38">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl80LTEtMS0xLTY4MDIy_8e7f0757-77e8-4c82-b9ad-fc12789253c7">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM2_ba0aba2e-16cb-463a-9157-962ed39bfa56">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;5, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ic63eda5373a64e0b98a90b18ccae37eb_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMjYw_822bce53-32bc-4595-8564-0b6830b2bfeb">102,764,840</ix:nonFraction> shares of common stock, $0.00001 par value per share, outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GUARDANT HEALTH, INC.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_13">Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_22">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_25">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_31">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_34">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_112">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_115">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_115">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_163">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_163">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_163">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_166">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_166">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_166">47</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_169">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_172">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_172">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_172">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_175">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_175">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_175">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_178">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_178">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_178">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_181">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_181">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_181">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_184">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_184">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_184">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_187">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_187">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_187">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_190">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_190">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_190">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id1808bc5647e45c0b487ecea2e9e50b0_193">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_193">51</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, including the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business, our financial condition, our results of operations, our cash flows, and the industry and environment in which we operate. Statements that include words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;intend&#8221; and &#8220;expect,&#8221; variations of these words, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and elsewhere in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, in Part II, Item 1A, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and elsewhere in this Quarterly Report on Form 10-Q, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated.&#160; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_10"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_13"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Item 1. Unaudited Condensed Consolidated Financial Statements</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_16"></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMy0xLTEtMS02ODAyMg_ecb3ac89-c854-4cae-9a3f-efbc5d3fcb5d">223,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMy0zLTEtMS02ODAyMg_32023592-a215-4166-9e4a-6bf631a7fd0f">141,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term marketable debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNC0xLTEtMS02ODAyMg_3738f449-aa6c-46a2-a0e9-bd2e80a7a279">713,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNC0zLTEtMS02ODAyMg_2d198eb8-6592-4028-b4b9-0bebb53d1dc0">869,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNS0xLTEtMS02ODAyMg_477faa97-56fe-49b2-bd97-71f4c7efcea2">87,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNS0zLTEtMS02ODAyMg_7f4228a2-edad-4497-9a94-bc3e9c113367">97,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventory, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNi0xLTEtMS02ODAyMg_6901337a-cddd-40ff-974d-1a02da63d6d5">46,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNi0zLTEtMS02ODAyMg_bb5606e2-e3c9-4751-af09-bd27b4cda6f2">51,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNy0xLTEtMS02ODAyMg_e17fb377-87f4-4120-86cd-533517b55ef6">33,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNy0zLTEtMS02ODAyMg_4ea4adef-ab8c-422c-8266-0cc8bd9c835f">31,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfOC0xLTEtMS02ODAyMg_7cecd297-6693-42e4-8b63-f79d206c9c81">1,104,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfOC0zLTEtMS02ODAyMg_4be1f910-4083-4d98-a706-96db94dbc443">1,191,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTAtMS0xLTEtNjgwMjI_a3a8ed3e-b683-4bac-9437-3ec630c9d04e">163,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTAtMy0xLTEtNjgwMjI_4244ef18-e0f4-4d46-bfda-49b0f7bff0d6">167,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTEtMS0xLTEtNjgwMjI_a0abad74-ca89-4b5f-8ec6-afc0004fe047">170,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTEtMy0xLTEtNjgwMjI_18e981a7-9b4d-472d-880a-4c604396a0f0">174,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intangible assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTItMS0xLTEtNjgwMjI_8d72ad3b-c4e0-4f36-9d6f-47f064543cb6">11,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTItMy0xLTEtNjgwMjI_bc7ae66b-693f-44be-b867-0b857b2bb540">11,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTMtMS0xLTEtNjgwMjI_ed63741a-9436-4529-8e85-f3b78f8abd10">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTMtMy0xLTEtNjgwMjI_f0ff77be-1083-4a2a-9326-2c6361428c85">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTUtMS0xLTEtNjgwMjI_480c3208-557b-4d62-93b2-93458d0713b3">58,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTUtMy0xLTEtNjgwMjI_c58ea46f-f878-4cc9-a500-7b1878af9baf">61,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTYtMS0xLTEtNjgwMjI_d9def67a-0fc8-4510-b041-86ca873fd7b1">1,511,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTYtMy0xLTEtNjgwMjI_6069f237-3e3f-49cb-ac0e-f141d8b7d96e">1,609,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTktMS0xLTEtNjgwMjI_2ab5a984-3026-480d-b774-a65c1e3b27d2">190,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTktMy0xLTEtNjgwMjI_80530f22-e840-492e-b9b2-d46c69c6be1e">175,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjEtMS0xLTEtNjgwMjI_9ccb8be1-f8b1-401c-90b0-83cb99ec0cbc">13,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjEtMy0xLTEtNjgwMjI_a19d80ab-b954-4a0c-ae66-4032fbea12d1">17,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjMtMS0xLTEtNjgwMjI_d4f3feb3-8ae7-4bdf-a148-76ea1c3c960b">204,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjMtMy0xLTEtNjgwMjI_2cd62f6c-5837-4e4d-87a8-b298e81e1f12">193,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjQtMS0xLTEtNjgwMjI_be755334-2ecc-4d0b-b222-cf6f516ed1ba">1,138,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjQtMy0xLTEtNjgwMjI_33e4645a-d244-4192-bd36-1a071a0b5d9a">1,137,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjUtMS0xLTEtNjgwMjI_07218f33-f33d-484a-a33f-5b1d1344528e">204,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjUtMy0xLTEtNjgwMjI_89c39988-5f55-41d7-944f-a42f8b97ae11">210,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjctMS0xLTEtNjgwMjI_a94ab9cd-9bbe-4a3b-ab7b-35c10a83408d">9,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjctMy0xLTEtNjgwMjI_3d4ee115-aa96-40d7-8356-7129158657c2">9,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjgtMS0xLTEtNjgwMjI_eb5655bb-a32b-44c1-ba30-f5fd87aa07e8">1,556,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjgtMy0xLTEtNjgwMjI_72ac2880-fa32-4f70-a8ea-b79048953cf2">1,549,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjktMS0xLTEtNzYxODI_2f9bd128-9ee5-4288-817c-0db84552cd8f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:8pt;padding-right:6.75pt;text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjktMy0xLTEtNzYxODI_e4306d16-79fc-4b38-96b0-284d7aa5d4b7"></ix:nonFraction>Stockholders&#8217; (deficit) equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF8zNA_09d3977c-393a-4ff8-9fd6-5ff97ec408ab"><ix:nonFraction unitRef="usdPerShare" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF8zNA_5a5ad465-fa0a-4d59-a590-7e7d7648733b">0.00001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF80OA_13a3bf16-8227-4036-bb64-d6185f7913d1"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF80OA_9b95daba-dbdf-49cd-a741-6e5d947efaf6">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_2fddb157-4a92-4d60-a7e4-62c4c3117b55"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_941b0371-1a58-4d4e-9535-f86dd679cf4e"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_c1b980d0-00d0-4378-b294-1bbfd773b8dc"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_f46d9922-550f-4f3e-8088-06eacc87490f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMS0xLTEtNjgwMjI_049f2d83-6193-40d6-8b37-fa4d11a45212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMy0xLTEtNjgwMjI_7508dd6e-74f3-4044-8f17-6acf1336af2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl8zMg_b091af7a-d0d3-4f0b-840d-3069fed0e536"><ix:nonFraction unitRef="usdPerShare" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl8zMg_bac0a932-a70e-44cc-bc1f-207289f31ae3">0.00001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl80Ng_b2644ad6-3f37-4b34-8717-65e874eb74e1"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl80Ng_da4a39e2-30b6-493f-9885-91b4239bd985">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2023, and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl84NQ_7ea8e92b-10a8-4452-834e-ad277e812ed7"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl84NQ_c7d5f05c-8859-4bde-b785-87a27cd1ff92">102,708,305</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl85Mg_38ecb38d-986c-485f-b42e-928e31e2bcfd"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl85Mg_caa2bdd7-7415-44df-b6c2-2f9da7bcbc3e">102,619,383</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023, and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMS0xLTEtNjgwMjI_b0608dc3-933a-44c0-92aa-9b5146de3346">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMy0xLTEtNjgwMjI_033bcdf4-5f81-4370-9b75-83bcf2c85436">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzQtMS0xLTEtNjgwMjI_e651810e-399f-4e45-8f39-e82eb64b5cc7">1,763,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzQtMy0xLTEtNjgwMjI_b96be258-53a0-4555-b616-a049021bd0c2">1,742,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzUtMS0xLTEtNjgwMjI_49222629-04a4-423a-a186-a941154bd80c">12,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzUtMy0xLTEtNjgwMjI_752ef535-f37d-4083-b7cc-333589af7454">19,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzYtMS0xLTEtNjgwMjI_ef943ffd-7a40-4569-93f5-29477874ce26">1,795,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzYtMy0xLTEtNjgwMjI_42b8ec88-cffb-4e90-aeb5-6f4105076e73">1,662,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Stockholders&#8217; (Deficit) Equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzctMS0xLTEtNjgwMjI_1e6aebbe-5c61-4bf4-b58b-d6ce716c6d8a">44,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzctMy0xLTEtNjgwMjI_09fb76db-5ad8-4d52-b34c-6793c95b276e">60,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Liabilities and Stockholders&#8217; (Deficit) Equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzgtMS0xLTEtNjgwMjI_b509c590-689a-4263-ad43-9ebe58da4e3c">1,511,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzgtMy0xLTEtNjgwMjI_15914222-1e9d-474d-a2e5-5aa43c704451">1,609,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.656%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:RevenueFromPrecisionOncologyTesting" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNC02LTEtMS02ODAyMg_ba8ecc28-80aa-484e-a1c9-0a4d2b542610">113,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:RevenueFromPrecisionOncologyTesting" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNC04LTEtMS02ODAyMg_5468a2ea-b41a-4c17-ad1e-08143c8abd87">84,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:RevenueFromDevelopmentServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNS02LTEtMS02ODAyMg_bc14e140-178a-4dfa-8b6d-807bf4a00bd9">15,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:RevenueFromDevelopmentServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNS04LTEtMS02ODAyMg_63823d7f-bebe-4df9-804f-9d3ec288d1ba">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNi02LTEtMS02ODAyMg_4ddd3220-21c2-4e54-be29-b34aa8c0ed25">128,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNi04LTEtMS02ODAyMg_810e9361-67cd-4fc6-9c23-d79db19e3a05">96,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:CostsOfPrecisionOncologyTesting" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOC02LTEtMS02ODAyMg_d485602b-c4f6-452b-b229-df5a6eab2dbe">45,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:CostsOfPrecisionOncologyTesting" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOC04LTEtMS02ODAyMg_aa993c53-46ce-4966-bed3-a7e999a62e4d">30,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:CostOfDevelopmentServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOS02LTEtMS02ODAyMg_14d6f26b-fabf-4ba5-8a54-84f1b01eb418">7,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:CostOfDevelopmentServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOS04LTEtMS02ODAyMg_eae54503-58ec-438b-b75e-81d1e3417d18">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTAtNi0xLTEtNjgwMjI_78b60f73-92d4-4913-85df-09134d1eba95">93,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTAtOC0xLTEtNjgwMjI_01da086b-07aa-4d4f-bb6b-23d4f0e55359">81,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTEtNi0xLTEtNjgwMjI_2b66a199-27b6-4a85-84d9-dd7d5f2b1b1a">76,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTEtOC0xLTEtNjgwMjI_9e503580-bb3b-4961-b605-9c89632f4388">64,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTItNi0xLTEtNjgwMjI_c92e129f-2dd5-48da-978a-1c72b2135a44">40,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTItOC0xLTEtNjgwMjI_dbf03db0-f594-42b0-b72d-8ee3877ccf96">41,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total costs and operating expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTMtNi0xLTEtNjgwMjI_fdb0daf5-b7f7-414a-af10-4daf5ca95615">262,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTMtOC0xLTEtNjgwMjI_7827da45-c341-4156-b85d-d28b4f6b6fd9">219,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTQtNi0xLTEtNjgwMjI_e5715f74-d1ec-413c-8cc6-fbd7c7ef07e1">134,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTQtOC0xLTEtNjgwMjI_05a9c526-8c6c-468b-9a6f-0a29c45a4b4d">123,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTUtNi0xLTEtNjgwMjI_ce0fade1-26b8-473a-9256-0b24aa7eced0">3,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTUtOC0xLTEtNjgwMjI_4a6f9486-b1c9-49b7-bb39-a64f76f9d6ec">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTYtNi0xLTEtNjgwMjI_bb74fff4-43ef-43a7-be70-5eb4cb1a5f78">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTYtOC0xLTEtNjgwMjI_7a04794a-62d8-4b7a-b257-615502838c1a">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTctNi0xLTEtNjgwMjI_6fc22521-77f8-4994-9eea-1e1015e61703">1,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTctOC0xLTEtNjgwMjI_2c1e2170-89f9-42a8-b9b0-c4bc0e0c9d63">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for (benefit from) income taxes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTktNi0xLTEtNjgwMjI_3aef2887-108c-4b0b-9fff-d7ad7454caa9">133,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTktOC0xLTEtNjgwMjI_bc63573a-208b-4e77-ab15-66915e41d2e5">123,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjAtNi0xLTEtNjgwMjI_26237e99-067a-42fe-8123-6d7e7b0d8b25">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjAtOC0xLTEtNjgwMjI_d1410565-c997-4273-a636-570a9bc0dbc3">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjMtNi0xLTEtNjgwMjI_3f31189f-26e9-4498-b74f-b790ba957612">133,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjMtOC0xLTEtNjgwMjI_df1fda21-cd5b-4dbf-addf-bc97f2012670">123,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtNi0xLTEtNjgwMjI_220036eb-9cb2-4229-997c-f75a3a4187bc"><ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtNi0xLTEtNjgwMjI_99ba037c-76cf-43f9-a1b9-381b75d4c261">1.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtOC0xLTEtNjgwMjI_bc0d5ead-d3f6-42e7-a0c1-952d25e72d13"><ix:nonFraction unitRef="usdPerShare" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtOC0xLTEtNjgwMjI_be5e8e7d-8d03-40d1-9338-20aba2d1fd32">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtNi0xLTEtNjgwMjI_2ec3080a-ff39-47e6-b71a-e8f38512eece"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtNi0xLTEtNjgwMjI_cf495f91-7a1a-4287-a035-a4f8e9cf1a39">102,663</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtOC0xLTEtNjgwMjI_42d4f00a-5bc5-4667-a29f-4a0ee6c05d64"><ix:nonFraction unitRef="shares" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtOC0xLTEtNjgwMjI_8508b8c9-90da-4c65-b52c-d97143f69c4a">101,853</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfMy02LTEtMS02ODAyMg_67e1bb7e-e7a4-4792-90d4-4c9f8dffd9a7">133,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfMy04LTEtMS02ODAyMg_333ddad9-4f7b-43f4-89ef-3c9f810d1a98">123,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNS02LTEtMS02ODAyMg_42067375-b0d3-4609-ad11-6a7e5fa6adc5">7,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNS04LTEtMS02ODAyMg_e7b09f65-d57e-4b1e-9e14-ad1339bb5367">12,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNi02LTEtMS02ODAyMg_20518eab-a052-4cd2-b7a1-0d7bd9966a2c">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNi04LTEtMS02ODAyMg_48f376bf-3ff0-42c5-9859-0f53a258b4da">792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNy02LTEtMS02ODAyMg_9beb1ab3-afe0-4886-88f9-8dd2cde1045e">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNy04LTEtMS02ODAyMg_ee68f5c1-09b4-4bc7-a614-beb1ac969b31">13,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfOC02LTEtMS02ODAyMg_a6cb0556-7816-4f79-833d-3a2bcf122225">126,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfOC04LTEtMS02ODAyMg_4d9ca77e-7bbd-4a8a-8f82-25edd476b606">136,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.076%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; <br/>(Deficit) Equity </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id314243f2ead4456aa30110c9be601cb_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0zLTEtMS02ODAyMg_99c3bcb1-afcc-4a1a-906d-57b1d3b483f7">102,619,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id314243f2ead4456aa30110c9be601cb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy01LTEtMS02ODAyMg_ad3d94e7-dd3d-440e-83f7-1c160839a0db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b4fdb150214c56afcbdbb322033b7d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy03LTEtMS02ODAyMg_e421f413-5ffb-4467-ac13-ff1b0e31f028">1,742,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i061c59efe2d945519dfb0e5134ddbbfe_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy05LTEtMS02ODAyMg_5c265692-8887-4cc1-a7db-a4d8a421f5f3">19,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08422884f60b4434b3801e044a34720c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0xMS0xLTEtNjgwMjI_75492170-6250-4caa-ab99-67a2454f312b">1,662,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0xMy0xLTEtNjgwMjI_44b5de4c-aba7-4612-966d-53a1d4077b0e">60,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS0zLTEtMS02ODAyMg_c8f9ef3c-57fd-49ac-953e-575a5a77eb5a">21,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS03LTEtMS02ODAyMg_0974470c-6f73-4abb-87f5-9d625e41cc0a">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS0xMy0xLTEtNjgwMjI_86d5d4ca-21d7-4364-a068-1ef4ea12e5ef">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNi0zLTEtMS02ODAyMg_f8f91bbc-359d-4aae-867d-f234d0c2ff4f">67,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfOS03LTEtMS02ODAyMg_d8d3a641-006d-4cc2-980c-54cbf264d828">993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfOS0xMy0xLTEtNjgwMjI_dd0177ff-490d-4217-acfc-1c42ef22ebce">993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTAtNy0xLTEtNjgwMjI_a42fc83a-1915-492f-8133-9de40c3282dd">22,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTAtMTMtMS0xLTY4MDIy_84035139-c022-49d9-a64a-c07cfa505f55">22,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65627937720c45f5af483254a1fe5f4b_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTMtOS0xLTEtNjgwMjI_b697266c-b0dd-494d-9928-a9973ba2646e">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTMtMTMtMS0xLTY4MDIy_bbe09162-1f34-485e-bdda-f018de041da3">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia281fcd22cc54accbefe8d9b460bd5cd_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTQtMTEtMS0xLTY4MDIy_6e141829-6084-4927-b534-e1e356e74f7a">133,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTQtMTMtMS0xLTY4MDIy_a41243a1-733e-494d-b968-5962060b3f78">133,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae9eaada43ef4cfd925883681dcbc4c2_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMy0xLTEtNjgwMjI_eba77059-30e2-426f-aac9-057c67da0a2c">102,708,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9eaada43ef4cfd925883681dcbc4c2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtNS0xLTEtNjgwMjI_e3a425cc-85fe-4dd2-96ec-de572967b6aa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234915b13fca42879cd971070e15ee06_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtNy0xLTEtNjgwMjI_3ad6307a-c786-4aa0-8211-4c1cc81b1a34">1,763,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2f8f14dc64d49c6be419158cec74a14_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtOS0xLTEtNjgwMjI_dfbf4665-a5e8-4af8-870d-a74cff5bd00c">12,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie23b9007cc9d4791bd36771afacf5634_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMTEtMS0xLTY4MDIy_0e29a059-3749-475a-a564-290df27bff2c">1,795,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMTMtMS0xLTY4MDIy_430967fa-bfef-4554-9158-5b279625c961">44,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.076%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; <br/>(Deficit) Equity </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0zLTEtMS02ODAyMg_2c2571d3-1dd1-4ca4-8788-9bcd336562c1">101,767,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy01LTEtMS02ODAyMg_237e09ac-9ecc-4137-b924-698a7c5371a9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c902d77713c48f9b6c55bb637b64351_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy03LTEtMS02ODAyMg_7a77179c-767d-43b0-ae85-81d78f42ef0c">1,657,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i004e4666a5184be996fa4c7ddf054bc4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy05LTEtMS02ODAyMg_5e4aec98-b8a1-4792-9f7d-865d956a3972">4,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49b965e37113409d8d7d5afef90e67b8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0xMS0xLTEtNjgwMjI_078de641-fdf7-4211-bde8-0f782d5f7617">1,007,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bad5d6e63649409643e7d759322b03_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0xMy0xLTEtNjgwMjI_b1d7d358-7f60-44e1-a8c8-f772b81229d0">645,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi0zLTEtMS02ODAyMg_499fddf9-616b-4aac-be06-aded0e6213fe">105,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi03LTEtMS02ODAyMg_c5d7a8dc-d7ec-49bc-a709-3c8d481a747b">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi0xMy0xLTEtNjgwMjI_9bdff7ba-5f9b-4f41-a82e-b6ba30ca164f">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNy0zLTEtMS02ODAyMg_14c34d6a-3fab-45b3-ab4a-5cd662398795">23,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock exercised early</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331" decimals="-3" name="gh:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfOC03LTEtMS02ODAyMg_dd1249b2-a884-4968-96b1-0cbe944e6e69">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfOC0xMy0xLTEtNjgwMjI_54bcb811-72f0-4e13-90cb-14454c266d30">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTAtNy0xLTEtNjgwMjI_635d1db8-0538-4bac-9f84-1d7dff0cd9ba">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTAtMTMtMS0xLTY4MDIy_5d4fd916-5d1f-4842-bfb4-33fe21501d5e">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTEtNy0xLTEtNjgwMjI_d5c7e147-b389-406c-9f6d-afe0674b20b7">24,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTEtMTMtMS0xLTY4MDIy_e1ba93d9-b8d0-4bf9-89e7-5973a25a8cb4">24,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i837fd30e88e14cca94ef2ffcde2af73e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTMtOS0xLTEtNjgwMjI_22120f99-35ba-4cee-8d8c-c52ed877397f">13,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTMtMTMtMS0xLTY4MDIy_a2617989-774d-4ff0-89ab-a086a7e428b2">13,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6340409bc504436ca385dbfa0f3ec40c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTQtMTEtMS0xLTY4MDIy_7a38bda4-6049-4d83-91e1-50dd37e35cb4">123,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTQtMTMtMS0xLTY4MDIy_802c26ca-00cc-4c7b-833d-34935c5be43d">123,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61824cd12b914964a5a603b514d2a3de_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMy0xLTEtNjgwMjI_27af6f4e-ffc5-4838-a531-43cf326e326e">101,895,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61824cd12b914964a5a603b514d2a3de_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtNS0xLTEtNjgwMjI_5a3ad51d-4d5d-4a88-83c2-9145ccfdd213">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ecdc52faa648b9851cd7fd4d341e4d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtNy0xLTEtNjgwMjI_ce7e4590-16c8-4c27-a2b6-7b49b0f6ae30">1,682,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeefd32a5fc49089e432e6ef771b042_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtOS0xLTEtNjgwMjI_3cfea41d-5e1e-4015-a0e3-d55bf280edf9">18,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10781cf49c274a30b77473e1ab3caaa8_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMTEtMS0xLTY4MDIy_0cc145cf-a151-43f2-ba94-e432a8c89707">1,131,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMTMtMS0xLTY4MDIy_ce783f0d-0afe-4d10-9698-6742a2b7b0f5">533,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES:</span></div></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNC0xLTEtMS02ODAyMg_5d48b267-19da-450c-90b9-f3c253d171ae">133,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNC0zLTEtMS02ODAyMg_54b9200f-bc2d-4c9d-81d3-af65499a4817">123,228</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNi0xLTEtMS02ODAyMg_9190cce2-d93d-4524-a0aa-78ca3b0704c6">10,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNi0zLTEtMS02ODAyMg_1598e7bd-2420-4e9c-ba98-37679973f3b3">7,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:NonCashOperatingLeaseCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNy0xLTEtMS02ODAyMg_89bea0cf-4e67-4032-bdd5-d4491eb4aff1">7,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:NonCashOperatingLeaseCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNy0zLTEtMS02ODAyMg_f754a81a-2c1e-4a64-94c8-a1266ceb68c7">6,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTAtMS0xLTEtNjgwMjI_2219f0a9-8896-40ce-bc05-b60000411be0">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTAtMy0xLTEtNjgwMjI_f22e4225-e68c-4f2f-aa8f-17df865bbf14">2,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTEtMS0xLTEtNjgwMjI_fedda806-e5b4-4175-92b4-37118ab05d39">22,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTEtMy0xLTEtNjgwMjI_4fddec9c-d295-4eaf-aef1-b1b16ae74b10">24,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTItMS0xLTEtNjgwMjI_ee493627-59c1-4352-9ddc-8e32fdc522f0">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTItMy0xLTEtNjgwMjI_773a4386-4c65-42f4-890d-7a0e6bb72d0c">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (discount) premium on marketable debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTMtMS0xLTEtNjgwMjI_78f1a41c-2da9-4f57-b839-2911d9b026ba">1,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTMtMy0xLTEtNjgwMjI_62d6444c-a945-493e-aad2-06710c5003f2">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTQtMS0xLTEtNjgwMjI_c8a1b819-8d34-4a2a-b6d5-b6d6892caa1e">3,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTQtMy0xLTEtNjgwMjI_bf38384a-b696-474b-a209-ce77820e3ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTUtMS0xLTEtNjgwMjI_bc377ff7-f737-49cd-9887-10f5f51bb091">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTUtMy0xLTEtNjgwMjI_155155f9-8de7-4970-b2b4-a3339b6ddb5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTctMS0xLTEtNjgwMjI_1100dcae-15ea-48b7-97ac-5cedfd4a8157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTctMy0xLTEtNjgwMjI_b0bbc2d2-aa00-44f7-8bfc-dfcb8ffd378c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTktMS0xLTEtNjgwMjI_093fe345-3a63-4248-aba7-443c8a6a132a">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTktMy0xLTEtNjgwMjI_c4c308ee-f67c-49a4-9d6e-b5a03c3a6d5d">13,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjAtMS0xLTEtNjgwMjI_7e1d8009-a98c-474b-beb2-a49247a7897d">5,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjAtMy0xLTEtNjgwMjI_642531b3-7e36-4f3b-8a03-eb30514c7131">5,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjEtMS0xLTEtNjgwMjI_e15839b8-b4df-44ff-9c1b-c27c2d15fcd5">3,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjEtMy0xLTEtNjgwMjI_98e89721-7454-421e-bb30-040aad1ca784">21,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjItMS0xLTEtNjgwMjI_86be599b-cbce-461d-bb83-e8f3b12100c4">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjItMy0xLTEtNjgwMjI_03c519a1-8f19-4833-adfe-e4e0c38bd8c2">3,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjMtMS0xLTEtNjgwMjI_875e0d44-f1b5-4548-96fe-c159670fc25f">13,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjMtMy0xLTEtNjgwMjI_55642a31-3e83-4682-8b09-f521b041b1e9">20,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjQtMS0xLTEtNjgwMjI_d9d341ef-2a7c-4cac-bfff-9e8a246c673b">7,422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjQtMy0xLTEtNjgwMjI_2a015415-9ea9-43c4-af2c-7e59d8fc9dbc">3,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjUtMS0xLTEtNjgwMjI_4b0a290b-5ae5-42e2-9338-c3dbd233fee4">4,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjUtMy0xLTEtNjgwMjI_d7bf302e-8efd-47f6-bf58-fa57cdccaec5">757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjYtMS0xLTEtNjgwMjI_1d0d70de-282f-4c05-b727-f70b3c68c71a">74,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjYtMy0xLTEtNjgwMjI_baf08f15-7e45-418c-a7cc-8095ea9c7f71">28,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjgtMS0xLTEtNjgwMjI_46f0857e-13ab-449d-bd84-a0b1c6031ff8">63,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjgtMy0xLTEtNjgwMjI_e42dc2b4-63c1-4872-9a92-746b29b77d44">163,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity of marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjktMS0xLTEtNjgwMjI_97b93850-a44b-4250-b31b-90eca3c189fc">228,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjktMy0xLTEtNjgwMjI_78338e36-c52c-4e0f-98f2-a062b16cb343">310,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-marketable equity securities and other related investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzAtMS0xLTEtNjgwMjI_ebc4f4aa-3825-49f2-8935-bdd945a78611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzAtMy0xLTEtNjgwMjI_80cbbf2e-5de6-40f0-9faf-98e275201573">12,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment   </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzEtMS0xLTEtNjgwMjI_fda2527f-9fd6-4512-b945-c355adc8b8eb">7,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzEtMy0xLTEtNjgwMjI_7f3c7b13-6c7d-4c39-9570-63c1468ec549">22,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzQtMS0xLTEtNjgwMjI_462e70c9-3deb-4865-a717-e1f39e5bce81">157,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzQtMy0xLTEtNjgwMjI_f1e94dc2-edc2-4e3c-a870-ccabd8f25f4e">110,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made on finance lease obligations   </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzctMS0xLTEtNjgwMjI_408508b6-00ef-47b0-85ce-2f9808c0524e">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzctMy0xLTEtNjgwMjI_877f46d4-4afa-4d9d-b499-1de64740a8ee">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of stock options   </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzgtMS0xLTEtNjgwMjI_b12afa69-0912-4622-ac6d-fcc3f8d3ae4e">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzgtMy0xLTEtNjgwMjI_068b17a3-f076-4231-b3e9-235a3eaf9411">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDAtMS0xLTEtNjgwMjI_c95c3645-b563-44a1-ba05-a8c0a2a350f8">993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDAtMy0xLTEtNjgwMjI_5f5b2641-bc98-4952-9ec2-b00cc66450d3">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDgtMS0xLTEtNjgwMjI_64ab9104-71ab-4d8d-b89b-8f47f8231912">854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDgtMy0xLTEtNjgwMjI_c4e2def3-34de-44cc-9377-2b3476697c7b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDktMS0xLTEtNjgwMjI_ce67c5c4-cbd3-4efe-a3bc-483e379c2cc4">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDktMy0xLTEtNjgwMjI_818bccc3-9870-4876-a34a-e4750fbd9b2d">792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTAtMS0xLTEtNjgwMjI_d05cce5e-16ee-47ce-bd19-fc7db0caf709">81,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTAtMy0xLTEtNjgwMjI_9ec557a5-809b-4310-81eb-8625d393ef32">81,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash&#8212;Beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTEtMS0xLTEtNjgwMjI_291693f2-386e-4529-ba58-e1f5fbf02bc3">141,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bad5d6e63649409643e7d759322b03_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTEtMy0xLTEtNjgwMjI_2aab32a9-70a8-4992-a596-bca48654cf8f">492,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash&#8212;End of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTItMS0xLTEtNjgwMjI_c0669881-f725-462c-8e0a-28c09c83da16">223,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTItMy0xLTEtNjgwMjI_d2bffe8e-7051-4630-ae7b-8d8fab587023">573,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTQtMS0xLTEtNjgwMjI_c8834f99-bb14-4219-a402-5c136423c854">1,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTQtMy0xLTEtNjgwMjI_f488e921-262a-40b0-9ac0-ddd205af3c67">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Noncash Investing and Financing Activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTgtMS0xLTEtNjgwMjI_73cb4a2d-3cd2-4e0b-bcb3-bb799bfc44e9">8,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTgtMy0xLTEtNjgwMjI_b2e22001-e87a-40db-938b-df4ae8e18410">19,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjUtMS0xLTEtNjgwMjI_97b58389-fc3f-4bee-9095-30a6fa69d14b">223,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjUtMy0xLTEtNjgwMjI_9d962c51-7646-4e93-a796-b073e1fc8bb7">573,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; included in other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjctMS0xLTEtNjgwMjI_ad3bbb25-0928-4725-80b1-b429567fffbb">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjctMy0xLTEtNjgwMjI_23a1ed06-02c9-400f-bfff-f7c836a7d102">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjgtMS0xLTEtNjgwMjI_73311fa9-05a2-436d-b2a1-125cd7a5e45f">223,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjgtMy0xLTEtNjgwMjI_6215dc20-5f9e-407c-821b-be9bd81a9e71">573,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_37"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zNy9mcmFnOjJhYTRjNjJlODllODRjZGE4ZmNhNWVhMzU4MThlNjRmL3RleHRyZWdpb246MmFhNGM2MmU4OWU4NGNkYThmY2E1ZWEzNTgxOGU2NGZfMzc4Mg_01603f7a-4664-4ae4-8f83-d2d7b1b5db9f" continuedAt="i0803b27af916455ebe17837285972d04" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i0803b27af916455ebe17837285972d04" continuedAt="ie0a97399a6994534a7a4cad6bbcd44cc"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guardant Health, Inc., or the Company, is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company believes its tests can transform cancer care by unlocking insights that will help patients at all stages of the disease, including at its earliest stages, when it&#8217;s most treatable. For patients with advanced stage cancer, the Company has commercially launched Guardant360 LDT and Guardant360 CDx, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, and breast cancer. The Company has also launched the Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. In addition, the Company has developed Guardant Galaxy suite of advanced analytical technologies to enhance the performance and clinical utility of its portfolio of cancer tests, and to power the next generation of biomarker and drug discovery.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also collaborates with biopharmaceutical companies in clinical studies by providing the above-mentioned tests, as well as the GuardantOMNI blood test for advanced-stage cancer, and the GuardantINFINITY blood test, a next-generation smart liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. Using data collected from its tests, the Company has also developed its GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For early cancer detection, the Company has launched the Shield LDT test to address the needs of individuals eligible for colorectal cancer screening. From a simple blood draw, Shield uses a novel multimodal approach to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors. In December 2022, the Company announced that the ECLIPSE study, an over <ix:nonFraction unitRef="segment" contextRef="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231" decimals="INF" name="gh:NumberOfPatients" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zNy9mcmFnOjJhYTRjNjJlODllODRjZGE4ZmNhNWVhMzU4MThlNjRmL3RleHRyZWdpb246MmFhNGM2MmU4OWU4NGNkYThmY2E1ZWEzNTgxOGU2NGZfMTY0OTI2NzQ0OTExOQ_9d058b64-bbdc-47d1-a804-002466ec9bf4">20,000</ix:nonFraction> patient registrational study evaluating the performance of its Shield blood test for detecting colorectal cancer in average-risk adults, met co-primary endpoints. In addition, in March 2023, the Company submitted a premarket approval application for its Shield blood test to the FDA in March 2023. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0a97399a6994534a7a4cad6bbcd44cc">The Company was incorporated in Delaware in December 2011 and is headquartered in Palo Alto, California.</ix:continuation> </span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_40"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjQ_db397346-537c-43de-abde-ecc2e715c25a" continuedAt="i4b9a28c7719049b5a4b58c2a09516c6e" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4b9a28c7719049b5a4b58c2a09516c6e" continuedAt="i871441cc6ccb4667b0e60d0b87d9d154"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjU_5f152a86-2538-464a-8f20-7ee680f2246b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts were made to conform with the current period presentation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable debt securities as of March&#160;31, 2023, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i871441cc6ccb4667b0e60d0b87d9d154" continuedAt="ia70318d4b83c4b20bfb03ec8cd9a6c90"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzM_d3291347-8ce5-43be-a083-26472fa0363c" continuedAt="i806fc13fc6204b1a931a1d58cf08ca41" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. </span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i806fc13fc6204b1a931a1d58cf08ca41">The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.</ix:continuation> </span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjc_bc5b2133-4b5a-430d-8282-6936078b0997" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended, or the Securities Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwODU_3aab49b0-01b1-4135-a9d2-fbcc9ba9c17a" continuedAt="i71b33235f2ef4b499c71739b4388c6b7" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71b33235f2ef4b499c71739b4388c6b7">Restricted cash consists of payroll withholding related to the Company's enrollment in a voluntary disability insurance plan.</ix:continuation> Restricted cash balance was $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTk4MQ_dcb51ba1-8110-444a-a076-ef112ebda124">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTk4OA_888b2dc4-79e1-4b69-85dc-9950ac9b3f37">0.3</ix:nonFraction> million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, which was included in other assets, net in the accompanying condensed consolidated balance sheets. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ia70318d4b83c4b20bfb03ec8cd9a6c90" continuedAt="i3e631618092644f49478bf31398e3e15"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:NonMarketableSecuritiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzE_46576de5-3ea1-4653-b457-269542a4ad59" continuedAt="i46de1e93413245d7937a067c20c92d9f" escape="true">Non-Marketable Securities</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i46de1e93413245d7937a067c20c92d9f">The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investees. One of the investees is concluded to be a variable interest entity, or VIE, but the Company is deemed not to be the primary beneficiary as the Company does not have the power to direct the activities that most significantly impact the VIE&#8217;s economic performance. The Company's non-marketable equity and other related investments totaled $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNjQ5NQ_67e3a3e3-0b04-496b-9bc2-d2e231b9e415">19.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNjUwMg_e9c50f51-c45b-4256-8972-c3c652ad057c">25.0</ix:nonFraction>&#160;million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, and are included in other assets, net on the accompanying condensed consolidated balance sheets. Non-marketable securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. As a result of the evaluation, the Company recorded an impairment of $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="gh:EquitySecurityFVNIImpairmentOfPurchaseRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTY0OTI2NzQ4OTI1MA_fcd50c9f-01f2-4760-8071-163c1e448dc8">5.5</ix:nonFraction>&#160;million for one of its non-marketable equity security investments for the three months ended March&#160;31, 2023 based on an independent third-party valuation. In addition, pursuant to one of the investments in non-marketable securities purchased by the Company, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. In September 2022, the Company decided not to exercise such rights to purchase the investee and recorded an impairment of $<ix:nonFraction unitRef="usd" contextRef="idd26156a544941a48ee279e2b62c8c3f_D20220901-20220930" decimals="-5" name="gh:EquitySecurityFVNIImpairmentOfPurchaseRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTY0OTI2NzQ4NzMyMQ_8164103e-cac6-4118-ab86-0d4ef158d4b6">5.3</ix:nonFraction>&#160;million based on an independent third-party valuation. <ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzI_c462091a-ace8-4c6b-abf0-027b29de2b0e">No</ix:nonFraction> other impairment or downward adjustments to the carrying value of non-marketable securities have been otherwise recorded. In addition, pursuant to another investment in non-marketable securities purchased by the Company in October 2022, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the Company, on or before October 1, 2023.</ix:continuation>  </span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTI_7754cb0f-2d0d-4a32-83e4-a5a1d3feeb83" continuedAt="i4a1f50767b14442eb54ab6aa6f36e6e2" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i3e631618092644f49478bf31398e3e15" continuedAt="i93530b3b291e4e008ad49bd3662821c8"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTM_58a24d38-0843-45bc-b753-dd581e672eea" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNS0xMi0xLTEtNjgwMjI_8a1d3224-683a-4c10-a2ea-842169dd4425">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id35cadfe3a234269bcb1f5e099b19840_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi02LTEtMS02ODAyMg_4f34697c-1e71-4118-b831-1bc9c10493c2">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70f9229bf0864d9e814f7520f6d69d7d_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi04LTEtMS02ODAyMg_e141945e-1498-4d1f-9b61-eaffb6fe655e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6f93c12cead4d2c895bca577a25be67_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi0xMC0xLTEtNjgwMjI_66a78fb0-8de4-47c8-90d1-d447aacb1598">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cfb22333f754690bd602bfaec6d0504_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi0xMi0xLTEtNjgwMjI_f9cfeeee-ccb8-47f0-851e-28203997752f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3f4f6ec0d8c49d09f2cbdc348b5a7c7_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfOS0xMC0xLTEtNjgwMjI_2bdb4241-8b93-492e-a203-fd76219d8654">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i966b9062789c40178998266340270e67_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfMTAtMTAtMS0xLTY4MDIy_b552e418-7334-4d43-a5d7-24e39bf9ebab">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a1f50767b14442eb54ab6aa6f36e6e2">The Company is also subject to credit risk from its other receivables and other assets.</ix:continuation> The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $<ix:nonFraction unitRef="usd" contextRef="i5fb596e53d6d4e77aa67b76c30c717a5_I20200831" decimals="-5" name="gh:ContractualReceivablesBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTA5ODU_862e7de2-d2d5-4dcf-90c6-dcf2f39c77f0">8.0</ix:nonFraction>&#160;million payable over a period of <ix:nonNumeric contextRef="i251adc25d68b484abdc116bdcad141c8_D20200801-20200831" name="gh:ContractualReceivablesTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEwMTM_8d538621-c60b-4904-8659-7cc976c6e134">6</ix:nonNumeric> years. In December 2020, 2021 and 2022, the Company received the first, second and third installment payments of $<ix:nonFraction unitRef="usd" contextRef="iaa6502eac62f4edfbd8f440e52695d9f_D20201201-20201231" decimals="-5" name="gh:ProceedsFromContractualReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEwODk_8f6b10fa-4b58-4ae9-9ac4-fd2e06193854">1.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i28ecc6c83a29450f8f6715df23f4d2d3_D20211201-20211231" decimals="-5" name="gh:ProceedsFromContractualReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTExNzA_e535a625-b3ce-4842-a1ba-4e34342cd76a">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231" decimals="-5" name="gh:ProceedsFromContractualReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODU1MDM1_1f973501-9619-42f3-9a63-7bd470fc9b1d">1.1</ix:nonFraction>&#160;million, respectively. The Company has evaluated and recorded a credit loss for the remaining $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEyNDU_8903036a-b268-4d05-a2f7-2948a47965ae">4.8</ix:nonFraction>&#160;million considering the third-party's credit worthiness and lack of financial history. </span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzY_d85afd54-21c0-4636-802a-2122205f3e69" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the receivable and the related credit loss amounts:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNS0yLTEtMS02ODAyMg_e76da631-2845-4ab6-9f0a-ae7afad61578">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNS00LTEtMS02ODAyMg_170fab12-b462-4f54-972f-286f6e992feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNi0yLTEtMS02ODAyMg_3a55da01-429c-4613-8a1c-0f53ed4d37c5">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNi00LTEtMS02ODAyMg_bfd6c67a-11c4-468c-b817-104195eef011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNy0yLTEtMS02ODAyMg_e8d90811-3aa6-4610-aba0-2ff3a1951751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNy00LTEtMS02ODAyMg_939be085-5f74-46d1-824d-c0058f26efcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfOS0yLTEtMS02ODAyMg_e65112ec-05b5-49d6-b463-b556b32253fa">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfOS00LTEtMS02ODAyMg_d6a6df52-d39f-4cd4-b334-93984af04e86">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTAtMi0xLTEtNjgwMjI_c76b3f6c-1db1-44d9-b547-14d82067d4c7">3,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTAtNC0xLTEtNjgwMjI_d62ec513-1c5a-4bee-8e79-fd8ffa57a8c5">4,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTEtMi0xLTEtNjgwMjI_a683c17f-4dcc-4462-aabc-6c18c85eca64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTEtNC0xLTEtNjgwMjI_4d6a32ab-5c2d-4934-befe-c46d5695a327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allowance for credit losses activities for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfNi0yLTEtMS02ODAyMg_d9681402-1dbc-49db-ad3e-771f2aee38c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bad5d6e63649409643e7d759322b03_I20211231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfNi00LTEtMS02ODAyMg_728d2210-592a-42ab-8ca3-55690fafd17f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="gh:ContractualReceivablesCreditLossReclassificationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOC0yLTEtMS02ODAyMg_48346bac-a47f-4d80-9b8f-25cfc62d9cf0">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="gh:ContractualReceivablesCreditLossReclassificationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOC00LTEtMS02ODAyMg_29c82dfc-8508-4e6e-b222-970572bed60c">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOS0yLTEtMS02ODAyMg_a01bc6ae-2e88-489f-90cb-bea7acd69a2f">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOS00LTEtMS02ODAyMg_4ac0838c-98f7-423b-aff4-157ea64e0086">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTEtMi0xLTEtNjgwMjI_6c145f5e-e92e-4fa3-8c39-d422ed53b1b5">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bad5d6e63649409643e7d759322b03_I20211231" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTEtNC0xLTEtNjgwMjI_5c339cce-2950-431a-842a-2b2206c81a36">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="gh:ContractualReceivablesCreditLossReclassificationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTMtMi0xLTEtNjgwMjI_b9909d39-1337-45a3-838f-c6a1fd3ae27d">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="gh:ContractualReceivablesCreditLossReclassificationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTMtNC0xLTEtNjgwMjI_78951f1f-0637-45fc-9988-2933adec4da2">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTQtMi0xLTEtNjgwMjI_3ee95280-2d0f-42ca-acc2-b29a7b8d5734">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331" decimals="-3" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTQtNC0xLTEtNjgwMjI_10e7e070-162b-40c2-87cf-d0a44a7c8f62">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i93530b3b291e4e008ad49bd3662821c8" continuedAt="iea0490ef1a4646b08298ba4d2d36ed50"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzM_7e15eae1-4ddd-4f1a-a7c7-08107ef1ea51" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against commercial and governmental payers, biopharmaceutical companies, research institutes, international laboratory partners and distributors, including unbilled receivables, and royalty payments due from third parties for licensing the Company&#8217;s technologies. Unbilled receivables include balances due from biopharmaceutical customers related to development services and other revenues that are recognized upon the achievement of performance-based milestones but prior to the achievement of contractual billing rights. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had unbilled receivables of $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTIyMzk_8f3b278f-9afa-43b5-9cd3-a9d6207f1166">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTIyNDY_b089d966-c011-47c5-8ec4-a9eaa6a7a3c8">5.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had an immaterial allowance for credit losses related to its accounts receivable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:AssetAcquisitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTQ_3ab70e2a-8dda-46a3-9ef2-47ba6b068d68" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzQ_8f4bb92d-2b0a-4dae-9ec9-cff07d723676" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs, or IPR&amp;D, acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In connection with the launch of Shield LDT in May 2022, the Company's IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="id85a3adbc9da44018010d9f2fcd08a6c_I20220531" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ0NzM_956782d2-635e-4fae-a42e-4829fca8ee94">1.6</ix:nonFraction>&#160;million was reclassified as an intangible asset with a useful life of <ix:nonNumeric contextRef="ieb5caeb66ee94198aa9cd342c3f706e3_D20220501-20220531" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ1Mzg_83940b6b-682f-4d64-966b-eb4edc611704">2</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill is not amortized but is tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate its value may no longer be recoverable. The Company continues to operate in&#160;<ix:nonFraction unitRef="segment" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ4Nzc_1043fe8d-d635-4099-be3e-8f72665f5ffd">one</ix:nonFraction>&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level. As of&#160;March&#160;31, 2023, there has been&#160;<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUwMzk_46fb3b00-890f-4c64-8c6f-bde2c9be3b2f">no</ix:nonFraction>&#160;impairment of goodwill.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately <ix:nonNumeric contextRef="i6691016ad5b34d59883ed1923b33bed4_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUzNDY_f0d3f085-fd4c-4071-911d-10258555a632">2</ix:nonNumeric>&#8212;<ix:nonNumeric contextRef="i604eb9f9835e4c13814c14e8654cb3e8_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUzNDk_a9084c15-6fc7-428c-b9e7-92b382448388">12</ix:nonNumeric> years.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:PostAcquisitionCompensationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNDk_f541c02c-9ced-4a99-890a-9a2510ea3a34" continuedAt="i19cca06317f54c77a734584aae291b20" escape="true">Post-acquisition Contingent Consideration </ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i19cca06317f54c77a734584aae291b20">Post-acquisition contingent consideration is recognized over the service period, subject to meeting the respective service requirements and performance metrics.</ix:continuation> For the three months ended March 31, 2023, and 2022, the Company recorded post-acquisition contingent consideration expense of $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="gh:PostAcquisitionContingentConsiderationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODU1MTYw_b83f4b39-61a5-49cb-9ec6-042c5663eefb">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="gh:PostAcquisitionContingentConsiderationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxMDU2_dcab9950-618e-45f6-9b30-84d4a0ee49c8">2.1</ix:nonFraction> million, respectively, in research and development expenses on the Company's condensed consolidated statement of operations.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="iea0490ef1a4646b08298ba4d2d36ed50" continuedAt="ic1c6a1b774bf4a168c0e3660abd97090"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNDY_6f5f7212-69e6-449e-bf6f-210244075e32" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use, or ROU, assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjI_23058f9d-fe9e-4733-8433-6e7e12c3ccad" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible senior notes are accounted for as a liability and measured at their amortized cost. Transaction costs related to the issuance of the notes are netted with the liability and are amortized to interest expense over the term of the notes, using an effective interest rate method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzA_e4d0f3d8-95a2-4259-ac14-6d0bc8782f50" continuedAt="i8f0a0a33d3bc46a1a04011bb25a224c5" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services, as well as from development services and other. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing the Company's technologies, kit fulfillment and screening services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes, international laboratory partners and distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its test to a clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ic1c6a1b774bf4a168c0e3660abd97090" continuedAt="i2f094228bbfa4185b87d108e18e62c07"><ix:continuation id="i8f0a0a33d3bc46a1a04011bb25a224c5" continuedAt="i4761e0f964b04b21afa54c0a4548b6b8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s testing panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For the companion diagnostic development and regulatory approval services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of these contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other revenue includes amounts derived from licensing the Company's digital sequencing technologies to its domestic customers and international laboratory partners, kit fulfillment and screening services. For the licensed technology, the Company is compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Kit fulfillment related revenues are recognized when such products are delivered. </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i2f094228bbfa4185b87d108e18e62c07" continuedAt="id2fbb70b96da4b839192cbfde65d9056"><ix:continuation id="i4761e0f964b04b21afa54c0a4548b6b8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers and international laboratory partners may include multiple distinct performance obligations, such as provision of precision oncology testing, the above-mentioned development services, and digital sequencing technology licensing, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers and international laboratory partners to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of March&#160;31, 2023 and December&#160;31, 2022, the deferred revenue balance was $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzAyODM_43a47230-1bcc-4fe2-b2d5-da0294d77754">17.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxNDE4_cbd643fe-a846-485c-b3ca-af4f493d9bac">21.2</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzAyOTY_48edecbc-e531-4f9d-a93a-e77bcfe07a9e">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxNDM5_57be3c91-f39c-432a-a5b0-dba30368bccb">3.8</ix:nonFraction> million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets. Revenue recognized in the three months ended March 31, 2023 that was included in the deferred revenue balance as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzA1NzM_ef2a7154-4faa-4aeb-8e06-af24ad781e96">6.4</ix:nonFraction> million, and revenue recognized in the three months ended March 31, 2022 that was included in the deferred revenue balance as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzA2NzM_e0ad5d8d-f948-45c8-8455-74857a5d7837">3.5</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next <ix:nonNumeric contextRef="i39a86681777f4f5a97cdce262db9a555_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNDM5ODA0NjU1NDA3OQ_ba7809a9-7188-48e1-96bd-6e31985c75a1">1</ix:nonNumeric>-<ix:nonNumeric contextRef="i7810d83be2d148339c6e185649dcccc3_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNDM5ODA0NjU1NDA3Ng_23a3d9d8-2bba-4e33-ba43-f156e6216adc">2</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:CostsOfPrecisionOncologyTestingPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzU_c3189e98-99ca-46e8-98c9-a3e0c3cd63b7" continuedAt="id6f6255e9b6e4936a60fe80a31546f5b" escape="true">Costs of Precision Oncology Testing</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id6f6255e9b6e4936a60fe80a31546f5b">Cost of precision oncology testing generally consists of cost of materials, cost of labor, including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing test samples (including sample accessioning, library preparation, sequencing, and quality control analyses), freight, curation of test results for physicians, phlebotomy, and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, lease costs, amortization of leasehold improvements, and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="id2fbb70b96da4b839192cbfde65d9056"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="gh:CostOfDevelopmentServicesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzE_03702fbd-59f2-44e6-bd53-bd53cc796b14" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers, and costs associated with the Company's partnership agreements and screening services. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzg_ddacc6e7-cf69-4136-b34a-d149d7c99a34" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzY_6d45892a-0771-4907-bf8d-71683ad00838" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan (as amended and restated), or the 2012 Plan, and the 2018 Incentive Award Plan, or the 2018 Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics, or PSUs, is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. No stock-based compensation expense is recorded for PSUs, unless it is determined to be probable that the related performance metrics will be met. Any PSUs that remain unvested at the end of the performance period will be forfeited.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzI_7c5325cb-c0e3-4e2e-a726-b1f7b3ab105a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.</span></div></ix:nonNumeric></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_43"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNTQ3OQ_bf56d26a-8417-4699-b169-7b387daecaa9" continuedAt="i3471dcd3046843e8bf4a3c5780599e3e" escape="true">Joint Venture</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3471dcd3046843e8bf4a3c5780599e3e" continuedAt="i6a46771c383748c9ad666886f3f3d452">In May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc., the Joint Venture, for the sale, marketing and distribution of the Company&#8217;s tests generally outside the Americas and Europe, and to accelerate commercialization of its products in Asia, the Middle East and Africa. Under the terms of the joint venture agreement, each party held an approximately <ix:nonFraction unitRef="number" contextRef="i17dac8c118b84995ab3b80232dab1573_I20180531" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNjIw_ff685ffa-d6cb-4dd7-96db-eef1ae21b291">50</ix:nonFraction>% ownership interest in the Joint Venture and <ix:nonFraction unitRef="seat" contextRef="i17dac8c118b84995ab3b80232dab1573_I20180531" decimals="INF" name="gh:EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNTQ5NzU1ODE5ODA5_0266522f-7d5e-4704-bb24-bbf15f43a488">two</ix:nonFraction> seats on the board of the Joint Venture. </ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a46771c383748c9ad666886f3f3d452" continuedAt="i94a34d717d6f45e0a920c9c7e04ad3fd">In June 2022, the Company purchased all of the shares of the Joint Venture, or the Joint Venture Acquisition, held by SoftBank and its affiliates in consideration for a cash payment of the aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ia536ff2c58f1448390655c51b679d617_D20220601-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNDkzNA_599adc1a-700b-4b2d-8f54-49c655867e04">177.8</ix:nonFraction>&#160;million, which resulted in $<ix:nonFraction unitRef="usd" contextRef="ia536ff2c58f1448390655c51b679d617_D20220601-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNDk1Ng_af1e28a0-e0be-4fe0-882b-64bfb6b84a37">99.8</ix:nonFraction>&#160;million of fair value adjustments to the noncontrolling interest liability. In connection with the Joint Venture Acquisition, the Company also issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options held by the Joint Venture's employees. </ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i94a34d717d6f45e0a920c9c7e04ad3fd">Prior to the completion of the Joint Venture Acquisition, the Joint Venture was deemed to be a VIE, and the Company had been identified as the VIE&#8217;s primary beneficiary. As the primary beneficiary, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation. Upon completion of the Joint Venture Acquisition and the tender offer, Guardant Health AMEA, Inc. became the Company's wholly owned subsidiary.</ix:continuation> </span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_46"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzMx_d5dda5e1-20a4-4b7a-bc60-e133bcd6dab4" continuedAt="i467fb4d894e04141b42b7c0b1e153632" escape="true">Condensed Consolidated Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i467fb4d894e04141b42b7c0b1e153632"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzI2_912a9be6-f491-4f3d-99ad-bf85ae83f533" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40dd21d206c406fb998d0a9b6cd895f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMy0xLTEtMS02ODAyMg_ba501e8e-ac3f-41a6-8f1f-d429eefde67f">100,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd08dde4eb843418c0ae87833fedcdf_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMy0zLTEtMS02ODAyMg_39a846e2-4442-45e2-b26f-0d65d19837d7">95,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcb14cec5f44c8289340eb8d4348692_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNC0xLTEtMS02ODAyMg_910eb21d-5918-40d7-849e-ab20cf3f38b4">99,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1670651f92b400b9f911d06867002b5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNC0zLTEtMS02ODAyMg_f2152d5c-1b14-45a1-8917-88aad2c721fb">99,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic021058209134f95a1e8e10b009c7ace_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNS0xLTEtMS02ODAyMg_72ef6f34-0df8-4515-b78b-ab218ffc2fe0">31,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246a5d493f5c473b88cd065c03268005_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNS0zLTEtMS02ODAyMg_38179a0e-89cf-46db-a078-ae4ecab5f3ce">29,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a29ac54766d4a0f8b2b24b51cdb55b4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNi0xLTEtMS02ODAyMg_363efbdc-a497-495a-86ae-f91f03929034">18,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b5561c4b114d22bafce063538c856e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNi0zLTEtMS02ODAyMg_90537237-d9a2-448d-9d8c-5e6e4280a688">20,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d186d3354934b5a8f8bbe42c4c14495_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNy0xLTEtMS02ODAyMg_6a34b41f-b03f-4556-815c-797e12bf36e3">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bdcfada3cd4a2cbbe095e2aa5e702a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNy0zLTEtMS02ODAyMg_fccb4885-f5ff-43d9-801f-013896f5217a">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca178fdb5534ed4b35053a5ba325f0d_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOC0xLTEtMS02ODAyMg_f3723144-a94d-45d5-a845-720f51b25b57">1,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae2f9a0766ce44c6af97879837c1db9d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOC0zLTEtMS02ODAyMg_298bdfc2-666a-4bbc-8b99-9ab8e736a1dc">1,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOS0xLTEtMS02ODAyMg_d81eec26-586c-4041-8026-179727380923">260,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOS0zLTEtMS02ODAyMg_70f756c6-87e1-4405-84d6-1218f1a84e4d">256,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTAtMS0xLTEtNjgwMjI_c8f3b5c4-18a4-4888-b1ea-032197a049cd">97,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTAtMy0xLTEtNjgwMjI_ca2c6125-e568-4295-b01d-433855222ab0">88,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTEtMS0xLTEtNjgwMjI_fb75aff2-20ec-41d3-839e-f00bad8103b2">163,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTEtMy0xLTEtNjgwMjI_4f56bb6a-a448-4ed4-99c9-d97339768fcc">167,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNTI1_58373af8-4cdd-4dbc-bce1-d48eda9c893d">9.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNTMy_6b15f511-423d-4142-a3ea-b33bae10224e">6.7</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzI5_0ab2e7d0-37f8-4d60-97c3-843dde7fe20d" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfMy0xLTEtMS02ODAyMg_0a01990f-26fd-42eb-b89b-1c2a38e337d8">67,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfMy0zLTEtMS02ODAyMg_9d95d056-4fc1-4518-8d78-d7be9c1da9fd">68,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNC0xLTEtMS02ODAyMg_30583b9f-b65e-4206-9e27-ef5b045ad92d">69,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNC0zLTEtMS02ODAyMg_238559c2-a11e-4fe2-84bf-35a07a3d8c1b">55,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214">Operating lease liabilities</span></span></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0xLTEtMS02ODAyMg_76cd82f0-0544-4205-9ec4-1ae806399ab4">23,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0zLTEtMS02ODAyMg_85ee27f1-8caf-40f2-aa48-c02dd9ce492d">21,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNi0xLTEtMS02ODAyMg_63a65f5b-d448-420e-bdd4-4130768c3ee8">30,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNi0zLTEtMS02ODAyMg_89e725fa-178a-4403-9d8e-bed74f091432">29,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNy0xLTEtMS02ODAyMg_91d0871e-62ca-40f9-9c73-d38fbe6db39e">190,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNy0zLTEtMS02ODAyMg_92279d6c-3cce-4b74-9c37-5dadc3997337">175,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_52"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3MA_530ba4c1-8760-4adb-ac5c-c3134cea1414" continuedAt="ief91426e1847430ebe156b544d11dcf8" escape="true">Fair Value Measurements, Cash Equivalents and Marketable Securities </ix:nonNumeric></span></div><ix:continuation id="ief91426e1847430ebe156b544d11dcf8" continuedAt="i0ae683b139e64fa3a66f5dbb60353d67"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3Ng_c15827de-82fc-4dac-bc1a-05af92a1693b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, and accounts payable and accrued liabilities. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, and accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3OA_c2871a12-64dd-43ae-9174-9e6a8fd9d78a" continuedAt="i943e288640b6434bacde37700712df6e" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5c289384e245aa892095bbc5f2ab2b_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi0xLTEtMS02ODAyMg_c3423b91-d3eb-4ddb-aea7-44a018bb9d94">54,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f279ce6f9246c4848f2a4e3e17128a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi0zLTEtMS02ODAyMg_4fd26b0b-b1f5-4581-92a7-0c5b27d79f9b">54,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc566dc53fa4e07bf56f8a8aabdb279_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi01LTEtMS02ODAyMg_3d22846f-048a-4a93-aefb-5c76444367d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3168dac582d49e69c1516251fd3e0dd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi03LTEtMS02ODAyMg_98cf980d-976e-4aa0-8bd1-56527ad0b1bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e3cdcf1bbe4a9b81b4b8bdc2e6ab64_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0xLTEtMS03MTc3MQ_a8579a40-b80b-424f-9409-28e03562be5b">74,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3214563d103944fcad24fe9145d19d95_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0zLTEtMS03MTc3Mw_aa7b33ac-94a0-4150-b136-4c03585ada25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f02aa3d8ed8418682e04a58b2a857df_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy01LTEtMS02OTcxNQ_56fe025c-8141-4262-87a5-a49119b5d86e">74,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a924e51c984ac7b0fbc1fd9ad60d4d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy03LTEtMS03MTc3NQ_e31729e4-d169-453d-bb52-d58c036838de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0xLTEtMS02ODAyMg_6e24a9ea-2084-4d0e-a92b-415f7202f155">129,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0zLTEtMS02ODAyMg_6115e9ab-1620-42ae-b070-a8d1f2d55ffc">54,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy01LTEtMS02ODAyMg_94534add-ffcf-4d04-a90a-a103c50084a6">74,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy03LTEtMS02ODAyMg_05f679ab-22e1-453d-bdb7-70b85bbeaf6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5558266daa4fd5803cd22934821259_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtMS0xLTEtNjgwMjI_da37c488-1b60-4f85-bd54-a493b21686c2">713,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af15fbc37d84fa1955e0848cbda5aaa_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtMy0xLTEtNjgwMjI_23a5ebd1-6f49-4331-a54c-5e96a6cc525d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d01132e1c54427979eb175a61dff09_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtNS0xLTEtNjgwMjI_e3ee1a6b-c5f0-4e3c-a679-81cb5db16866">713,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1963c0481247479c9f779e03f6b467ab_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtNy0xLTEtNjgwMjI_b60ebfd6-4cf2-4249-8566-8e5a84c0b4bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtMS0xLTEtNjgwMjI_9c6a9145-ec8b-4678-9605-31c28582ab6d">713,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtMy0xLTEtNjgwMjI_e49a5b61-f874-49b3-af03-73d52f498eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtNS0xLTEtNjgwMjI_1035f60c-0466-4dce-b249-d3a430ad412e">713,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtNy0xLTEtNjgwMjI_02d6d6e0-4028-4646-b24e-2f26340344ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtMS0xLTEtNjgwMjI_a8e4b38d-ea1a-431b-9f9d-918626467a77">22,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtMy0xLTEtNjgwMjI_8747907f-0232-4e11-8aaf-86ea00f0cad4">22,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtNS0xLTEtNjgwMjI_65ba2a0b-170d-49fb-9349-8017a2bfcac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtNy0xLTEtNjgwMjI_24f64aa5-e35d-4fb7-bb01-d4d21985ccbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctMS0xLTEtNjgwMjI_6b9a4903-9d0e-4fe2-9abf-59aeb54fa18d">864,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctMy0xLTEtNjgwMjI_af81f1df-5f9d-4d99-8669-576c082e05b6">76,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctNS0xLTEtNjgwMjI_9846e70b-a878-46c2-b9cf-1332b7b41e7a">788,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctNy0xLTEtNjgwMjI_89b0fcce-85f7-4a1d-8b2d-2bc82215e32c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtMS0xLTEtNjgwMjI_e9b013e6-f13b-4f45-a67b-97e0405a3a14">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtMy0xLTEtNjgwMjI_aeb05bd1-2168-44a8-a769-1bedb8fb77d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtNS0xLTEtNjgwMjI_45cd8e6d-54a4-45eb-9151-c134c96ca8af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtNy0xLTEtNjgwMjI_2cef0cdc-24d1-42a6-a28f-f4f3f28063c3">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtMS0xLTEtNjgwMjI_a20d5086-043a-48f4-9965-d3619a1f45e9">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtMy0xLTEtNjgwMjI_4b0f2317-b9da-4602-9efb-9abb4e88cdd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtNS0xLTEtNjgwMjI_1790d579-4c1f-4139-a918-4ef3af3d94fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtNy0xLTEtNjgwMjI_a8c147cb-e741-4a58-9ced-999a8654256a">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i0ae683b139e64fa3a66f5dbb60353d67" continuedAt="i0e86d9cbc9cd4d3fb8bb631d4678713c"><div style="margin-bottom:8pt"><ix:continuation id="i943e288640b6434bacde37700712df6e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698a971f2120433494d66c1f389aa846_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS0xLTEtMS02ODAyMg_6809708a-a376-49eb-ade4-219d46ab249a">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645a895f548a4ff28015517f297d96a1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS0zLTEtMS02ODAyMg_d7986061-72a3-495c-a116-ccf7ac5a215e">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c5fb94fc744d39b9304cf6183f81e1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS01LTEtMS02ODAyMg_cd4b8c38-76b4-473a-9c91-a560032ee71b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie641c330319e42cb920c03007560f205_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS03LTEtMS02ODAyMg_97b2ee2e-08a2-4680-99fe-9cf66ea78231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfd089f28904d93b229f01b003d873a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0xLTEtMS03MTc3Nw_ead55eb5-aa1c-4d9a-9258-f73a6e851ec7">14,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d21756670fa4cdd8e4365d35747d8c9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0zLTEtMS03MTc3OQ_03736727-8465-4df6-a7e9-6a9486054edc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58665cb260e34ed2974fba4c7d288b91_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi01LTEtMS02OTY4Nw_75451b96-99ab-4645-8863-164d2b9163e0">14,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63bc9236559423696b0059bb44368a3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi03LTEtMS03MTc4Mg_a47cdf8c-3f71-461d-a673-e0ba0e532113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0xLTEtMS02ODAyMg_9992642a-881e-44ca-8249-01c46f1d63d7">18,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0zLTEtMS02ODAyMg_7d8cb44b-f36f-4ae6-a01e-298a47162fca">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi01LTEtMS02ODAyMg_7591809e-ad3c-445c-b9f5-885e88fb82a9">14,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi03LTEtMS02ODAyMg_38e3017f-fa7f-446d-8598-2ee873d35244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6d2513d70d4e718e77e46a90e3914f_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS0xLTEtMS02ODAyMg_a43b4859-8cf1-4a20-aa4f-cf52c20cece1">869,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ed47738cd74c8e8c229d9ce44342ad_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS0zLTEtMS02ODAyMg_3c53e2a8-e37b-4925-ac87-0b5e796c3790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c04821a302247519fa063baf7a9e04a_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS01LTEtMS02ODAyMg_24df1f3e-c28d-406e-a9fb-f11f2df45d67">869,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c4a003031e4fc18e276dd67fb04ae3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS03LTEtMS02ODAyMg_0b631294-454a-4c9f-8594-bb2bbfb2ed2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtMS0xLTEtNjgwMjI_1e2302cb-9073-4aab-bd84-b8b71975079a">869,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtMy0xLTEtNjgwMjI_5aa78c8d-772e-4453-ba53-7b5e95bd6096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtNS0xLTEtNjgwMjI_c02987e9-386d-4cf2-8827-749306de6dea">869,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtNy0xLTEtNjgwMjI_8c3a385f-9dfb-4781-8eec-71317a070b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtMS0xLTEtNzE3ODQ_11d6b435-1048-40a0-84d1-7aa1136c1e0f">18,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293edf8bd4704d8884ce7ede54eb1f69_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTUtMy0xLTEtNjk2NzM_1bc2d96b-ef5e-4b2f-9315-dc991b610b95">18,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtNS0xLTEtNzE3ODY_a95fe609-3e5f-4add-9cab-7264e52249e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtNy0xLTEtNzE3ODg_8be608fe-abc2-4c5d-9ed3-260dee8348bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtMS0xLTEtNjgwMjI_6a847554-76c6-468f-9422-ae435281a2df">905,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtMy0xLTEtNjgwMjI_6f19a4b9-0181-4c4d-9390-2bf34dd76f1c">21,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtNS0xLTEtNjgwMjI_53799d5a-07f1-4ddd-a15c-7bf99f813cc2">884,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtNy0xLTEtNjgwMjI_e5c49f5e-1d62-4a10-a5a1-0498400ae82b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctMS0xLTEtNjgwMjI_896faebb-ef88-4432-b0b1-aa94699521e0">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctMy0xLTEtNjgwMjI_94287d72-625c-412b-8f6e-aadb4628dd18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctNS0xLTEtNjgwMjI_a9991d42-6c84-428d-93bc-d589dedce4f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctNy0xLTEtNjgwMjI_c84a5841-d4e8-4710-8007-9bf405a79af9">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtMS0xLTEtNjgwMjI_28e95d1d-e09a-4d50-976c-e0f994512acb">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtMy0xLTEtNjgwMjI_b7f3945a-9462-4d4e-b3e6-48f300b1b7e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtNS0xLTEtNjgwMjI_d5d913af-a062-473e-ae5b-5fed6bc921d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtNy0xLTEtNjgwMjI_fb6f57c6-a69d-4683-a73c-d1b35f368483">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, one of the Company's equity investees completed its IPO, subsequent to which, the Company started to account for the investment at fair value on a recurring basis, and classified the investment within Level 1 of the fair value hierarchy as the investment is valued using the quoted market price. The Company is subject to a <ix:nonNumeric contextRef="i8b77f5413426453b85bf391a9398dbb7_D20220701-20220731" name="gh:SaleOfStockLockUpPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMzE2NA_3e3a4664-83ce-438e-bc04-f4b8693cd0ed">2</ix:nonNumeric>-year lock-up period from the IPO date, during which the Company shall not transfer the investee's shares between accounts, establish or cancel pledges, sell, or withdraw such shares, without approval from the local securities and exchange commission. As of March&#160;31, 2023 and December&#160;31, 2022, the balance of the investment was $<ix:nonFraction unitRef="usd" contextRef="i967d903179d741649abf3b3123b84ae7_I20230331" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMzQ1Mw_25b869d6-a0d3-4aab-83b1-fcccd1a03fc5">22.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i293edf8bd4704d8884ce7ede54eb1f69_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMTA5OTUxMTYzNzk5Mg_0842d5fe-620f-4122-8236-09acb79f4f24">18.3</ix:nonFraction> million, respectively, included in other assets, net on the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's contingent consideration liability was $<ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDYwNg_67986701-9c77-4f37-85e1-106f706fbaa2">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMTA5OTUxMTYzODAwMA_3b435553-0aa9-4256-aad8-73b7961551a7">6.4</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDY0Ng_15597675-801b-4fb8-a331-dd8b3bc081a5">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNTQ5NzU1ODIxODcy_5b5e3108-3950-48c3-95b0-4dab146ed433">4.9</ix:nonFraction> million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the Joint Venture Acquisition in June 2022, the fair value of the noncontrolling interest liability was considered to be a Level 3 measurement and was determined based on an annual internal rate of return of <ix:nonFraction unitRef="number" contextRef="i6d8629622e1d44fb9a12b229ec47a1f7_D20180501-20180531" decimals="2" name="gh:VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNjA0NzMxMzk2Mjk3Nw_1d82b4f3-0256-4b28-bd2c-bba83834a566">20</ix:nonFraction>% on the initial amount of $<ix:nonFraction unitRef="usd" contextRef="ib473620977be4b178565e23e78583e12_I20180531" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDM5ODA0NjUyMTI5OA_904d0da6-70fe-46ef-9ffc-67a219ac20c3">41.0</ix:nonFraction>&#160;million invested by SoftBank in May 2018, to the date of Company's exercising the call right in November 2021. The noncontrolling interest liability was fully paid by June 30, 2022 (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i0e86d9cbc9cd4d3fb8bb631d4678713c" continuedAt="i8bd0635d003a41a1ad0f7dd2be840ce1"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3Mw_5312b0e0-77c4-4e93-91c8-f6682f5bd832" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.050%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interest Liability</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9f5b8c565a4dca904ac822c40abf74_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi02LTEtMS02ODAyMg_35f7b7f1-c402-4dec-98ba-5593f676587a">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7491d2ac94a0486e8c65beb38d59a2ad_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi0xMC0xLTEtNjgwMjI_f6f2c7f9-fc22-4f78-a549-a8d8640ac64e">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cd2d2a717f448ca58407271970c8e4_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi0xMi0xLTEtNjgwMjI_f109e0af-3f54-4d99-be18-7841ac9d234b">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in fair value </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f16d72a05843cbbd0a5e1691d4c754_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC02LTEtMS02ODAyMg_2c1bbcf9-c583-4f38-b17c-f9e691dbf52b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb285d391a2d4b938bbb5a745115ea97_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC0xMC0xLTEtNjgwMjI_f6055898-952f-4736-97b5-e72720301f3c">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379830d644434dba8ff6a21e1c68f858_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC0xMi0xLTEtNjgwMjI_9f9edfe2-97f7-4487-8e15-2fec16eb1037">2,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebfefb0eb874a23853e2e48b2069dc0_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtNi0xLTEtNjgwMjI_130620d3-0899-478d-ada6-89104fce6641">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1e2b5f8f4a47bca104f021c60c4860_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtMTAtMS0xLTY4MDIy_c404a6f9-725e-4045-bb2e-503e468fca84">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d73083e0eca473a97a807ca5c0d2592_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtMTItMS0xLTY4MDIy_60a79ea5-9429-4faa-87f5-6286f0d8d26a">6,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the Convertible Notes as of March&#160;31, 2023, and December&#160;31, 2022, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to the fair value of the Convertible Notes.</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2NQ_d0a8c657-e87f-4452-8bb8-6ebfb8792f80" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash equivalents and marketable debt securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS0xLTEtMS02ODAyMg_838ae98c-884e-4951-aae8-44c974f4d7de">54,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS0zLTEtMS02ODAyMg_51348caf-5643-4af0-829b-1399209a6e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS01LTEtMS02ODAyMg_4e168e52-4eea-45ad-8d9e-084da7ee25a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS03LTEtMS02ODAyMg_bc22fdcc-7ad8-4e14-ae82-a1e633b77ce0">54,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy0xLTEtMS02ODAyMg_5a822125-c7d0-4b23-bd68-b972f4c498b5">797,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy0zLTEtMS02ODAyMg_087849b0-8931-413f-a29d-4141c50a05e5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy01LTEtMS02ODAyMg_6cbeec0c-dda2-44cb-9b2a-ade213517392">9,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy03LTEtMS02ODAyMg_e82b65d8-5517-4f8e-a0b6-5f14ff35d87b">788,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC0xLTEtMS02ODAyMg_3cce18de-619b-4285-adae-a702b8e1b953">851,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC0zLTEtMS02ODAyMg_338a5b14-99dd-479a-aaf8-8979556c7795">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC01LTEtMS02ODAyMg_b1faeeb4-ef55-4ebb-9a7a-d4fff82aa568">9,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:CashCashEquivalentsAndDebtSecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC03LTEtMS02ODAyMg_2dd3893b-7fcb-43fb-9bf1-ef75cc329dc0">842,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC0xLTEtMS02ODAyMg_bdc866c0-b4ab-421c-b0c2-e0429c0a1d06">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC0zLTEtMS02ODAyMg_526ae411-aae6-4aa0-ae3f-3049d31773e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC01LTEtMS02ODAyMg_cfd35fb9-1274-4e78-8494-6985eb5c22fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC03LTEtMS02ODAyMg_6190c1e0-0f8d-49fd-b489-affb8f8cbdd8">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi0xLTEtMS02ODAyMg_1adbdc69-7e94-4d7f-8d4a-0c0018d8e514">901,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi0zLTEtMS02ODAyMg_8dfa80de-0c12-4780-a5f2-efd42c8e15b1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi01LTEtMS02ODAyMg_140273f8-3a24-4acf-b3cb-109cd6a1f1af">16,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi03LTEtMS02ODAyMg_125f79e8-3fb9-414a-a827-c37eb8f4c078">884,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy0xLTEtMS02ODAyMg_c5253ae5-6356-4aa2-9957-3310bf4a8ed5">904,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy0zLTEtMS02ODAyMg_3ddc38da-89a5-4225-9f27-8223dbebf486">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy01LTEtMS02ODAyMg_088728d5-4841-41ee-b63d-a12e72834a05">16,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:CashCashEquivalentsAndDebtSecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy03LTEtMS02ODAyMg_be7375fe-8424-44d1-ae66-81da9ab1c059">887,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MQ_a57cce32-70f2-4c81-bc09-7e5bd99c8950" continuedAt="i760986bd30354231a8e49967aed6951b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the estimated fair values and gross unrealized losses of the Company's marketable debt securities that have been in a continuous unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0xLTEtMS02ODAyMg_d984d870-6015-49f8-88e2-d9c9d5d89128">99,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0zLTEtMS02ODAyMg_dd96d88e-b707-481b-9fea-899f05e4a9f0">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC01LTEtMS02ODAyMg_c58e3697-1e56-4cef-bf61-0ed2e40c3fbd">590,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC03LTEtMS02ODAyMg_644f40a4-14bd-405d-8923-354cd9320e97">9,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC05LTEtMS02ODAyMg_80f599c9-7660-4e56-8145-3906fa797309">690,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0xMS0xLTEtNjgwMjI_36e34523-397e-4530-badc-04d61e075533">9,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMS0xLTEtNjgwMjI_e90b11e0-a39e-428f-af09-8ad7f500ebb0">99,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMy0xLTEtNjgwMjI_d966264a-5430-43c8-95a8-44528f617d2f">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtNS0xLTEtNjgwMjI_7d2359b1-6dce-47ad-9963-990c65661a90">590,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtNy0xLTEtNjgwMjI_f49e0b70-ab86-4f4f-85c2-75a6d1fa3f6e">9,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtOS0xLTEtNjgwMjI_34f67d6e-47d5-4193-80f8-646cf455ce7e">690,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMTEtMS0xLTY4MDIy_1689be91-5ddd-4a82-ab22-e96bbad9e881">9,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="i8bd0635d003a41a1ad0f7dd2be840ce1" continuedAt="i1868e73d3a2840dab51de2013badf823"><ix:continuation id="i760986bd30354231a8e49967aed6951b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC0xLTEtMS03MDU2Ng_71bb7c83-7f97-4827-b13a-3bbc5782b50b">170,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC0zLTEtMS03MDU2Ng_f2a74a35-c2c7-43e8-be24-71ccbeb9d1ae">2,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC01LTEtMS03MDU2Ng_44609ff8-f367-435f-a801-d19b34fcca73">685,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC03LTEtMS03MDU2Ng_ffb766c2-7e15-431f-91a5-4dc90af2dda8">13,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfNy05LTEtMS03MTgxMA_7b75c2d7-b344-46ee-b6c1-19b54a99afb4">856,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfNy0xMS0xLTEtNzE4MTI_37114f0c-9ee8-4382-b56c-f46fcbb1588c">16,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0xLTEtMS03MTc5Nw_13b7cb31-02a6-4682-8d47-b57b3451003b">170,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0zLTEtMS03MTgwMQ_97872b33-7ffd-4191-a427-94093f76b899">2,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS01LTEtMS03MTgwNA_c4a9e978-9477-4655-af71-52a312784784">685,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS03LTEtMS03MTgwNw_38d63991-ed7b-4b8e-93e0-f8571d294d9b">13,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS05LTEtMS03MTgxMA_76d9a294-c1f9-4751-aa5c-3a26853b0e5a">856,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0xMS0xLTEtNzE4MTI_b194d5c9-a02b-420d-8ae0-9e7b9889cc8d">16,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1868e73d3a2840dab51de2013badf823">There have been <ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MA_c1849d97-63c5-4a2a-be26-5259e4756cde"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MA_d4dfeb6c-5a73-44b9-9010-8d5f25028474">no</ix:nonFraction></ix:nonFraction> material realized gains or losses on marketable debt securities for the periods presented. The Company determined that it did have the ability and intent to hold all marketable debt securities that have been in a continuous loss position until maturity or recovery and the loss position was temporary due to market volatility, thus there has been <ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzE1Mw_149ac3fd-0090-40b2-bae1-7f727a2bac60"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzE1Mw_e3793cac-f4a0-4a90-86ee-6d89a1c40bfc">no</ix:nonFraction></ix:nonFraction> recognition of credit losses in the three months ended March&#160;31, 2023, and 2022, respectively. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzM1NA_41f90a03-c717-4530-9373-50623f441ebe"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzM1NA_4e20a0c5-f7ec-489d-b565-ca5fc4a559c1">3.9</ix:nonFraction></ix:nonFraction> million unrealized gains on marketable equity securities for the three months ended March 31, 2023, included in other income (expense), net on the Company's condensed consolidated statement of operations. The Company did <ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfOTIyMg_af2e1f3d-e04f-490f-a7fe-a947cdfb853e">not</ix:nonFraction> record any unrealized gains or losses on marketable equity securities for the three months ended March 31, 2022.</ix:continuation> </span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_61"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzky_8883f287-28bf-4684-9469-c09a4e2591bc" continuedAt="i4dcfd91f96a5470cb39fdef446136b19" escape="true">Intangible Assets, Net and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i4dcfd91f96a5470cb39fdef446136b19" continuedAt="i9aeaefe0e66348e0af584b90f87f7448"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzg5_de0c9b8c-af1d-4400-9f4e-342f4468d439" continuedAt="i7c5e19ecbd65422d889c28da19705515" escape="true"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzk1_36478b91-1c4d-4512-ac8a-dada5f79a120" continuedAt="ic884e8e469ca458c9fc6ddb4577d9d46" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi0yLTEtMS02ODAyMg_463b79c7-8fa4-4346-abc5-b8a9e2112003">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi00LTEtMS02ODAyMg_02e254d3-b779-424d-acc7-37982f67c983">3,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi02LTEtMS02ODAyMg_4b87680d-f220-44f0-8699-2f0d74472c24">8,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea8dad0b65c142c5b15551bf9029a808_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi04LTEtMS02ODAyMg_d86c4f0c-03e9-46c5-9fe7-ec099052fa40">7.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy0yLTEtMS02ODAyMg_a4592bdc-c559-4c03-94ea-8fae493b521d">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy00LTEtMS02ODAyMg_7c735f04-aff7-42a4-b698-9909771a574b">2,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy02LTEtMS02ODAyMg_0baf9f84-657a-489c-bd15-eece47a7a030">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3add32afcf0e47928bccc0d9a1e4ab89_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy04LTEtMS02ODAyMg_b86e4359-73da-4a45-be1e-3ce8cbd38217">2.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC0yLTEtMS02ODAyMg_8b431c18-dc67-4dca-9850-74fdd72add0b">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC00LTEtMS02ODAyMg_f018bc34-ad36-4b46-9973-343f8ae33033">733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC02LTEtMS02ODAyMg_0f138e65-d90f-4750-91e0-7a43ebcc0887">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47c2c3e9fc144decaddb722e0a2f7ce2_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC04LTEtMS02ODAyMg_9fefe373-ea9d-4000-a74c-af8ae55843ff">1.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS0yLTEtMS02ODAyMg_6c635c11-1aa0-40be-834d-02111128e11b">18,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS00LTEtMS02ODAyMg_78fda6d6-8972-4970-a79f-08c2f884b09b">7,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS02LTEtMS02ODAyMg_685a8820-b287-43b5-9d1b-08ed29f3a5e5">11,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTItMi0xLTEtNjgwMjI_1ce88628-cea3-47d4-aa0d-f4c2f0779c7e">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTItNi0xLTEtNjgwMjI_23bd963b-2ad2-40c1-89da-23759e65fd38">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtMi0xLTEtNjgwMjI_4ffdc897-65ae-4c8d-ba4d-194ef7a73112">21,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtNC0xLTEtNjgwMjI_768cbe47-72cf-49d5-947b-6723ac00c129">7,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtNi0xLTEtNjgwMjI_932b4959-0586-40d3-a2b5-0501378c3cb4">14,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i9aeaefe0e66348e0af584b90f87f7448"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><ix:continuation id="i7c5e19ecbd65422d889c28da19705515"><ix:continuation id="ic884e8e469ca458c9fc6ddb4577d9d46"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS0yLTEtMS02ODAyMg_daafa59b-28b4-47df-84ad-15cca77fca5a">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS00LTEtMS02ODAyMg_fbf2a6e0-391f-49fb-bd7f-321ac0d12f90">3,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS02LTEtMS02ODAyMg_b8f7c52c-9f12-4b31-8915-3793ddf163a8">8,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d450e08fff545ebb9a7c77e00ca86e1_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS04LTEtMS02ODAyMg_8b78345d-7376-4b87-9b1b-8aafda5c2077">7.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ad0ce630064286a222741120078585_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi0yLTEtMS02ODAyMg_5b390804-fabd-44cb-a3b6-fbd3e6cae43b">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1ad0ce630064286a222741120078585_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi00LTEtMS02ODAyMg_cfdd375a-c8ae-4ba1-b0ab-98245c908bb0">2,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ad0ce630064286a222741120078585_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi02LTEtMS02ODAyMg_1bf07a35-9ac2-48ca-ba00-4c0c73fafefd">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef1b08124ca422d8c5fde0b52484dbe_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi04LTEtMS02ODAyMg_2c292515-f9e6-4a83-897c-52adeb5f2a47">2.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy0yLTEtMS03MDY5MA_77126bca-3e40-4393-bb70-f7fbedcf4f06">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy00LTEtMS03MDY5Mw_04a54c4e-f3ae-4baf-a3ae-e1f2e8e52327">533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy02LTEtMS03MDY5Ng_2b766914-2f89-44d3-89ac-1242500a3211">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20def10aa5d14802a5363d3f0e99bcb8_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy04LTEtMS03MDcwNQ_4f6dbf8a-ceda-48f9-b5be-002e76034a95">1.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy0yLTEtMS02ODAyMg_b157e23c-a420-40a1-b080-7ac363369c6e">18,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy00LTEtMS02ODAyMg_445520cf-00fd-470a-ad00-6254a8936bd4">6,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy02LTEtMS02ODAyMg_a70d7d58-1422-4987-890f-092f1c490f4e">11,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTAtMi0xLTEtNjgwMjI_623169ff-2bf4-4e29-aa6b-e40045dce4c0">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTAtNi0xLTEtNjgwMjI_66409dbc-9475-4450-bfa4-83d601bdc019">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="gh:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtMi0xLTEtNjgwMjI_9c197ee2-f64f-4db3-9cba-5d0bd21c3e17">21,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtNC0xLTEtNjgwMjI_16b76b3f-0cb7-45e0-956a-90471b4e9c7d">6,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtNi0xLTEtNjgwMjI_1cc2e71e-82f4-4fd8-bb39-82214915c86f">15,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMTg3_90794f00-f1e5-4230-9ea0-c2e0d069fc76">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMTk0_fdc17767-7a27-4867-ae6b-fc0712a10e05">0.5</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively.</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzk2_3e4512b9-e51b-4b1b-85a0-42a34a831d46" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets, net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfMy0yLTEtMS02ODAyMg_13e2df80-51d8-4182-bc21-83ff40679b55">2,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNC0yLTEtMS02ODAyMg_6d650449-0312-44ef-bf25-3428eed7f6fd">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNS0yLTEtMS02ODAyMg_c1cdf6bd-92a0-4b3c-80c4-e9fb408d2c7b">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNi0yLTEtMS02ODAyMg_e8650912-76e7-47ca-991e-fa7f926a4c40">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNy0yLTEtMS02ODAyMg_8e677392-9a9b-487f-880c-48ebc681cb52">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfOC0yLTEtMS02ODAyMg_fa242fec-26ab-4315-a6ee-17afc4c48421">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfOS0yLTEtMS02ODAyMg_f0ceaa85-a6eb-41e8-816e-c785de9ac645">11,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_64"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjYyNw_0716eef7-c612-46af-b733-56cefc1cdd9d" continuedAt="i0fef070865e849a887018ec37bd550af" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i0fef070865e849a887018ec37bd550af" continuedAt="i232d79bf035342d6bfee0e8ac008e0f4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNzY_7a898682-6296-4a98-89c0-d16af71cdedb">1.15</ix:nonFraction>&#160;billion principal amount of its <ix:nonFraction unitRef="number" contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTAz_19e0410b-9d6a-4529-afcd-19681680edc4">0</ix:nonFraction>% Convertible Senior Notes due 2027, or the 2027 Notes. The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding <ix:nonFraction unitRef="number" contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130" decimals="3" name="gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzY2_37a0e470-9d4a-40b9-a66b-33dcd12e5e7c">0.50</ix:nonFraction>% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i232d79bf035342d6bfee0e8ac008e0f4" continuedAt="i17dee67985b54c1681f1087bc8d01cd2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTAxOQ_78761599-3c12-4555-9d01-adcc261b98f2">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="d" contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTA2Nw_b6d932ac-6042-452f-be62-ebd564feb738">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="d" contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTEyMw_48c289b8-2e5a-4b8c-87c9-2d8709b72a78">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter, or the sale price condition;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the <ix:nonFraction unitRef="d" contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTI2OQ_b8df7575-8458-48f4-93a5-2ceef0d360e1">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="d" contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTMyMA_46c93d42-7629-402e-9837-a037d9a74516">ten</ix:nonFraction> consecutive trading day period, or the measurement period, if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than <ix:nonFraction unitRef="number" contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130" decimals="2" name="gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTUwMA_7e58a211-3d9e-49b0-96b7-e579f1312a10">98</ix:nonFraction>% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon the occurrence of specified corporate events</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#8217;s election. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMjI3OA_5cf62606-bf0b-40e1-82e2-ee351885c97a">139.82</ix:nonFraction> per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#8220;Make-Whole Fundamental Change&#8221; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&#8217;s common stock exceeds <ix:nonFraction unitRef="number" contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzIzOQ_4a390f50-3832-408a-a578-26a5774b49fa">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="d" contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzI5MA_c5241be3-24e5-4371-800d-97bc0313e36e">20</ix:nonFraction> trading days, whether or not consecutive, during the <ix:nonFraction unitRef="d" contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzM0Ng_c4274377-bfcc-49a4-bef4-2f729aa443da">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain corporate events that constitute a &#8220;Fundamental Change&#8221; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the 2027 Notes were not convertible as of March&#160;31, 2023 and December&#160;31, 2022, the net carrying amount of the 2027 Notes was classified as a long-term liability.</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjYyNA_7a8ce495-6d25-4603-8304-5f2a025c9030" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net carrying amounts of the 2027 Notes as of March&#160;31, 2023, and December&#160;31, 2022: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNC0yLTEtMS02ODAyMg_d44ce159-c5b8-4117-b17c-d07166b1139d">1,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNC00LTEtMS02ODAyMg_0aca490b-a4d9-4d4c-9755-be88e76d6d26">1,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNi0yLTEtMS02ODAyMg_9e78a488-9fb1-43b9-8682-e19b1125784a">11,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNi00LTEtMS02ODAyMg_45d36f81-70ed-4111-80b0-7b86469e4b82">12,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNy0yLTEtMS02ODAyMg_5f7c3a4b-e017-4d5b-8898-096e4c39c629">1,138,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNy00LTEtMS02ODAyMg_84b1ecf2-3a00-48be-b7e2-c6d5d4ebd47a">1,137,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i17dee67985b54c1681f1087bc8d01cd2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of the 2027 Notes was $<ix:nonFraction unitRef="usd" contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDc3NA_4eb6d2bf-b484-4cec-b5b3-95edaec07cd0">0.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDc4MQ_edb36214-537b-4c59-9dbb-7db118c5359b">0.7</ix:nonFraction> billion as of March&#160;31, 2023, and December&#160;31, 2022, respectively. The fair value was determined based on the closing trading price per $<ix:nonFraction unitRef="usd" contextRef="ie06cffa6cd1640db8649a5e4f20e89f0_I20230331" decimals="0" name="gh:DebtInstrumentMeasurementInputDenominator" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDg4NQ_7c999bd8-5e96-4aa7-bc7d-8749479e23bf">100</ix:nonFraction> of the 2027 Notes as of the last day of trading for the period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized in relation to amortization of debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="iafd5c38886184fd6af5573e63dd61acd_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTAzOQ_010cd4b2-a9ff-4ee4-ba3e-35ddfecf3ab1">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c8b26b7ee69436e81522ee5db3fb810_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTY0OTI2NzQ0ODMwNQ_abbf718a-14ad-46ac-abe9-eec3989e66d5">0.6</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively, which represented an effective interest rate of <ix:nonFraction unitRef="number" contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTE0OQ_44144867-c83c-450c-9a84-2b0501395a53">0.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib6a0869ad8ec4e6aa0ab8611139bf5b8_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTE1Ng_343a8ce6-4418-4957-b259-fba4de1dbda4">0.2</ix:nonFraction>% for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Hedges</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions, or the 2027 Note Hedges, with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116" decimals="2" name="gh:ConvertibleDebtHedgeStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTY4MA_c9b5650d-b9a7-4203-90de-8ae45b98e066">182.60</ix:nonFraction> per share, which represents a premium of <ix:nonFraction unitRef="number" contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116" decimals="2" name="gh:ConvertibleDebtHedgeSharePricePremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTcyNA_87be85e6-c598-4e75-aefa-c75474ba8bbd">75</ix:nonFraction>% over the last reported sale price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTc5NA_e86ac494-cfcb-444b-b4be-521cf2cdcca9">104.34</ix:nonFraction> per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#8217; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ifa6e61cb42a24541ada6ecb600b9aafe_D20201101-20201130" decimals="-5" name="gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjUwMA_e8454abc-5c8b-46b5-9c35-f48ed4291e10">90.0</ix:nonFraction>&#160;million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_70"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIyMA_cab18179-7e12-4b64-ad4e-3f3f24d7e132" continuedAt="i266943d24f5547298291afcc06eb22d6" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i266943d24f5547298291afcc06eb22d6" continuedAt="ia6c0d331f4234b79a23bad4a285c80a1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements for office space, data center, lab and warehouse use, with remaining terms ranging from <ix:nonNumeric contextRef="i1e94bdae869e4b2a9849b1c8d02651a5_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTY4_39f740a1-9e9b-47f3-9f8c-7e948e6d8ee8">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="ie6cdfb5a23124fe8acf8a056dc1ce503_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc0_3e92cbfc-9f4a-4003-99a0-cb27a172c7c7">11</ix:nonNumeric> years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc4Mw_7c98f67c-3e0e-4cd9-a411-4c343e642095">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc5MA_8527f98c-73d9-4030-a4f3-06a504ae0a0d">6.9</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). </span></div><div style="margin-bottom:3pt;text-align:center"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIyMg_16c3c471-e8b3-42da-8c37-a9d4e5086e09" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:71.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMi0yLTEtMS02ODAyMg_eb97213c-6445-46e6-acfd-493a1832b1f8">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMi00LTEtMS02ODAyMg_3f918c5a-798b-43c8-85b2-ee6422c51828">9.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMy0yLTEtMS02ODAyMg_43d54edc-5a7c-48bb-8d85-0292bf7c0ac6">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMy00LTEtMS02ODAyMg_6c51c488-011b-4d48-9f7b-cec6a32011c9">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ia6c0d331f4234b79a23bad4a285c80a1"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIxOQ_b2e43640-9657-4bfb-a2c7-b45eabe93d86" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March&#160;31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMy0xLTEtMS02ODAyMg_53c87d47-a219-4fd7-9ad7-568b1088545b">23,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNC0xLTEtMS02ODAyMg_fb3eb627-30d4-45d9-a6cc-46bb1a622cf9">33,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNS0xLTEtMS02ODAyMg_3b9ac785-5607-4030-9cb5-ced3989ca98e">32,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNi0xLTEtMS02ODAyMg_96690855-bc31-401b-b4ad-9fbe20f2c909">27,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNy0xLTEtMS02ODAyMg_c6c7eef6-e6d6-4e0a-bd4c-e1d8de87c2f0">24,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfOC0xLTEtMS02ODAyMg_7f51cb20-fbfe-4270-b2d6-d0eae2d6fc92">125,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfOS0xLTEtMS02ODAyMg_6ee09f0e-afa8-440e-9ace-44e8bcfe77ee">267,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMTAtMS0xLTEtNjgwMjI_00ef1e3a-2a16-4d24-9289-a4f9291c6c65">38,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMTItMS0xLTEtNjgwMjI_46ada688-6336-44a7-8979-1a1ece8d0cc8">228,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_76"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83Ni9mcmFnOmUzNzFlYzRhMGJkYjRjNjI5ZTQzYWVmYWM4MTQ0ZTMxL3RleHRyZWdpb246ZTM3MWVjNGEwYmRiNGM2MjllNDNhZWZhYzgxNDRlMzFfNjI4OA_3d9a4e2a-b695-414a-912b-3615e7ce9dbd" continuedAt="i733da1b99f644312b53a2ec7c0360488" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i733da1b99f644312b53a2ec7c0360488" continuedAt="i603e9993566847e08af5aace7f292403"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i603e9993566847e08af5aace7f292403"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Disputes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, TwinStrand Biosciences, Inc., or TwinStrand Biosciences, and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#8217; allegations and asserted counterclaims of invalidity, unenforceability due to inequitable conduct and infringement of <ix:nonFraction unitRef="patent" contextRef="idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83Ni9mcmFnOmUzNzFlYzRhMGJkYjRjNjI5ZTQzYWVmYWM4MTQ0ZTMxL3RleHRyZWdpb246ZTM3MWVjNGEwYmRiNGM2MjllNDNhZWZhYzgxNDRlMzFfMzQ5NA_07f16d0c-f785-4f40-8466-c32ae23350cd">four</ix:nonFraction> of the Company&#8217;s patents. Discovery in the case is ongoing and trial is scheduled to commence in November 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Illumina Inc., or Illumina, filed suit in the United States District Court for the District of Delaware against the Company and its Co-Chief Executive Officers, Drs. Helmy Eltoukhy and AmirAli Talasaz, or collectively, the Defendants, alleging that Illumina is the owner of certain of the Company&#8217;s patents and patent applications, and that the Defendants allegedly misappropriated Illumina trade secrets. Illumina also alleges that Drs. Eltoukhy and Talasaz breached various Illumina employment contracts, company policies, and implied covenants of good faith and fair dealing as part of their former employment with Illumina prior to starting the Company. Illumina is requesting unspecified compensatory and punitive damages, attorneys&#8217; fees, and specific performance in the form of a declaration of ownership and assignment of intellectual property filed for or obtained by the Defendants that derives from the alleged misuse of Illumina confidential information. The Defendants deny the allegations of misconduct, and in March 2023, the District Court granted in part the Defendants&#8217; motion to dismiss the complaint, without prejudice to amend, effectively staying discovery on the dismissed allegations.  In April 2023, Illumina filed an amended complaint to which Defendants will respond by June 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Advertising Dispute</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company also filed a lawsuit against Natera, Inc., or Natera, in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#8217;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#8217;s Signatera assay. The Company is seeking an injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. The Company moved to dismiss Natera&#8217;s counterclaims, and in January 2022, the court granted in part and denied in part the Company's motion to dismiss. The Company and Natera have both moved for summary judgment on various claims, with the court granting in part non-dispositive motions brought by each party. Trial is scheduled to commence in July 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Investigative Demand</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company received a Civil Investigative Demand, or CID, from the United States Attorney for the Northern District of California in connection with an investigation under the False Claims Act. The CID requests information and documents regarding billing of government-funded programs for the Company&#8217;s panel of genetic tests known as Guardant360. The Company is fully cooperating with the investigation. At this time, the Company is unable to predict the outcome of this investigation.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_82"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMzY1_b923c4fd-30e8-4cf6-9f22-c9b7234d95db" continuedAt="ieadb83050a944eb8b139f9854741a58e" escape="true">Common Stock</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieadb83050a944eb8b139f9854741a58e" continuedAt="ib188f4be97eb4dcdaed56f3329c3e5fe">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors, or the Board of Directors. As of March&#160;31, 2023, and December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMTg1_285140bf-3616-4c88-852b-13554776516c"><ix:nonFraction unitRef="usd" contextRef="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231" decimals="-3" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMTg1_7fe81e41-d2f8-45ca-a210-038460ababe5">no</ix:nonFraction></ix:nonFraction> dividends on the Company's common stock had been declared by the Board of Directors.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ib188f4be97eb4dcdaed56f3329c3e5fe"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMzY4_866c7d2d-94db-4842-95f0-6fc477971526" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c7c95d575374df5873ad5d340d429dc_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMi0xLTEtMS02ODAyMg_4f745229-5f08-4cb1-a692-c26aac6ac3f8">3,372,561</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i471e1119a5c84de99cc7a66a9091e4b6_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMi0zLTEtMS02ODAyMg_726e185d-844b-431c-a92a-2c1012772b9e">3,402,574</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24e6708f9c264d729a87143b05a29523_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMy0xLTEtMS02ODAyMg_396031a5-307a-4620-8e49-b49d39be7db0">3,430,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMy0zLTEtMS02ODAyMg_d3fb09d2-cd95-4196-97d6-a9dd203ac625">3,687,888</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b6c755d9322493ea937d75411cca741_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNC0xLTEtMS02ODAyMg_516787d0-d553-42ff-bbb0-e166e206f922">2,260,764</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b801579905e486f9d16da0424368dea_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNC0zLTEtMS02ODAyMg_f5c45211-7be6-4c54-b26a-a52c96b067cc">2,260,764</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67005148159d4de98f4625a633c07616_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNS0xLTEtMS02ODAyMg_134437c2-1f6d-4203-b533-2ca5346976e6">333,275</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNS0zLTEtMS02ODAyMg_7146dfc5-a608-49e1-b2a5-ed5d87183647">341,713</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12acc1844c7547209359a2ebd3bbac18_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNi0xLTEtMS02ODAyMg_096d6ffc-4c68-46e3-9ec9-4ba4007ce9d9">9,333,892</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2888bc5ff0cd47c1b681eb96ef6bc6c2_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNi0zLTEtMS02ODAyMg_e46cdb4c-9d60-4687-83fc-f32fe4a7b02e">5,438,296</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8b85720538549e793c0ea411f6d2926_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNy0xLTEtMS02ODAyMg_21ffc150-76d6-4daf-9414-38d9eb82ca20">2,144,505</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4744fe70bd24460bded39c69c9e72eb_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNy0zLTEtMS02ODAyMg_6706cb40-64c3-4fc4-8b77-4e16efa429c4">1,118,311</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfOC0xLTEtMS02ODAyMg_9f0dae77-aafd-48b0-9911-230ef68ce911">20,875,818</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfOC0zLTEtMS02ODAyMg_aa642cc6-eab6-4fc2-9eb3-a2e79ef2d2e3">16,249,546</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_85"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODE_9e4aaa19-3776-4528-8945-cf3a2828bc59" continuedAt="if0d296c40f104ef9a3b188a0d4a5d498" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if0d296c40f104ef9a3b188a0d4a5d498" continuedAt="i9161c71f94c34cee929da5bf2e6f2451"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzE_d4c4019e-d4f3-44b4-8e78-c4af83a40c84" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:30.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS0xLTEtMS02ODAyMg_c73defe8-4e51-413c-9483-6e7215ab91e8">5,438,296</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS0zLTEtMS02ODAyMg_4ae728af-e78b-4dc3-b367-2651d6e2ef37">3,402,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS01LTEtMS02ODAyMg_9946ff22-8035-4cc2-a8b8-fd0a890bfb46">34.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS03LTEtMS02ODAyMg_e289ad41-46f7-4508-889f-398d1a7c3f81">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS05LTEtMS02ODAyMg_e84872f5-2427-4ff7-88f6-3c7a8e7f824b">39,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNi0xLTEtMS02ODAyMg_f5e48a4d-c8f1-42fa-a634-3e5b4f8a1367">3,689,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy0xLTEtMS02ODAyMg_44f929ff-76a2-4fd5-8dbd-9ea12d216969">40,091</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy0zLTEtMS02ODAyMg_26e011ff-65f6-43af-8ff3-c37c8e15031a">40,091</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy01LTEtMS02ODAyMg_9fd1cc47-ab11-4bf1-b1b2-1ab2ecbdc72a">30.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfOS0zLTEtMS02ODAyMg_1856da11-67dd-419c-9bc6-72436955b030">21,049</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfOS01LTEtMS02ODAyMg_acc53d07-6dbc-4cc8-a894-b3651913a766">7.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtMS0xLTEtNjgwMjI_0886f721-ff31-4928-b5fc-f4075df5271f">49,055</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtMy0xLTEtNjgwMjI_f0841487-214b-4507-b6fb-8837cb88b092">49,055</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtNS0xLTEtNjgwMjI_eff7df11-1994-4ae3-abc2-79a76e3a91a2">60.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTEtMS0xLTEtNjgwMjI_f61dd4c5-33c6-4c89-ba79-c7adf6b93a51">176,717</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTItMS0xLTEtNjgwMjI_95fddfda-f360-4e6c-b452-6c5e6018d638">365,911</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTYtMS0xLTEtNjgwMjI_ec262df2-a4d3-426c-9535-ac84008ec80b">8,438</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctMS0xLTEtNjgwMjI_53cbfc84-1cbd-42d5-acab-249801a7fedf">9,333,892</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctMy0xLTEtNjgwMjI_42c1fd2a-ff68-4ece-9e71-5d38596c5bd8">3,372,561</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctNS0xLTEtNjgwMjI_13eed666-b7f7-44cd-9afd-00348bad316b">34.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctNy0xLTEtNjgwMjI_fe55bd57-57cb-4cef-8b35-6476efa510f6">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctOS0xLTEtNjgwMjI_cbfa6a4c-b88b-4d54-bccd-c00b32ae2b3d">32,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtMy0xLTEtNjgwMjI_a6f21e44-2f05-43ba-ac94-801a9a750cad">2,091,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtNS0xLTEtNjgwMjI_a38f265c-32ce-4ec0-beed-039db4007dcb">21.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtNy0xLTEtNjgwMjI_ddc61e18-858f-47ad-841e-70f7925ddcfd">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtOS0xLTEtNjgwMjI_a8d0bd3b-395c-490d-844b-82ef5c42726d">32,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2023, an additional <ix:nonFraction unitRef="shares" contextRef="i09bde5cb1e9146c78e36910bd9edc42c_D20220101-20220101" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzE4_d490a2d4-4f47-406c-9841-cbea1bb9bedd">3,689,000</ix:nonFraction>&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $<ix:nonFraction unitRef="usd" contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzA3_05c8a5c6-4bd0-4f91-a9af-fd800a221abe">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzE0_646341e0-dde3-475e-8438-4504b7115d59">7.3</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODY1_607a5f79-8416-4e36-8a3e-e239affb1e67">19.82</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODcy_b46bce6e-10ba-4b59-967f-702ac9b839a4">36.32</ix:nonFraction> per share for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested options as of March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTA0Mw_e678590c-e8d4-4c8f-b5ef-38884cef820a">39.7</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTExNg_d65463c2-7384-42ae-a2aa-8248820c6284">2.9</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i9161c71f94c34cee929da5bf2e6f2451" continuedAt="i20ce47b9d1614dabbf7cc41dc8c14c8a"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODM_2ecc133e-e7dd-4dab-8782-59e1c64f1bd7" continuedAt="i1d74972046534960bd53b96884681991" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfMy0yLTEtMS02ODAyMg_d4a9f458-854e-4988-9478-1fe5e9ebdb47">3,687,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfMy00LTEtMS02ODAyMg_298fcdd8-2172-4cb4-b423-0a81742398e6">60.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNC0yLTEtMS02ODAyMg_3e9eb232-1f33-4a6c-a875-5401f976ab73">176,717</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNC00LTEtMS02ODAyMg_a0de7918-ee9f-49fa-9d1a-d45842bfca46">30.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNi0yLTEtMS02ODAyMg_51bf24c1-99a1-4d7a-9ebc-3c3be61f117b">67,873</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNi00LTEtMS02ODAyMg_98565a34-4a7a-4dff-8b8d-0fd5acf0ff0c">67.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNy0yLTEtMS02ODAyMg_7d0f36e8-47fb-4065-b13f-cd4b719be544">365,911</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNy00LTEtMS02ODAyMg_90674272-4638-4c0f-a2fb-1ea68daf9988">57.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24e6708f9c264d729a87143b05a29523_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfOC0yLTEtMS02ODAyMg_5720fb7f-9d96-441d-be25-ddde2a9f12e7">3,430,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24e6708f9c264d729a87143b05a29523_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfOC00LTEtMS02ODAyMg_a2372c42-0b14-4fdf-8674-89c0c286810c">59.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested restricted stock units as of March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i24e6708f9c264d729a87143b05a29523_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQzMw_defccea7-f93f-4809-a63c-156a5b703a5d">161.5</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTUwNg_e7add42e-2435-4d85-9b24-9fbf03d054af">2.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant PSUs, under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of <ix:nonNumeric contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2MjcxMA_4394cecc-b6c8-4ae8-98dd-4c20cfacb632">1.5</ix:nonNumeric> years to <ix:nonNumeric contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTg3MA_39f1ed31-2753-4d46-b808-81597e5e1b31">4</ix:nonNumeric> years and an additional service period requirement of <ix:nonNumeric contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTkyMQ_ea75319a-50a0-41a7-a0ba-5ea60db791d7">six months</ix:nonNumeric> to <ix:nonNumeric contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2MjcxNw_b7b3a207-ac56-4ee4-a53d-1a4932706523">one year</ix:nonNumeric> after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of <ix:nonNumeric contextRef="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjA3NQ_51b76bfa-e143-4768-839e-43a1aa713cdd">4</ix:nonNumeric> years. The PSUs are expected to be expensed over a period of approximately <ix:nonNumeric contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjE0Nw_6600c810-01ce-4c9e-8512-18f3d490faf3">2.5</ix:nonNumeric> years to <ix:nonNumeric contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjE1Mw_a67cd013-6de9-4868-b26e-88230c47ba1f">4.5</ix:nonNumeric> years subject to meeting the respective performance metrics and service requirements. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, and as part of these PSU programs, the Company granted restricted stock units with certain performance metrics consisting of a performance period of <ix:nonNumeric contextRef="id371f8b5f52a447a988f5108d595d824_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNjA0NzMxMzk3NTYwNA_66297644-5d0e-4bed-95b9-363ecbe0f48f">4</ix:nonNumeric> years combined with an additional service period requirement of <ix:nonNumeric contextRef="id371f8b5f52a447a988f5108d595d824_D20201101-20201130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNjA0NzMxMzk3NTYxOA_4cb47e2e-d050-4c39-8f7a-c4f58e730fc6">six months</ix:nonNumeric> should the vesting criteria be met. As of March&#160;31, 2023, these PSUs had a grant-date fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="if79268d66ccd4c498d88b492e67d4b78_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2NDQ1Mw_61ad685d-4058-4e79-8cd1-229ba88566bf">28.0</ix:nonFraction>&#160;million, net of forfeitures, however <ix:nonFraction unitRef="usd" contextRef="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2NDQ2Nw_3403a52d-9a5f-44fb-849f-76f6dcf086a8">no</ix:nonFraction> compensation expense for these PSUs has been recorded to-date since the achievement of the performance metrics was not determined to be probable as of that point time. </span></div><ix:continuation id="i1d74972046534960bd53b96884681991"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfMy0yLTEtMS02ODAyMg_0e774255-55e0-4630-af34-cd3e93acfefe">341,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfMy00LTEtMS02ODAyMg_5dd04892-9447-4b57-a15b-0129867b90c9">110.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNi0yLTEtMS02ODAyMg_4fb65497-a413-48a8-b291-c0827183252c">8,438</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNi00LTEtMS02ODAyMg_9e0906e0-3363-4e1b-a607-adacc7c8eef0">122.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67005148159d4de98f4625a633c07616_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNy0yLTEtMS02ODAyMg_6c0d1d74-aeb9-4620-8900-0c78e60c55b4">333,275</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67005148159d4de98f4625a633c07616_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNy00LTEtMS02ODAyMg_9bc86504-87d4-40e7-983a-02a1c4756a76">110.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation recorded for the PSUs was $<ix:nonFraction unitRef="usd" contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjY0MA_ea4d8e83-4bcb-42a9-b53b-d37cc19d6a84">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i90f4b6d3e1a44b50bca2cfe317198cd9_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjY0Nw_40625594-a2f2-4c7e-bfbd-fbec9ed4fab7">0.3</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i67005148159d4de98f4625a633c07616_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjgyMQ_d8c4aaf2-8d72-44db-973a-652a02440d8b">2.6</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjg5NA_54686555-a3f6-45d2-9719-22f7ee00a608">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="i20ce47b9d1614dabbf7cc41dc8c14c8a" continuedAt="ic5dc027640b54e0984484dfc5290713f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Board of Directors approved and granted <ix:nonFraction unitRef="shares" contextRef="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjk5MQ_17f655c2-0423-4b17-b519-4e4e127767ab">1,695,574</ix:nonFraction> market-based restricted stock units, or MSUs, under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of <ix:nonFraction unitRef="tranche" contextRef="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODQ_c1ffff8a-4244-4ed5-a412-cb1965ab9eb4">three</ix:nonFraction> separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of <ix:nonNumeric contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzQzMg_5e9c8a8c-7b00-4af9-98b7-68259df99b25">30</ix:nonNumeric> consecutive calendar days. The share price goal can be met any time during the <ix:nonNumeric contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzI_1147d4c8-e077-4a38-9fd0-3d30e4cd75a7">seven-year</ix:nonNumeric> performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYxNw_60b18dda-66c2-4999-b9be-3ed7aa5e2977">six</span> to <ix:nonNumeric contextRef="if0ae71f8bf884fe38ffe82c44c115460_D20200501-20200531" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYyMw_244c8512-e051-4864-86dd-49ac317d2822">twelve months</ix:nonNumeric> depending on the time of vesting within the <ix:nonNumeric contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NjQ_53b0fb12-369b-45bd-a3bb-12e15b5a1ef5">seven-year</ix:nonNumeric> performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. Any MSUs that remain unvested at the end of the <ix:nonNumeric contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODU_e4f9dd2c-eb39-4438-81eb-9767739bc734">seven-year</ix:nonNumeric> performance period will automatically be forfeited and terminated without further consideration. <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NTk_bdd2b6fe-dc7b-45aa-ab18-33f14a568abe" continuedAt="if0e88449b73446438e49a724e52f18ab" escape="true">The following table presents additional information relating to each MSU award:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><ix:continuation id="if0e88449b73446438e49a724e52f18ab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"></td><td style="width:33.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331" decimals="0" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMS0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOmQ4Mjg2ZWFkNTA3ODRhZTI4OWU2YTBhM2UzMjY3ZWZlXzQ_bafc6cfe-84be-4cd0-b0d0-584a444c3cba">120</ix:nonFraction> per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMS00LTEtMS02ODAyMg_1728d4e5-1089-42fd-8f22-87b0d6ed86f2">565,192</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331" decimals="0" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMi0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOmUzNjY1NjY2MTUyYzQyNmI4YzZlYWRkY2Y0MDcxYjQ0XzQ_cded186e-a862-4d99-a1fd-6f6eaadfd3cf">150</ix:nonFraction> per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMi00LTEtMS02ODAyMg_19c706ab-0ddd-4a41-8562-47a3eae8e380">565,191</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331" decimals="0" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMy0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOjM5ZTFjZDIwZmMwNTRmZmE4NmRiMzI5NmI0NmUzN2Y1XzQ_641dd72b-27ed-42d1-9c80-4895f989eb32">200</ix:nonFraction> per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMy00LTEtMS02ODAyMg_0bcd1e00-a4f5-434c-9773-423a49368e7e">565,191</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche was recognized based on an accelerated attribution method over the estimated derived service period. The derived service period was the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model used assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU. The weighted-average grant date fair value of the MSUs was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTA4OA_c6abb5d3-ef6c-42cf-84c0-29d64d5ae5a3">67.00</ix:nonFraction> per share and the weighted-average derived service period was estimated to be in the range of <ix:nonNumeric contextRef="i31a0dc3163854d6cb56d919865f28f0f_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTE4NQ_74995172-4d60-4f86-bf3e-757239c227cb">0.83</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i8355f22e8d444065acdca383af614973_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTE5MA_f3c3cc13-181d-4111-8351-3e44f7e9f60a">2.07</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2021, Tranche 1 of the MSUs became vested because it had met both service requirement and market-based performance metrics as the predetermined share price goal of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie817ff3c12124b78a03fdb6de0e8038d_D20200501-20200531" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTM3Mw_d6ebdd59-bc0e-472b-801a-deb90f65559a">120</ix:nonFraction> per share was achieved for a period of <ix:nonNumeric contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQxNQ_5e9c8a8c-7b00-4af9-98b7-68259df99b25">30</ix:nonNumeric> consecutive calendar days. As of March&#160;31, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i4b6c755d9322493ea937d75411cca741_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ2Mg_131d5784-957e-403e-9290-9fd7a31ee5dc"><ix:nonFraction unitRef="shares" contextRef="i3b801579905e486f9d16da0424368dea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ2Mg_e9a6cf5e-111c-4c55-a6a3-3c56b1177eaf">2,260,764</ix:nonFraction></ix:nonFraction> shares of market-based restricted stock units, with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b6c755d9322493ea937d75411cca741_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTU2MQ_0ac28a4c-3a7b-4408-ac23-325f05c93a31">65.20</ix:nonFraction> per share, were outstanding under the 2018 Plan. <ix:nonFraction unitRef="shares" contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_aa18a1a7-907a-4d31-93e0-8a983f45874e"><ix:nonFraction unitRef="shares" contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_c6b660d3-ae00-4412-84f1-4765ab253440"><ix:nonFraction unitRef="shares" contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_d4129b22-80d9-453b-a04e-17e1a3fdbc3c">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> MSUs were granted, vested or canceled during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All <ix:nonFraction unitRef="tranche" contextRef="iab8405ea1a894bd49c95fae94c570714_D20220630-20220630" decimals="INF" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTA5OTUxMTY0OTE4MQ_cf25d4b1-df86-4dc4-b7be-eacac09322d5">three</ix:nonFraction> tranches of the MSUs were fully expensed as of June 30, 2022. Stock-based compensation for the MSUs was $<ix:nonFraction unitRef="usd" contextRef="i9210d17c359d4a029aa0d629f68b0d32_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTc1OA_07216b30-1f5d-41f5-a87a-9d5b55cb82c2">8.5</ix:nonFraction> million for the three months ended March&#160;31, 2022, which was recorded in general and administrative expenses on the Company's condensed consolidated statement of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMEA 2020 Equity Incentive Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan, or the AMEA 2020 Plan, under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, in connection with the Joint Venture Acquisition, the Company issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia06f00d018a84185bf63dbd26b8fcf13_D20220601-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzkxMg_ca0806ee-42e0-4f44-accb-74884525c308">4.44</ix:nonFraction> per share determined pursuant to an independent valuation. In July 2022, the Company settled the tender offer with the <ix:nonFraction unitRef="grantee" contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODAyNw_fd6855bb-93d8-46c9-95fd-2feac47d7fd4">39</ix:nonFraction> grantees for a total amount of $<ix:nonFraction unitRef="usd" contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODA2MQ_6836bd9b-42c6-4de7-b6b1-91930a43500f">13.7</ix:nonFraction>&#160;million. In addition, in connection with the Joint Venture Acquisition, the unvested Joint Venture's stock options were cancelled and such grantees received replacement awards covering a number of shares of the Company's common stock. The replacement awards, valued at $<ix:nonFraction unitRef="usd" contextRef="i5f314cba04f147aaa5a0130ab210f819_I20220731" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODMyNQ_7e89d3d0-19ff-4b0e-8501-5c3d123b823c">4.1</ix:nonFraction>&#160;million, are subject to the same vesting schedule that applied to the unvested Joint Venture's stock option immediately prior to the close of the Joint Venture Acquisition transaction, to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODU1Ng_2e1fdf9e-574f-489b-95c9-c3eaf5cd7aea">2.2</ix:nonNumeric> years. The Company accounted for this as a modification which resulted in an immaterial incremental stock-based compensation expense. After the settlement of the tender offer in July 2022, the Company cancelled the AMEA 2020 Plan. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ic5dc027640b54e0984484dfc5290713f" continuedAt="if829a7c897f543deb88fdf10e77d054b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzM_c6ea910a-c912-4f7f-b717-23b322de5a9a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e84c2df8114b2ca174af7f12413df9_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNS02LTEtMS02ODAyMg_1f7f1307-f589-4b80-bd53-934cb7ce68fd">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22845a3df5054db690d00e20e26e9de7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNS04LTEtMS02ODAyMg_1adfe862-ca5b-4374-8376-6f7c38704919">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of development services and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa36b882d6a4a99b4d65b78a2f7f31f_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi02LTEtMS03MzM4MQ_7cf7eb35-3be1-44bb-897a-830378e27f7c">474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb41fcfde104edeb7f180200c669ff1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi04LTEtMS03MzM4OQ_4c2ea273-132f-42be-80d7-8e89ec2b6089">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257ec7f3adfd447980af46db25d249da_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi02LTEtMS02ODAyMg_54623d23-33bd-4229-8bc1-1730d7e6aca8">8,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525b368da8b94090b710ab4a0286430d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi04LTEtMS02ODAyMg_bd1a78ab-f323-4c31-aa71-e4dd2c7f0ca4">5,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e6b4f53ad9427188ba1f105f093cba_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNy02LTEtMS02ODAyMg_725adcda-5dde-4d75-9620-fb5a015aa6df">7,503</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0babdde2fcb4400f8a4240d151c2273f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNy04LTEtMS02ODAyMg_7d70f09a-50e4-4da6-8f9e-4c957a9ab497">5,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f08d30f39d4fd18d425c922f9e450a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOC02LTEtMS02ODAyMg_18456223-95ab-4409-9293-ecfc40c1ab38">4,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5740f52d90ea487290d3e3b20b00fe62_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOC04LTEtMS02ODAyMg_3e636e2f-3bc8-4e80-9eec-7b53d2e357e5">12,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOS02LTEtMS02ODAyMg_10f6f770-b521-40e5-b673-4c0af51ad3b4">22,266</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOS04LTEtMS02ODAyMg_c6c4e586-d6e2-497d-90c3-b896eb987835">24,799</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODc_8f0a4a10-c41a-4489-89b3-cbc786800294" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjdiNGYyMjNiNDM4ODQyMWJiMjAyNTczYTgzY2Q4OWY5XzQ_521ccb2e-9681-4829-93fb-9f12a9839cd2">5.95</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjdiNGYyMjNiNDM4ODQyMWJiMjAyNTczYTgzY2Q4OWY5Xzk_11e07d63-f669-45ed-a0fe-ff7a281ff946">6.10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC04LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQwZWY0OGEyZmRjNDQxNzc4YWFmNjA5M2NjMTY0ZTM3XzQ_8f9dc973-a735-4a8b-9ee3-ff688f359306">5.97</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNS02LTEtMS02ODAyMi90ZXh0cmVnaW9uOmZjZjlhMjAwZDg0NTQ0MzdhNmVlOTVkZDZkYWJiNGZkXzQ_7deae766-a9d8-4cc0-ad5b-c0f3fb1e34a6">69.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNS04LTEtMS02ODAyMi90ZXh0cmVnaW9uOmY3ZTlkMGVlOGY0NTQ5NmNiMWE4ZTFlZDZlNmM4Y2U4XzQ_e0c92e09-18af-439c-86a4-f61a0198505f">63.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQ1NDQ5YzZlYzEyNDRjNzY4ZmFjMDhiZmEwYzkyNGViXzQ_01f89353-ac59-4e80-8f57-b986e4ba4b8b">4.1</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQ1NDQ5YzZlYzEyNDRjNzY4ZmFjMDhiZmEwYzkyNGViXzk_539cf65d-cd3f-44cf-b263-6598f2ed3e62">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi04LTEtMS02ODAyMi90ZXh0cmVnaW9uOjhjNjhlMDMxOGEzOTRiNzhiMmE5Y2Q5N2I2MDExOTg0XzQ_e18b0bab-9f09-4a02-8ed5-29c132f62de9">1.9</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNy02LTEtMS02ODAyMi90ZXh0cmVnaW9uOmJkNTIwNDlhMDg2ZTRjMmE4ZDAwZDkzNTZmYWEwYzY4XzQ_11b68cf4-1f19-4fec-8aae-71489bf881d9">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNy04LTEtMS02ODAyMi90ZXh0cmVnaW9uOmZlMjk1YjU4YmZjNjQ1NDhhOTY5ZjQ0NjY2NjQ4MDBhXzQ_4b70733b-ac01-4e73-9105-721d21db99d6">&#8212;</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="if829a7c897f543deb88fdf10e77d054b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI2MDA_9aaffe29-8578-4537-b6a4-98b74896956c">zero</ix:nonFraction>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan, or the ESPP. A total of <ix:nonFraction unitRef="shares" contextRef="ibf899f29153c4ae48025cc44a9774ca0_I20180930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI3OTE_cbdf7b1d-f68e-43a9-9935-5ef57fc49669">922,250</ix:nonFraction> shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020 and March 2, 2023, an additional <ix:nonFraction unitRef="shares" contextRef="ie2e087e17e0e420b8c053b525bbb7093_D20200101-20200101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI5MDQ_87a35cc2-e98d-4143-a2ca-291632c89bc9">942,614</ix:nonFraction>&#160;and <ix:nonFraction unitRef="shares" contextRef="i8d35aee771524865b1b3cd4a8ec1d0ac_D20230302-20230302" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODM0ODg4_832c45b0-f72d-4d03-93bf-d5d8777a9a47">1,026,194</ix:nonFraction> shares of common stock became available for issuance under the ESPP.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;<ix:nonFraction unitRef="number" contextRef="id8b85720538549e793c0ea411f6d2926_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTMxMDI_1d148564-353d-4d8b-bbea-3c95a09533fc">10</ix:nonFraction>%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;<ix:nonFraction unitRef="number" contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTMyNzU_4ce4cb59-598a-4bae-84af-9c8f6b6aaf72">85</ix:nonFraction>%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;<ix:nonNumeric contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzA_25595991-34c2-4553-bc2e-4cbec66bb001">six-month</ix:nonNumeric> offering periods beginning on May 15 and November 15 of each year. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1OTI_5b775613-debe-4f8a-b905-9762e4dc6aef"><ix:nonFraction unitRef="shares" contextRef="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1OTI_79887490-844c-40b0-8054-b1dbb8e22dac">No</ix:nonFraction></ix:nonFraction> ESPP shares were granted or purchased for the three months ended March 31, 2023, and 2022. The total compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODI5MzQz_de0ae7e7-c422-46ec-b3c7-d1db4c9866eb">1.6</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODI5MzUx_f99a4771-6085-432d-a7b5-65b04cc25a24">1.0</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="id8b85720538549e793c0ea411f6d2926_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ0Njg_1fa81ee9-7316-4613-8121-7e80df8bbfa9">0.8</ix:nonFraction> million, which is expected to be recognized over the remaining term of the offering period of <ix:nonNumeric contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NTc_57e5f38b-f166-445a-bd67-76ba69036819">0.1</ix:nonNumeric> years.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_94"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODM1_8f97338f-69ed-41af-8804-90a96d43dbca" continuedAt="i2493fd1669fe4083873b1a3165ccb958" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i2493fd1669fe4083873b1a3165ccb958" continuedAt="ib3d26e579f3348f9aeaa4fbd62f5b8c8"><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODQx_72343d9d-28ae-4a52-85bf-ce92073f9302" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:64.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy02LTEtMS02ODAyMg_45eafcd1-7cee-4f26-a12f-d58578e5356f"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy02LTEtMS02ODAyMg_4adeca11-df28-4384-833b-20a4a4612f60">133,533</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy04LTEtMS02ODAyMg_22d03f21-ecc0-4a63-aa2f-286b73e39074"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy04LTEtMS02ODAyMg_91ca3818-983e-4b46-930e-cbc2178326fb">123,228</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC02LTEtMS02ODAyMg_36c91bd9-fdc6-4245-837c-13ee687b6942"><ix:nonFraction unitRef="usdPerShare" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC02LTEtMS02ODAyMg_c9348b6b-4b66-4ea2-9d5c-fa70b1db7ba3">1.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC04LTEtMS02ODAyMg_774d9a86-4071-4daf-b516-040e797b28cb"><ix:nonFraction unitRef="usdPerShare" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC04LTEtMS02ODAyMg_81760556-6b90-4b14-a081-d4dd7a807781">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS02LTEtMS02ODAyMg_2ec3080a-ff39-47e6-b71a-e8f38512eece"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS02LTEtMS02ODAyMg_cf495f91-7a1a-4287-a035-a4f8e9cf1a39">102,663</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS04LTEtMS02ODAyMg_42d4f00a-5bc5-4667-a29f-4a0ee6c05d64"><ix:nonFraction unitRef="shares" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS04LTEtMS02ODAyMg_8508b8c9-90da-4c65-b52c-d97143f69c4a">101,853</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><ix:continuation id="ib3d26e579f3348f9aeaa4fbd62f5b8c8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. <ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODMy_d3f8ad3a-ad7c-4cb6-8ffe-e0b3f90cd284" continuedAt="if33607b963ca442689b074aef5f7929d" escape="true">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:</ix:nonNumeric></span></div><ix:continuation id="if33607b963ca442689b074aef5f7929d"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib07e4ec43ccf4868a95b7cba38569e07_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNS02LTEtMS02ODAyMg_2bfe2c4e-037b-494a-821f-320fb8ad8231">3,378</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8405bc3396f043d38ac107f7e621ea0b_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNS04LTEtMS02ODAyMg_4283be41-b25d-47c6-a6ce-5981f0a3a07c">2,550</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dfcb8b82cc435bafa0737693ff7b95_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNi02LTEtMS02ODAyMg_42616d87-2264-46a5-bf91-e9ead2151f2b">3,550</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a7782cf20244b492722ced02d556d4_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNi04LTEtMS02ODAyMg_6a908396-2997-460a-b022-49f75f3ef0b0">1,484</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i018eca720b2b4bee988fdb517bb09d46_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNy02LTEtMS02ODAyMg_4238ad1f-7e7a-4170-b0b6-f9cd9836e3ad">2,261</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i784a2015beb447b480ff240ec2998829_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNy04LTEtMS02ODAyMg_82ad7f53-8490-4e0c-97b7-c9eea3132f78">2,261</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b84667fc3047d39ba495dfdb6af2a5_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOC02LTEtMS02ODAyMg_c2bef0f1-dd20-4f72-80d9-029544c80d67">337</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c434d2375a64859af229e0a8a1a79c2_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOC04LTEtMS02ODAyMg_dcc2f4bc-7e76-42e9-abf6-b2506f9e9612">357</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f00602410084027a24ca5b4c50e87c8_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOS02LTEtMS02ODAyMg_0e2f52a0-fa58-4f70-b391-c76e9936e199">264</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436487de8e484b5891dc7aaa105cc2dd_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOS04LTEtMS02ODAyMg_55ba8d2f-b9c8-4687-801a-dc686eda2ebb">84</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92d27c009cdc4d3c997e7de9fc339551_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTEtNi0xLTEtNjgwMjI_8f08098d-6991-4829-8965-ed9e3318aa58">8,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c5f7a63f9954f08adb2cdcc6eafb151_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTEtOC0xLTEtNjgwMjI_80d36ec3-00cb-4f33-8f20-bd2f592b8a95">8,225</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTItNi0xLTEtNjgwMjI_5cc85ce7-bb2b-456f-9cc0-fe6e9d55aa80">18,015</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTItOC0xLTEtNjgwMjI_ca0286c4-fe2b-4f32-955e-00756ace7568">14,961</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Excludes stock options of <ix:nonFraction unitRef="shares" contextRef="i3d27e6a526f14a71b27f8d0b9f9a0f23_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfNTQ5NzU1ODE0OTA0_4bda7cbd-881d-4ff2-839a-4281d10cdab8">2,995,200</ix:nonFraction> shares of the Joint Venture's Class B common stock granted under the AMEA 2020 Plan as of March&#160;31, 2022.</span></div></ix:continuation></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_97"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85Ny9mcmFnOmQxMmU4MzViNzM4YTQxMzQ5MWIzMGI0MWI5M2E2NjUwL3RleHRyZWdpb246ZDEyZTgzNWI3MzhhNDEzNDkxYjMwYjQxYjkzYTY2NTBfNjI3_25e1e24d-e4c7-404e-a1c0-7d88670c0b14" continuedAt="i8ffa55ccdca54b7d989eecf91110c9df" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i8ffa55ccdca54b7d989eecf91110c9df"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three months ended March&#160;31, 2023 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three months ended March&#160;31, 2023, and 2022, relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_100"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0MQ_9f7613b0-9bc9-448a-9d96-2ce1e29d398d" continuedAt="ibae6e1edb72644dfbf386154dec8e9e7" escape="true">Segment and Geographic Information</ix:nonNumeric></span></div><ix:continuation id="ibae6e1edb72644dfbf386154dec8e9e7"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0Mg_ca687bce-3c50-43c7-bbc9-f6ebec46f048">one</ix:nonFraction> operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.</span></div><ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0NQ_bd733364-037c-4b8d-9873-9b390825c8eb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9213a2532134ae5b9a645905cc1fbad_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzUtNi0xLTEtNjgwMjI_98bbc68e-bcb5-44ad-8b58-aa4cf224ce54">118,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3794fca71da4bfdaa6a037250b08ea1_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzUtOC0xLTEtNjgwMjI_77eee094-d874-41ae-ac3d-306658d2b03d">90,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a0c4f0823b457fb2f4cda5edce7d8f_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzYtNi0xLTEtNjgwMjI_bb90a37e-f07a-41f0-9011-22a763a3047c">9,803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e06c37d3dbd437d892d43f95983c3c7_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzYtOC0xLTEtNjgwMjI_9699ab7c-1947-430f-b68d-7eedf7d9cfbd">5,228</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzctNi0xLTEtNjgwMjI_370840dc-b19f-43e4-9163-223feb578507">128,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzctOC0xLTEtNjgwMjI_56cec516-e33a-4583-952c-4bae223fc493">96,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three months ended March&#160;31, 2023,&#160;and&#160;2022, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, and December&#160;31, 2022, <ix:nonFraction unitRef="number" contextRef="i25302361b67443c4a5fa5c0994f68a46_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzYyMw_36d935e8-6773-4d96-9805-8d2633d1072d">98</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9cbb23a4c4404fd09cf2220d10bbfd76_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzYzMA_a2018df2-017d-43b4-a56e-0c5d2944b03c">99</ix:nonFraction>%, respectively, of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div></ix:continuation><div id="id1808bc5647e45c0b487ecea2e9e50b0_103"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDMvZnJhZzo0OTMxYjAxMTI4NzE0NjEzOWQ3ZjFjMWMwZWI4MjI4ZC90ZXh0cmVnaW9uOjQ5MzFiMDExMjg3MTQ2MTM5ZDdmMWMxYzBlYjgyMjhkXzEwNzE_a1c389c9-3a12-4cb4-9c58-9853af1f02c9" continuedAt="i24b46e462a884efa8a82d0f4b107d553" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="i24b46e462a884efa8a82d0f4b107d553"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. Prior to the completion of the Joint Venture Acquisition in June 2022, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation.</span></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, beliefs, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and in Part II, Item 1A, &#8220;Risk Factors&#8221;  of this Quarterly Report on Form 10-Q.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_118"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading precision oncology company focused on helping conquer cancer globally through the use of our proprietary tests, vast data sets and advanced analytics. We believe our tests can transform cancer care by unlocking insights that will help patients at all stages of the disease, including at its earliest stages, when it&#8217;s most treatable. For patients with advanced-stage cancer, we have commercially launched Guardant360 LDT and Guardant360 CDx, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, and breast cancer. We have also launched the Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. In addition, we have developed Guardant Galaxy suite of advanced analytical technologies to enhance the performance and clinical utility of our portfolio of cancer tests, and to power the next generation of biomarker and drug discovery.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also collaborate with biopharmaceutical companies in clinical studies by providing the above-mentioned tests, as well as the GuardantOMNI blood test for advanced-stage cancer, and the GuardantINFINITY blood test, a next-generation smart liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. Using data collected from our tests, we have also developed our GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For early cancer detection, we have launched the Shield LDT test to address the needs of individuals eligible for colorectal cancer screening. From a simple blood draw, Shield uses a novel multimodal approach to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors. In December 2022, we announced that the ECLIPSE study, an over 20,000 patient registrational study evaluating the performance of our Shield blood test for detecting colorectal cancer in average-risk adults, met co-primary endpoints. In addition, in March 2023, we submitted a premarket approval application for our Shield blood test to the FDA. We also expect to expand into lung and multi-cancer screening with our investigational, next-generation Shield assay. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform our tests in our laboratories located in Redwood City, California, and San Diego, California. Our Redwood City laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states. Our San Diego laboratory is CAP-accredited and CLIA-certified. In addition, our Palo Alto, California laboratory is currently operated as a center for our research and technology development. We have also received CAP accreditation, and In Vitro Diagnostic, or IVD, sample processing approval from Japan's Ministry of Health, Labour and Welfare, or the MHLW, for our laboratory in Japan where we expect to commence processing samples following receipt of reimbursement approval.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated total revenue of $128.7 million and $96.1 million for the three months ended March 31, 2023, and 2022, respectively. We also incurred net losses of $133.5 million and $123.2 million for the three months ended March 31, 2023, and 2022, respectively. We have funded our operations to date principally from the sale of our stock, convertible senior notes, and revenue from our precision oncology testing and development services and other. As of March&#160;31, 2023, we had cash, cash equivalents and marketable debt securities of approximately $937.0 million.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors affecting our performance</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Testing volume, pricing and customer mix. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average reimbursement for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients&#8217; insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Revenue from clinical tests for patients covered by Medicare represented approximately 44% and 44% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precision oncology revenue from clinical customers</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March 31, 2023, and 2022, respectively. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Payer coverage and reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Precision oncology revenue from tests for clinical customers is calculated based on our expected cash collections, using the estimated variable consideration. The variable consideration is estimated based on historical collection patterns as well as the potential for changes in future reimbursement behavior by one or more payers. Estimation of the impact of the potential for changes in reimbursement requires significant judgment and considers payers' past patterns of changes in reimbursement as well as any stated plans to implement changes. Any cash collections over the expected reimbursement period exceeding the estimated variable consideration are recorded in future periods based on actual cash received. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider&#8221;. Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. Because we are not contracted with these payers, they determine the amount that they are willing to reimburse us for any of our tests and they can prospectively and retrospectively adjust the amount of reimbursement, adding to the complexity in estimating the variable consideration. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our tests and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our tests are reimbursed both from commercial and governmental payers. In addition, Z-Code Identifiers are used by certain payers, including under Medicare's Molecular Diagnostic Services Program, or MolDx, to supplement CPT codes for our molecular diagnostics tests. Changes to the codes used to report to payers may result in significant changes in its reimbursement. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In January 2021, a proprietary laboratory analyses, or PLA code was issued for our Guardant360 CDx with an effective date in April 2021. Additionally, based on this new PLA code, we applied to the Centers for Medicare and Medicaid Services, or CMS, for our Guardant360 CDx test to become an advanced diagnostic laboratory test, or ADLT. In March 2021, CMS approved ADLT status to the Guardant360 CDx test, based on which Medicare paid us at the lowest available commercial rate per test, from April 1, 2021 to December 31, 2021. Effective January 1, 2022, Medicare has started to reimburse Guardant360 CDx services at the median rate of claims paid by commercial payers and this rate will apply until December 2023. In March 2022, Palmetto GBA, the Medicare administrative contractor for MolDX, conveyed coverage for our Guardant360 TissueNext test under the existing local coverage determination. The policy covers our Guardant360 TissueNext test for Medicare fee-for-service patients with advanced solid tumor cancers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Palmetto GBA conveyed coverage for our Guardant Reveal test for fee-for-service Medicare patients in the United States with stage II or III colorectal cancer whose testing is initiated within three months following curative intent therapy, with an effective date of December 2021. In April 2023, Palmetto GBA conveyed coverage for our Guardant360 Response test for fee-for-service Medicare patients in the U.S. with metastatic or inoperable solid tumors who are on an immune checkpoint inhibitor therapy, tested four to ten weeks from therapy initiation. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our tests, we estimate the amount of revenue to be recognized at the time a test is provided and record revenue adjustments if </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and when the cash subsequently received differs from the revenue recorded. Due to this variability and unpredictability, previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. Additionally, if coding changes were to occur, payments for certain uses of our tests could be reduced, put on hold, or eliminated. This variability and unpredictability could increase the risk of future revenue reversal and result in our failing to meet any previously publicly stated guidance we may provide.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Biopharmaceutical customers. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue also depends on our ability to attract, maintain and expand relationships with biopharmaceutical customers. As we continue to develop these relationships, we expect to support a growing number of clinical studies globally and continue to have opportunities to offer our platform to such customers for development services, including companion diagnostic development, novel target discovery and validation, as well as clinical study enrollment. For example, our tests are being developed as companion diagnostics under collaborations with biopharmaceutical companies.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Research and development. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant aspect of our business is our investment in research and development, including the development of new products. In particular, we have invested heavily in clinical studies as we believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers. With respect to Guardant Reveal, in October 2021, we initiated a 1,000-patient prospective, observational, multi-center study, which we refer to as the ORACLE study, designed to evaluate the performance of our Guardant Reveal liquid biopsy test to predict cancer recurrence after curative intent treatment, across 11 solid tumor types. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with respect to Guardant Reveal, in December 2022, we entered into a partnership with Susan G. Komen&#174;, the world&#8217;s leading breast cancer organization, to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy. With respect to Shield, in December 2022, we announced that the ECLIPSE study, an over 20,000 patient registrational study evaluating the performance of our Shield blood test for detecting colorectal cancer in average-risk adults, met co-primary endpoints. The test demonstrated 83% sensitivity in detecting individuals with colorectal cancer. Specificity was 90% in both individuals without advanced neoplasia and in those who had a negative colonoscopy result. These results exceed the performance criteria set forth by the CMS for reimbursement. This test also demonstrated 13% sensitivity in detecting advanced adenomas. Based on these study results, in March 2023, we submitted a premarket approval application for our Shield blood test to the FDA. In addition, to evaluate the performance of our investigational, next-generation Shield assay in detecting lung cancer in high-risk individuals ages 50-80, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2022, we enrolled the first patient in a nearly 10,000-patient prospective, registrational study, which we refer to as the SHIELD LUNG study. The study is anticipated to run in approximately 100 centers in the United States and Europe. We </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are continuing to enroll more patients for these on-going studies, and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">International expansion. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships, direct contracts with hospitals or partnerships with research organizations. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we formed and capitalized Guardant Health AMEA, Inc., with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the Americas and Europe, and to accelerate commercialization of our products in Asia, the Middle East and Africa. In June 2022, we purchased all of the shares held by SoftBank and its affiliates, and upon completion of the transaction, we obtained full control over operations of Guardant Health AMEA, Inc. throughout the Asia, Middle East and Africa region. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we signed our first public private partnership agreement with Vall D'Hebron Institute of Oncology, or VHIO, one of Europe&#8217;s leading cancer research institutions, and in May 2022, the first blood-based cancer testing services in Europe based on our industry-leading digital sequencing platform became available at the VHIO testing facility in Spain. In October 2021, we signed a partnership agreement with The Royal Marsden NHS Foundation Trust, a premier cancer center within the United Kingdom for patient care, research and teaching of all types of cancer. We expect these partnerships will lead to the establishment of our testing services at the partner laboratories, using our digital sequencing technology, as well as generation of clinical and economic evidence to support commissioning in other areas of Europe.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we signed a strategic partnership agreement with Adicon Holdings Limited, a leading independent clinical laboratory company based in China, to offer our industry-leading comprehensive genomic profiling tests to biopharmaceutical companies conducting clinical studies in China. We expect the partnership to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our international expansion strategy depends on a number of factors, including the internal and external constraints placed on our international laboratory partners and biopharmaceutical companies in the context of broader global, regional and U.S. economic and geopolitical conditions. For example, deterioration in the bilateral relationship between the United States and China may impact international trade, government spending, regional stability and macroeconomic conditions. The impact of these potential developments, including any resulting sanctions, export controls or other restrictive actions that may be imposed against governmental or other entities in, for example, China, may contribute to disruption of our international partnerships and instability and volatility in the global markets, which in turn could adversely impact our operations and weaken our financial results.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Sales and marketing expense.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our sales and marketing expense, increase in headcount, and in particular, our various marketing programs around existing and new product introductions.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our general and administrative expense, and in particular, our stock-based compensation expense. Our equity awards, including market-based and performance-based restricted stock units, are intended to retain and incentivize employees to lead us to sustained, long-term superior financial and operational performance.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">COVID-19 Global Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The glob</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al coronavirus 2019, or COVID-19, pandemic has negatively affected, and we expect will continue to negatively affect, our revenue and our clinical studies. For example, our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical studies to advance their pipelines, for which our tests could be utilized. In addition, disruptions caused by the pandemic have adversely affected the quantity and quality of certain sequencers, reagents, blood tubes and other similar materials that are critical to our commercial and research and development programs. We currently have a limited amount of stock of these components. Failure in the future to secure sufficient supply of critical components could materially and adversely affect our ability to manufacture or supply marketed products and product candidates or complete our ongoing research and development programs on the timelines previously established, which could materially and adversely affect our business and future prospects. The severity of the impact on our business will depend on a number of factors, including the duration and severity of the pandemic and the impact of any variants of the virus on us, our customers, and our suppliers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A,&#160;&#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q, for more information.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_127"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of results of operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenue from two sources: (i) precision oncology testing, and (ii) development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Precision oncology testing revenue is generated from sales of our tests to clinical and biopharmaceutical customers. In the United States, through March&#160;31, 2023, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. We also submit claims to Medicare for reimbursement for our Guardant360 CDx, Guardant360 LDT, Guardant360 TissueNext and Guardant Reveal clinical testing performed for qualifying patients. Revenue from clinical tests for patients covered by Medicare represented approximately 44% and 44% of our precision oncology revenue from clinical customers during the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Development services revenue primarily represents services that we provide to biopharmaceutical companies, large medical institutions and international laboratory partners. We collaborate with biopharmaceutical companies in the development and clinical studies of new drugs. As part of these collaborations, we provide services related to regulatory filings to support companion diagnostic device submissions for our test panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. In addition to companion diagnostic development and regulatory approval services, we also provide other development services, including clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing our technologies, kit fulfillment and screening services.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of precision oncology testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of precision oncology testing generally consists of cost of materials, including inventory write-downs; cost of labor, including employee benefits, bonus, and stock-based compensation; equipment and infrastructure expenses associated with processing test samples, such as sample accessioning, library preparation, sequencing, and quality control analyses; freight; curation of test results for physicians; phlebotomy; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, depreciation of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. While we do not believe the technologies underlying the third-party licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but we expect the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of development services and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of development services and other primarily includes costs incurred for the performance of development services requested by our biopharmaceutical customers, and costs associated with our partnership agreements and screening services, which comprise of labor and material costs including any inventory write-downs. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services and other will vary depending on the nature, timing and scope of customer projects.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits including stock-based compensation, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs. We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical studies.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses and stock-based compensation, as well as marketing, sales incentives, and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our tests.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our general and administrative expenses include costs for our executive, accounting and finance, information technology, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. In addition, our general and administrative expenses also include severance costs related to workforce reduction. We expect that our general and administrative expenses will continue to increase as we incur additional costs to support the growth of our business. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses being incurred.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents and marketable debt securities.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of charges relating to amortization of debt issuance costs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists of foreign currency exchange gains and losses, fair value adjustments of marketable equity securities, impairment of non-marketable equity securities and other assets, and non-recurring payments due and received in relation to the settlement of license and patent disputes, net of credit losses. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates. </span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_130"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the significant components of our results of operations for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:71.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision oncology testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development services and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of development services and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,338)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for (benefit from) income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,293)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,252)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,533)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,228)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts include stock-based compensation expense as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:71.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of development services and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we granted restricted stock units with certain performance metrics consisting of a performance period of 4 years combined with an additional service period requirement of six months should the vesting criteria be met. As of March&#160;31, 2023, these PSUs had a grant-date fair value of approximately $28.0&#160;million, net of forfeitures, however no compensation expense for these PSUs has been recorded to-date since the achievement of the performance metrics was not determined to be probable as of that point time. At each reporting date, we will continue to assess the likelihood of the performance criteria being met and will record a cumulative catch-up adjustment should the achievement of the performance metrics be determined to be probable.  For example, had the achievement of the performance metrics been determined to be probable as of March&#160;31, 2023, we would have recorded a total charge of $15.0&#160;million, of which $1.3&#160;million would have been recorded to cost of development services and other, and $5.2&#160;million, $5.6&#160;million and $2.9&#160;million would have been recorded as components of research and development expense, sales and marketing expense, and general and administrative expense, respectively, in the condensed consolidated statements of operations for the three months ended March 31, 2023. In addition, any of these PSUs that remain unvested at the end of the performance period would be forfeited.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_133"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $128.7 million for the three months ended March 31, 2023, compared to $96.1 million for the three months ended March 31, 2022, an increase of $32.6 million, or 34%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing revenue increased to $113.4 million for the three months ended March 31, 2023, from $84.1 million for the three months ended March 31, 2022, an increase of $29.3 million, or 35%. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for clinical customers was $91.5 million for the three months ended March 31, 2023, up 39% from $66.0 million for the three months ended March 31, 2022. This increase in clinical testing revenue was driven primarily by an increase in sample volume. Total tests for clinical customers increased to over 39,100 for the three months ended March 31, 2023, from approximately 27,100 for the three months ended March 31, 2022. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for biopharmaceutical customers was $21.8 million for the three months ended March 31, 2023, and $18.1 million for the three months ended March 31, 2022, respectively. This increase in revenue was primarily due to an increase in sample volume, including our GuardantINFINITY smart liquid biopsy test launched in September 2022. Total tests for biopharmaceutical customers increased to approximately 6,150 for the three months ended March 31, 2023, from approximately 5,100 for the three months ended March 31, 2022, primarily due to an increase in the number of biopharmaceutical customers and their contracted projects.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other revenue increased to $15.3 million for the three months ended March 31, 2023, from $12.0 million for the three months ended March 31, 2022, an increase of $3.4 million, or 28%. This increase in development services and other revenue was primarily attributable to revenues earned from our partnership agreements during the three months ended March 31, 2023. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue </span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue was $53.1 million for the three months ended March 31, 2023, compared to $32.0 million for the three months ended March 31, 2022, an increase of $21.1 million, or 66%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing was $45.1 million for the three months ended March 31, 2023, compared to $30.7 million for the three months ended March 31, 2022, an increase of $14.4 million, or 47%. This increase in cost of precision oncology testing was primarily attributable to an increase in sample volume, resulting in a $8.2&#160;million increase in material costs, a $4.9 million increase in production labor and overhead costs, and a $1.1 million increase in other costs, including costs related to kits, freight and curation of test results for physicians.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other was $8.0 million for the three months ended March 31, 2023, compared to $1.3 million for the three months ended March 31, 2022, an increase of $6.7 million. This increase in cost of development services and other was primarily due to costs associated with providing screening testing services and  our partnership agreements during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $93.1 million for the three months ended March 31, 2023, compared to $81.8 million for the three months ended March 31, 2022, an increase of $11.4 million, or 14%. This increase in research and development expense was primarily related to continued investment in the development of our technologies and products, and our clinical studies, resulting in an increase of $8.9 million in outside service fees, an increase of $3.3 million in stock-based compensation, and an increase of $2.9 million in personnel-related costs, partially offset by a decrease of $5.0 million in material costs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing expense</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $76.1 million for the three months ended March 31, 2023, compared to $64.4 million for the three months ended March 31, 2022, an increase of $11.7 million, or 18%. This increase was related to commercial infrastructure buildout and marketing activities to support existing products and new product launch, primarily resulting in an increase of $7.7 million in personnel-related costs, and an increase of $2.0 million in stock-based compensation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $40.4 million for the three months ended March 31, 2023, compared to $41.3 million for the three months ended March 31, 2022, a decrease of $0.8 million, or 2%. This decrease was primarily due to a decrease of $8.4 million in stock-based compensation, of which $6.1 million decrease was primarily related to the market-based restricted stock units issued to our Co-Chief Executive Officers which were fully expensed as of June 30, 2022, and $2.3 million decrease was related to forfeitures, respectively, and a decrease of $2.7 million in acquisition related contingent consideration, partially offset by an increase of $7.5 million in severance costs related to a workforce reduction incurred in the first quarter of 2023, and an increase of $2.6 million in personnel-related costs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $3.1 million for the three months ended March 31, 2023, compared to $0.8 million for the three months ended March 31, 2022, an increase of $2.3 million, primarily due to higher U.S. treasury interest rates, partially offset by a decrease in cash and cash equivalents and marketable debt securities balances.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was primarily attributable to the amortization of debt issuance costs related to our convertible senior notes issued in November 2020, for the three months ended March 31, 2023, and 2022. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, other income (expense), net was primarily attributable to $5.5 million of impairment recorded for our non-marketable equity securities, partially offset by $3.9&#160;million of unrealized gains recorded for our marketable equity securities. For the three months ended March 31, 2022, other income (expense), net was immaterial. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for (benefit from) income taxes</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for (benefit from) income taxes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for (benefit from) income taxes was immaterial for the three months ended March 31, 2023, and 2022.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_145"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses and negative cash flows from operations since our inception, and as of March&#160;31, 2023, we had an accumulated deficit of $1.8 billion. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical studies and develop new products, expand our sales organization, and increase our marketing efforts to drive market adoption of our tests. As demand for our tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements could also increase if we require additional laboratory capacity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date principally from the sale of stock, convertible debt and through revenue from precision oncology testing and development services and other. As of March&#160;31, 2023, we had cash and cash equivalents of $223.6 million and marketable debt securities of $713.4 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to provide liquidity while ensuring capital preservation. Additionally, we have investments held in marketable debt securities consisting of United States treasury securities that can be immediately liquid.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plan, we believe our current cash, cash equivalents and marketable debt securities and anticipated cash flows from operations, will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this Quarterly Report on Form 10-Q. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development services and other is expected to grow long-term, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued liabilities, which could impact our working capital balances.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our available cash, cash equivalents and marketable debt securities and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in this Quarterly Report on Form 10-Q and in our Form 10-K for the year ended December&#160;31, 2022, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods presented:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the three months ended March 31, 2023, was $74.4 million, which resulted from a net loss of $133.5 million, partially offset by non-cash charges of $40.9 million and net change in our operating assets and liabilities of $18.2 million. Non-cash charges primarily consisted of $22.3 million of stock-based compensation, $10.3 million of depreciation and amortization, $7.3 million&#160;of operating lease costs, and $5.5 million of impairment of non-marketable equity securities, partially offset by $3.9 million of unrealized gains on marketable equity securities. The net change in our operating assets and liabilities was primarily the result of a $13.9 million increase in accounts payable and accrued liabilities, primarily due to increased personnel, a $12.3 million decrease in accounts receivable, net, primarily due to increased collections, and a $5.1 million decrease in inventory, net, partially offset by a $7.4 million payment of operating lease liabilities net of receipt of tenant improvement allowance, a $4.1 million decrease in deferred revenue, and a $3.4 million increase in prepaid expenses and other current assets, net. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the three months ended March 31, 2022 was $28.6 million, which resulted from a net loss of $123.2 million, partially offset by non-cash charges of $44.5 million and net change in our operating assets and liabilities of $50.2 million. Non-cash charges primarily consisted of $24.8 million of stock-based compensation, $7.2 million of depreciation and amortization, $6.9 million of operating lease costs, $2.4 million of amortization of premium on marketable debt investments, and $2.4 million of revaluation adjustments to contingent consideration. The net change in our operating assets and liabilities was primarily the result of a $21.9 million decrease in prepaid expenses and other current assets, net, primarily driven by a $25.0&#160;million one-time payment pursuant to a settlement and license agreement entered into in December 2021, a $20.9 million increase in accounts payable and accrued liabilities, primarily due to increased personnel and increase in accrued and other liabilities, a $13.3 million decrease in accounts receivable, net, primarily driven by collection from our clinical and biopharmaceutical customers and receipt of royalty payments, and a $3.8 million decrease in other assets, net, partially offset by a $5.9 million increase in inventory, net, due to forecasted higher testing volumes, and increased inventory level to offset potential disruption in supply chain, and a $3.1 million payment of operating lease liabilities net of receipt of tenant improvement allowance.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the three months ended March 31, 2023, was $157.2 million, which resulted primarily from maturities of marketable debt securities of $228.0 million, partially offset by purchases of marketable debt securities of $63.3 million, and purchases of property and equipment of $7.5 million. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the three months ended March 31, 2022, was $110.8 million, which resulted primarily from maturities of marketable debt securities of $310.0 million, partially offset by purchases of marketable debt securities of $163.7 million, purchases of property and equipment of $22.7 million, and purchase of non-marketable equity securities and other related investments of $12.8 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the three months ended March 31, 2023, was $0.9 million, which was primarily attributable to taxes paid related to net share settlement of restricted stock units of $1.0 million, partially offset by proceeds from exercise of stock options of $0.2 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the three months ended March 31, 2022, was immaterial, which was primarily attributable to taxes paid related to net share settlement of restricted stock units of $1.0 million, partially offset by proceeds from exercise of stock options of $1.0 million.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_154"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and in Item 7, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022. During the three months ended March&#160;31, 2023, there were no material changes to our critical accounting policies from those discussed previously. </span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_160"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_163"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable debt securities and our indebtedness. As of March&#160;31, 2023, we had cash and cash equivalents of $223.6 million held primarily in cash deposits and money market funds. Our marketable debt securities are held in U.S. government debt securities. As of March&#160;31, 2023, we had short-term marketable debt securities of $713.4 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of March&#160;31, 2023, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate $2.7 million decline of the fair value of our available-for-sale securities and a hypothetical 100 basis point decrease in interest rates would have resulted in an approximate $2.7 million increase of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue is generated in the United States. Through March&#160;31, 2023, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of March&#160;31, 2023, the effect of a hypothetical 10% change in foreign currency exchange rates would not be material to our financial condition or results of operations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_166"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Co-Chief Executive Officers, or Co-CEOs, and our Chief Financial Officer, or CFO with the participation of other members of our management, have evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of March&#160;31, 2023</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our Co-CEOs and our CFO have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on effectiveness of controls and procedures</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Co-CEOs and our CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_169"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_172"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies &#8211; Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Note 9 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_175"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, filed with the SEC on February 23, 2023. The risks and uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. During the first quarter of fiscal 2023, there were no material changes to our previously disclosed risk factors. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and Part I, Item 2, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_178"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_181"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_184"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_187"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_190"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:7.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit318-k.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-38683</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/9/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit328-k.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-38683</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/9/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex311.htm">Certification of the Co-Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex312.htm">Certification of the Co-Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex313.htm">Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex321.htm">Certification of the Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex322.htm">Certification of the Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-03312023x10qxex323.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">50</span></div></div></div><div id="id1808bc5647e45c0b487ecea2e9e50b0_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id1808bc5647e45c0b487ecea2e9e50b0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GUARDANT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Helmy Eltoukhy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ AmirAli Talasaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Bell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer <br/>(Principal Accounting Officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>gh-03312023x10qxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i931be814dbb74cd7a7f95fd7f49ed9e8_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helmy Eltoukhy, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>gh-03312023x10qxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5eebf170a91444b7adbed004815aa4d4_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, AmirAli Talasaz, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>gh-03312023x10qxex313.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac3f0edadd3e45c8b05a23ae7d11957b_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Bell, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>gh-03312023x10qxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0f4e4081f47148f58110b66d47f786c8_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>gh-03312023x10qxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie169a91252c94e56a4b84776cd495c9d_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.3
<SEQUENCE>7
<FILENAME>gh-03312023x10qxex323.htm
<DESCRIPTION>EX-32.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i50adf24a6bf64262980689aac94444ac_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>gh-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gh="http://guardanthealth.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://guardanthealth.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://guardanthealth.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://guardanthealth.com/role/DescriptionofBusiness">
        <link:definition>0000008 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JointVenture" roleURI="http://guardanthealth.com/role/JointVenture">
        <link:definition>0000010 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponents" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents">
        <link:definition>0000011 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecurities" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities">
        <link:definition>0000012 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwill" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill">
        <link:definition>0000013 - Disclosure - Intangible Assets, Net and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://guardanthealth.com/role/Debt">
        <link:definition>0000014 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://guardanthealth.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://guardanthealth.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://guardanthealth.com/role/CommonStock">
        <link:definition>0000017 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://guardanthealth.com/role/StockBasedCompensation">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://guardanthealth.com/role/NetLossPerShare">
        <link:definition>0000019 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://guardanthealth.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation">
        <link:definition>0000021 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://guardanthealth.com/role/RelatedPartyTransactions">
        <link:definition>0000022 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsTables" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables">
        <link:definition>0000025 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillTables" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables">
        <link:definition>0000027 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://guardanthealth.com/role/DebtTables">
        <link:definition>0000028 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://guardanthealth.com/role/LeasesTables">
        <link:definition>0000029 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://guardanthealth.com/role/CommonStockTables">
        <link:definition>0000030 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://guardanthealth.com/role/StockBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://guardanthealth.com/role/NetLossPerShareTables">
        <link:definition>0000032 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables">
        <link:definition>0000033 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails">
        <link:definition>0000034 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000035 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails_1" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails_1">
        <link:definition>0000035 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JointVentureDetails" roleURI="http://guardanthealth.com/role/JointVentureDetails">
        <link:definition>0000038 - Disclosure - Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
        <link:definition>0000039 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails">
        <link:definition>0000040 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails">
        <link:definition>0000041 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails">
        <link:definition>0000046 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
        <link:definition>0000047 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1">
        <link:definition>0000047 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillNarrativeDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails">
        <link:definition>0000048 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails">
        <link:definition>0000049 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://guardanthealth.com/role/DebtNarrativeDetails">
        <link:definition>0000050 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofConvertibleSeniorNotesDetails" roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails">
        <link:definition>0000051 - Disclosure - Debt - Components of Convertible Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails">
        <link:definition>0000052 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseInformationDetails" roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails">
        <link:definition>0000053 - Disclosure - Leases - Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails">
        <link:definition>0000054 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1">
        <link:definition>0000054 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000055 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://guardanthealth.com/role/CommonStockDetails">
        <link:definition>0000056 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000057 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000058 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails">
        <link:definition>0000059 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
        <link:definition>0000060 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>0000061 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationofStockOptionsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails">
        <link:definition>0000062 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofNetLossPerShareDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails">
        <link:definition>0000063 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>0000064 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationDetails" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails">
        <link:definition>0000065 - Disclosure - Segment and Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gh_ConvertibleDebtHedgeSharePricePremiumPercentage" abstract="false" name="ConvertibleDebtHedgeSharePricePremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_PostAcquisitionCompensationPolicyPolicyTextBlock" abstract="false" name="PostAcquisitionCompensationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_SoftBankMember" abstract="true" name="SoftBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="gh_GuardantHealthAMEAIncMember" abstract="true" name="GuardantHealthAMEAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gh_SaleOfStockLockUpPeriod" abstract="false" name="SaleOfStockLockUpPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_A2018EmployeeStockPurchasePlanMember" abstract="true" name="A2018EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_RevenueFromDevelopmentServices" abstract="false" name="RevenueFromDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" abstract="false" name="DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" abstract="false" name="UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" abstract="false" name="ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" abstract="false" name="CostsOfPrecisionOncologyTestingPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" abstract="false" name="ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PrecisionOncologyTestingMember" abstract="true" name="PrecisionOncologyTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" abstract="false" name="ContractualReceivablesCreditLossExpenseReversalNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CostOfDevelopmentServicesAndOtherMember" abstract="true" name="CostOfDevelopmentServicesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AssetAcquisitionPolicyTextBlock" abstract="false" name="AssetAcquisitionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" abstract="false" name="EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_NoncontrollingInterestLiabilityMember" abstract="true" name="NoncontrollingInterestLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ProceedsFromContractualReceivable" abstract="false" name="ProceedsFromContractualReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" abstract="false" name="ContractualReceivablesAllowanceForCreditLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gh_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_RevenueFromPrecisionOncologyTesting" abstract="false" name="RevenueFromPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_DebtInstrumentMeasurementInputDenominator" abstract="false" name="DebtInstrumentMeasurementInputDenominator" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EquityInvesteeWithIPOMember" abstract="true" name="EquityInvesteeWithIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_PostAcquisitionContingentConsiderationExpense" abstract="false" name="PostAcquisitionContingentConsiderationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" abstract="false" name="EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" abstract="false" name="ContractualReceivablesAllowanceForCreditLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" abstract="false" name="DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossReclassificationCurrent" abstract="false" name="ContractualReceivablesCreditLossReclassificationCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_A2018IncentiveAwardPlanMember" abstract="true" name="A2018IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_StockIssuedDuringPeriodValueExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" abstract="true" name="TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_CostsOfPrecisionOncologyTesting" abstract="false" name="CostsOfPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CostOfDevelopmentServicesPolicyTextBlock" abstract="false" name="CostOfDevelopmentServicesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossReclassificationNoncurrent" abstract="false" name="ContractualReceivablesCreditLossReclassificationNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossCurrent" abstract="false" name="ContractualReceivablesAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ConversionPeriodThreeMember" abstract="true" name="ConversionPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLoss" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" abstract="false" name="VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_NumberOfPatients" abstract="false" name="NumberOfPatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CostOfDevelopmentServices" abstract="false" name="CostOfDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EquitySecurityFVNIImpairmentOfPurchaseRights" abstract="false" name="EquitySecurityFVNIImpairmentOfPurchaseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_NonCashOperatingLeaseCosts" abstract="false" name="NonCashOperatingLeaseCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_NonMarketableSecuritiesPolicyTextBlock" abstract="false" name="NonMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_ConvertibleDebtHedgeStrikePrice" abstract="false" name="ConvertibleDebtHedgeStrikePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ContractualReceivablesTerm" abstract="false" name="ContractualReceivablesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_CashCashEquivalentsAndDebtSecuritiesFairValue" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AMEA2020PlanMember" abstract="true" name="AMEA2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ConvertibleSeniorNotesDue2027Member" abstract="true" name="ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>gh-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d7e9cfe-c8a7-4e15-9307-0e22e6749ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_AssetsCurrent_8d7e9cfe-c8a7-4e15-9307-0e22e6749ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0ae417f-fc99-4bb0-ac5f-f162757f4905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0ae417f-fc99-4bb0-ac5f-f162757f4905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_508f51d9-7f2b-4504-b687-12b817726975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_508f51d9-7f2b-4504-b687-12b817726975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b27a6f0-7bb0-44be-9a6b-42ab91081cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b27a6f0-7bb0-44be-9a6b-42ab91081cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_64a55953-b0dd-42fd-b250-f110d5741e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_Goodwill_64a55953-b0dd-42fd-b250-f110d5741e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_91b2f14b-1c13-462c-b35a-a3b57987f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f064ed83-7fa6-4b56-bbe5-fe4772b3775e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_91b2f14b-1c13-462c-b35a-a3b57987f34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c35fd9af-0abe-4d70-ac29-15b77436d7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b6b40ac-a00c-444a-96be-d53065c7beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c35fd9af-0abe-4d70-ac29-15b77436d7aa" xlink:to="loc_us-gaap_Liabilities_6b6b40ac-a00c-444a-96be-d53065c7beaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7d25b894-7368-47bd-bbf6-9af124f87082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c35fd9af-0abe-4d70-ac29-15b77436d7aa" xlink:to="loc_us-gaap_StockholdersEquity_7d25b894-7368-47bd-bbf6-9af124f87082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed2cd413-98ce-45ed-b864-fa7a47531888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c35fd9af-0abe-4d70-ac29-15b77436d7aa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed2cd413-98ce-45ed-b864-fa7a47531888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1811f49-464b-49ec-9d0a-1214a5e66e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1811f49-464b-49ec-9d0a-1214a5e66e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c5d9e7fe-5c5e-47bc-97aa-1fb0622cd380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c5d9e7fe-5c5e-47bc-97aa-1fb0622cd380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_75429cc5-87e2-4af5-b9eb-c57f6c47e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_75429cc5-87e2-4af5-b9eb-c57f6c47e4a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b3c014ce-29c9-498c-989c-e5878f197173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:to="loc_us-gaap_InventoryNet_b3c014ce-29c9-498c-989c-e5878f197173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3c603a0-84cb-49ed-a61b-0bb977b0f993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e2a4fc30-2ac9-41d5-a19f-18aeb07b90f6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3c603a0-84cb-49ed-a61b-0bb977b0f993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a13e4afb-ca1c-4998-8a81-6a64f815159b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f765d882-c4c6-4228-beb0-009a90947ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a13e4afb-ca1c-4998-8a81-6a64f815159b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f765d882-c4c6-4228-beb0-009a90947ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bd3f6ad-6403-44b6-be26-28d5b3aeee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a13e4afb-ca1c-4998-8a81-6a64f815159b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bd3f6ad-6403-44b6-be26-28d5b3aeee05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ea0977ec-b308-40b9-84a1-be616e9babcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_35f4f2a8-f848-4685-9203-7913c9577c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ea0977ec-b308-40b9-84a1-be616e9babcb" xlink:to="loc_us-gaap_LiabilitiesCurrent_35f4f2a8-f848-4685-9203-7913c9577c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_120e06ba-8474-4900-a76b-c81082ea6ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ea0977ec-b308-40b9-84a1-be616e9babcb" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_120e06ba-8474-4900-a76b-c81082ea6ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0186436-f50b-422a-add8-69821be7ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ea0977ec-b308-40b9-84a1-be616e9babcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0186436-f50b-422a-add8-69821be7ec0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c0a637fd-f312-4215-87bb-ac843eb612e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ea0977ec-b308-40b9-84a1-be616e9babcb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c0a637fd-f312-4215-87bb-ac843eb612e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_6e1ab158-cccc-4f8f-be6d-2051abc21c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:to="loc_us-gaap_CommonStockValueOutstanding_6e1ab158-cccc-4f8f-be6d-2051abc21c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4953624b-027a-451a-af6f-72deafb8e45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4953624b-027a-451a-af6f-72deafb8e45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b7ca29e-bc0d-4a5d-a62f-58627aa3ad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b7ca29e-bc0d-4a5d-a62f-58627aa3ad1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a40a2b36-83c4-429d-b56a-ad63fd7b4d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a40a2b36-83c4-429d-b56a-ad63fd7b4d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_a060e08b-4e97-4992-8824-38c09b6a7a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc1c29e9-be6f-4853-b5f4-5af0f4c66462" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_a060e08b-4e97-4992-8824-38c09b6a7a47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsOfPrecisionOncologyTesting_0146aeb0-2fc2-4993-a967-d8b177832e72" xlink:href="gh-20230331.xsd#gh_CostsOfPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:to="loc_gh_CostsOfPrecisionOncologyTesting_0146aeb0-2fc2-4993-a967-d8b177832e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServices_0954309d-d9bb-426d-b1b2-4d59d787ecef" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:to="loc_gh_CostOfDevelopmentServices_0954309d-d9bb-426d-b1b2-4d59d787ecef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f173023b-0e8b-4d75-91d6-8fec661d54f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f173023b-0e8b-4d75-91d6-8fec661d54f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_154e34ce-bc0b-452c-bd4c-7b45f0e44806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:to="loc_us-gaap_SellingAndMarketingExpense_154e34ce-bc0b-452c-bd4c-7b45f0e44806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b91c35b5-4620-4c85-8126-43b7183f8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d176dc6-977f-4154-8840-185d9a36b3cf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b91c35b5-4620-4c85-8126-43b7183f8cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d4a4fece-66dd-441f-ae48-ba11bb776da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4015adbc-1428-4266-88b0-30e930512bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4a4fece-66dd-441f-ae48-ba11bb776da9" xlink:to="loc_us-gaap_Revenues_4015adbc-1428-4266-88b0-30e930512bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5686b853-ce8f-4b84-ba12-b4e868cebac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4a4fece-66dd-441f-ae48-ba11bb776da9" xlink:to="loc_us-gaap_CostsAndExpenses_5686b853-ce8f-4b84-ba12-b4e868cebac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6424da29-50a5-46dc-b991-0427e66012c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f4d8c32-58e1-429c-967b-cc43c863aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6424da29-50a5-46dc-b991-0427e66012c6" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f4d8c32-58e1-429c-967b-cc43c863aedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a7d7d36f-bcff-4550-9517-8b7ccd67c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6424da29-50a5-46dc-b991-0427e66012c6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a7d7d36f-bcff-4550-9517-8b7ccd67c5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_37fc43a3-5a58-4018-959a-3098ee012a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6424da29-50a5-46dc-b991-0427e66012c6" xlink:to="loc_us-gaap_InterestExpense_37fc43a3-5a58-4018-959a-3098ee012a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e9d6251b-8095-433a-9e41-5f2a6bc6c1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6424da29-50a5-46dc-b991-0427e66012c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e9d6251b-8095-433a-9e41-5f2a6bc6c1a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77baba2b-ac79-400a-99c9-42b3cb9da437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6cc69c27-9a52-4123-bde9-33875a994aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_77baba2b-ac79-400a-99c9-42b3cb9da437" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6cc69c27-9a52-4123-bde9-33875a994aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c5ea61c0-92e8-45cb-b824-c6ab0cab45ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_77baba2b-ac79-400a-99c9-42b3cb9da437" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c5ea61c0-92e8-45cb-b824-c6ab0cab45ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_acdf7db2-7a06-49f4-b56e-270595c7e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromPrecisionOncologyTesting_c9b6fd4a-0b27-450a-bc97-1500a1aea8e3" xlink:href="gh-20230331.xsd#gh_RevenueFromPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_acdf7db2-7a06-49f4-b56e-270595c7e2da" xlink:to="loc_gh_RevenueFromPrecisionOncologyTesting_c9b6fd4a-0b27-450a-bc97-1500a1aea8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromDevelopmentServices_a6c47e01-8df4-4955-b94c-048602a7cc89" xlink:href="gh-20230331.xsd#gh_RevenueFromDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_acdf7db2-7a06-49f4-b56e-270595c7e2da" xlink:to="loc_gh_RevenueFromDevelopmentServices_a6c47e01-8df4-4955-b94c-048602a7cc89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91268f15-ab16-4a58-96ca-63a3e184f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c5d28be-06fd-4925-97fd-c5b69a5cd9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91268f15-ab16-4a58-96ca-63a3e184f57c" xlink:to="loc_us-gaap_NetIncomeLoss_8c5d28be-06fd-4925-97fd-c5b69a5cd9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f589c2e-d281-4959-b4e9-47f8bd46df76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91268f15-ab16-4a58-96ca-63a3e184f57c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f589c2e-d281-4959-b4e9-47f8bd46df76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2a2f08b-7cf6-4b70-96dd-67c5b0494813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ae4d3b37-bd10-4a94-ab3f-e6032a16f2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2a2f08b-7cf6-4b70-96dd-67c5b0494813" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ae4d3b37-bd10-4a94-ab3f-e6032a16f2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_72a18c35-84a5-4bf1-a6a8-1230936b0e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2a2f08b-7cf6-4b70-96dd-67c5b0494813" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_72a18c35-84a5-4bf1-a6a8-1230936b0e17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a83ad182-825c-4950-9345-fdb71f8ab8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0430a16f-e64e-47ee-a369-c799455c3db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a83ad182-825c-4950-9345-fdb71f8ab8cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0430a16f-e64e-47ee-a369-c799455c3db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07924156-b39d-49d2-a145-4edf7cb9c919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a83ad182-825c-4950-9345-fdb71f8ab8cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07924156-b39d-49d2-a145-4edf7cb9c919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_00f01f65-c44b-474a-938b-ef772e918003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a83ad182-825c-4950-9345-fdb71f8ab8cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_00f01f65-c44b-474a-938b-ef772e918003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16d1e346-1987-4113-9d6b-200c0e53cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a83ad182-825c-4950-9345-fdb71f8ab8cc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16d1e346-1987-4113-9d6b-200c0e53cef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0250d7c-7e1b-42be-8fea-eb12ce82ea57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_77863336-e5d5-42c3-86f4-a05d1f5cbdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0250d7c-7e1b-42be-8fea-eb12ce82ea57" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_77863336-e5d5-42c3-86f4-a05d1f5cbdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_02f6ac54-1bf1-42f2-baaf-3178bf2aeafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0250d7c-7e1b-42be-8fea-eb12ce82ea57" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_02f6ac54-1bf1-42f2-baaf-3178bf2aeafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3619517-0988-4b28-872b-d0890aad9bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0250d7c-7e1b-42be-8fea-eb12ce82ea57" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3619517-0988-4b28-872b-d0890aad9bb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_018e083a-74e1-4a0b-a3cf-4e3709a53cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4fb975c1-ef5f-492e-bb88-71cf48a21fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_018e083a-74e1-4a0b-a3cf-4e3709a53cbe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4fb975c1-ef5f-492e-bb88-71cf48a21fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6dee94af-0390-44c7-8610-4de33f9b7e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_018e083a-74e1-4a0b-a3cf-4e3709a53cbe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6dee94af-0390-44c7-8610-4de33f9b7e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_979640a5-b098-46cc-8630-d69d5c814cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_018e083a-74e1-4a0b-a3cf-4e3709a53cbe" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_979640a5-b098-46cc-8630-d69d5c814cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c6504e48-91a9-4957-aa19-40eb29dd74e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_018e083a-74e1-4a0b-a3cf-4e3709a53cbe" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c6504e48-91a9-4957-aa19-40eb29dd74e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35b0c4a3-0826-457c-a56d-9e0c0fa03336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_65adcacd-dec7-42d3-a24e-d09619ccbb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35b0c4a3-0826-457c-a56d-9e0c0fa03336" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_65adcacd-dec7-42d3-a24e-d09619ccbb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfe1c4ea-4e20-4fb1-aa14-fecf0371ac49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35b0c4a3-0826-457c-a56d-9e0c0fa03336" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfe1c4ea-4e20-4fb1-aa14-fecf0371ac49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_69a8c7d2-849c-4bcc-af1f-f1a5cddd77ad" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_69a8c7d2-849c-4bcc-af1f-f1a5cddd77ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f4c508b5-75fd-4aff-bb2f-aebaff30edef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f4c508b5-75fd-4aff-bb2f-aebaff30edef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_44cfb9d9-9f82-44e9-b3a7-aadea03fb60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_44cfb9d9-9f82-44e9-b3a7-aadea03fb60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a9c98c52-9a4c-4d1e-bd79-94be45c956aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a9c98c52-9a4c-4d1e-bd79-94be45c956aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a08cfc30-6596-4a44-b739-f65e76b19440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a08cfc30-6596-4a44-b739-f65e76b19440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95c170ee-9e7c-483b-a91b-ff45fd3048a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95c170ee-9e7c-483b-a91b-ff45fd3048a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6443a60d-b8a8-4fdf-ade4-5161d8ffb41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6443a60d-b8a8-4fdf-ade4-5161d8ffb41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de21f8c4-6053-4335-8b07-42233893ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de21f8c4-6053-4335-8b07-42233893ebeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d08e242d-b787-4ead-b84c-8a01781f4c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d08e242d-b787-4ead-b84c-8a01781f4c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_169f5b48-9da0-4d60-b790-cd762c38aabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_169f5b48-9da0-4d60-b790-cd762c38aabb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_48942a04-8ef4-4c80-8f6f-043e247c998c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_48942a04-8ef4-4c80-8f6f-043e247c998c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd5c99ce-a15d-42e6-a0c7-1b7c4839b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_NetIncomeLoss_bd5c99ce-a15d-42e6-a0c7-1b7c4839b7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d0e30e14-ff0f-4280-bf51-e475a8f945b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_ShareBasedCompensation_d0e30e14-ff0f-4280-bf51-e475a8f945b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_caafcde9-58b0-4b37-9ecd-8f63cbe962a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_caafcde9-58b0-4b37-9ecd-8f63cbe962a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts_e936665e-69ba-4826-b68a-290dce5b35c4" xlink:href="gh-20230331.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_gh_NonCashOperatingLeaseCosts_e936665e-69ba-4826-b68a-290dce5b35c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_fa629bc4-d50f-4112-b393-2ea2b0a47bfc" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_fa629bc4-d50f-4112-b393-2ea2b0a47bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_72ef81a4-b862-403b-971c-6f83c103aef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a21e6b9a-81f5-4f1b-80e8-64d90d48579c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_72ef81a4-b862-403b-971c-6f83c103aef2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_beb25ae4-d484-4664-88b7-f36e662ef0df" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_e47a0ad8-3de4-4ab8-b416-8fd993e9f85a" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_beb25ae4-d484-4664-88b7-f36e662ef0df" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_e47a0ad8-3de4-4ab8-b416-8fd993e9f85a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_f1d64d19-927f-4bf0-86f1-da21c4ea8e3e" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_beb25ae4-d484-4664-88b7-f36e662ef0df" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_f1d64d19-927f-4bf0-86f1-da21c4ea8e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_92cbc4f5-d9b0-40da-8824-fd4e46c45272" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_82f71a2d-eb72-4961-9306-554bdc4d3e91" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_92cbc4f5-d9b0-40da-8824-fd4e46c45272" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_82f71a2d-eb72-4961-9306-554bdc4d3e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_37632c54-03dc-4cb5-a6a7-890cb59bfee0" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_92cbc4f5-d9b0-40da-8824-fd4e46c45272" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_37632c54-03dc-4cb5-a6a7-890cb59bfee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d25db4cf-dd00-46d3-93ce-c27bd8a49108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e38bcc-592a-41ae-b852-0bdf4506c3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d25db4cf-dd00-46d3-93ce-c27bd8a49108" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e38bcc-592a-41ae-b852-0bdf4506c3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8462b9dc-35b0-4f82-af27-b6c031bb5ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d25db4cf-dd00-46d3-93ce-c27bd8a49108" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8462b9dc-35b0-4f82-af27-b6c031bb5ad5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7f076899-6a43-41b4-8b31-599a9b52e368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_60afbe2b-a182-418b-afa0-31e75cb5816c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7f076899-6a43-41b4-8b31-599a9b52e368" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_60afbe2b-a182-418b-afa0-31e75cb5816c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef26b824-a2d5-4308-b3a5-ad208da2cd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7f076899-6a43-41b4-8b31-599a9b52e368" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef26b824-a2d5-4308-b3a5-ad208da2cd8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ae60085f-14e6-4f87-b1ac-a7563b99be06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7f076899-6a43-41b4-8b31-599a9b52e368" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ae60085f-14e6-4f87-b1ac-a7563b99be06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fde907e0-0d4e-417e-be07-f4be3b20eac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7f076899-6a43-41b4-8b31-599a9b52e368" xlink:to="loc_us-gaap_AccountsPayableCurrent_fde907e0-0d4e-417e-be07-f4be3b20eac2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef68d4e4-e1ea-4cf2-b94d-ae1a83cadefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_94d3519b-dc77-484b-adc2-eb81ab73f874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef68d4e4-e1ea-4cf2-b94d-ae1a83cadefe" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_94d3519b-dc77-484b-adc2-eb81ab73f874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a13c866e-950d-48c4-97a0-70594b43ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef68d4e4-e1ea-4cf2-b94d-ae1a83cadefe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a13c866e-950d-48c4-97a0-70594b43ac40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_e8b51e45-b75f-4906-a381-669ddf783cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef68d4e4-e1ea-4cf2-b94d-ae1a83cadefe" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_e8b51e45-b75f-4906-a381-669ddf783cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_305de89b-e6ef-4432-8954-a47663308f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9aa0397e-f1a2-4bec-937b-e27117ecfd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_305de89b-e6ef-4432-8954-a47663308f9a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9aa0397e-f1a2-4bec-937b-e27117ecfd40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_e3fc7e7d-295c-4855-9693-8a839a1a8712" xlink:href="gh-20230331.xsd#gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_37851739-9e4f-43c1-b51d-a268cdbaa160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_e3fc7e7d-295c-4855-9693-8a839a1a8712" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_37851739-9e4f-43c1-b51d-a268cdbaa160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d2c320c-9170-4878-a23e-4276cd6cabc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_e3fc7e7d-295c-4855-9693-8a839a1a8712" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d2c320c-9170-4878-a23e-4276cd6cabc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_a9e038e0-8108-42ca-9c8e-f8d73b09bca6" xlink:href="gh-20230331.xsd#gh_CashCashEquivalentsAndDebtSecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_e3fc7e7d-295c-4855-9693-8a839a1a8712" xlink:to="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_a9e038e0-8108-42ca-9c8e-f8d73b09bca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ed7186cd-c677-467b-88af-e9843433cdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9216bebb-031e-4383-be30-919e21211665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ed7186cd-c677-467b-88af-e9843433cdaa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9216bebb-031e-4383-be30-919e21211665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_efbf4e7e-26b8-4933-a45e-750f6bfd1226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ed7186cd-c677-467b-88af-e9843433cdaa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_efbf4e7e-26b8-4933-a45e-750f6bfd1226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7fd525bd-e597-45f6-9fc6-e928a1d310a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ed7186cd-c677-467b-88af-e9843433cdaa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7fd525bd-e597-45f6-9fc6-e928a1d310a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_95de1cc1-2619-47fb-a30a-55e23b02feb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88756ba8-3488-4e74-9ccf-bc72641617c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_95de1cc1-2619-47fb-a30a-55e23b02feb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88756ba8-3488-4e74-9ccf-bc72641617c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_181ebe55-7141-4b2b-a134-22121f96dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_95de1cc1-2619-47fb-a30a-55e23b02feb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_181ebe55-7141-4b2b-a134-22121f96dd6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b1a0e434-3a05-4651-aac7-b0bfa1a6aae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_95de1cc1-2619-47fb-a30a-55e23b02feb3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b1a0e434-3a05-4651-aac7-b0bfa1a6aae2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ed0d70bf-0f18-4ce4-91e4-07bc4aa58029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_76325076-5e2a-4e2e-bfdb-d9fb764c9331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ed0d70bf-0f18-4ce4-91e4-07bc4aa58029" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_76325076-5e2a-4e2e-bfdb-d9fb764c9331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_81a43bf4-7518-48d4-a57d-ac901585188c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ed0d70bf-0f18-4ce4-91e4-07bc4aa58029" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_81a43bf4-7518-48d4-a57d-ac901585188c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_233ba9a9-f076-497c-9002-a48c93bad26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_68741595-d601-43fc-9396-a21f232c23bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_233ba9a9-f076-497c-9002-a48c93bad26a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_68741595-d601-43fc-9396-a21f232c23bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1722294d-0bcb-4bb9-a782-c406694e4acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_233ba9a9-f076-497c-9002-a48c93bad26a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1722294d-0bcb-4bb9-a782-c406694e4acf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_6d47daee-3d14-46f2-936b-701458463e35" xlink:href="gh-20230331.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6eb7b2ff-cbd3-4ef7-b2e9-347634bf3f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill_6d47daee-3d14-46f2-936b-701458463e35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6eb7b2ff-cbd3-4ef7-b2e9-347634bf3f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_130bf5e4-f9af-441a-930a-4f672a17c8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill_6d47daee-3d14-46f2-936b-701458463e35" xlink:to="loc_us-gaap_Goodwill_130bf5e4-f9af-441a-930a-4f672a17c8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca5d5900-e56a-4f60-90cb-c46784fd7791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_97e5eddf-1057-4f90-9e20-7002a9b32ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca5d5900-e56a-4f60-90cb-c46784fd7791" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_97e5eddf-1057-4f90-9e20-7002a9b32ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8037fdf7-dfb5-4f66-9502-cd7a5253a587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca5d5900-e56a-4f60-90cb-c46784fd7791" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8037fdf7-dfb5-4f66-9502-cd7a5253a587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_629b2df1-5c38-4cc5-a500-d52fe0696710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_54b4232f-c00b-47f3-853d-e454e781ce3b" xlink:href="gh-20230331.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_629b2df1-5c38-4cc5-a500-d52fe0696710" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_54b4232f-c00b-47f3-853d-e454e781ce3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e2f70ee-52c2-4a69-98df-dd3333402db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_629b2df1-5c38-4cc5-a500-d52fe0696710" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e2f70ee-52c2-4a69-98df-dd3333402db8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5c6f98bf-1ace-4f84-94ea-b85346ac9472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d67564c-ed18-492b-ba0c-1e610d9360ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5c6f98bf-1ace-4f84-94ea-b85346ac9472" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d67564c-ed18-492b-ba0c-1e610d9360ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bc64a5c4-74de-4adb-b994-a5e3ad05e2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5c6f98bf-1ace-4f84-94ea-b85346ac9472" xlink:to="loc_us-gaap_Goodwill_bc64a5c4-74de-4adb-b994-a5e3ad05e2a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d60be596-88a5-4d32-94f2-1a0007aab169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d60be596-88a5-4d32-94f2-1a0007aab169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8ad6537-f780-4afe-bcb5-1a905f118f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8ad6537-f780-4afe-bcb5-1a905f118f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b408c226-1ac2-47d4-a201-47aae3b09c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b408c226-1ac2-47d4-a201-47aae3b09c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4d4f8721-4ae7-44d6-bd5a-59f38702f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4d4f8721-4ae7-44d6-bd5a-59f38702f829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6ebd8628-e3a2-420b-987c-41ba33a0015f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6ebd8628-e3a2-420b-987c-41ba33a0015f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_35c48357-784b-4055-a1c4-fb21157b97de" xlink:href="gh-20230331.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8a1c6b2-ba83-41e5-82b5-3119a9b1ca02" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_35c48357-784b-4055-a1c4-fb21157b97de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4e130908-7e6b-4aac-ac1b-13dadc9b00ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e72cf963-e2f4-4093-8031-40067da6f125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4e130908-7e6b-4aac-ac1b-13dadc9b00ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e72cf963-e2f4-4093-8031-40067da6f125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_f2441af5-ff0c-4f46-8775-b0504798f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4e130908-7e6b-4aac-ac1b-13dadc9b00ff" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_f2441af5-ff0c-4f46-8775-b0504798f5c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_86bc12a2-a0e4-422f-81b2-480636b1609b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_86bc12a2-a0e4-422f-81b2-480636b1609b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8e23cc6-c95c-4212-8263-94cc112b6eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8e23cc6-c95c-4212-8263-94cc112b6eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ab3efdc8-e2c1-43de-b6c1-8338312528bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ab3efdc8-e2c1-43de-b6c1-8338312528bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_91630db2-0e80-40aa-b03d-6715f2d61676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_91630db2-0e80-40aa-b03d-6715f2d61676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d116d9f-cf66-4bad-8e81-59cfcc40478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d116d9f-cf66-4bad-8e81-59cfcc40478c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2f78dac1-bd72-4035-9814-b42654b914fc" xlink:href="gh-20230331.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4af9a983-9f20-41bf-b238-f7bcedbe05d4" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2f78dac1-bd72-4035-9814-b42654b914fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7eea01d4-64c6-47d8-98a4-2e94579d1a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_319da846-4db2-46ed-842a-cc9406ae7c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7eea01d4-64c6-47d8-98a4-2e94579d1a41" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_319da846-4db2-46ed-842a-cc9406ae7c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_28dc9f83-1370-4a3b-bea4-d60a9be30e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7eea01d4-64c6-47d8-98a4-2e94579d1a41" xlink:to="loc_us-gaap_OperatingLeaseLiability_28dc9f83-1370-4a3b-bea4-d60a9be30e47" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gh-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited" xlink:type="extended" id="ifed6c545bd35442c9ae3310dec8f3776_CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_efca6722-6ef2-4a88-8425-0d0db72c725b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_SharesOutstanding_efca6722-6ef2-4a88-8425-0d0db72c725b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_015c6f2b-ab1b-4bf0-b11a-36b274d55477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockholdersEquity_015c6f2b-ab1b-4bf0-b11a-36b274d55477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a0edd83-9d70-4cc4-8d80-5254740101a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a0edd83-9d70-4cc4-8d80-5254740101a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_632b4796-8ffd-4513-9b89-49ccc623dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_632b4796-8ffd-4513-9b89-49ccc623dfc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c1367979-61c1-4262-9516-6e69834d50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c1367979-61c1-4262-9516-6e69834d50e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_b4fd6253-7ff4-46fe-b880-371e6395372c" xlink:href="gh-20230331.xsd#gh_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_b4fd6253-7ff4-46fe-b880-371e6395372c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85ee7b51-c5d2-4ee0-96d1-e7ac944ca8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85ee7b51-c5d2-4ee0-96d1-e7ac944ca8f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5c172805-adcd-4807-a8b4-8781c882de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5c172805-adcd-4807-a8b4-8781c882de1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9622e62-1511-43e2-aa7c-9feb20741f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9622e62-1511-43e2-aa7c-9feb20741f2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf7adfd9-d5de-4602-ae78-c778d640abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_NetIncomeLoss_cf7adfd9-d5de-4602-ae78-c778d640abbf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_58c6258b-2b38-4474-9000-b6a294708c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_64d550c1-b616-4594-b36b-37a669d8d5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:to="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_23be17e2-db90-4290-8f5d-d8de80abcd4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:to="loc_us-gaap_EquityComponentDomain_23be17e2-db90-4290-8f5d-d8de80abcd4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:to="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf904c74-639c-45c4-8ce5-5aec3d5d4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_CommonStockMember_cf904c74-639c-45c4-8ce5-5aec3d5d4bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0cb9f94-c532-4d5d-878d-e974823e01e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0cb9f94-c532-4d5d-878d-e974823e01e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bea49fd2-79ce-41f6-83d9-878c9b031467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bea49fd2-79ce-41f6-83d9-878c9b031467" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8e222b62-11aa-427a-b17c-8da41b18d861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_RetainedEarningsMember_8e222b62-11aa-427a-b17c-8da41b18d861" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="if40f7f7f1f2847f9b297c2a92e2e5390_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOfPurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:href="gh-20230331.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:href="gh-20230331.xsd#gh_PostAcquisitionContingentConsiderationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd70511c-67b5-4403-9614-b313d117349c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd70511c-67b5-4403-9614-b313d117349c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c475935-1e62-46fa-ab93-8d314396d4ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:to="loc_srt_RangeMember_8c475935-1e62-46fa-ab93-8d314396d4ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:to="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_199f0821-8b8d-411f-816f-49b88fbd2c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_199f0821-8b8d-411f-816f-49b88fbd2c08" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails_1" xlink:type="extended" id="i5d7379bb0d754c98a04500cb26d896bf_SummaryofSignificantAccountingPoliciesNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOfPurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:href="gh-20230331.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:href="gh-20230331.xsd#gh_PostAcquisitionContingentConsiderationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd70511c-67b5-4403-9614-b313d117349c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd70511c-67b5-4403-9614-b313d117349c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c475935-1e62-46fa-ab93-8d314396d4ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:to="loc_srt_RangeMember_8c475935-1e62-46fa-ab93-8d314396d4ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:to="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended" id="i00368fe8c6524baa9e75742d9c22a40b_SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3049319a-f9bd-4eb9-a7ce-c03ba1433ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3049319a-f9bd-4eb9-a7ce-c03ba1433ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:to="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:to="loc_srt_NameOfMajorCustomerDomain_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:to="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_5c13a51c-c07f-49ec-924d-a0d20d798836" xlink:href="gh-20230331.xsd#gh_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerAMember_5c13a51c-c07f-49ec-924d-a0d20d798836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_96576a39-4b9b-4e95-bff5-917e8d73596b" xlink:href="gh-20230331.xsd#gh_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerBMember_96576a39-4b9b-4e95-bff5-917e8d73596b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_df689b1a-9f37-4ce7-b87d-d4d5df5648d8" xlink:href="gh-20230331.xsd#gh_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerCMember_df689b1a-9f37-4ce7-b87d-d4d5df5648d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_6ad792f7-bf07-4f64-923c-1c8c84f282ca" xlink:href="gh-20230331.xsd#gh_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerDMember_6ad792f7-bf07-4f64-923c-1c8c84f282ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe1ddb2c-6921-46d5-b001-c79ab68b5726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe1ddb2c-6921-46d5-b001-c79ab68b5726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3c9b7268-eea9-448b-9ed4-c1d010a5799e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3c9b7268-eea9-448b-9ed4-c1d010a5799e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6178a0bb-f6ad-4426-a738-77fc82640f8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6178a0bb-f6ad-4426-a738-77fc82640f8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_ea3b056d-8b3d-4a44-8bbf-9d26c4aa897b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:to="loc_us-gaap_SalesRevenueNetMember_ea3b056d-8b3d-4a44-8bbf-9d26c4aa897b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7f524767-51e4-41d4-8cd3-d9658e060cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:to="loc_us-gaap_AccountsReceivableMember_7f524767-51e4-41d4-8cd3-d9658e060cd1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/JointVentureDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#JointVentureDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/JointVentureDetails" xlink:type="extended" id="i290db4c41de34f5fa4b4054ba76da172_JointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dafd5cb-8a32-4292-b744-0e5811a1fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dafd5cb-8a32-4292-b744-0e5811a1fc76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_e7a8cde3-817a-42ba-86b1-ec2f3a6c4ef4" xlink:href="gh-20230331.xsd#gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_e7a8cde3-817a-42ba-86b1-ec2f3a6c4ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1745dff-1185-4340-b54f-abef26f6e3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1745dff-1185-4340-b54f-abef26f6e3a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1b525214-d079-410b-98d7-4a4a6d3d099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1b525214-d079-410b-98d7-4a4a6d3d099e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_22a806d9-edac-4cc7-a642-93c9430ad97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_22a806d9-edac-4cc7-a642-93c9430ad97b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_764a0bfe-fe0d-4486-b6b6-25f991492622_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_764a0bfe-fe0d-4486-b6b6-25f991492622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_d98f244a-d8a9-4a17-9969-8a54be4525f3" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:to="loc_gh_GuardantHealthAMEAIncMember_d98f244a-d8a9-4a17-9969-8a54be4525f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_afc3628f-3947-4b4b-b9c4-9575a6b3beff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:to="loc_us-gaap_ClassOfStockDomain_afc3628f-3947-4b4b-b9c4-9575a6b3beff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:to="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7aba9b30-c623-4106-9c9b-961afb3e9018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:to="loc_us-gaap_CommonClassBMember_7aba9b30-c623-4106-9c9b-961afb3e9018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4294f94a-3beb-4694-8c0a-80e2c1253845_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:to="loc_us-gaap_PlanNameDomain_4294f94a-3beb-4694-8c0a-80e2c1253845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:to="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_7b87fa31-bd1c-4193-8119-cadee18a49ad" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:to="loc_gh_AMEA2020PlanMember_7b87fa31-bd1c-4193-8119-cadee18a49ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cdf443d0-f33c-4f71-9b83-5940f5f87c50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cdf443d0-f33c-4f71-9b83-5940f5f87c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fda5578d-7cc0-4733-a7cc-1a17c706b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fda5578d-7cc0-4733-a7cc-1a17c706b3a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ced9deb9-5429-4ae7-b0db-202537361b45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ced9deb9-5429-4ae7-b0db-202537361b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e6b983f2-d180-4b27-b868-ccb6393e0fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e6b983f2-d180-4b27-b868-ccb6393e0fe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca5de895-c232-4710-ad8c-808a0a3f73e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca5de895-c232-4710-ad8c-808a0a3f73e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NoncontrollingInterestLiabilityMember_1744eb39-3c81-4ec2-b2cf-3e61ab4911cc" xlink:href="gh-20230331.xsd#gh_NoncontrollingInterestLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:to="loc_gh_NoncontrollingInterestLiabilityMember_1744eb39-3c81-4ec2-b2cf-3e61ab4911cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended" id="i09017577b97f4d98bd36a9e41196f5cf_CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0b35ca70-7fd5-4dc9-9ec2-dfffe10ec5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0b35ca70-7fd5-4dc9-9ec2-dfffe10ec5c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_485d4893-bfc2-4c06-b3ac-6ae5933833f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_485d4893-bfc2-4c06-b3ac-6ae5933833f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52cb8d18-c022-4608-b935-aba33043d287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52cb8d18-c022-4608-b935-aba33043d287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_369741d7-ae18-4507-ba3c-dc205bdf1f46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_369741d7-ae18-4507-ba3c-dc205bdf1f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_34c85a81-29df-4ed6-8686-4c6a79509a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_34c85a81-29df-4ed6-8686-4c6a79509a36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fe2210b8-53ea-40b4-83a7-0a1914b92f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fe2210b8-53ea-40b4-83a7-0a1914b92f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_122d2506-f188-405a-a189-58d350185c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_ComputerEquipmentMember_122d2506-f188-405a-a189-58d350185c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9a9e9580-6d93-43b6-9f8b-302b595b59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_ConstructionInProgressMember_9a9e9580-6d93-43b6-9f8b-302b595b59c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8df3107-774d-4512-af44-a0789978b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8df3107-774d-4512-af44-a0789978b169" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_95bd2204-1802-464a-af0a-43195c741494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_95bd2204-1802-464a-af0a-43195c741494" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="ie2586b5a775a4be4861e95382d2d6fce_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d0a680d-585b-4597-81c1-21af5843953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d0a680d-585b-4597-81c1-21af5843953e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_e6d84511-40c7-451f-a323-ec6830252c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_e6d84511-40c7-451f-a323-ec6830252c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f46b831c-e06a-462b-89dd-e0ecd53b8026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f46b831c-e06a-462b-89dd-e0ecd53b8026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_00b4c495-2873-40b3-9887-c6917dce6868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_00b4c495-2873-40b3-9887-c6917dce6868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_135fb637-0d94-4256-b697-73e6a01cbca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_135fb637-0d94-4256-b697-73e6a01cbca6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_70c60f6e-72f7-4173-9d58-f5df13b1fb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_70c60f6e-72f7-4173-9d58-f5df13b1fb36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1cca64eb-5d53-42af-961a-7cfceb265071_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1cca64eb-5d53-42af-961a-7cfceb265071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_103d1560-7cc4-4e56-8991-5fd9fa20dc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_103d1560-7cc4-4e56-8991-5fd9fa20dc16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a43ad0db-27e4-46c5-9085-ef2f158d9e22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a43ad0db-27e4-46c5-9085-ef2f158d9e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84d58776-cf5b-44dd-9225-fa570c06a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84d58776-cf5b-44dd-9225-fa570c06a517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_b43fe6bf-f3ce-43ce-adea-b3e26df838d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_b43fe6bf-f3ce-43ce-adea-b3e26df838d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d673d060-0a2e-4d0f-8006-75d9c26f3b32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d673d060-0a2e-4d0f-8006-75d9c26f3b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d5e54a10-a741-4b16-a861-4f78b17ea5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d5e54a10-a741-4b16-a861-4f78b17ea5e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b83de7c4-67ce-4198-bc5c-4e30b081dddc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b83de7c4-67ce-4198-bc5c-4e30b081dddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0944db0a-34e2-4ffa-b788-a8c17a276a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0944db0a-34e2-4ffa-b788-a8c17a276a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ad12e8c0-1719-450a-a897-b8f7b39b9456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ad12e8c0-1719-450a-a897-b8f7b39b9456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_470fef3e-bb7e-4ac9-9d44-f8faabcf501f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_470fef3e-bb7e-4ac9-9d44-f8faabcf501f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i6d20dcb5febd4693945173ba6e49d3d1_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SaleOfStockLockUpPeriod_5800f753-fbd7-40f9-9810-d7ae3ac34a7c" xlink:href="gh-20230331.xsd#gh_SaleOfStockLockUpPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_gh_SaleOfStockLockUpPeriod_5800f753-fbd7-40f9-9810-d7ae3ac34a7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_d1b2bbc7-1cf3-4888-9c3c-62e2ec8c52ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_d1b2bbc7-1cf3-4888-9c3c-62e2ec8c52ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ccf89355-1946-4298-aaf1-b7a41303f509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ccf89355-1946-4298-aaf1-b7a41303f509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a066fac2-1c6e-4d6d-ae2f-5aae0484d244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a066fac2-1c6e-4d6d-ae2f-5aae0484d244" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a43401ba-ba43-4767-813a-e0c5354c4278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a43401ba-ba43-4767-813a-e0c5354c4278" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_83b9d66e-c7ef-4f60-bfc8-bf2a98dc94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_83b9d66e-c7ef-4f60-bfc8-bf2a98dc94f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ad27852c-e93e-4c7b-bb14-853a60312814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ad27852c-e93e-4c7b-bb14-853a60312814" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_31279f9f-08e4-4435-bc70-451befc9cb5c" xlink:href="gh-20230331.xsd#gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_31279f9f-08e4-4435-bc70-451befc9cb5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_b3309fc8-c36e-4d2d-bb7a-8e6158f4d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_b3309fc8-c36e-4d2d-bb7a-8e6158f4d24d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c11a6665-d12d-460a-b72f-0f2149ef6181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c11a6665-d12d-460a-b72f-0f2149ef6181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d043b68b-d114-42f2-a090-defa83a722bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d043b68b-d114-42f2-a090-defa83a722bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66a187cb-d5cb-4177-a446-7700ff7b4d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66a187cb-d5cb-4177-a446-7700ff7b4d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4a7cb5a5-8783-47be-9a88-19883253b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4a7cb5a5-8783-47be-9a88-19883253b4b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_503d4cb7-1a02-47e3-b161-07028ee82017_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_503d4cb7-1a02-47e3-b161-07028ee82017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityInvesteeWithIPOMember_c17f794e-4999-4a1c-b415-b1c6cf3b2739" xlink:href="gh-20230331.xsd#gh_EquityInvesteeWithIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:to="loc_gh_EquityInvesteeWithIPOMember_c17f794e-4999-4a1c-b415-b1c6cf3b2739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_ab1fca40-4dbc-49a1-be55-9a3b6baa5b87" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:to="loc_gh_GuardantHealthAMEAIncMember_ab1fca40-4dbc-49a1-be55-9a3b6baa5b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce5d21e4-d54f-4ad7-a947-8eab12978c93_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:to="loc_dei_EntityDomain_ce5d21e4-d54f-4ad7-a947-8eab12978c93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:to="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_47c54044-95e9-4340-9fe7-f204bc808b42" xlink:href="gh-20230331.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:to="loc_gh_SoftBankMember_47c54044-95e9-4340-9fe7-f204bc808b42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended" id="i69b77bd364dd4489bb26b1612608b3a5_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_03e4b57f-3c10-4583-853e-b933c45dc64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_03e4b57f-3c10-4583-853e-b933c45dc64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_6bfe1781-7e3e-4351-aba4-65ba6af01032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_6bfe1781-7e3e-4351-aba4-65ba6af01032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5791d9d2-5d05-42ad-a0de-003a078b43c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cf8519c-3c14-4d8f-8315-eac282aeedc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cf8519c-3c14-4d8f-8315-eac282aeedc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NoncontrollingInterestLiabilityMember_6cb51a88-fcb1-4b09-a0d4-e54fcd802361" xlink:href="gh-20230331.xsd#gh_NoncontrollingInterestLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:to="loc_gh_NoncontrollingInterestLiabilityMember_6cb51a88-fcb1-4b09-a0d4-e54fcd802361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_249102a0-a443-48c8-b41e-b6ee3d2a9621" xlink:href="gh-20230331.xsd#gh_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:to="loc_gh_ContingentConsiderationMember_249102a0-a443-48c8-b41e-b6ee3d2a9621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8974e45-477f-4ba5-a1da-1fb1d3939328_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8974e45-477f-4ba5-a1da-1fb1d3939328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0187bbf0-fc63-4255-ac12-9010dd7fbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0187bbf0-fc63-4255-ac12-9010dd7fbdca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f952de6e-a844-4ccd-95d6-2b00c8301555_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f952de6e-a844-4ccd-95d6-2b00c8301555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3909a74a-7006-4e9d-b5b7-c2632209062e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3909a74a-7006-4e9d-b5b7-c2632209062e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="ia256395cd7994476a31fb191df263b8e_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b88922fb-4e5a-42f0-ac4d-ea7e8e8baed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b88922fb-4e5a-42f0-ac4d-ea7e8e8baed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a6504a6-38aa-44f8-8f4f-6396d05338e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a6504a6-38aa-44f8-8f4f-6396d05338e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_0d15be05-fef1-48a3-842d-6c56dd3aa595" xlink:href="gh-20230331.xsd#gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_0d15be05-fef1-48a3-842d-6c56dd3aa595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_36b58056-2475-44ec-ba61-81bc71e57751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_36b58056-2475-44ec-ba61-81bc71e57751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_adff0b25-7f10-4e7a-a516-087f5f6afca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_adff0b25-7f10-4e7a-a516-087f5f6afca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a632a73d-5506-4124-ac21-db17c6224932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a632a73d-5506-4124-ac21-db17c6224932" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_44e1c103-0035-4720-924f-b9ed4191a756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_44e1c103-0035-4720-924f-b9ed4191a756" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_3033eb26-eb34-42a3-ad73-8d685b942cb9" xlink:href="gh-20230331.xsd#gh_CashCashEquivalentsAndDebtSecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_3033eb26-eb34-42a3-ad73-8d685b942cb9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:to="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da03d9e6-e2a9-4deb-a135-11b26548bd9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da03d9e6-e2a9-4deb-a135-11b26548bd9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2f5b2cc0-c670-4e9f-ab27-4b7f0e838287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2f5b2cc0-c670-4e9f-ab27-4b7f0e838287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_fae25dad-eb79-443f-aff8-f1c6bdc8ed9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_fae25dad-eb79-443f-aff8-f1c6bdc8ed9c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="extended" id="i3fe674cfaa0a425f90924489e2bceb80_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1a3b58e-adfb-459c-9a56-424f98df7110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1a3b58e-adfb-459c-9a56-424f98df7110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bc376c7c-641c-4813-bbc8-1e7f11bc347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bc376c7c-641c-4813-bbc8-1e7f11bc347b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2a6eace4-ab24-4ad4-9037-def416cc67cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2a6eace4-ab24-4ad4-9037-def416cc67cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d1cb89a6-3068-4cf5-88eb-59d3791ac665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d1cb89a6-3068-4cf5-88eb-59d3791ac665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_aba09a18-eb0b-4698-8fc0-99129012f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_aba09a18-eb0b-4698-8fc0-99129012f2f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a540cfd4-89a9-4ce4-be90-cf8150bc76fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a540cfd4-89a9-4ce4-be90-cf8150bc76fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffb06a96-e9fb-4664-809d-f6d6356d84d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffb06a96-e9fb-4664-809d-f6d6356d84d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_20b1ac20-5cf6-451e-a43e-6bc9f1fb85ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_20b1ac20-5cf6-451e-a43e-6bc9f1fb85ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended" id="ic14250d8246346c7a48d384091977951_IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bc45e6e-5e74-43f7-b142-f2079f3a9633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bc45e6e-5e74-43f7-b142-f2079f3a9633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_489b9d4d-3f28-4590-bda8-d4cd5fc3ce82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_489b9d4d-3f28-4590-bda8-d4cd5fc3ce82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0c06f37-eee8-420a-9ac7-016d266a6445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0c06f37-eee8-420a-9ac7-016d266a6445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8da5d1a9-510a-45b6-a2d3-e534f442909a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8da5d1a9-510a-45b6-a2d3-e534f442909a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_efee0265-6602-4bec-9887-bfcbb1dc1067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_Goodwill_efee0265-6602-4bec-9887-bfcbb1dc1067" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_e97043bc-7bcd-4a02-974e-779e25aeb977" xlink:href="gh-20230331.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_e97043bc-7bcd-4a02-974e-779e25aeb977" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8ec8be86-220d-460d-af81-7a1508f35e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8ec8be86-220d-460d-af81-7a1508f35e5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3154bb9e-f347-4371-bf45-51813e4a4866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3154bb9e-f347-4371-bf45-51813e4a4866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b1285d9c-70c5-4fe8-be28-75be3c2b43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_LicensingAgreementsMember_b1285d9c-70c5-4fe8-be28-75be3c2b43e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4054c220-316f-4697-a238-41d2a1c1399a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4054c220-316f-4697-a238-41d2a1c1399a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_44b3f6ed-6609-41c8-a41b-9233b69ddcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_44b3f6ed-6609-41c8-a41b-9233b69ddcaa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="extended" id="i9ef776c568f94993a951ab67516032d6_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ae98d4e0-233f-46aa-a0ba-c81a82340230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ae98d4e0-233f-46aa-a0ba-c81a82340230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aa75bb1c-e8cb-4145-9899-d92fb3b1ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aa75bb1c-e8cb-4145-9899-d92fb3b1ae6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_f7fa6582-beac-42f1-8003-a1d9ea08edb5" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_f7fa6582-beac-42f1-8003-a1d9ea08edb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e25cd6b2-b3c2-451e-a23e-d3752133bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e25cd6b2-b3c2-451e-a23e-d3752133bb5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a3db7e50-b80f-4927-99c1-45f07b17b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a3db7e50-b80f-4927-99c1-45f07b17b8c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ce86a160-b81f-4d4f-8655-d4607a73c332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ce86a160-b81f-4d4f-8655-d4607a73c332" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_4f149090-e6eb-4de7-bc40-55f7a3db54b0" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_4f149090-e6eb-4de7-bc40-55f7a3db54b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec400260-261a-43be-a5b7-35aab17eee97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec400260-261a-43be-a5b7-35aab17eee97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b021f3a-0149-439d-945d-4db0dde9b108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b021f3a-0149-439d-945d-4db0dde9b108" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6c48f22e-fc95-42a6-b059-7b6f9987ffd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6c48f22e-fc95-42a6-b059-7b6f9987ffd3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMeasurementInputDenominator_534f5e69-3967-4154-bdea-05f7378e2a5e" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMeasurementInputDenominator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentMeasurementInputDenominator_534f5e69-3967-4154-bdea-05f7378e2a5e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0eb08024-3ebf-4308-b5d9-8a8cbfb13fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0eb08024-3ebf-4308-b5d9-8a8cbfb13fee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_88f1e97d-282c-4e8c-9979-4cec9dc3acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_88f1e97d-282c-4e8c-9979-4cec9dc3acfd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice_667431ed-0684-48d7-875a-35e27d715170" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_ConvertibleDebtHedgeStrikePrice_667431ed-0684-48d7-875a-35e27d715170" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_0dc64711-45e7-4afa-97df-1692e5beca09" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_0dc64711-45e7-4afa-97df-1692e5beca09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a635cc50-69f2-4b37-b54e-6df117876dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_SharePrice_a635cc50-69f2-4b37-b54e-6df117876dc3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_2f45d359-94c8-4603-aea2-7d72ffa09eb0" xlink:href="gh-20230331.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_2f45d359-94c8-4603-aea2-7d72ffa09eb0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_63d257f4-c699-4fcf-b86a-a2b0ba324b49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_63d257f4-c699-4fcf-b86a-a2b0ba324b49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_4c6e00dc-0ea7-4d67-b538-af4ea5d68269" xlink:href="gh-20230331.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_4c6e00dc-0ea7-4d67-b538-af4ea5d68269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42327bae-f00d-46ae-89ed-1680282edfc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42327bae-f00d-46ae-89ed-1680282edfc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_96dd0ab3-cf1b-4d14-ad9d-7774047f9f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_96dd0ab3-cf1b-4d14-ad9d-7774047f9f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3045d0a1-9934-4a70-b8eb-21450068e962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:to="loc_us-gaap_SeniorNotesMember_3045d0a1-9934-4a70-b8eb-21450068e962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_94b98e34-3975-4f97-8ce3-071f8e6a2f64_default" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:to="loc_gh_DebtInstrumentConversionDomain_94b98e34-3975-4f97-8ce3-071f8e6a2f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:to="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember_338917d3-b2cf-4dc3-8202-a73f7297fa72" xlink:href="gh-20230331.xsd#gh_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodOneMember_338917d3-b2cf-4dc3-8202-a73f7297fa72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember_5bce407b-3ea9-4fd7-aa41-69593e4e0da0" xlink:href="gh-20230331.xsd#gh_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodTwoMember_5bce407b-3ea9-4fd7-aa41-69593e4e0da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember_8128510f-bfdb-409b-8536-d441d28269b7" xlink:href="gh-20230331.xsd#gh_ConversionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodThreeMember_8128510f-bfdb-409b-8536-d441d28269b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_cdaea583-4919-4234-8a86-85a6e0b3464b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_cdaea583-4919-4234-8a86-85a6e0b3464b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9d882756-81c0-47c5-98e7-563a258b393b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9d882756-81c0-47c5-98e7-563a258b393b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputQuotedPriceMember_976c5d13-4fe5-425b-b573-01ff7cbba20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputQuotedPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:to="loc_us-gaap_MeasurementInputQuotedPriceMember_976c5d13-4fe5-425b-b573-01ff7cbba20b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended" id="i315be4d0f8ef4e9ba24d1243890d7d81_DebtComponentsofConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e61bf31-1e42-4322-87de-73d2edcbfc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e61bf31-1e42-4322-87de-73d2edcbfc5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ae4c707f-b2a3-4974-843d-eed84cee78ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ae4c707f-b2a3-4974-843d-eed84cee78ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d49915f-371c-450e-ae2b-bd2df495b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_LongTermDebt_6d49915f-371c-450e-ae2b-bd2df495b5c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_04015def-a045-4f74-9224-51fbd69a3d13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_04015def-a045-4f74-9224-51fbd69a3d13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a10fb808-d569-4a81-9819-c05bf1408a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:to="loc_us-gaap_ConvertibleDebtMember_a10fb808-d569-4a81-9819-c05bf1408a12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:to="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_fab23968-5364-44ea-bffe-302afc924e27" xlink:href="gh-20230331.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_fab23968-5364-44ea-bffe-302afc924e27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ia70b3a630b8b4f748faef41f346f0960_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ead16d98-d7fe-4876-92f0-86064a0bbc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ead16d98-d7fe-4876-92f0-86064a0bbc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e615630a-17b5-4cab-8a6d-22795af338fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:to="loc_us-gaap_OperatingLeaseExpense_e615630a-17b5-4cab-8a6d-22795af338fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:to="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:to="loc_srt_RangeMember_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:to="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_79cda434-ea73-4cbd-b9f0-0d5a7bb8250f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:to="loc_srt_MinimumMember_79cda434-ea73-4cbd-b9f0-0d5a7bb8250f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0fa0a930-38ac-4c32-8e9c-36f4d10b17d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:to="loc_srt_MaximumMember_0fa0a930-38ac-4c32-8e9c-36f4d10b17d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i05d55decaf4d447491a97dc2a41d7168_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_9b6b3d6a-5e5e-4b60-98c2-e21fe66030e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_9b6b3d6a-5e5e-4b60-98c2-e21fe66030e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:to="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:to="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e8b6c897-a976-48f6-994c-cfaca1a770aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:to="loc_srt_LitigationCaseTypeDomain_e8b6c897-a976-48f6-994c-cfaca1a770aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:to="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_c4c0a3f7-7e8c-4d9c-84b9-9715f34e1b09" xlink:href="gh-20230331.xsd#gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:to="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_c4c0a3f7-7e8c-4d9c-84b9-9715f34e1b09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended" id="i83cb6f5206d942a68300eda1fc446485_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_1812fec8-659d-42f1-b580-dfcb3ab9db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:to="loc_us-gaap_DividendsCommonStock_1812fec8-659d-42f1-b580-dfcb3ab9db9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e537e37-e9df-43b2-bb26-c5fb77c68ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e537e37-e9df-43b2-bb26-c5fb77c68ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:to="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687172ff-316e-48cd-b1b0-04321b2fb301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687172ff-316e-48cd-b1b0-04321b2fb301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_879463f0-aff1-4db3-aa39-e53cd28f5917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_879463f0-aff1-4db3-aa39-e53cd28f5917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb90357e-9f6d-45c8-9574-7c8d2645c6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb90357e-9f6d-45c8-9574-7c8d2645c6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_301f9a22-e8a9-4b72-be7f-710757d9526c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_PerformanceSharesMember_301f9a22-e8a9-4b72-be7f-710757d9526c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_25bec2f4-10ac-4959-bc12-4b81e1e1e7bf" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_25bec2f4-10ac-4959-bc12-4b81e1e1e7bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_331e9b66-6b2c-4a16-a855-b1b7e3cf008c" xlink:href="gh-20230331.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_331e9b66-6b2c-4a16-a855-b1b7e3cf008c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bbd2af65-3872-44fb-9a9e-56da348792aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_EmployeeStockMember_bbd2af65-3872-44fb-9a9e-56da348792aa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="ie97336f4e7724cc6823a88a50b2cc78a_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:href="gh-20230331.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_232ee9a0-99de-4398-a9f4-3abf3514bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_232ee9a0-99de-4398-a9f4-3abf3514bbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_ac90dcdf-0684-456f-b52f-85f15e97e09f" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_ac90dcdf-0684-456f-b52f-85f15e97e09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_0a24dfa7-7edb-451a-9da3-c76b7d7e970a" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_0a24dfa7-7edb-451a-9da3-c76b7d7e970a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_299e7588-375a-409d-bb7a-75d9ec95beae" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_299e7588-375a-409d-bb7a-75d9ec95beae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_212e521c-a71d-4b65-bf07-2a59a0e3ab67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463b9a44-fc18-45e5-ab02-a4e356cb476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463b9a44-fc18-45e5-ab02-a4e356cb476b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ace5be57-2648-4ec8-8f73-27ee8aa8de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ace5be57-2648-4ec8-8f73-27ee8aa8de13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91bbac0c-1d5e-425b-a078-7d84239b98ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91bbac0c-1d5e-425b-a078-7d84239b98ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9759db58-f519-4ad1-bf28-6e8068d7e90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9759db58-f519-4ad1-bf28-6e8068d7e90a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1849e033-f71b-483e-b718-40919e894f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7ab2b3b-5b56-4741-b77e-8fc8def14d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7ab2b3b-5b56-4741-b77e-8fc8def14d2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb126d20-4d8f-47d8-9ed0-23da843b7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb126d20-4d8f-47d8-9ed0-23da843b7731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_214280db-16fb-4b9e-bd2d-e9504e7c8ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_214280db-16fb-4b9e-bd2d-e9504e7c8ffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d093f422-a3f3-4f96-8409-57a555e2eb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d093f422-a3f3-4f96-8409-57a555e2eb73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cfec9f1c-bef0-47c7-b5f6-108eec628bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cfec9f1c-bef0-47c7-b5f6-108eec628bbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d2d8dcc-fe53-4a29-b15f-d0c6335fe5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1660c1a4-e76d-4794-85cf-aadc5e9edc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1660c1a4-e76d-4794-85cf-aadc5e9edc03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_570749c6-27a8-4dce-99b6-d053c9dbfe43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_570749c6-27a8-4dce-99b6-d053c9dbfe43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c9d87c52-06f7-47be-b07f-a158e0d06f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c9d87c52-06f7-47be-b07f-a158e0d06f60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad2dd11a-258e-4eb2-8c94-6b9eff7a2853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad2dd11a-258e-4eb2-8c94-6b9eff7a2853" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_18a050d6-f5b0-487f-88f3-1786dfaaff15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_18a050d6-f5b0-487f-88f3-1786dfaaff15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_679a4bab-1b62-4ee3-8f40-d06d4f72bf92" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:to="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3994fb55-b893-4e55-b208-e8b51f0f77ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_us-gaap_StockOptionMember_3994fb55-b893-4e55-b208-e8b51f0f77ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d5dbfc0c-82fd-41e5-a4b7-ccc2e3c33d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_us-gaap_RestrictedStockMember_d5dbfc0c-82fd-41e5-a4b7-ccc2e3c33d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_5f306092-2195-4990-a263-6896e24894ad" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_5f306092-2195-4990-a263-6896e24894ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i4c48bf5cd2f043c2b27f436ab585a0d6_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ce1d6a4-e3fe-461f-bef4-d0806eeb2684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ce1d6a4-e3fe-461f-bef4-d0806eeb2684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_424491ea-25ac-4af9-8207-bc019476e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_424491ea-25ac-4af9-8207-bc019476e4fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9b5649ca-7f36-4bf6-b3a8-d66c4507eb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9b5649ca-7f36-4bf6-b3a8-d66c4507eb77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e33d3956-736a-46d5-899a-14998779bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e33d3956-736a-46d5-899a-14998779bc31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a20fd105-e541-4117-b079-a6d326ff72d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a20fd105-e541-4117-b079-a6d326ff72d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ee45ab2-4044-49d4-95eb-2c8e409e68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ee45ab2-4044-49d4-95eb-2c8e409e68b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c7374987-de1c-4a75-821a-f2f4091d9ca0" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c7374987-de1c-4a75-821a-f2f4091d9ca0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52824ee3-4813-4e1e-9901-861c7ab4e866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52824ee3-4813-4e1e-9901-861c7ab4e866" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2708bf2d-13ad-4178-8b00-5c20ada13a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2708bf2d-13ad-4178-8b00-5c20ada13a55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d505bf49-4f94-4f56-acb8-74daa4d55dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d505bf49-4f94-4f56-acb8-74daa4d55dc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_693d17a0-f785-467c-91b8-4668a5f8031f" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_693d17a0-f785-467c-91b8-4668a5f8031f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_08ce7a30-879d-4b81-9b28-1cddbb53377d" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_08ce7a30-879d-4b81-9b28-1cddbb53377d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_cd1b5408-403f-4dc2-8c40-3a6d3c2d837e" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_cd1b5408-403f-4dc2-8c40-3a6d3c2d837e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_3b5accbb-22d2-4352-9226-405173ab6a24" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_3b5accbb-22d2-4352-9226-405173ab6a24" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ac07f6-d7fd-42ec-a9f5-850e99ce86c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ac07f6-d7fd-42ec-a9f5-850e99ce86c3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_b435dcb9-60d3-4f81-88e1-10b532d1eb44" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_b435dcb9-60d3-4f81-88e1-10b532d1eb44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa30df73-aad5-46b8-8b88-968eca7114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa30df73-aad5-46b8-8b88-968eca7114f5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f860098-a9a1-42b7-8c42-6dfea7b1b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f860098-a9a1-42b7-8c42-6dfea7b1b146" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35b2fc1b-cc58-4b22-b761-2a86a67aeb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35b2fc1b-cc58-4b22-b761-2a86a67aeb37" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ea6cd6e8-7992-4125-b34b-1630f14d338b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ea6cd6e8-7992-4125-b34b-1630f14d338b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6d270406-8393-40d2-a738-30ecb5ae6e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6d270406-8393-40d2-a738-30ecb5ae6e5c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94665ae-3a60-4848-af86-ff4aa2e3ad38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94665ae-3a60-4848-af86-ff4aa2e3ad38" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ac739c8-5a84-41ce-8a9c-11930665123c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ac739c8-5a84-41ce-8a9c-11930665123c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_839545e2-8462-4970-a520-27c3ebc3e06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_839545e2-8462-4970-a520-27c3ebc3e06a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_42a09f5d-dbd0-48b0-9f54-795482963fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_42a09f5d-dbd0-48b0-9f54-795482963fe5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c27f0a53-a18b-483a-94a9-7621342d0509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c27f0a53-a18b-483a-94a9-7621342d0509" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfa233e0-95a1-40d0-8b00-7caca2763345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfa233e0-95a1-40d0-8b00-7caca2763345" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9847f232-5269-47ee-bb21-a5cda998e064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9847f232-5269-47ee-bb21-a5cda998e064" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aee8b4fa-7ff6-4122-82b9-511f0cbee32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aee8b4fa-7ff6-4122-82b9-511f0cbee32f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7e21b9d6-91c1-4a98-8035-521bfe7d68ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7e21b9d6-91c1-4a98-8035-521bfe7d68ba" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_808935fd-8072-4f93-abb5-3c82dfda8f6a" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_808935fd-8072-4f93-abb5-3c82dfda8f6a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a67705b-a2d4-4501-adb6-b942f7f7096c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a67705b-a2d4-4501-adb6-b942f7f7096c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83f3a044-786a-4274-b48d-58c7ae8b0b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83f3a044-786a-4274-b48d-58c7ae8b0b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f4082f1f-2959-401e-a53f-ecaf885cc795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f4082f1f-2959-401e-a53f-ecaf885cc795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_68fb9410-bdc8-4fea-a91f-9599f81d7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_68fb9410-bdc8-4fea-a91f-9599f81d7ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_64a62753-d825-4609-aa49-9da7b2a3dea7" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_64a62753-d825-4609-aa49-9da7b2a3dea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_b08f4fc5-55e4-4e6d-82ad-4d14d45f1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_b08f4fc5-55e4-4e6d-82ad-4d14d45f1a94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d7bfdeb1-6949-447d-91e8-db0af4a34c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_PerformanceSharesMember_d7bfdeb1-6949-447d-91e8-db0af4a34c58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5aa6a0e3-649f-4a07-a79a-8b8ec4d53d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_EmployeeStockMember_5aa6a0e3-649f-4a07-a79a-8b8ec4d53d6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afe8b550-c30c-4218-9b37-4c805a77a92d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:to="loc_srt_RangeMember_afe8b550-c30c-4218-9b37-4c805a77a92d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:to="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb85d48f-ace2-4205-b97b-c103de7895c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:to="loc_srt_MinimumMember_fb85d48f-ace2-4205-b97b-c103de7895c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89428a8d-78e7-4526-b8b7-d59a1bd79d68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:to="loc_srt_MaximumMember_89428a8d-78e7-4526-b8b7-d59a1bd79d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_246ba26f-8862-4097-b7a6-4af3e2e36650_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_246ba26f-8862-4097-b7a6-4af3e2e36650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3cc7a3b6-75a0-4f55-a549-81b3d462541b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3cc7a3b6-75a0-4f55-a549-81b3d462541b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d5aa29f5-1d61-4434-b004-635a3250004c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d5aa29f5-1d61-4434-b004-635a3250004c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_2f295ce4-cc41-4427-8c75-fc06472e3745" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:to="loc_gh_GuardantHealthAMEAIncMember_2f295ce4-cc41-4427-8c75-fc06472e3745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:to="loc_us-gaap_ClassOfStockDomain_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:to="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_dc091edb-cb64-46c7-8a3e-0e2b5cd56a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:to="loc_us-gaap_CommonClassBMember_dc091edb-cb64-46c7-8a3e-0e2b5cd56a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0482ec43-ed81-414a-8593-0a718b367977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:to="loc_us-gaap_VestingDomain_0482ec43-ed81-414a-8593-0a718b367977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:to="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a080c76d-9346-4b44-a77e-b0fca77bdffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a080c76d-9346-4b44-a77e-b0fca77bdffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_84e3e593-15af-4dc6-b531-b34c39ad5bfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:to="loc_us-gaap_PlanNameDomain_84e3e593-15af-4dc6-b531-b34c39ad5bfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:to="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_bb1e9d8f-7448-489a-b61c-aa46730806c6" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:to="loc_gh_AMEA2020PlanMember_bb1e9d8f-7448-489a-b61c-aa46730806c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember_a0b49125-10e9-4a1c-8c55-590b441482c2" xlink:href="gh-20230331.xsd#gh_A2018EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:to="loc_gh_A2018EmployeeStockPurchasePlanMember_a0b49125-10e9-4a1c-8c55-590b441482c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" id="ib5a6e03594624c7e8978a7a7837e8cdb_StockBasedCompensationRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2cf675b2-a48d-4018-a268-1110904c61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2cf675b2-a48d-4018-a268-1110904c61cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae04e08e-fb43-4baf-bee4-4a48fbeb4834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae04e08e-fb43-4baf-bee4-4a48fbeb4834" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7580ac1c-2d58-43e6-990f-795e23f6e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7580ac1c-2d58-43e6-990f-795e23f6e0d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dea9ee03-2d8b-4fb7-bf4e-61d93c8fd56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dea9ee03-2d8b-4fb7-bf4e-61d93c8fd56e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45faa0d5-64ee-4f66-9b49-b7a0700addd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa953573-9bb6-4d35-b46c-386203e65ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa953573-9bb6-4d35-b46c-386203e65ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738e7457-0efe-4be9-af12-155a8e29e020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738e7457-0efe-4be9-af12-155a8e29e020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_142ed2af-e809-4242-8ea2-50530a4de5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_142ed2af-e809-4242-8ea2-50530a4de5eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a361d93c-52b4-4fd4-8170-641c9298bb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a361d93c-52b4-4fd4-8170-641c9298bb90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_746be12d-4740-4e2e-a243-88d58b79dae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:to="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f9dc804-a6b5-467c-8f94-97209ac2e25c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f9dc804-a6b5-467c-8f94-97209ac2e25c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1cbe82f1-ce18-458a-9d4a-9b80f40fd71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1cbe82f1-ce18-458a-9d4a-9b80f40fd71b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_90dfa5c0-106b-44f5-8df7-f6c434f37765" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_90dfa5c0-106b-44f5-8df7-f6c434f37765" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended" id="ic0e99fd1157f43ea82d0c76a378baad4_StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_76b4ee81-1c0f-4c1f-b2ac-d72d11b3424e" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_76b4ee81-1c0f-4c1f-b2ac-d72d11b3424e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_1a047c99-a4e8-428b-94e9-6b9b7a2028e6" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_1a047c99-a4e8-428b-94e9-6b9b7a2028e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:to="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d932e9ee-cb3c-4aa2-989c-7063abea3bab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d932e9ee-cb3c-4aa2-989c-7063abea3bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_872f26e2-14bd-4017-b0b8-a2e08b547de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:to="loc_us-gaap_PerformanceSharesMember_872f26e2-14bd-4017-b0b8-a2e08b547de3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:to="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f90b8dfe-f107-42d1-b4c2-b0debec75efc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:to="loc_us-gaap_VestingDomain_f90b8dfe-f107-42d1-b4c2-b0debec75efc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:to="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_88f88a4e-11d8-4eab-bc2a-da029e193423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_88f88a4e-11d8-4eab-bc2a-da029e193423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8dbc92ea-6494-46f2-842b-6ba3f44e5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8dbc92ea-6494-46f2-842b-6ba3f44e5aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b06c3f37-305c-4c5c-828a-6ba6a647d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b06c3f37-305c-4c5c-828a-6ba6a647d7c1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i4a80a392f5f5464ca47d5f580771fae0_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_814d6acf-305f-4a27-b2eb-a0ee3882fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_814d6acf-305f-4a27-b2eb-a0ee3882fb22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e36e7b4-d618-4858-8c4c-062e7da9bcec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e36e7b4-d618-4858-8c4c-062e7da9bcec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_e1138e48-522d-482f-b70e-2f466a3229f2" xlink:href="gh-20230331.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_gh_PrecisionOncologyTestingMember_e1138e48-522d-482f-b70e-2f466a3229f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServicesAndOtherMember_5eb3394e-461d-4da2-b60d-96e84f0fcd51" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServicesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_gh_CostOfDevelopmentServicesAndOtherMember_5eb3394e-461d-4da2-b60d-96e84f0fcd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f1bdba08-96f7-4008-9112-7f1e81a9d262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f1bdba08-96f7-4008-9112-7f1e81a9d262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_0605393b-5d48-4b0c-9d4e-32c51645b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_0605393b-5d48-4b0c-9d4e-32c51645b193" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89b15c16-a52f-45be-a9b1-66bc671a7a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89b15c16-a52f-45be-a9b1-66bc671a7a05" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended" id="ia91eb98722154120ad90cc3bd09a0b6c_StockBasedCompensationValuationofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6bf7b513-a72f-4985-8a14-d9d4baca89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6bf7b513-a72f-4985-8a14-d9d4baca89d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cad91474-10d6-4ec6-851b-13243fd24a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cad91474-10d6-4ec6-851b-13243fd24a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0648a2d6-08bd-4150-a908-b73616c7500c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0648a2d6-08bd-4150-a908-b73616c7500c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfcd52c4-8278-4d1d-b647-181e44068f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfcd52c4-8278-4d1d-b647-181e44068f49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:to="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cc285174-1113-4cae-9e86-1589a751878b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cc285174-1113-4cae-9e86-1589a751878b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_76bd35f8-7a29-4f96-9d1d-c1a9850ae1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:to="loc_us-gaap_EmployeeStockMember_76bd35f8-7a29-4f96-9d1d-c1a9850ae1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:to="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd6c24ce-50b2-4a48-b937-a951c06ade06_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:to="loc_srt_RangeMember_cd6c24ce-50b2-4a48-b937-a951c06ade06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:to="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_805c7277-7c5c-4c7d-bf70-8c9c9740f7f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:to="loc_srt_MinimumMember_805c7277-7c5c-4c7d-bf70-8c9c9740f7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f5f2952-3418-4a08-9ede-fa931c1a06e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:to="loc_srt_MaximumMember_8f5f2952-3418-4a08-9ede-fa931c1a06e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="i1a316236cd3647128f2ffaa2f95c7e1f_NetLossPerShareScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1382e9-6f2a-4cd8-84f1-1c3880dda618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1382e9-6f2a-4cd8-84f1-1c3880dda618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12a9bcb2-fda3-4a08-9d7d-787f825a5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12a9bcb2-fda3-4a08-9d7d-787f825a5b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b7283f0-083f-411d-9054-1c37f7a59e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b7283f0-083f-411d-9054-1c37f7a59e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76543f72-41b7-48c6-af6b-86d2c9085a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76543f72-41b7-48c6-af6b-86d2c9085a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8557fcf6-f700-4114-b9ee-8b950b15bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8557fcf6-f700-4114-b9ee-8b950b15bb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d833dcfc-c832-44c9-b5f8-de7719552623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_PerformanceSharesMember_d833dcfc-c832-44c9-b5f8-de7719552623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_8042bdb3-778f-4580-a142-6f58912eda6d" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_8042bdb3-778f-4580-a142-6f58912eda6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_19722e24-2ecd-4823-a90f-a7a1f52e431c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_EmployeeStockMember_19722e24-2ecd-4823-a90f-a7a1f52e431c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5bd177d8-0c17-41c0-a4f3-6f941e2f61e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_SeniorNotesMember_5bd177d8-0c17-41c0-a4f3-6f941e2f61e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06f61f2b-4118-4331-a102-2643b4b2fa40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:to="loc_us-gaap_PlanNameDomain_06f61f2b-4118-4331-a102-2643b4b2fa40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:to="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_b64f2bc7-938b-4d39-accd-3fd84835caa2" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:to="loc_gh_AMEA2020PlanMember_b64f2bc7-938b-4d39-accd-3fd84835caa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b876cfc1-c31f-492c-b796-fb7897d51b36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:to="loc_us-gaap_ClassOfStockDomain_b876cfc1-c31f-492c-b796-fb7897d51b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:to="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_27b9cf9c-0f46-4666-beb9-f9f419b06511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:to="loc_us-gaap_CommonClassBMember_27b9cf9c-0f46-4666-beb9-f9f419b06511" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SegmentandGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended" id="i04537da0df9449a883975a7197d6e746_SegmentandGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b43f4aa0-7a9f-491a-9a38-e659f4deb648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b43f4aa0-7a9f-491a-9a38-e659f4deb648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_878c5acb-092a-49bb-9872-8e405ca861a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_Revenues_878c5acb-092a-49bb-9872-8e405ca861a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a8ec1e4d-0ad3-4835-bb8e-afb36ceeb333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a8ec1e4d-0ad3-4835-bb8e-afb36ceeb333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_743d8ba9-2b9f-4495-b5bc-29e216e370a1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:to="loc_srt_SegmentGeographicalDomain_743d8ba9-2b9f-4495-b5bc-29e216e370a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:to="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9aae61a-f288-4cd5-8b5a-21a0e657c4bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:to="loc_country_US_a9aae61a-f288-4cd5-8b5a-21a0e657c4bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_285966f2-123c-4b07-9cc1-95a3d3ae7a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:to="loc_us-gaap_NonUsMember_285966f2-123c-4b07-9cc1-95a3d3ae7a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6cde60c3-8329-408e-9ae2-34fea4a46d05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6cde60c3-8329-408e-9ae2-34fea4a46d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_1691c55a-4852-4541-9888-9a702f9be654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:to="loc_us-gaap_AssetsMember_1691c55a-4852-4541-9888-9a702f9be654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a00c7895-a38f-4a03-9adc-b7292ef655f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a00c7895-a38f-4a03-9adc-b7292ef655f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_07a9d455-8832-4fd3-9962-3710480f89db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_07a9d455-8832-4fd3-9962-3710480f89db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6b377246-0036-40cc-bd87-ec783bc5ff1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6b377246-0036-40cc-bd87-ec783bc5ff1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_19010e5f-92da-436e-b8cb-9f9c811dc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_19010e5f-92da-436e-b8cb-9f9c811dc0f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gh-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_203cdb7c-79f5-438f-9f10-58e0ef8d3ecb_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SoftBankMember_adc2ec43-40c3-4bcf-8037-ad2a1d159cb2_terseLabel_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank</link:label>
    <link:label id="lab_gh_SoftBankMember_label_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:label id="lab_gh_SoftBankMember_documentation_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember" xlink:href="gh-20230331.xsd#gh_SoftBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SoftBankMember" xlink:to="lab_gh_SoftBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83f76f60-b003-4845-accb-087fdd2dc085_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_464f8307-e2ac-4cf3-86e7-4df6893402c5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4719a47c-3704-497a-bf5c-e16bbf941989_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9bb6a5c6-f631-4c8c-812f-544d472974d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9ac0dfb5-5755-49ea-8db3-c6b166313cb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_dbbfc2a0-0118-4778-9d7a-c01323653783_totalLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:to="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_520ba0a4-ff8f-4784-b27d-e928fe139836_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_907893c9-994c-40aa-935d-9c0b73abd965_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a0f16cf7-4aa0-4e0e-8ee4-49063dc22686_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f53882d7-7dd2-44bb-b0c7-1dc7ae1e5174_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_2a6dbc0c-61c8-4d8a-af10-314830f2f831_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ac2f333f-ef7b-4230-8917-426b43768ef6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_16ff7ef8-bb5e-4f5f-b05c-03ccab173a0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_6c7e44c2-4103-457b-8524-ea23d1ef6f6f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f4f5c20f-4500-4274-807b-1d655566c947_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6dc1bc6d-29bf-4272-85f3-d52aa75cc174_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6ab127ec-e5d1-4381-8206-4a6f97b24ea0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_9351f556-acce-41dd-afdd-3f7446c0d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_6b58e51b-8107-47a0-9878-6b0b4249d7c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_68ece701-85c4-464a-9102-637b31b8e42f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_bb65f60b-c214-4762-92c6-4c0f4fbef1d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_59fc81b8-4b40-4f84-8d49-083c50cc87b2_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_label_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_documentation_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthAMEAIncMember" xlink:to="lab_gh_GuardantHealthAMEAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4b717d5-a8a9-4fdb-963e-2f868b4e9d18_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6a53cc21-8409-4281-95cb-44802c01069f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d7f166df-ab45-4efc-a0dc-72f0afeb58b9_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_fa2bd0d7-5890-4c88-b76a-43865ebf9c77_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual receivables, credit loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89411845-7366-4c35-868f-aba4d0dc92c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0f4cfb6-2d7a-4860-ad65-ae708779ad1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_717b0322-6c93-42b8-8037-b59918ca9fd0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1522b55-862b-4db5-9818-d6a0d515e408_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ac309790-dd50-4f07-8f8a-4b6ed6cfee81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_5dab02c3-e9eb-4132-bfcc-a9e2281dd323_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81118df7-538a-4519-b754-3f4a10b3376f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_d5ee7f58-64bb-4d0d-a497-9cc0aef2e612_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Receivables and Related Credit Loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss [Table Text Block]</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerBMember_60d3f3b8-1463-4b15-a00b-0a549f8b8f58_terseLabel_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_gh_CustomerBMember_label_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gh_CustomerBMember_documentation_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember" xlink:href="gh-20230331.xsd#gh_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerBMember" xlink:to="lab_gh_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_468b5f0c-e1c1-4ed9-81ed-9c95c6fba825_terseLabel_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible senior note hedges</link:label>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_label_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</link:label>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_documentation_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:href="gh-20230331.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:to="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c98c18ed-0b39-4c4a-9291-b0961aedb699_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e0dca61c-1293-455b-ac18-50fbdeb03aaf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_64ac5310-0ddf-49c5-bffc-5d4783806a84_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7af09409-8831-4196-bfaf-a90115169e1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6648f1ca-4b0a-4aba-a134-b3fa99790e91_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_88387346-a0de-4880-9ed5-c4f594a1abdc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_52a39836-5eca-46e3-b64b-9dfb79462fbc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_762593e1-3b73-4ffb-bcef-cb324c5f05e3_negatedLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, allowance for credit losses, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_567c9be8-2151-4cfa-9137-63041f85cf38_periodStartLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, financing receivable, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_2e57acd2-5b35-4107-8d61-470a4aa4e36e_periodEndLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, financing receivable, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_63ea0698-de53-46f0-aaab-fb5377b2e3c1_terseLabel_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8e61e1f7-1921-4ab0-8b8e-b50372347f2b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_124bec97-f744-4977-8e50-24a256daa727_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_0b9ec0f6-ad30-45a2-ba23-6eb90f139fc0_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_73321544-c8fd-4d8d-83d0-c5b54bc66a4e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_b615d1cc-8ec6-4b35-9d32-fdbd4b755bf5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c1245dd4-427b-409e-b488-be0e71ca5177_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional service period requirement</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_aadf0aa9-5d13-41fe-985f-9e638eea2822_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_85c8135d-2b43-4863-bc09-cf03d0659b57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_01be0db8-a03b-4a0f-a17c-6518db768622_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_25103daf-69fc-4ff3-be9f-23eb4347547b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_0a9fc4f4-ed88-469a-936d-5404deee65bb_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConversionDomain" xlink:to="lab_gh_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67b80a60-ea74-4140-b0ab-1dde718c9299_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_14c592e0-1948-4b8d-9a31-e71d6c1764bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1ce26844-7cb0-4484-9cdb-54291974d793_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2b0c1d13-4370-455a-8c6e-0ffb03653015_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_c47aef2c-5f49-40be-84b9-11123c08e40a_terseLabel_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phantom Share Units</link:label>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_label_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:to="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6928a78b-b3f1-465a-8d78-0f492df630ba_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenueFromDevelopmentServices_04b53055-40d2-4342-ac10-c32d307d987f_terseLabel_en-US" xlink:label="lab_gh_RevenueFromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development services and other</link:label>
    <link:label id="lab_gh_RevenueFromDevelopmentServices_label_en-US" xlink:label="lab_gh_RevenueFromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Development Services</link:label>
    <link:label id="lab_gh_RevenueFromDevelopmentServices_documentation_en-US" xlink:label="lab_gh_RevenueFromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromDevelopmentServices" xlink:href="gh-20230331.xsd#gh_RevenueFromDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenueFromDevelopmentServices" xlink:to="lab_gh_RevenueFromDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8249c437-11c0-4730-a8ac-4d19b511aba6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_678194b4-0026-43e8-8959-dd4f1266f26c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0fb4d22d-395e-41c7-bbea-a09f8edda46a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3b278a76-4b0a-4314-abde-73f5b64b6c84_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a3c331a2-7e04-4a20-987f-aaabb52697a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March&#160;31, 2023, and December&#160;31, 2022; 102,708,305 and 102,619,383 shares issued and outstanding as of March&#160;31, 2023, and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_70ae0786-c6bf-4e31-8dff-d77170a0023e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_075b9b41-078f-4cc6-a826-fbdf2cc75ed2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f6afd23e-3ac3-418d-8d7b-e3baf52a4602_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_4c0265ef-63d8-409b-ace9-4821ff251be6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP obligation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e9e8d91-8f06-4e90-a641-a289de9da71c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9d418d3d-0e71-4ff0-a961-c1689dcf2a33_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock_06e07e9c-a063-45eb-98f6-afc217fc1fc6_terseLabel_en-US" xlink:label="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition Contingent Consideration</link:label>
    <link:label id="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Acquisition Compensation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Acquisition Compensation, Policy Text block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_PostAcquisitionCompensationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:to="lab_gh_PostAcquisitionCompensationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_591308c6-437d-4881-b2b1-c5123919ede4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_8a8b8797-69fe-433a-991b-32b86638038f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected recognition period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8819067e-1be2-4ffc-a59a-e23df944587e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_dcec555c-d839-4f36-a915-2a049b01ddc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_b0d7fa21-9578-41b0-97f2-668e558074ae_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42b7c4ed-83a0-45c2-96c0-bc0af8d189a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_efb867cc-881c-484d-bf60-62ba41a1cc46_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49e550bc-9787-4472-bb25-b9575ce74cc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4ed6cc1b-8e29-4cf7-aeca-e95ecff003ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_bdd1b5e4-0752-4b40-acd3-55484a2f1a4e_terseLabel_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2027</link:label>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member" xlink:href="gh-20230331.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleSeniorNotesDue2027Member" xlink:to="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_9ac97462-c2c2-4a72-9644-f801830181b4_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NonMarketableSecuritiesPolicyTextBlock_b11ba8d8-e3fc-4c7a-b4d3-acb687882b37_terseLabel_en-US" xlink:label="lab_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Marketable Securities</link:label>
    <link:label id="lab_gh_NonMarketableSecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_gh_NonMarketableSecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Marketable Securities Policy Text block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_NonMarketableSecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:to="lab_gh_NonMarketableSecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_482f698f-88d4-4d7c-a67b-88d4c744c11e_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price goal (in dollars per share)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7b84eb4b-c8fb-4d88-b01b-6f6678487418_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContingentConsiderationMember_afa8aa9e-e375-4531-a069-0e12f2a5d59e_terseLabel_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_label_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember" xlink:href="gh-20230331.xsd#gh_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContingentConsiderationMember" xlink:to="lab_gh_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f3ee359-1b05-4d14-bad2-a49701ef3283_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_678c6a3b-9e4c-47f4-b863-26b24fbfc23c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a737ae52-58ec-4b49-ab8f-e77a739df6ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c31f46d-ead6-4a94-bc4c-d1a562f5755d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_89008358-e7a6-46fe-ad8a-86d1c2adaab3_verboseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesTerm_067751f7-c4d5-429b-9202-bda648e8958c_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and other assets, term</link:label>
    <link:label id="lab_gh_ContractualReceivablesTerm_label_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Term</link:label>
    <link:label id="lab_gh_ContractualReceivablesTerm_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesTerm" xlink:to="lab_gh_ContractualReceivablesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bf0250f3-787e-406d-86a4-df282b58dd52_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb6b89e-ee32-4a3d-beb3-e4ce15f92975_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6df25c1c-a8cd-4653-acf1-4c417c674dd4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5a38f050-c40b-41b0-8413-afeccb0ba434_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0b500b14-7258-456b-ab14-114cfe0ac4d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_53981339-4c27-4f37-b912-f143230d2b57_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ad937894-98e5-4806-9082-639040dc59a6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_080f2333-78af-4041-8e52-a6553b4e5ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price&#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9b1bc6b0-1d0a-4115-b195-09a2c7253708_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_95a229c0-53de-4aa5-bd7d-3529a0df9e68_terseLabel_en-US" xlink:label="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and debt securities, fair value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_label_en-US" xlink:label="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Debt Securities, Fair Value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_documentation_en-US" xlink:label="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Debt Securities, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:href="gh-20230331.xsd#gh_CashCashEquivalentsAndDebtSecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:to="lab_gh_CashCashEquivalentsAndDebtSecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0e6c73b5-e433-4eac-b1b6-8d0c43f0196f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_91c4234c-b5be-41dc-bfb0-ce2cfa6df0d6_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConversionAxis" xlink:to="lab_gh_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_da00f343-a729-44b8-88ae-ef0c1025deb4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2ba77fe-70a3-4b18-a66d-d6ad7ff9d2b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1332ec1a-fd36-4916-abdb-0b265b7ca7ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cde48315-cc5e-43ec-aac4-ebd5ec678c12_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5b4477fe-8db3-4918-9d0a-838cbf573132_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_e4320e82-03fb-41ab-9011-2502f751ffba_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, gross amount, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_1a1f2101-f04a-4c37-9dad-4a2bdd0e2f8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a80c7002-851c-40df-abf0-cd7edfc5d20d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_34519a58-6494-48a2-86f5-bbfdc6d8c50c_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant&#160;</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:href="gh-20230331.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_3732429e-0ec5-4690-a4b8-a5056ddeb56e_terseLabel_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of non-marketable equity securities</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_label_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Of Purchase Rights</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_documentation_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Of Purchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOfPurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:to="lab_gh_EquitySecurityFVNIImpairmentOfPurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_77e89bbc-d26d-42e7-a92c-f2c301520721_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3087295c-6905-4433-b1e3-5cbc52a9a4dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_211f015b-3c92-442e-9945-f65085b9e504_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8fe8ad64-3c06-43d4-9f17-c17b0255d2d6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4720f287-f3e1-4077-8ef7-4e7d4d007457_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, patents allegedly infringed upon, number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_08e48192-2a12-47b8-9c58-be04da179f54_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_ee406459-a242-45f8-9c00-79ef63647f31_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_label_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Policy Text Block]</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:to="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3549be1a-d1d1-46e7-b105-00de591823cb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28aac3b7-4bf5-4ec4-8e8c-ec29b6ef9529_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 1 - $120 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4db8887d-3729-461e-bced-2420da100687_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c1b5090c-a5ab-479c-a3a2-d921dbbce6bd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_466e07c5-e323-4194-b510-b6bdc617156b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5dd06adf-7e51-4a40-ab72-8b9995b38de7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_ab226aa1-cc0d-4792-affd-b2d9209f6090_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 3 - $200 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9b5bbb4-d5da-41a0-8269-f62d25619095_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e3f12c6e-5b0b-4d11-82a6-680d67beb6fb_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_c155cb52-9287-4dd2-8052-720348abfb81_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_bd18cb57-0b80-42ff-942a-a81dc6c047b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-marketable equity and other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentMeasurementInputDenominator_985e0c28-2617-4ba5-a671-95b2415fbcaa_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentMeasurementInputDenominator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, measurement input denominator</link:label>
    <link:label id="lab_gh_DebtInstrumentMeasurementInputDenominator_label_en-US" xlink:label="lab_gh_DebtInstrumentMeasurementInputDenominator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input Denominator</link:label>
    <link:label id="lab_gh_DebtInstrumentMeasurementInputDenominator_documentation_en-US" xlink:label="lab_gh_DebtInstrumentMeasurementInputDenominator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMeasurementInputDenominator" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMeasurementInputDenominator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentMeasurementInputDenominator" xlink:to="lab_gh_DebtInstrumentMeasurementInputDenominator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_844fbfcf-e12f-4a01-ba71-94b579e7c28d_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_207636cf-50d4-476e-a52c-c9190de43aa1_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock exercised early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="gh-20230331.xsd#gh_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="lab_gh_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c23b725d-414d-4317-bb21-b0896f3d87aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e5af0dd-14a8-4f41-a9e9-81ad94a4dafb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_98fa2521-dbfa-4ea4-b018-3c65bf95390a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ee83c20-674a-4a70-bc5c-a7cf5aa5e2a2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_171b5a70-bd9f-4478-93a4-637d70ade47f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; (deficit) equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e33a591-f16f-4c18-a2f8-43af4c20677d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, net</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e2f863c1-0d86-4fba-a584-d59d85d92a92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f8a3d4d6-212b-46df-8120-4206dc6733e1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a361e1ef-63f8-408e-a61b-8bf2f2a00468_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_72749639-6f4c-460c-86e2-1c46268fa561_terseLabel_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_gh_A2018EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_gh_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember" xlink:href="gh-20230331.xsd#gh_A2018EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_A2018EmployeeStockPurchasePlanMember" xlink:to="lab_gh_A2018EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22b52779-6e0c-4512-9554-bf17580bb235_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2b7f89a-1df4-48a0-8b7a-5dbbdadefbba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e2f4f0f9-e663-4492-8b0d-e4070ccb0b5b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aec8d6f7-ebc1-4539-9a2b-ab0de76b41fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_14912348-c4bc-4f38-9bc8-746cdff14087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_b194d10a-2a50-4fcb-99e0-b43ab2639d41_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0ceced0a-eb70-4655-a3db-91e7587a1381_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_085e66b3-1629-425a-b02f-12f383053ced_terseLabel_en-US" xlink:label="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_label_en-US" xlink:label="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Accrued and Other Liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_documentation_en-US" xlink:label="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Accrued and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:to="lab_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3ae7bd03-77a9-4c07-82e4-ceb17d10b3dc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_6f44fad8-6605-45cb-8ba9-4b58d261538c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities'</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostOfDevelopmentServicesPolicyTextBlock_a02416c3-c252-4a52-b217-ff7f42835252_terseLabel_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services and Other</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServicesPolicyTextBlock_label_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Development Services [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServicesPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServicesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:to="lab_gh_CostOfDevelopmentServicesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1d1e3c62-5cc5-4195-adbb-d1ee7f0f74aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_98d25048-454b-4ad4-9250-08ed9bdb8ac3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_20b93e13-3145-4398-aea0-8c2e7393b9bf_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_869ed3f2-963b-43e0-a742-b2ed33787e07_terseLabel_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual receivables, installment payment</link:label>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_label_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Receivable</link:label>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_documentation_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable" xlink:href="gh-20230331.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ProceedsFromContractualReceivable" xlink:to="lab_gh_ProceedsFromContractualReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fecb6109-c72f-4393-9784-eb8957e8cc65_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_54403f8b-08cd-4d4e-b9a9-5c65e1576142_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9e5b6b4d-e1f7-4e3b-8e4f-07950a26e659_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_22a7c865-09db-4b64-9de2-f805707609f5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3e25f403-f2b3-443d-b430-c08763eb9537_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a32a8bc6-9f80-43ae-bbde-af5c6d674d59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt issuance costs, net of amortization</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_274c61ee-a1fa-49ff-8286-63e64fbf6b10_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fcc1310e-a5dc-4555-ad91-4571b9b19acf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6046a27f-f336-48b5-a781-e1cc96926f7e_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f1f2ebe7-beb9-4bfb-93a0-dcb49cf295ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d4f19be4-eefe-4c3b-bfed-768d699bb87b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_1f77e1e3-ae58-416d-854c-2cdd0c85f3b0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f481ebb3-b137-4521-bf02-2ac1a09f3079_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f4551d5f-79c7-4744-a100-2ca3817237f5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerDMember_09fcdcbe-634d-47fc-bb3a-7e07013e58b8_terseLabel_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_gh_CustomerDMember_label_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gh_CustomerDMember_documentation_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember" xlink:href="gh-20230331.xsd#gh_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerDMember" xlink:to="lab_gh_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostOfDevelopmentServicesAndOtherMember_be9dbc3b-fb43-41c7-9d2f-48236607e1d1_terseLabel_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of development services and other</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServicesAndOtherMember_label_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Development Services And Other [Member]</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServicesAndOtherMember_documentation_en-US" xlink:label="lab_gh_CostOfDevelopmentServicesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Development Services And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServicesAndOtherMember" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServicesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostOfDevelopmentServicesAndOtherMember" xlink:to="lab_gh_CostOfDevelopmentServicesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bd367277-264d-4800-85ec-1b4d60b29e24_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fdc12a74-c5f7-471b-91e1-184aaa2af1aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue long term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c8461025-0d95-40ac-a478-8cd87b4fc994_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_9a856c8c-07dd-4d99-a264-339793658931_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0c9d5d-b009-47b4-8388-4369b7828abf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f95fae9e-b54e-4b39-b90c-0f7228eeda7c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ab9be763-db43-476f-ab20-3b2178f8c582_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60749253-a55a-4d79-83f0-784e33353ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b8b11b3b-71ff-4fc6-bcf5-f6e88d981fcf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0b070ca9-7e5b-4a17-8b04-1f60dd86f783_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d932d559-8b04-4596-8285-db15f4f46c50_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7d170d33-4f2b-4332-9410-5cc2533fa600_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_6725a0d5-cccf-4e3c-8279-1065dcdb003b_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2a38a5d-a5a6-459d-a747-493b47c5d959_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca2d5298-2ba6-444d-abe5-9eaa86296907_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8460b023-3668-4c79-9396-b11e3d125fbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1f99a541-b07e-44bc-8373-6f4d47aadedb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_fb46b3c9-eb46-4b5f-9344-3e20760c297b_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_dd20dd09-9413-436f-b7a9-0a5b976b11aa_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d1324a52-30e7-479f-9962-a429512fc90d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_94766a1e-5867-4882-8840-6bf046511ebf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bde1feaf-10a4-493f-a7ce-da49a6a0ce62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_030d5c2b-f5ee-4a84-8032-0f202bcca68f_terseLabel_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_label_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:to="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_64e7e121-dc28-4e04-90a4-ec6ec8f27719_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_b5ea4e38-fe81-4a3e-9837-6b4ad8b09071_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6d00b236-e16f-48dc-8774-4bf4fd10e874_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0bbb63a0-4868-4119-b63a-f95521b5de24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share , basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b54cb725-1b82-4974-8b10-3993466710b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average derivative service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3597176a-7127-42ca-a9a4-6d542cf9036d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b8da2029-06f0-4aa3-b2cc-fa2f694dd76a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6e1262f2-d4a9-478a-bbff-90da1a445d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled of tender, amount</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_770a706f-9de1-4a55-9982-1637dd131df4_negatedLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, allowance for credit losses, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_97c81ba3-419c-4194-b799-407ce988b308_periodStartLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, financing receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_71670755-4f87-4ef1-bf56-9b65ad0bc466_periodEndLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, financing receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8cc03d64-522b-4cb9-8b1d-b939aa185e9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_4453a91e-b42d-48d8-8504-15f29701a889_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ed1d3f6a-2d6d-4722-ba45-dbbf41db9c48_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_20ac68dc-6e19-4bae-9228-7e964c7dc30b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f51fa24b-944c-47d3-af3f-28c93522a14a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f95652f-d49b-409c-b41a-a10e0a23d4d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_74c080b9-d3f9-4f53-92f5-65fd7141cab4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_63a6caf5-073e-487c-9f4d-a2aef7c4187e_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_86aff305-9b38-4de8-974a-ab0b44dd3750_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6b4cdeb-f78f-47b9-ab8d-8aa9aeca37e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_dd259d77-26ea-4e19-8cf1-9ae506ebfcea_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossReclassificationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338c1a19-2d1b-47d3-8001-e7c97e5a79d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4d1dd3d9-7b0e-4857-af7c-dea13b5251a1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ba51fa21-ed80-4bec-94b5-56698ab2e5bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Level 3 Activity</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_771a9ffd-92a6-4402-a798-dae4561d7f42_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3a49e704-3e6c-4692-b9e2-8f6ed8e21003_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f8b586d5-b9ec-42b2-aad3-27ae3bde76c5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_e74d2b94-de01-43cd-ba57-12f3e84803b1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9121d645-64e8-4548-a8e4-171e4cbe41d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTesting_402359d1-a16a-410b-ab3c-19d5b0383ce4_terseLabel_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Of Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsOfPrecisionOncologyTesting" xlink:href="gh-20230331.xsd#gh_CostsOfPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsOfPrecisionOncologyTesting" xlink:to="lab_gh_CostsOfPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7d9d0b14-96f6-41db-93bc-5f1f0cd79451_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_572584c9-c0cf-4e30-b3fc-e419ae4f9a6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate, ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8ccf453c-d0f0-4f10-be0f-f4e66fa19bbf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6f739465-54ce-4be6-94c9-a456bcd26f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f2ee6f5d-109a-4d17-9626-2aa5144ba6a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d0dc1084-c65d-4866-b5e7-21265d56c35c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0b5d64fb-a108-42c1-b397-ecd88e7bcb3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_e6561a76-fd1a-469d-9fe5-a7ac20f26418_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Available For Grant, Forfeitures In Period, Gross</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Available For Grant, Forfeitures In Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e2e1617c-e5a0-4035-af96-7ab96c2d6564_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_4504d11f-615f-4971-a99d-6659c9adca0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, short-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_45a4e302-aa98-4aa4-96e1-18b366144d4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b6f60f98-5121-4708-8109-8bec3de6bd22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_227979c0-35dd-4fca-9b58-1ee463415651_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c3f240b7-ee1c-45fa-a40f-8029566b109e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2998ffc5-cca7-4462-815f-c412e6bfdf7c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d0da2815-b958-4455-8b04-9ebb5c61f077_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_91f5b2a9-1cdc-426a-942d-3bea7f66b2c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_edb4699c-ee55-40bf-8f3c-61821218d2e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_028e0cc5-7e74-4cbe-9697-76b926c10320_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9a3606b8-d064-4105-97a0-6316240a77db_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_f6631aef-17cb-4b91-9b09-5da5d050b826_terseLabel_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_label_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_documentation_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember" xlink:href="gh-20230331.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PrecisionOncologyTestingMember" xlink:to="lab_gh_PrecisionOncologyTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_691e12b5-33ff-4c4b-b475-e318b1040d7a_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Tranches</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5da69aa2-ed21-42ca-b9c7-96009b2bd5e5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cd75579f-4f04-48dd-9225-8cea3f57d268_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c9e84558-45b6-45db-baee-a26e3a8a3846_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f0607a77-3ed6-4034-8bfa-71594a9f3092_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_91fe83b2-ca21-4d52-9e6f-0e03a09740f9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_87a168d1-a9b2-4405-be76-dfe9597a2aa4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a44375db-d596-4d94-9949-955493046fe2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d36ec75c-cd19-4b71-b175-d409e607d1da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average exercise price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c029873d-139e-4cfa-ba44-d53a84bab9b9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_071b0a70-6212-44a2-8764-1531e12581dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_585fbeeb-48c2-4a1d-a6d6-08238cabe402_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_210606e8-a0c0-4670-b429-23a85a3e0666_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_27f54d9a-bc1f-4bf1-a8bf-c15a8b9d732c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e3902a6a-213c-42b7-842d-59a87abb821f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_65be5d36-c668-4c7c-9f02-bc1c50df177b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_974ceea0-7749-4e2c-a530-c0e0fddaf9e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a92024b7-7540-4884-866f-d545a5adcab2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04893e10-2477-40d6-876b-fc0a4a435632_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c0a34075-c98b-4791-860a-25cd9af2bda3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f8532109-714a-43e4-85fc-36d8a1b05795_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a94294c2-bbec-4f80-902f-4dc6b059077d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_41025511-1f9e-4701-bf30-a8061d0f3976_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of MSUs (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eef420f9-cad1-4772-aa25-32c84cbf14b0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0231df65-d3f5-441d-9f98-c9b89ae41140_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_18563031-0c31-423e-9888-d4fbc2153a03_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_0331c5c4-7f20-4a83-ac54-5b4b8ac6aa5c_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of fair value that is no less than internal rate of return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value That Is No Less Than Internal Rate of Return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value That Is No Less Than Internal Rate of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:href="gh-20230331.xsd#gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:to="lab_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_35b218dd-d50b-4687-9318-0ff0468bd174_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_c92fd555-dfc8-4310-8344-95c2fae86208_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_1e9b69e6-99c3-4303-91d8-e2f2e6008b1e_negatedTerseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_83529431-5ff9-4355-b9bd-2d0cc641b4a3_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total market-based restricted stock units approved and granted (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_46587d98-eda8-4245-8b95-89f7faa3d6b0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f9ff19af-7e09-4a45-8a8b-918144eb450b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsMember_e8d4ce98-7873-4ebe-9356-2981c021cf86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsMember_label_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsMember" xlink:to="lab_us-gaap_AssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_60cd8726-919a-4613-acad-9db161d2ec55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fb5ae175-4023-4101-ba72-4b1b2d5798d6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_99d6c27c-178a-41bf-8371-168bbf0e971e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_f0a94db9-db71-424f-ae7d-31fe2fee9328_totalLabel_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:href="gh-20230331.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00f40e68-908c-4d3d-b71c-70e759dfe8f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8f33b2d7-fed4-46ca-95d9-2197da2fb3a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_32ce06b0-c263-42ce-8c74-f0ce3b1f0761_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_76425a3b-f428-413d-9745-b0b943c43aba_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1a8ede50-8106-4a65-ae0e-93ae5e926a87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and nonfinancial liabilities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77fe1d17-59fa-4264-b2b4-28e24cbe0f77_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AMEA2020PlanMember_056d983f-0d64-4547-a637-8387da9a6e18_terseLabel_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan</link:label>
    <link:label id="lab_gh_AMEA2020PlanMember_label_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan [Member]</link:label>
    <link:label id="lab_gh_AMEA2020PlanMember_documentation_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AMEA2020PlanMember" xlink:to="lab_gh_AMEA2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SaleOfStockLockUpPeriod_d2f86431-4198-4797-80d4-24b5e247873e_terseLabel_en-US" xlink:label="lab_gh_SaleOfStockLockUpPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock up period</link:label>
    <link:label id="lab_gh_SaleOfStockLockUpPeriod_label_en-US" xlink:label="lab_gh_SaleOfStockLockUpPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Lock Up Period</link:label>
    <link:label id="lab_gh_SaleOfStockLockUpPeriod_documentation_en-US" xlink:label="lab_gh_SaleOfStockLockUpPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Lock Up Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SaleOfStockLockUpPeriod" xlink:href="gh-20230331.xsd#gh_SaleOfStockLockUpPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SaleOfStockLockUpPeriod" xlink:to="lab_gh_SaleOfStockLockUpPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ced62f26-4ac5-4e1b-a618-2736339b2763_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_863cbee5-f568-4fd3-a6dc-97f3a99f8cf0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dd52ab5a-ecd3-482f-9088-5508d828fd49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d9589e86-477c-4098-9870-5a4ee0f4a73a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f3ce4cc-6989-4e57-8d8b-0a4572f3a20a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3f6d24b5-dfbf-40b6-8fc9-d4e352486499_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd482f9d-d218-4c6b-8039-940f7a73d812_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_542c88ec-c83d-4414-a946-38c21c2f0584_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95dc74ec-eff4-4e63-b0d7-f6880e04bd35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0a420819-a15a-4ccb-aba1-41381d2eef41_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_acfa0bd2-745b-4b2e-a763-642875f5c825_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_332bcc53-5efb-4892-b570-c22bbe3b92da_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ce1d1585-e94e-4c5b-bc24-233cc32830e1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_0c6e4862-04ee-4b20-8024-02fd6f9d8b5c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; included in other assets, net</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_64d5b88a-2c49-4c07-b099-fffca8f0ad3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21c8aa4d-0470-425a-943f-48f4376be29c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45d1363b-32ae-4b76-b0cb-bcbe8fa36afe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share , diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_a366beb5-7ea1-4ba9-84e1-795ccb20f7bd_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock units holding period during vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_589879c4-3ba7-4728-a073-b54e8cbc0157_verboseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan annual increase (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_d5faa609-7275-41f0-9b25-6bdb0edadd0a_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 plan annual increase (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a117db6a-8ae1-40d7-907d-dbcb9f42c4f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_78dabe89-d4a5-4100-9e39-a71649caf521_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_900cf27e-e94b-4017-b038-c0c3952dfd61_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35b18202-9b10-4ae9-a814-2e0be18bb6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_754f3a31-4557-44bd-a1cf-e10d19ab28e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1331dbb9-e218-48c9-baa1-5daa41516507_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7c24e598-ea06-4bf4-86e1-7d2df9cb8f37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_bfdc748c-6e7b-42bf-965c-5c9af04beeda_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_9ac8469c-dba7-4c3d-966e-75f0e6d3f683_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a1fa96a-d07b-49fd-ab0f-9cf7e2b532f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of MSU (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_ebbe8211-03c7-4f0b-8be6-e4a056d28e34_terseLabel_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price, premium</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_label_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Share Price, Premium Percentage</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_documentation_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Share Price, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:to="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_d4dfc402-72ff-4688-a602-79eb5515c649_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8f6b9548-89e9-4c21-bf7b-3955913d4bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_de8b6617-df2e-4ebf-9d96-f3724fa2237a_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum special interest rate percentage</link:label>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_label_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</link:label>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_documentation_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:to="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_22909ff2-a9cf-4804-b1ee-f86912047ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_09afe789-13e8-485f-acdf-854c3c75f653_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_73e0b68a-c53b-48c1-8db2-2823a3081f9a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0f22e611-afd9-4fb2-94d1-27eeef94610a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9d9fd1e-ecea-4c19-b60c-08275a2bc582_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c9ade7c-3ed2-487f-8369-bdb916c322e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c49ce81-1017-48b5-8c20-b185cc641c2c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_002f8877-43b8-4a27-bd7d-fee4f02c3327_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-based Restricted Stock Units Vesting Conditions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_72416b94-106c-44a8-a7b5-bd5b3340607f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7ca9ea10-94c6-4c58-adc9-64800e0fb845_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f35e2a8f-fd41-41dd-8a55-4b70ea38e9ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f998f535-4c62-46d4-be4d-aa0394da1778_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_55257f00-8808-46f1-be62-7e44a65b67a6_terseLabel_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_label_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Strike Price</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_documentation_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleDebtHedgeStrikePrice" xlink:to="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_53d9445b-684a-4dad-9613-8ef316931c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4d70c9dc-ba67-4809-876e-46c54cb674ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_ed6044ef-981e-412a-80b4-e959e1a12d05_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_22c27fda-5bf3-45ee-8883-e561a1fc9678_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dfae2a32-340a-4243-9d3a-0f5c24b7a860_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_0d056ed0-97a8-4a22-8cb1-e961548885e1_terseLabel_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_label_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_documentation_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:href="gh-20230331.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_e63b0d54-721f-4f5e-86d3-e80c63247cd8_terseLabel_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or adjustments of non-marketable securities</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_label_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_documentation_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:to="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3bacc558-5892-4770-9352-0c3c6032934e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47594893-be02-4f87-89db-5a58b0472008_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c4348a24-e6d2-4fb8-9de8-69298ebc1afe_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cae769e4-7472-43dc-aa48-750c66f07a41_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_953f3e29-381e-4421-9921-b6f20701652b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3860bcca-1a31-4165-9cae-7fca7878ed8e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_aa6da744-42e6-4767-97a7-a59ccdd68b33_terseLabel_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_label_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Operating Lease Costs</link:label>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_documentation_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Operating Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts" xlink:href="gh-20230331.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NonCashOperatingLeaseCosts" xlink:to="lab_gh_NonCashOperatingLeaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d4f69114-96ef-4e3c-9412-f49f02e2d316_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d673d63c-4e43-4521-a99b-cbec6f1bee8c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputQuotedPriceMember_b70e1da4-4fab-4d0a-ae55-92a8e61f89fb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputQuotedPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Quoted Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputQuotedPriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputQuotedPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Quoted Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputQuotedPriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputQuotedPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputQuotedPriceMember" xlink:to="lab_us-gaap_MeasurementInputQuotedPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67579c8a-1a56-4c16-815a-7061e2bacaad_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ca91841f-9770-48a3-a9fe-b18df1530913_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d1a1b1ce-9b12-4fde-aeaa-4d027056b8e3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_acc03006-d164-41f2-a4a5-a9cf9405a14c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodThreeMember_bb53af73-9ae4-41b0-931a-9a38ab7db8a8_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three</link:label>
    <link:label id="lab_gh_ConversionPeriodThreeMember_label_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodThreeMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember" xlink:href="gh-20230331.xsd#gh_ConversionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodThreeMember" xlink:to="lab_gh_ConversionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_1f02523f-1983-43bb-b148-02aae7123a4a_terseLabel_en-US" xlink:label="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.</link:label>
    <link:label id="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_label_en-US" xlink:label="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_documentation_en-US" xlink:label="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:href="gh-20230331.xsd#gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:to="lab_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NoncontrollingInterestLiabilityMember_98c6ec14-bee6-427b-a324-3b78551b61fb_terseLabel_en-US" xlink:label="lab_gh_NoncontrollingInterestLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Liability</link:label>
    <link:label id="lab_gh_NoncontrollingInterestLiabilityMember_label_en-US" xlink:label="lab_gh_NoncontrollingInterestLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Liability [Member]</link:label>
    <link:label id="lab_gh_NoncontrollingInterestLiabilityMember_documentation_en-US" xlink:label="lab_gh_NoncontrollingInterestLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Liability Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NoncontrollingInterestLiabilityMember" xlink:href="gh-20230331.xsd#gh_NoncontrollingInterestLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NoncontrollingInterestLiabilityMember" xlink:to="lab_gh_NoncontrollingInterestLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7987b8b5-f2ba-4149-9832-5731cb588c92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d4c8e93-4b7e-49dd-9e85-ace5d3cb0c9e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_3bc6f0de-9634-4e6d-8b60-d930253308ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_daec871a-414f-4f29-85c7-fe35aca263ef_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a65315c-684a-498e-89d5-35635c424685_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_68060aee-59a5-4049-8af3-ae06d87d2280_terseLabel_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Market Approach</link:label>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Market Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:to="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8d0bbb23-f881-4fca-9fd0-fdacdc269fce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1d98d52f-2f9b-43d7-b9a6-5873637e4636_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b332ef68-cdcf-4d03-abd3-5c020b4351b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_211b5617-284b-4356-aa9d-bf780642a74e_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock share price goal</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b245d475-0f3a-4f72-9caa-b5c7766782b7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_16001670-f74e-4171-88b3-0e56987863ee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (as a percent of the fair value of common stock)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_bc38a033-b7be-4784-a476-9cb98a7373dd_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostOfDevelopmentServices_47a85d0f-76b2-46b2-9502-21490a2316ce_terseLabel_en-US" xlink:label="lab_gh_CostOfDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of development services and other</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServices_label_en-US" xlink:label="lab_gh_CostOfDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Development Services</link:label>
    <link:label id="lab_gh_CostOfDevelopmentServices_documentation_en-US" xlink:label="lab_gh_CostOfDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServices" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostOfDevelopmentServices" xlink:to="lab_gh_CostOfDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_96517d66-d00b-4add-8ae8-76c2451c1c9b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8ce1f0c3-a2d3-424a-ad47-692d7da584c5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_deafd897-3db5-4ba4-a594-8f1d617b9cff_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40c98cb1-5327-48ac-9dad-d0d86c689c4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4159cd24-14f1-4d39-812b-3198b06f5d10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_afa8c682-4b6d-4b63-b9fc-362447150070_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4770bd9b-61c1-46f9-af57-ccf018e48e50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_a96ef2b9-4659-40ef-ae87-e46f6227c8d3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_659a6296-b422-432f-9431-dd2ad953c5b6_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossReclassificationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_baa90a7a-20ab-4a86-a03a-6a19a2c0a7d2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1f4d89a-0085-4079-8eaa-a2d36c04a0cb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3f5a4d6a-c4de-4392-9a24-d9a0dcc44330_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8aba7f31-f2bf-41f3-8ece-9b61153f3fde_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_17ee6f40-76d2-4bbf-85ff-e0c697612fcc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6aed9447-7089-48eb-89d7-7697defacb07_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b7eb9cb6-405e-4f46-9267-033896bd50b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerCMember_a96f5e98-13df-4dc0-b408-2aaa3b96ab4f_terseLabel_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_gh_CustomerCMember_label_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gh_CustomerCMember_documentation_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember" xlink:href="gh-20230331.xsd#gh_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerCMember" xlink:to="lab_gh_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_eb5d2d03-cafe-45d2-bd95-9a829ab9ae0d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_efe7d9ec-c2ec-48bc-9966-99a8940d7217_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_16a1bd6f-8fd8-4eed-92cf-960adefa0226_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_78d6d20c-f4d4-40b3-9b66-3f4abcfa87de_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_1b5d469f-50ef-441a-914e-818b2e38cedd_totalLabel_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, cash and cash equivalents and debt securities available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, And Cash And Cash Equivalents Amortized Cost</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, And Cash And Cash Equivalents Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:href="gh-20230331.xsd#gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:to="lab_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6780bda2-e8fa-4a26-b28a-2282cb5dd533_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f7085f9b-a2ff-47bb-8084-3926a23a9f9f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68a41009-60a7-4c3a-8d20-d6a4c6c6f188_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_79a46096-868e-4b36-9c2d-abe728f9413c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4d239711-4c0e-4c4c-bb86-2d2a01efc197_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_bde7217d-43e0-44c3-802a-f9d594b2cb04_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f650d5d7-265b-4d3c-aeee-c35a8f0f2698_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_640ef688-4a2b-404c-81f9-3d6e59a0710d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f682fab-ec87-4fa2-83a9-b55ab4eded31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_38710855-8095-4c5a-9aa6-0a7ee706b89f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42be7984-4462-493e-a132-2b784352ee2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_300ac256-7b17-43da-8046-94bb9c74e436_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8a4b941-137b-41a8-9ab1-8aa14ee74326_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18525d4e-afbb-45d3-b54c-a0a02b9a8078_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_77d86237-2ff8-4760-89f2-e9a19108647f_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization cost, cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b127c868-4ab6-4b09-92e1-a7d4d9627088_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c637dc4b-f33e-4760-a0e1-d9e9ca82bb54_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0a0f2b16-2dff-45c1-b72e-18a973818226_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8c796657-4885-418a-9437-b44cce6b96c1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_032fb9b0-7e87-4f7b-83af-844fc68513f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_6a7d6eba-05f9-4bdb-bb43-74eb735db4aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_030f69ce-b8a4-4066-9fda-ddf90186a70a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9344f931-eb29-4929-a684-db24d49efbff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3936d62e-cf64-407a-9bfe-263986439ecc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8e2a7725-0adb-4c31-8677-c3c79e237cdd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f7d80f10-98b8-4dbb-9b11-b129f10b9e82_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_91a2689a-16a4-4a02-9e78-4889a891714d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c9ef4f5a-cd87-40f6-9d52-16a53fba29ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d9aef23-4378-47d3-940e-d805170eabab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d02959f1-8f60-4a26-a9cd-e33debd11a27_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d6e32c4d-4b74-41e4-bd4c-9ab998768007_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerAMember_4b4f52d1-f181-4f82-b180-ead232a70dc3_terseLabel_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_gh_CustomerAMember_label_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gh_CustomerAMember_documentation_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember" xlink:href="gh-20230331.xsd#gh_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerAMember" xlink:to="lab_gh_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5cc9a5a8-9414-484a-865d-29f994a75429_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9d8d3ad3-2ac0-42d5-ab73-0bc1d7d37fc4_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodOneMember_967175da-ddc6-4d2e-8aeb-febfac9d0bb7_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_gh_ConversionPeriodOneMember_label_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember" xlink:href="gh-20230331.xsd#gh_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodOneMember" xlink:to="lab_gh_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de8af2cf-c594-42dc-974a-304d0ea91ad3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8bc49f33-6c7e-4f81-bb03-a4835553da59_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d24c2522-1015-4da6-be04-48cd09ed2a80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_55a29526-da4a-47f7-a7f7-b22e62e93830_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_10402448-c048-4782-b80e-1ac669a34292_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_31c86d18-7236-41e5-8deb-3b35d7a4bf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of exercise of vested stock option granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_04447e2d-e83c-4beb-b08c-1352debf753c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_991bad5d-996f-461d-9c58-7035c1705e00_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6ef1239e-4e29-400b-9907-0de4086b0b29_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ff8c8911-3377-49da-876b-51ecfd36cc9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_39bb5ebc-c5d6-42e0-bd11-fa3eb48a6ad0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2760316e-774d-490c-add3-d789d7f9696b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f85d1f04-1684-40e6-990d-1c4f9c26040d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_326efeb0-a872-4b8e-892d-dc9cc632004c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discount) premium on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_6b235332-f045-41ec-b594-e45fec5964cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_466b0bc5-3707-4eb3-9e6c-a8eec935be3b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ac0bf869-42c6-493b-93ab-9cebd3b15f76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_d0ba8134-b7a3-413b-9974-a231b3cd3e38_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9fe8120-cf7b-46cf-94f2-89fa67d8355d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_86c10bd9-be03-4b6f-9cbd-b11cd8e32caa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3a0887a9-f532-4fb1-bae8-cbbbff26634f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dda1ea8a-45b0-4bcf-8a44-c61ef6bcd03f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_33510af8-472f-4852-92d1-dc00a95844ea_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2d66dd76-f814-439a-83b2-17067f990815_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_447df37a-21a9-47b2-b4ac-191c946d541d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ebf5fc1d-f4de-4183-a9fa-d7287557e97f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d93c9143-1464-48d4-b974-2f03e7359a1f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_ca79ebab-6993-4cd9-b0f9-03df17bcd692_terseLabel_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_94c5ce23-31a7-433a-86fc-26766acfc6a0_verboseLabel_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6bf1e280-8028-4636-8fd4-af449cba536d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share , basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6c4e52ee-6c33-4186-8b1e-843ee4655bf4_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_f7fda1e7-6552-4f80-ab8a-b4822dac94ba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_588f124a-e4cd-4a18-9f96-5a6a5caac3af_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_978e4489-8ddd-4b8f-9af3-3191d00a2209_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d7723407-e569-4122-961d-b186d392b379_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8a1d837b-a228-4705-8fd9-c7d00d957408_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09247b31-7435-47b5-a546-d8df35c45149_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7fca9a5-9a87-462a-9d6a-5f262a9cc0df_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_384ca4ce-f2e5-4360-8f06-5400e934471b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_00cf3711-65dc-46cc-9f84-4688cd5e1b9f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ac0ee162-a832-40ae-b16a-8538fea5efaf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c86b67cd-f547-461c-a349-ccf387e718da_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e67fcacd-058d-4fa2-97a7-f8265acb77a9_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and other assets due from a third-party</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityInvesteeWithIPOMember_6eb3892e-0f29-4adc-9def-b2d60206669b_terseLabel_en-US" xlink:label="lab_gh_EquityInvesteeWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investee With IPO</link:label>
    <link:label id="lab_gh_EquityInvesteeWithIPOMember_label_en-US" xlink:label="lab_gh_EquityInvesteeWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investee With IPO [Member]</link:label>
    <link:label id="lab_gh_EquityInvesteeWithIPOMember_documentation_en-US" xlink:label="lab_gh_EquityInvesteeWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investee With IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityInvesteeWithIPOMember" xlink:href="gh-20230331.xsd#gh_EquityInvesteeWithIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityInvesteeWithIPOMember" xlink:to="lab_gh_EquityInvesteeWithIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_25aaac25-6475-4d71-ab83-881853a68cff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2db359ab-8b4f-483d-a25d-1aff00ac659d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_98b9e807-1ae0-40ef-a202-f5a32041e3a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_d66b9eee-cd25-48c7-a151-1abd6cafb22c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cab5ee13-19a9-4510-a993-af253bce922c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9921ce41-de6a-4598-8ab9-61171d58811f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b3565c2e-96c6-436e-87fe-fa474b4b3d73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_903e293f-b069-43e2-b538-8671627cb1b0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodTwoMember_20d0882b-0867-471b-8257-36d36b556a14_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_gh_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember" xlink:href="gh-20230331.xsd#gh_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodTwoMember" xlink:to="lab_gh_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_00facc3e-6e87-4492-98ce-8965eb04623c_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_74bf9da5-db4e-42ee-a988-c793f9d975fd_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c715abd0-59bb-4b16-b7c5-da97cf93eb4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_621331d1-9cd6-445a-bcd3-f52fc621bf41_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="gh-20230331.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d9fc9677-30cb-4e98-a004-af90f472052e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_40c47089-6673-4f3d-92ec-869ae6fc4e42_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a468fbbd-e08b-4134-90e5-fa6baaebb91b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_545f7242-8116-4678-956e-61de4e1cfd89_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_19f3ef34-da98-4798-a35a-a07a225d7488_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c66d021-97fe-442d-af51-387406dd9c59_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3ca4cd5a-16ee-4289-961b-9eef18c5d82b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_b177af99-b080-4794-8d9d-dec66cca2ba3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_4fe2a280-86dd-4cae-a3bb-d64f8d40b423_terseLabel_en-US" xlink:label="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of seats</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_label_en-US" xlink:label="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number Of Seats Each Party Holds On The Board</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_documentation_en-US" xlink:label="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number Of Seats Each Party Holds On The Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:href="gh-20230331.xsd#gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:to="lab_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b77d3a16-93e5-4370-bbe0-60d1e8362b78_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eaf16416-1d76-43ed-b032-91377898a8e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_5286c9a3-9a37-458d-8a40-834f09678654_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_label_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:to="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_79d9840b-b3f0-43fe-81da-b2949a071a1b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c97ef79b-ffec-467b-8936-50d3ac5e1783_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d3c7e037-6264-4f6c-ac7f-f5daf3920980_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_eaccbfc0-a08b-43f9-a89c-b2bc206c1dca_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_341e1a5d-008f-450b-80e5-4de65bc5f94b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share , diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7c3f426d-c169-4ace-8ba3-cf2ae68fd10a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_dc4a6e36-eaf8-470d-b215-579cc7d9c10e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 - $150 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32bc4079-acef-4ec8-8a22-639f683ee4a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock unit vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_8df060ef-4ec6-47b1-a29e-8c720453598e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e8d8e2-0500-43f1-b1d7-99b64654929b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenueFromPrecisionOncologyTesting_74f0b136-0b55-4c87-aa27-a0a88b6ea9a0_terseLabel_en-US" xlink:label="lab_gh_RevenueFromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision oncology testing</link:label>
    <link:label id="lab_gh_RevenueFromPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_RevenueFromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Precision Oncology Testing</link:label>
    <link:label id="lab_gh_RevenueFromPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_RevenueFromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromPrecisionOncologyTesting" xlink:href="gh-20230331.xsd#gh_RevenueFromPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenueFromPrecisionOncologyTesting" xlink:to="lab_gh_RevenueFromPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_2d171d1f-f66d-4d46-b7a0-a30b78a6b5ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a1e08e5a-4dc8-4c36-aef3-f7052a4f27a5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0f260e3e-a8cd-4137-a084-b739b217022b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_771cba6e-e1e2-43ef-b9fd-f58b069dd9c5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_61ed9503-12cf-4ab1-a25b-80cb043569f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of non-marketable equity securities</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberOfPatients_5c0ca2b1-9ba9-4251-a25a-bf94516c22f4_terseLabel_en-US" xlink:label="lab_gh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_gh_NumberOfPatients_label_en-US" xlink:label="lab_gh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:label id="lab_gh_NumberOfPatients_documentation_en-US" xlink:label="lab_gh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfPatients" xlink:href="gh-20230331.xsd#gh_NumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberOfPatients" xlink:to="lab_gh_NumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_221afc12-57a2-46d5-b8d5-24be0119c379_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2a849429-e35a-463d-971a-3939288f6446_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7fae6168-1a68-4529-9324-35dd4634cd86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f50eff5d-dcba-4c63-9622-fc9adba5f905_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_2bf2e953-8dec-4f51-8e05-d2f5e8356c97_totalLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss Net, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:to="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c92beffb-e27b-452d-9767-0510fe5bf03f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5cc8c137-fbae-44c9-b4ec-9f0f7a4574e9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c951d245-d0a1-4ed0-924c-557a73d0c28c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7ce6bc72-b95b-419a-85a2-31c7ff8eb9ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_54ca0c01-2061-4301-ba68-3dcf52232f91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0d1331d6-2d79-46a9-b2e9-d539fcd4d809_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0015830-7a51-49dc-ba86-0f5048c27006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_36dbe775-3407-49db-8aae-1c356378962e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_788877a1-705a-47d5-bfd9-81f609803abd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_544f096f-b3ee-4271-bd35-f392185ce49b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instrument Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7a24a511-721b-491e-9bbe-e77667038c54_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_e1c43621-ee6b-4626-abb0-7ae5878475e6_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_03485f55-a881-45d0-bdd1-2b52cb054d79_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d25b74e0-65ce-4664-b693-cb6a7a8698c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bd5faf99-69b8-4c90-acb8-279140a2df5c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2f7c5805-c145-4358-9588-e3fb55c01aa6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares approved (in share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PostAcquisitionContingentConsiderationExpense_b7b9492b-891a-4b89-ada6-1f8ec9633120_terseLabel_en-US" xlink:label="lab_gh_PostAcquisitionContingentConsiderationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition contingent consideration expense</link:label>
    <link:label id="lab_gh_PostAcquisitionContingentConsiderationExpense_label_en-US" xlink:label="lab_gh_PostAcquisitionContingentConsiderationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Acquisition Contingent Consideration Expense</link:label>
    <link:label id="lab_gh_PostAcquisitionContingentConsiderationExpense_documentation_en-US" xlink:label="lab_gh_PostAcquisitionContingentConsiderationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Acquisition Contingent Consideration Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionContingentConsiderationExpense" xlink:href="gh-20230331.xsd#gh_PostAcquisitionContingentConsiderationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PostAcquisitionContingentConsiderationExpense" xlink:to="lab_gh_PostAcquisitionContingentConsiderationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_9f93fd01-3dee-4a3b-a254-79d75d0284e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-marketable equity securities and other related investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b086d2b9-c95e-4605-9eef-16db76111961_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_62542e01-a523-43f8-98c3-1958c61880be_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreements and other covenant rights</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock_43e84318-c8b1-4406-9b5c-617c9b5bfc47_terseLabel_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock_label_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:href="gh-20230331.xsd#gh_CostsOfPrecisionOncologyTestingPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:to="lab_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a9386125-88cf-4712-8669-79b50d3ed7ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_534679e9-39bb-441e-bd39-773b784fb9c3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_181dfb1b-f4e2-425d-aca1-f99e04ff8464_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_377b1311-79d4-4f34-b64d-2594b7dbc7b7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_002fbdd0-4e28-4ba6-9a98-17c54e1bc782_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4630ffea-1712-4fc2-9cc9-85f75921e723_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ab836e24-4e08-481d-952f-1cd165ed5809_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_67e91101-1d29-462d-b63e-82cf68376894_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a243c749-d208-4e46-8680-28ff40e4148b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_763ebbc1-4db0-4860-bf3c-a4dd04c615b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_6691b981-3691-45a2-9ef7-2c630805d53d_terseLabel_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area</link:label>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_label_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:to="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2c4ca342-1463-49b7-8c77-13aadb6baa9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_935c7a9d-f1d3-4c8d-b4d4-c996fcea312c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ab4a538b-6774-4a36-ac86-c60d75b09154_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5d2a7a64-62ed-4fe1-b618-78d31f118508_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f4b4ce49-df32-468e-8be4-85fe31198923_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3eb58072-fd4d-4609-87d6-3e408b8116bf_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c5007b7b-8e59-41bf-922f-c81b9f8aa4d4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_21318daa-7cfe-4999-b9ae-ac50ce91cc2f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_246690c4-69ae-4c32-8de4-33b6400f3cd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e748072b-cc90-47b8-8826-e3fd244b565a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3839fb04-1a09-4b56-b081-df92a4e526d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_31f0deaf-5410-44b6-8ce0-331d5ea7dd24_verboseLabel_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Incentive Award Plan</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_label_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember" xlink:href="gh-20230331.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_A2018IncentiveAwardPlanMember" xlink:to="lab_gh_A2018IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5dfd6072-7ea8-45af-a94a-a6b7e87be0dd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_60fd1d4d-dae8-4831-8f50-549a93deeee2_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8645b705-5d99-4398-9448-1590c52fc8ad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4e88395b-3f4e-4d39-b16b-2f173c8bff34_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_35f1f322-8912-42a2-b5a7-0701b6ada75c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_3e84e972-dc1a-4c50-af84-4336c8c1476d_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, redemption value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a615da26-248a-4113-a534-35b30ca11a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, grants in period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_039079c6-9cdb-43dc-92c2-778efe5482a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_84b02cf2-06ce-464a-9078-efea162394d5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a3a9dc54-d075-40b6-b8da-4159e50f634b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8bfffce3-0134-44a5-b825-7fc9176342b7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2d42f8a7-251a-4dd8-bd58-d4f6b392669d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2da1caf7-ccfc-4edc-bac1-69ddc21d52cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_338d3108-a510-4537-9749-2ddc64068dd1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_823762d1-a5c7-4170-9cff-d095c96887a0_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gh-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5eb19166-8523-4b5a-a5b4-3d7b66670417,g:e7b25df2-ac60-4ecd-b4c6-8c5b1d255433-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/Cover" xlink:type="simple" xlink:href="gh-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a0a87157-5b2f-4d3b-88b2-a8a741a803fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentType_a0a87157-5b2f-4d3b-88b2-a8a741a803fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8bd4788f-a0ee-490d-8404-155108905822" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentQuarterlyReport_8bd4788f-a0ee-490d-8404-155108905822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f639c190-b63d-4674-b49c-026d7d75cd2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentPeriodEndDate_f639c190-b63d-4674-b49c-026d7d75cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_99c34a2f-4ba8-418c-ae5d-3ae931dfa8b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentTransitionReport_99c34a2f-4ba8-418c-ae5d-3ae931dfa8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0089c4b1-0424-41b0-a13b-e417d3371f99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityFileNumber_0089c4b1-0424-41b0-a13b-e417d3371f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_005cec36-c0f9-4398-b992-52d5eac667fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityRegistrantName_005cec36-c0f9-4398-b992-52d5eac667fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_36e714e3-371f-43c2-8ee6-af9ecbeeac17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_36e714e3-371f-43c2-8ee6-af9ecbeeac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_45db24d7-a645-4c38-85ef-727876650dff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityTaxIdentificationNumber_45db24d7-a645-4c38-85ef-727876650dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a07f3cc6-234a-435a-a661-9e3aad910d2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityAddressAddressLine1_a07f3cc6-234a-435a-a661-9e3aad910d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fa6790c1-25bb-4cec-bb2e-ee250a56e4f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityAddressCityOrTown_fa6790c1-25bb-4cec-bb2e-ee250a56e4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e4fbd8a8-7b68-4b2d-bb15-417ea4a2279c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityAddressStateOrProvince_e4fbd8a8-7b68-4b2d-bb15-417ea4a2279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c10e1b9c-298e-4dd0-b11e-c7569d40283d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityAddressPostalZipCode_c10e1b9c-298e-4dd0-b11e-c7569d40283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3768ec6f-1140-4fc2-8c78-19e0dd2eb338" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_CityAreaCode_3768ec6f-1140-4fc2-8c78-19e0dd2eb338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1897bf4c-54c7-4e02-aa85-c240bb22436e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_LocalPhoneNumber_1897bf4c-54c7-4e02-aa85-c240bb22436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0f18aaaa-029f-4440-8399-1715b9703f91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_Security12bTitle_0f18aaaa-029f-4440-8399-1715b9703f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d4d7bddd-ee35-4cc0-b166-52c08f81969b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_TradingSymbol_d4d7bddd-ee35-4cc0-b166-52c08f81969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_24e17ef4-defc-425a-ba02-5b822114dac1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_SecurityExchangeName_24e17ef4-defc-425a-ba02-5b822114dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_de7d66ab-66eb-4c04-9dd7-1612d590828e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityCurrentReportingStatus_de7d66ab-66eb-4c04-9dd7-1612d590828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b703e5c6-0250-4cec-86e7-9dc5cef5b965" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityInteractiveDataCurrent_b703e5c6-0250-4cec-86e7-9dc5cef5b965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_092e0c4d-37fe-489d-aafa-fae5ad6167f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityFilerCategory_092e0c4d-37fe-489d-aafa-fae5ad6167f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2e9622cc-bcec-4e53-b556-2a1670a9d509" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntitySmallBusiness_2e9622cc-bcec-4e53-b556-2a1670a9d509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c13ab1d6-2874-409d-a800-f574acfab97c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityEmergingGrowthCompany_c13ab1d6-2874-409d-a800-f574acfab97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38df1390-cea3-4b0f-a8ab-15510627ae2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityShellCompany_38df1390-cea3-4b0f-a8ab-15510627ae2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9d213f82-626b-42e3-98f8-95b8a0963bee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9d213f82-626b-42e3-98f8-95b8a0963bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c89a9a16-b55f-4773-906c-c7ad879b8307" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_AmendmentFlag_c89a9a16-b55f-4773-906c-c7ad879b8307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4b37d3ba-3679-4ad1-bf15-a3c0c07d1812" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentFiscalYearFocus_4b37d3ba-3679-4ad1-bf15-a3c0c07d1812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eab10935-3ca7-4252-9eeb-a053aaa5298b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eab10935-3ca7-4252-9eeb-a053aaa5298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ee1ed24b-b595-49a9-8fa6-1006a266cde9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_EntityCentralIndexKey_ee1ed24b-b595-49a9-8fa6-1006a266cde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_60bcbc63-8c26-4072-9bd9-745e8f150907" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bb1eb71-7f5e-4898-8f22-6e619cd384f4" xlink:to="loc_dei_CurrentFiscalYearEndDate_60bcbc63-8c26-4072-9bd9-745e8f150907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6fc4cdc2-38cc-47dc-8e55-038f5689ddb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fc4cdc2-38cc-47dc-8e55-038f5689ddb9" xlink:to="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1278fa54-2d91-402a-912b-4e3d0cc98a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1278fa54-2d91-402a-912b-4e3d0cc98a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9e46be40-320b-47df-bc28-64139fab6585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9e46be40-320b-47df-bc28-64139fab6585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2b00e484-be86-4187-aca2-f2fc0538f53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2b00e484-be86-4187-aca2-f2fc0538f53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_035a7886-5273-4afa-9421-4031fe331566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_InventoryNet_035a7886-5273-4afa-9421-4031fe331566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4248a948-940f-4058-b76b-08d0b69e43af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4248a948-940f-4058-b76b-08d0b69e43af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cf60942-8b75-42c1-8f77-fe84cf938668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ef98b7-970a-46bb-8458-7480cbe9966a" xlink:to="loc_us-gaap_AssetsCurrent_6cf60942-8b75-42c1-8f77-fe84cf938668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_434f076d-6845-4b34-86b6-becf0a52b8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_434f076d-6845-4b34-86b6-becf0a52b8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d144c16d-7413-411f-9121-0d5c87cee826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d144c16d-7413-411f-9121-0d5c87cee826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6b4cc53-f7fd-4dd3-96a4-4f2956bd1d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6b4cc53-f7fd-4dd3-96a4-4f2956bd1d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e678e964-36cc-4090-9c49-9f29446f55f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_Goodwill_e678e964-36cc-4090-9c49-9f29446f55f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_955b792c-6780-4949-86ee-40d7f7cdb7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_955b792c-6780-4949-86ee-40d7f7cdb7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d45e62cf-5a04-4e73-92aa-b6ab566638b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ecef7d81-8b1c-45c0-8d3e-fb4171dd8408" xlink:to="loc_us-gaap_Assets_d45e62cf-5a04-4e73-92aa-b6ab566638b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fc4cdc2-38cc-47dc-8e55-038f5689ddb9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ca863617-1e8b-4865-8959-47ad619ac12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ca863617-1e8b-4865-8959-47ad619ac12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb14dc9d-657c-498e-83a8-e144b9be5a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca863617-1e8b-4865-8959-47ad619ac12b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb14dc9d-657c-498e-83a8-e144b9be5a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a28e9ba0-3567-4c9c-9682-fd9bf4134e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca863617-1e8b-4865-8959-47ad619ac12b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a28e9ba0-3567-4c9c-9682-fd9bf4134e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b90422e8-8da3-4e06-b67d-45d13d4e5144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca863617-1e8b-4865-8959-47ad619ac12b" xlink:to="loc_us-gaap_LiabilitiesCurrent_b90422e8-8da3-4e06-b67d-45d13d4e5144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_14baaa05-91cd-48b5-b3b0-a54a2bcd527e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_14baaa05-91cd-48b5-b3b0-a54a2bcd527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_992e83a9-874a-45b7-bd94-f1d5affab35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_992e83a9-874a-45b7-bd94-f1d5affab35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b1805bda-924a-4a4f-b7fc-c112fa345ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b1805bda-924a-4a4f-b7fc-c112fa345ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_88e93c95-14c1-4eff-ab9c-064298f011a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_Liabilities_88e93c95-14c1-4eff-ab9c-064298f011a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c386f833-61bb-4013-b1ab-a14f21898de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c386f833-61bb-4013-b1ab-a14f21898de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_e4d0dfa5-93b7-47a5-9cfd-98b32c72033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_e4d0dfa5-93b7-47a5-9cfd-98b32c72033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_924c3b00-9cb9-460d-99c8-9f19a95c1e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_CommonStockValueOutstanding_924c3b00-9cb9-460d-99c8-9f19a95c1e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a02c8d40-e24a-4160-b597-553b80fec94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a02c8d40-e24a-4160-b597-553b80fec94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c64adde-da01-4f6f-ae55-11078016810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c64adde-da01-4f6f-ae55-11078016810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02295e6b-6ef3-4135-8ee7-ac6c9395917b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02295e6b-6ef3-4135-8ee7-ac6c9395917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b1969a9-1cae-42f7-ac18-714ce5a9b2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ebe6ac6b-12c2-4498-85e0-56f138d84937" xlink:to="loc_us-gaap_StockholdersEquity_5b1969a9-1cae-42f7-ac18-714ce5a9b2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbd55a01-3e2c-44c2-b84e-f6831bca540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dd98d5c-13db-45f2-b30f-a0fdc42aa556" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbd55a01-3e2c-44c2-b84e-f6831bca540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7df02352-0670-4413-801a-01e7db084693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7df02352-0670-4413-801a-01e7db084693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_85ff5d96-936e-4c49-8026-f5ea7cbd665c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_85ff5d96-936e-4c49-8026-f5ea7cbd665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4967b140-7658-4719-a70c-9fbad0ec33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4967b140-7658-4719-a70c-9fbad0ec33a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_aabede5c-5da2-4c52-9c79-a0949424f9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_aabede5c-5da2-4c52-9c79-a0949424f9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f94299c8-e795-48f3-9486-11281c3809c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f94299c8-e795-48f3-9486-11281c3809c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_432490c9-dac2-49d7-b8b4-80b170c0a127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_432490c9-dac2-49d7-b8b4-80b170c0a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ef0eb329-532a-4d3e-9749-700fba8385c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_CommonStockSharesIssued_ef0eb329-532a-4d3e-9749-700fba8385c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ee130dec-31f2-42d7-bdfa-7f5685faf2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f01f9e25-1419-4f53-851b-f2e617670d4b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ee130dec-31f2-42d7-bdfa-7f5685faf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_66fc6c9d-9070-4b26-9a9a-001ded40eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_RevenuesAbstract_66fc6c9d-9070-4b26-9a9a-001ded40eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromPrecisionOncologyTesting_5016af21-e9bd-4cb5-aee0-fe4dbb1ac391" xlink:href="gh-20230331.xsd#gh_RevenueFromPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_66fc6c9d-9070-4b26-9a9a-001ded40eae2" xlink:to="loc_gh_RevenueFromPrecisionOncologyTesting_5016af21-e9bd-4cb5-aee0-fe4dbb1ac391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenueFromDevelopmentServices_6a70a161-1d23-4638-bbd7-70eadcafa351" xlink:href="gh-20230331.xsd#gh_RevenueFromDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_66fc6c9d-9070-4b26-9a9a-001ded40eae2" xlink:to="loc_gh_RevenueFromDevelopmentServices_6a70a161-1d23-4638-bbd7-70eadcafa351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_22b913ce-5c6a-498f-9515-3316b2157c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_66fc6c9d-9070-4b26-9a9a-001ded40eae2" xlink:to="loc_us-gaap_Revenues_22b913ce-5c6a-498f-9515-3316b2157c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsOfPrecisionOncologyTesting_e47ac4da-684b-4929-bb71-9fd1e1dc03b7" xlink:href="gh-20230331.xsd#gh_CostsOfPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_gh_CostsOfPrecisionOncologyTesting_e47ac4da-684b-4929-bb71-9fd1e1dc03b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServices_1872c5a7-a331-4d24-990c-95fb71fb8636" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_gh_CostOfDevelopmentServices_1872c5a7-a331-4d24-990c-95fb71fb8636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b596f9bf-3078-4f1d-ac35-cf3fb8234409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b596f9bf-3078-4f1d-ac35-cf3fb8234409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a8dcad71-d33f-496c-896e-c985a6bafc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a8dcad71-d33f-496c-896e-c985a6bafc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81d1b1f7-9d06-4e9f-b54b-331e494ea4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81d1b1f7-9d06-4e9f-b54b-331e494ea4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e3ac6a88-8870-41ff-897c-ead008ebf0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9780882a-e904-4ff3-8917-bf8d5b90e093" xlink:to="loc_us-gaap_CostsAndExpenses_e3ac6a88-8870-41ff-897c-ead008ebf0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a72a0a5b-6954-464b-bc79-e0f0990b3a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_OperatingIncomeLoss_a72a0a5b-6954-464b-bc79-e0f0990b3a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9ae61825-486a-4008-88db-72332d609cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9ae61825-486a-4008-88db-72332d609cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2682b2f4-89d3-422b-9e42-7bf40d1efb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_InterestExpense_2682b2f4-89d3-422b-9e42-7bf40d1efb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_457bda04-eb80-46f7-aad2-c77755c661a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_457bda04-eb80-46f7-aad2-c77755c661a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18927ec2-9d58-4be7-be61-24a15035a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18927ec2-9d58-4be7-be61-24a15035a35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_599500cb-169d-4fe3-96ef-1dbdfd474144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_599500cb-169d-4fe3-96ef-1dbdfd474144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c88368d-8923-4b86-8256-f0ac78f313c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_NetIncomeLoss_2c88368d-8923-4b86-8256-f0ac78f313c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_95fc3a67-3187-4a6f-9f60-e37093bc99fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_EarningsPerShareBasic_95fc3a67-3187-4a6f-9f60-e37093bc99fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b60d5b0a-04d8-4612-9183-5a6f0bd51d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b60d5b0a-04d8-4612-9183-5a6f0bd51d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e709a0f1-7cfe-42a7-b17f-7596236477f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e709a0f1-7cfe-42a7-b17f-7596236477f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82b49d6d-4bd1-4d4e-8746-2e35c384dd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b48e518-caff-4b73-85a9-8c36ecbefb87" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82b49d6d-4bd1-4d4e-8746-2e35c384dd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7fbaa137-7cd9-43a9-8a05-0ddd2b45d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b6ef123-5487-4571-bf83-622ee636a15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7fbaa137-7cd9-43a9-8a05-0ddd2b45d65f" xlink:to="loc_us-gaap_NetIncomeLoss_2b6ef123-5487-4571-bf83-622ee636a15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c53ea30f-2e69-427a-a2a9-930ea679d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7fbaa137-7cd9-43a9-8a05-0ddd2b45d65f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c53ea30f-2e69-427a-a2a9-930ea679d30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_96a507d7-0302-46f3-9e94-a3711989939a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c53ea30f-2e69-427a-a2a9-930ea679d30e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_96a507d7-0302-46f3-9e94-a3711989939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d9320750-4203-4dbe-bbff-b8eeb55b2c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c53ea30f-2e69-427a-a2a9-930ea679d30e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d9320750-4203-4dbe-bbff-b8eeb55b2c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e90c7195-3d02-4f9e-a12f-2cfd9d0d5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c53ea30f-2e69-427a-a2a9-930ea679d30e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e90c7195-3d02-4f9e-a12f-2cfd9d0d5a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c5c35316-0918-4a8c-a3c0-de486d18696b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7fbaa137-7cd9-43a9-8a05-0ddd2b45d65f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c5c35316-0918-4a8c-a3c0-de486d18696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1be5b19a-f027-48b7-bce3-f2154ecdd9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1be5b19a-f027-48b7-bce3-f2154ecdd9b2" xlink:to="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_23be17e2-db90-4290-8f5d-d8de80abcd4d" xlink:to="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf904c74-639c-45c4-8ce5-5aec3d5d4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_CommonStockMember_cf904c74-639c-45c4-8ce5-5aec3d5d4bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0cb9f94-c532-4d5d-878d-e974823e01e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0cb9f94-c532-4d5d-878d-e974823e01e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bea49fd2-79ce-41f6-83d9-878c9b031467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bea49fd2-79ce-41f6-83d9-878c9b031467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8e222b62-11aa-427a-b17c-8da41b18d861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f50b8581-fdea-45f4-8b1c-f8010c9c1309" xlink:to="loc_us-gaap_RetainedEarningsMember_8e222b62-11aa-427a-b17c-8da41b18d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2d1e723-e7bb-47e9-9564-f136a831af60" xlink:to="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_968e8cfb-0258-4398-abc8-ab6e0ec24cc5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_efca6722-6ef2-4a88-8425-0d0db72c725b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_SharesOutstanding_efca6722-6ef2-4a88-8425-0d0db72c725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_015c6f2b-ab1b-4bf0-b11a-36b274d55477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockholdersEquity_015c6f2b-ab1b-4bf0-b11a-36b274d55477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a0edd83-9d70-4cc4-8d80-5254740101a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a0edd83-9d70-4cc4-8d80-5254740101a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_632b4796-8ffd-4513-9b89-49ccc623dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_632b4796-8ffd-4513-9b89-49ccc623dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c1367979-61c1-4262-9516-6e69834d50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c1367979-61c1-4262-9516-6e69834d50e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_b4fd6253-7ff4-46fe-b880-371e6395372c" xlink:href="gh-20230331.xsd#gh_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_gh_StockIssuedDuringPeriodValueExerciseOfWarrants_b4fd6253-7ff4-46fe-b880-371e6395372c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85ee7b51-c5d2-4ee0-96d1-e7ac944ca8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_85ee7b51-c5d2-4ee0-96d1-e7ac944ca8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5c172805-adcd-4807-a8b4-8781c882de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5c172805-adcd-4807-a8b4-8781c882de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9622e62-1511-43e2-aa7c-9feb20741f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9622e62-1511-43e2-aa7c-9feb20741f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf7adfd9-d5de-4602-ae78-c778d640abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_NetIncomeLoss_cf7adfd9-d5de-4602-ae78-c778d640abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_58c6258b-2b38-4474-9000-b6a294708c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_SharesOutstanding_58c6258b-2b38-4474-9000-b6a294708c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_64d550c1-b616-4594-b36b-37a669d8d5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebc285cb-d3cc-4ae7-9acd-1b690ed759af" xlink:to="loc_us-gaap_StockholdersEquity_64d550c1-b616-4594-b36b-37a669d8d5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a1cdea0-da5f-41c7-9142-39b8bf7a143e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a1cdea0-da5f-41c7-9142-39b8bf7a143e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_26dbb5ae-6da5-4189-9bcb-259ebdee9eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a1cdea0-da5f-41c7-9142-39b8bf7a143e" xlink:to="loc_us-gaap_NetIncomeLoss_26dbb5ae-6da5-4189-9bcb-259ebdee9eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a1cdea0-da5f-41c7-9142-39b8bf7a143e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5b08affd-8361-4429-9265-66e161725787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5b08affd-8361-4429-9265-66e161725787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts_5e81fb1c-4baf-4a91-932a-f761dba91e59" xlink:href="gh-20230331.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_gh_NonCashOperatingLeaseCosts_5e81fb1c-4baf-4a91-932a-f761dba91e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cd579d03-9029-4d0c-b259-e28806ff2682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cd579d03-9029-4d0c-b259-e28806ff2682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a29830af-e7b5-44d9-98a2-33be537befde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_ShareBasedCompensation_a29830af-e7b5-44d9-98a2-33be537befde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_28f110b3-835d-4045-a1c1-72c7bd85bbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_28f110b3-835d-4045-a1c1-72c7bd85bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e1152af-e43d-4e75-8259-1e963e5de77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e1152af-e43d-4e75-8259-1e963e5de77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4d37cf5-f06e-4310-b92c-00efa614e414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4d37cf5-f06e-4310-b92c-00efa614e414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_8cc70335-ec75-45c5-b7de-d1929fca7af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_8cc70335-ec75-45c5-b7de-d1929fca7af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2e658007-e667-41d8-b6a4-0fdf476fd310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2e658007-e667-41d8-b6a4-0fdf476fd310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_537f7d62-104d-497e-b958-f25971b5a7c6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6e670585-ae12-4b3f-a673-ee5f8c92d481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6e670585-ae12-4b3f-a673-ee5f8c92d481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bc84d1e3-602a-495d-963f-9244d64cf529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bc84d1e3-602a-495d-963f-9244d64cf529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8da7018a-51eb-484b-9824-13f356008a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8da7018a-51eb-484b-9824-13f356008a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7831deb7-5e2f-45ae-9f5e-b4ec4d97abc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7831deb7-5e2f-45ae-9f5e-b4ec4d97abc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_7f10ec17-46c5-4d3c-983d-2ca2fd5cf693" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities_7f10ec17-46c5-4d3c-983d-2ca2fd5cf693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_ab7cedc8-a398-4393-976f-011692f2b61f" xlink:href="gh-20230331.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_ab7cedc8-a398-4393-976f-011692f2b61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_454a819b-5c13-4377-be90-96741fa36843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_59a58b00-cce5-400e-ab9e-7f7e3f3b2750" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_454a819b-5c13-4377-be90-96741fa36843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94fd45a5-979b-4653-82dc-3a9a8df018d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a1cdea0-da5f-41c7-9142-39b8bf7a143e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94fd45a5-979b-4653-82dc-3a9a8df018d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_eedb35fb-f0aa-47ae-be96-20f8f8313686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_eedb35fb-f0aa-47ae-be96-20f8f8313686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_993e789e-6016-478c-9db0-5297847e686f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_993e789e-6016-478c-9db0-5297847e686f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_e3768943-887b-4b60-8a18-b1213f178840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_e3768943-887b-4b60-8a18-b1213f178840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ffd89de-f483-456e-bd23-18d97aa2ac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ffd89de-f483-456e-bd23-18d97aa2ac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45e15e94-06ca-4042-9959-0a299cd7da71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_090c0e90-2e16-440b-9cac-c770d6bb664b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45e15e94-06ca-4042-9959-0a299cd7da71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f009adcd-aa05-4cb8-a629-a1b31fddc899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f009adcd-aa05-4cb8-a629-a1b31fddc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8aa4a9f1-449d-4144-9f1b-e703faf81b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8aa4a9f1-449d-4144-9f1b-e703faf81b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8f21b523-83b0-4b8e-8a00-3d4796cc1d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8f21b523-83b0-4b8e-8a00-3d4796cc1d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44472a07-0aab-4523-a3a5-3754f230723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7afeb56-bcb4-42ce-8aee-8829efb8e219" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44472a07-0aab-4523-a3a5-3754f230723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd3a2e4d-39e1-4bb3-9961-38548a2013c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd3a2e4d-39e1-4bb3-9961-38548a2013c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dfb2663-b221-457d-9461-5bd917e01efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dfb2663-b221-457d-9461-5bd917e01efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f43e1ccd-2deb-4292-a85a-dd15b523f8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f43e1ccd-2deb-4292-a85a-dd15b523f8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c43ae59-9768-48f4-9899-eda3f1679d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c43ae59-9768-48f4-9899-eda3f1679d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_20b3f860-8765-460b-81dc-5ebc8e891c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_20b3f860-8765-460b-81dc-5ebc8e891c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4b68d9bc-ff49-4998-9241-e3a455ba6dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_20b3f860-8765-460b-81dc-5ebc8e891c8e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4b68d9bc-ff49-4998-9241-e3a455ba6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a074d3fb-b29c-430f-88f2-4f00c609815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a074d3fb-b29c-430f-88f2-4f00c609815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a7c2d396-a7be-48dd-8422-fdab3ccb5b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a074d3fb-b29c-430f-88f2-4f00c609815e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a7c2d396-a7be-48dd-8422-fdab3ccb5b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c1e16a7d-760e-4b85-aeb6-7c644270a91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a205cc19-512b-4be2-993b-cbbba5b0add7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c1e16a7d-760e-4b85-aeb6-7c644270a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ab44eb9-6711-4f52-9aa9-19c3ef6e9abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c1e16a7d-760e-4b85-aeb6-7c644270a91b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ab44eb9-6711-4f52-9aa9-19c3ef6e9abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fca07cf5-c147-47b2-b374-4fd9d084ad8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c1e16a7d-760e-4b85-aeb6-7c644270a91b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fca07cf5-c147-47b2-b374-4fd9d084ad8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b926b35-208e-4242-87b6-a72a2616b989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c1e16a7d-760e-4b85-aeb6-7c644270a91b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b926b35-208e-4242-87b6-a72a2616b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gh-20230331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_147eb89a-d416-4ecd-beaa-a73a90ec6a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_31570fac-46c1-4613-9416-ffe668acbc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_147eb89a-d416-4ecd-beaa-a73a90ec6a8e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_31570fac-46c1-4613-9416-ffe668acbc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43994b76-d58e-4d40-bb74-9a16f04442f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ddbb2b28-d349-499e-b2eb-7bec05672cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43994b76-d58e-4d40-bb74-9a16f04442f4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ddbb2b28-d349-499e-b2eb-7bec05672cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/JointVenture" xlink:type="simple" xlink:href="gh-20230331.xsd#JointVenture"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/JointVenture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d798a0bc-2364-4ce6-8b0c-985582965122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_42a9f38b-43d7-463b-8560-a64e58f041bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d798a0bc-2364-4ce6-8b0c-985582965122" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_42a9f38b-43d7-463b-8560-a64e58f041bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9ba6f07d-f42c-4c03-a45d-b82ec463be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_3472ca73-45b4-4025-9405-f003c20fb66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9ba6f07d-f42c-4c03-a45d-b82ec463be7e" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_3472ca73-45b4-4025-9405-f003c20fb66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2702bcc2-eff1-4c0a-8fb3-96b4b2f660a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e9069e63-1da6-4b6a-a0e3-4a9f4de2b60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2702bcc2-eff1-4c0a-8fb3-96b4b2f660a6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e9069e63-1da6-4b6a-a0e3-4a9f4de2b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwill"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc651ae9-3b5d-497f-8f24-3cf5ac597519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ca4fd036-56ff-48c6-abe7-96ff00867b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc651ae9-3b5d-497f-8f24-3cf5ac597519" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ca4fd036-56ff-48c6-abe7-96ff00867b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Debt" xlink:type="simple" xlink:href="gh-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c0e9399a-8e88-4667-a097-e06f91563720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f4770706-b7f1-4464-8e3e-7b29734e170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c0e9399a-8e88-4667-a097-e06f91563720" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f4770706-b7f1-4464-8e3e-7b29734e170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:type="simple" xlink:href="gh-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7f930eae-eef2-43ee-a62c-3b316ccb2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d6d15d05-07b0-4bc0-b26a-16e73639d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f930eae-eef2-43ee-a62c-3b316ccb2f51" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d6d15d05-07b0-4bc0-b26a-16e73639d4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gh-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a74ccbad-1efe-4e0f-9f7f-ea508fbdc2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_94dcf0bf-9571-4507-9839-de539671f343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a74ccbad-1efe-4e0f-9f7f-ea508fbdc2f2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_94dcf0bf-9571-4507-9839-de539671f343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:type="simple" xlink:href="gh-20230331.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2710b073-5e03-4204-a6ac-de6508f44409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8ff6f7b7-18ad-47de-927d-aeac98e7a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2710b073-5e03-4204-a6ac-de6508f44409" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8ff6f7b7-18ad-47de-927d-aeac98e7a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccb8bd8f-1e85-40f2-bc6c-8c8b28e6a5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_116b522d-6aea-4136-b998-3f1901d4839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccb8bd8f-1e85-40f2-bc6c-8c8b28e6a5f8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_116b522d-6aea-4136-b998-3f1901d4839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShare" xlink:type="simple" xlink:href="gh-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_31a1bf17-e28c-4454-b11a-05b0327bd1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_70a43a7e-c6f7-412c-81fc-746cae8b5838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_31a1bf17-e28c-4454-b11a-05b0327bd1d7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_70a43a7e-c6f7-412c-81fc-746cae8b5838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gh-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dfe65ec7-d784-4af1-8f61-363e3a94cf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e85bba8c-275e-4f03-a350-025fa5e5334f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfe65ec7-d784-4af1-8f61-363e3a94cf59" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e85bba8c-275e-4f03-a350-025fa5e5334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="gh-20230331.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5aa5558b-396b-43aa-90e9-14ced31f2c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7337704e-10ad-40cb-8181-503299caeff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5aa5558b-396b-43aa-90e9-14ced31f2c97" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7337704e-10ad-40cb-8181-503299caeff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="gh-20230331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0221a031-e335-4cf5-ab34-834f6a1dc99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_923aa5f2-6f6b-44a7-b365-7a6805f36ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0221a031-e335-4cf5-ab34-834f6a1dc99a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_923aa5f2-6f6b-44a7-b365-7a6805f36ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61d58641-5a87-4f93-b1cd-e486d9332c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61d58641-5a87-4f93-b1cd-e486d9332c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_72464088-c68b-4000-9057-74a4f72cf8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_UseOfEstimates_72464088-c68b-4000-9057-74a4f72cf8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_b907736a-11db-4081-9d11-15c752b20190" xlink:href="gh-20230331.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_b907736a-11db-4081-9d11-15c752b20190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_b5f8462a-8779-4bdf-b461-d91f792209f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_b5f8462a-8779-4bdf-b461-d91f792209f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonMarketableSecuritiesPolicyTextBlock_18fbc3b6-40d1-4c8c-8a34-76cc8cd28d86" xlink:href="gh-20230331.xsd#gh_NonMarketableSecuritiesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_NonMarketableSecuritiesPolicyTextBlock_18fbc3b6-40d1-4c8c-8a34-76cc8cd28d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_80e1e9ad-9bce-43eb-9f54-d7bf80077283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_80e1e9ad-9bce-43eb-9f54-d7bf80077283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_6f3eb3ea-564d-4efe-8aa9-585dafa08351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_6f3eb3ea-564d-4efe-8aa9-585dafa08351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock_de19cca1-339d-43c6-be38-48b372a14552" xlink:href="gh-20230331.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_AssetAcquisitionPolicyTextBlock_de19cca1-339d-43c6-be38-48b372a14552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_da291237-6f2b-4b95-b792-4253f93199bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_da291237-6f2b-4b95-b792-4253f93199bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionCompensationPolicyPolicyTextBlock_e355861d-32e3-4af4-aedc-618c9a97dc81" xlink:href="gh-20230331.xsd#gh_PostAcquisitionCompensationPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_PostAcquisitionCompensationPolicyPolicyTextBlock_e355861d-32e3-4af4-aedc-618c9a97dc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_77356253-d56e-4b65-88c4-d69b7aa6f262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_77356253-d56e-4b65-88c4-d69b7aa6f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_963b773f-b3c1-43ca-bbd0-c05e59b1b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_DebtPolicyTextBlock_963b773f-b3c1-43ca-bbd0-c05e59b1b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_464af2eb-1b29-469a-839b-907856f40b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_464af2eb-1b29-469a-839b-907856f40b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock_552d1a96-31b3-491d-bc16-1a255c4afe37" xlink:href="gh-20230331.xsd#gh_CostsOfPrecisionOncologyTestingPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock_552d1a96-31b3-491d-bc16-1a255c4afe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServicesPolicyTextBlock_6ca3f902-f814-428f-a399-97d4594798a1" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServicesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_gh_CostOfDevelopmentServicesPolicyTextBlock_6ca3f902-f814-428f-a399-97d4594798a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_68448dab-4842-4e90-a8b0-13bb756ef286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_68448dab-4842-4e90-a8b0-13bb756ef286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64912e40-37f2-413f-940d-a3bfe9daa72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_64912e40-37f2-413f-940d-a3bfe9daa72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c87ebc43-633d-4d1b-8620-c613a2f9f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c87ebc43-633d-4d1b-8620-c613a2f9f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6f22730c-aa7e-48e6-a51f-3ef939037ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adaf47b2-bd28-42ad-8d5d-a36a39e0ed5b" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6f22730c-aa7e-48e6-a51f-3ef939037ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf3e78e9-63c0-446d-8fee-77d6fa349e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2d715275-9e10-475e-b327-dd098e41dd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf3e78e9-63c0-446d-8fee-77d6fa349e76" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2d715275-9e10-475e-b327-dd098e41dd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_41f72828-9b14-4ac0-a3dc-6bc5248df79e" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf3e78e9-63c0-446d-8fee-77d6fa349e76" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_41f72828-9b14-4ac0-a3dc-6bc5248df79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8af8bdf6-56f5-447b-aad2-7d5c2fc9159c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1f7addc-8919-4ef1-8555-ea8ad7f944e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8af8bdf6-56f5-447b-aad2-7d5c2fc9159c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1f7addc-8919-4ef1-8555-ea8ad7f944e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4ce8ded5-e02d-473c-add2-e13a15bdfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8af8bdf6-56f5-447b-aad2-7d5c2fc9159c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4ce8ded5-e02d-473c-add2-e13a15bdfac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86dae469-f3b8-42e0-9993-96d11efe949b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_83094420-e72e-4932-b750-df9d8cbe9c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86dae469-f3b8-42e0-9993-96d11efe949b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_83094420-e72e-4932-b750-df9d8cbe9c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_72a5bdf5-5b59-4987-a21c-46429903e629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86dae469-f3b8-42e0-9993-96d11efe949b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_72a5bdf5-5b59-4987-a21c-46429903e629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_3fb8143a-a35b-493a-9b21-32084de1d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86dae469-f3b8-42e0-9993-96d11efe949b" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_3fb8143a-a35b-493a-9b21-32084de1d9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_3feb7b0e-00ab-4e79-b112-07783c062b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86dae469-f3b8-42e0-9993-96d11efe949b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_3feb7b0e-00ab-4e79-b112-07783c062b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b692ca9-d222-4320-9f24-55859c1fd58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_055088db-85eb-44bc-9934-1f4ce772e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b692ca9-d222-4320-9f24-55859c1fd58b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_055088db-85eb-44bc-9934-1f4ce772e6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_112488e0-0ee0-4582-a8fe-9dd83df7495f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b692ca9-d222-4320-9f24-55859c1fd58b" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_112488e0-0ee0-4582-a8fe-9dd83df7495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_600ee1b8-9f6f-4420-a2fd-2b581dd9b983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b692ca9-d222-4320-9f24-55859c1fd58b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_600ee1b8-9f6f-4420-a2fd-2b581dd9b983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtTables" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2d9ceeb2-ff55-46ca-8b7a-8eb44d39cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1dea9639-97e1-454d-bc6c-f79929771b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d9ceeb2-ff55-46ca-8b7a-8eb44d39cef4" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1dea9639-97e1-454d-bc6c-f79929771b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1fbad2e7-6053-422c-b27a-3db5f5a50b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e3da823c-e07d-460d-92a0-9bfeb1c005a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1fbad2e7-6053-422c-b27a-3db5f5a50b05" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e3da823c-e07d-460d-92a0-9bfeb1c005a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a4631a34-9028-4da4-84c6-76c931fe08f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1fbad2e7-6053-422c-b27a-3db5f5a50b05" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a4631a34-9028-4da4-84c6-76c931fe08f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockTables" xlink:type="simple" xlink:href="gh-20230331.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7786c6b4-72ee-4e98-88d2-47007c3fab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_24b7d51b-a0e7-41fb-8150-44b63142e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7786c6b4-72ee-4e98-88d2-47007c3fab64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_24b7d51b-a0e7-41fb-8150-44b63142e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9a70ea3-b686-4c37-994f-dfc33624a219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9a70ea3-b686-4c37-994f-dfc33624a219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_04d927a3-bd89-4851-baac-6f0275f2fe92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_04d927a3-bd89-4851-baac-6f0275f2fe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_06bfe832-c0f7-4eef-8dfa-f1297b0b2788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_06bfe832-c0f7-4eef-8dfa-f1297b0b2788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b0e66818-2b37-40de-9049-788dd9e019ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b0e66818-2b37-40de-9049-788dd9e019ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e6f02c17-8aec-40ef-87da-596db94ca408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c872aed-d575-466d-b0cc-396956ea296f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e6f02c17-8aec-40ef-87da-596db94ca408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="gh-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5883cb0d-2ac6-49e0-aa14-5c50964527d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5d878de7-b682-4390-b3bd-c623133e3bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5883cb0d-2ac6-49e0-aa14-5c50964527d9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5d878de7-b682-4390-b3bd-c623133e3bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_92b69193-ddb9-409c-8d1e-031a451ba395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5883cb0d-2ac6-49e0-aa14-5c50964527d9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_92b69193-ddb9-409c-8d1e-031a451ba395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="gh-20230331.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0b000795-aecc-45c3-9bec-759c127cb9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58288c20-9dcb-4249-a130-0b1599b2e4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b000795-aecc-45c3-9bec-759c127cb9be" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58288c20-9dcb-4249-a130-0b1599b2e4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f7ecb9e0-6b19-4ac3-b84c-3d5e1e095ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfPatients_73de4e1d-c57a-45c2-8400-ade31826c60b" xlink:href="gh-20230331.xsd#gh_NumberOfPatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f7ecb9e0-6b19-4ac3-b84c-3d5e1e095ade" xlink:to="loc_gh_NumberOfPatients_73de4e1d-c57a-45c2-8400-ade31826c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a046b4f-bb28-445a-bf7b-13394253ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a046b4f-bb28-445a-bf7b-13394253ed91" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd70511c-67b5-4403-9614-b313d117349c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09903a96-711b-450d-896b-595b4b8a2127" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_45461a5d-b4bf-4655-835c-eaf4a7a92edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8c475935-1e62-46fa-ab93-8d314396d4ad" xlink:to="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MinimumMember_0a4402f1-5756-4fc9-964f-8ad6a5e6ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68c64c7c-cdd6-4f74-913d-16d22b5f0ff1" xlink:to="loc_srt_MaximumMember_29c4ab90-64f8-4325-88e8-2e3768529c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_199f0821-8b8d-411f-816f-49b88fbd2c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_199f0821-8b8d-411f-816f-49b88fbd2c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e9a9feb0-8ac0-40f1-beda-d5084223cf66" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RestrictedCash_118cd0d5-82c4-4cef-8054-bdd788d5e174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3e6a81b8-2373-40cd-96a7-ba3b5911eaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOfPurchaseRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOfPurchaseRights_7572a7e8-9f0c-428d-af25-299f22958a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:href="gh-20230331.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_81b8a3e6-b582-479e-ad23-f8a17f587535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_e1185105-7dc4-4afb-9524-ab8a1d82bf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesTerm_0e02d2a9-83a6-4dcf-b30d-f32c9510f4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:href="gh-20230331.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ProceedsFromContractualReceivable_b1589ca0-99e2-4370-b3cc-859d3fe0b223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_5f114503-6a5d-4e22-a061-c10848b8f798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_04c9a4c6-83cb-452b-a958-79fd75eb6250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9584dcf2-061f-4573-a109-4b76336f3b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1be581e4-5a1c-4195-8a12-b0e5ab941b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_NumberOfOperatingSegments_46fe65f6-0f05-4621-95d9-712a504632ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_83081723-43e6-48c1-80ab-a0b6af5b4692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:href="gh-20230331.xsd#gh_PostAcquisitionContingentConsiderationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_gh_PostAcquisitionContingentConsiderationExpense_c43599d8-7f4a-4622-8d65-b70ceddd27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d85f4c7-2e20-4cfa-962d-613b90047af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b742b60e-86de-4d1e-8a97-3be60e12443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ece16e92-41eb-4fdc-88c9-396825fbd5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6930c3ba-e90f-46d8-b4f0-db023c2b0256" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_a324092d-d743-4c7e-9b84-5c37a84407a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7029d039-ca4c-4964-985b-05d247dc5201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7029d039-ca4c-4964-985b-05d247dc5201" xlink:to="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9cfd91ce-b4a0-43e4-8c27-6b8659de6a04" xlink:to="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_5c13a51c-c07f-49ec-924d-a0d20d798836" xlink:href="gh-20230331.xsd#gh_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerAMember_5c13a51c-c07f-49ec-924d-a0d20d798836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_96576a39-4b9b-4e95-bff5-917e8d73596b" xlink:href="gh-20230331.xsd#gh_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerBMember_96576a39-4b9b-4e95-bff5-917e8d73596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_df689b1a-9f37-4ce7-b87d-d4d5df5648d8" xlink:href="gh-20230331.xsd#gh_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerCMember_df689b1a-9f37-4ce7-b87d-d4d5df5648d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_6ad792f7-bf07-4f64-923c-1c8c84f282ca" xlink:href="gh-20230331.xsd#gh_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_98792ad2-cd49-4fff-8ab9-2beac60232fe" xlink:to="loc_gh_CustomerDMember_6ad792f7-bf07-4f64-923c-1c8c84f282ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe1ddb2c-6921-46d5-b001-c79ab68b5726" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3c9b7268-eea9-448b-9ed4-c1d010a5799e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a094672f-308c-4cb5-b05b-e631f48f7967" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3c9b7268-eea9-448b-9ed4-c1d010a5799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6178a0bb-f6ad-4426-a738-77fc82640f8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_ea3b056d-8b3d-4a44-8bbf-9d26c4aa897b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:to="loc_us-gaap_SalesRevenueNetMember_ea3b056d-8b3d-4a44-8bbf-9d26c4aa897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7f524767-51e4-41d4-8cd3-d9658e060cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f6dc6c6-52c4-405e-8a0d-732e5c48f5d6" xlink:to="loc_us-gaap_AccountsReceivableMember_7f524767-51e4-41d4-8cd3-d9658e060cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_91569ffc-51bc-4a98-ad96-859049947bf6" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3049319a-f9bd-4eb9-a7ce-c03ba1433ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_56a033f1-5840-46e0-839d-a53b53284aa6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3049319a-f9bd-4eb9-a7ce-c03ba1433ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_2864f57d-0b50-4bbf-98cc-388383b9b570" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_2864f57d-0b50-4bbf-98cc-388383b9b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_0e15a492-fd03-40d4-847b-84dfa7c4a071" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_0e15a492-fd03-40d4-847b-84dfa7c4a071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_01963209-a6b4-4886-a316-8e3bdde4ab0a" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_01963209-a6b4-4886-a316-8e3bdde4ab0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_7e4b4682-a419-4aa5-b7e8-9740a480fc81" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_7e4b4682-a419-4aa5-b7e8-9740a480fc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_77f8ecba-788c-4772-96dd-58ca02a0f642" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_77f8ecba-788c-4772-96dd-58ca02a0f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_fc4b85b4-8658-47c4-913a-09178be3e9ed" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_fc4b85b4-8658-47c4-913a-09178be3e9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a8d6053-e555-4548-927e-465530947a9a" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_756f0da0-3fd6-45f5-95a7-1cf391278882" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_756f0da0-3fd6-45f5-95a7-1cf391278882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent_a3627b8f-cbc6-405f-b03f-e7d09395a8d8" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossReclassificationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent_a3627b8f-cbc6-405f-b03f-e7d09395a8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_2ae1b87b-d384-4ba7-9b5f-42c09f942286" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_2ae1b87b-d384-4ba7-9b5f-42c09f942286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_cef09f7e-bd80-4d4c-af54-3dc30ce69efd" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_cef09f7e-bd80-4d4c-af54-3dc30ce69efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_20052908-88b8-49fe-b7af-508c08cb089f" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesCreditLossReclassificationNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_20052908-88b8-49fe-b7af-508c08cb089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_3948df69-e5df-4439-9110-7b30893d8fb5" xlink:href="gh-20230331.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_c64257de-2f02-4eed-b7fd-739ee6bddc18" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_3948df69-e5df-4439-9110-7b30893d8fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/JointVentureDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#JointVentureDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/JointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f171e2cb-256f-48c6-b1f7-58da1218ca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f171e2cb-256f-48c6-b1f7-58da1218ca1b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_764a0bfe-fe0d-4486-b6b6-25f991492622" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_d98f244a-d8a9-4a17-9969-8a54be4525f3" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6da7a26e-a19f-4fb8-92d1-6bf1f771021f" xlink:to="loc_gh_GuardantHealthAMEAIncMember_d98f244a-d8a9-4a17-9969-8a54be4525f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_afc3628f-3947-4b4b-b9c4-9575a6b3beff" xlink:to="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7aba9b30-c623-4106-9c9b-961afb3e9018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18dc99dc-1d62-47db-95db-25c4d103c2e7" xlink:to="loc_us-gaap_CommonClassBMember_7aba9b30-c623-4106-9c9b-961afb3e9018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4294f94a-3beb-4694-8c0a-80e2c1253845" xlink:to="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_7b87fa31-bd1c-4193-8119-cadee18a49ad" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8f0b5ded-c269-4fe2-972d-488765634049" xlink:to="loc_gh_AMEA2020PlanMember_7b87fa31-bd1c-4193-8119-cadee18a49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdf443d0-f33c-4f71-9b83-5940f5f87c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fda5578d-7cc0-4733-a7cc-1a17c706b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c5d66d2-faf6-405f-8e8d-b37521de5baf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fda5578d-7cc0-4733-a7cc-1a17c706b3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ced9deb9-5429-4ae7-b0db-202537361b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e6b983f2-d180-4b27-b868-ccb6393e0fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d5a1e261-94a6-4cfe-a931-ea6ebc86166c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e6b983f2-d180-4b27-b868-ccb6393e0fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca5de895-c232-4710-ad8c-808a0a3f73e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NoncontrollingInterestLiabilityMember_1744eb39-3c81-4ec2-b2cf-3e61ab4911cc" xlink:href="gh-20230331.xsd#gh_NoncontrollingInterestLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ab091da-07bb-4b29-8447-084501b100d5" xlink:to="loc_gh_NoncontrollingInterestLiabilityMember_1744eb39-3c81-4ec2-b2cf-3e61ab4911cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1f24d87d-3638-4d1c-ab55-a3519b90c7d3" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dafd5cb-8a32-4292-b744-0e5811a1fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dafd5cb-8a32-4292-b744-0e5811a1fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_e7a8cde3-817a-42ba-86b1-ec2f3a6c4ef4" xlink:href="gh-20230331.xsd#gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard_e7a8cde3-817a-42ba-86b1-ec2f3a6c4ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1745dff-1185-4340-b54f-abef26f6e3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1745dff-1185-4340-b54f-abef26f6e3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1b525214-d079-410b-98d7-4a4a6d3d099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1b525214-d079-410b-98d7-4a4a6d3d099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_22a806d9-edac-4cc7-a642-93c9430ad97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_118a1c8c-6b09-4a67-b48d-1effa862e7ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_22a806d9-edac-4cc7-a642-93c9430ad97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b8770a60-2c11-4795-9461-ee41b18fc3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b8770a60-2c11-4795-9461-ee41b18fc3e0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369741d7-ae18-4507-ba3c-dc205bdf1f46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_34c85a81-29df-4ed6-8686-4c6a79509a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_34c85a81-29df-4ed6-8686-4c6a79509a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fe2210b8-53ea-40b4-83a7-0a1914b92f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fe2210b8-53ea-40b4-83a7-0a1914b92f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_122d2506-f188-405a-a189-58d350185c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_ComputerEquipmentMember_122d2506-f188-405a-a189-58d350185c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9a9e9580-6d93-43b6-9f8b-302b595b59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_ConstructionInProgressMember_9a9e9580-6d93-43b6-9f8b-302b595b59c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8df3107-774d-4512-af44-a0789978b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8df3107-774d-4512-af44-a0789978b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_95bd2204-1802-464a-af0a-43195c741494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40547dcf-b53d-4d70-b719-da7d3f66698e" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_95bd2204-1802-464a-af0a-43195c741494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34817389-5268-4743-9a2c-e4552b983247" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0b35ca70-7fd5-4dc9-9ec2-dfffe10ec5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0b35ca70-7fd5-4dc9-9ec2-dfffe10ec5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_485d4893-bfc2-4c06-b3ac-6ae5933833f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_485d4893-bfc2-4c06-b3ac-6ae5933833f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52cb8d18-c022-4608-b935-aba33043d287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_338aa421-deb8-4d7e-af7c-2d9adf757491" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52cb8d18-c022-4608-b935-aba33043d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9c3792ad-b787-483c-b3b3-38d9f381fabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_78d59a34-cd74-449b-9194-96e931e1a50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9c3792ad-b787-483c-b3b3-38d9f381fabe" xlink:to="loc_us-gaap_Depreciation_78d59a34-cd74-449b-9194-96e931e1a50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f4719bc9-bf25-4819-aa41-862342333d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_AccountsPayableCurrent_f4719bc9-bf25-4819-aa41-862342333d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c52838ba-d7b4-4fb3-937f-ec714ce0a218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c52838ba-d7b4-4fb3-937f-ec714ce0a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_95a34fd0-cf2f-4483-b187-43fd13db0b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_95a34fd0-cf2f-4483-b187-43fd13db0b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f0adc6ec-9723-41b1-bbd9-bd806d8901e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f0adc6ec-9723-41b1-bbd9-bd806d8901e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b039842-8e01-49d9-93b0-814ffe857781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b039842-8e01-49d9-93b0-814ffe857781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f14c2925-664a-4866-b132-1eec2ca2eee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9f73a54b-6622-4e86-b8fe-287953f00cd9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f14c2925-664a-4866-b132-1eec2ca2eee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2358fb41-c30b-4481-a496-4690715c3cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2358fb41-c30b-4481-a496-4690715c3cbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1cca64eb-5d53-42af-961a-7cfceb265071" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_103d1560-7cc4-4e56-8991-5fd9fa20dc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93d96271-9b61-4629-b07b-982adbe792f2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_103d1560-7cc4-4e56-8991-5fd9fa20dc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a43ad0db-27e4-46c5-9085-ef2f158d9e22" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84d58776-cf5b-44dd-9225-fa570c06a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84d58776-cf5b-44dd-9225-fa570c06a517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_b43fe6bf-f3ce-43ce-adea-b3e26df838d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_01c47b8e-adeb-4006-b2f4-d3fad62fb00c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_b43fe6bf-f3ce-43ce-adea-b3e26df838d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d673d060-0a2e-4d0f-8006-75d9c26f3b32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d5e54a10-a741-4b16-a861-4f78b17ea5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c0744f0-54ab-4a3a-8734-ba192d15e74b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d5e54a10-a741-4b16-a861-4f78b17ea5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b83de7c4-67ce-4198-bc5c-4e30b081dddc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0944db0a-34e2-4ffa-b788-a8c17a276a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0944db0a-34e2-4ffa-b788-a8c17a276a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ad12e8c0-1719-450a-a897-b8f7b39b9456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ad12e8c0-1719-450a-a897-b8f7b39b9456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_470fef3e-bb7e-4ac9-9d44-f8faabcf501f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e758be3c-7654-4603-a37f-eee237ec5c06" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_470fef3e-bb7e-4ac9-9d44-f8faabcf501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_edf7cd02-9688-4f77-b3c0-305b9dd149f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d0a680d-585b-4597-81c1-21af5843953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d0a680d-585b-4597-81c1-21af5843953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_e6d84511-40c7-451f-a323-ec6830252c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_e6d84511-40c7-451f-a323-ec6830252c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f46b831c-e06a-462b-89dd-e0ecd53b8026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f46b831c-e06a-462b-89dd-e0ecd53b8026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_00b4c495-2873-40b3-9887-c6917dce6868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_00b4c495-2873-40b3-9887-c6917dce6868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_135fb637-0d94-4256-b697-73e6a01cbca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_135fb637-0d94-4256-b697-73e6a01cbca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_70c60f6e-72f7-4173-9d58-f5df13b1fb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31cb2637-12b2-45f3-862d-f4b799e40ff6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_70c60f6e-72f7-4173-9d58-f5df13b1fb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_214b04ce-08be-4591-b39b-71237b917e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_214b04ce-08be-4591-b39b-71237b917e16" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c11a6665-d12d-460a-b72f-0f2149ef6181" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d043b68b-d114-42f2-a090-defa83a722bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d043b68b-d114-42f2-a090-defa83a722bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66a187cb-d5cb-4177-a446-7700ff7b4d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af7a5a2-1ef0-4cac-b69f-55651ef60cda" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66a187cb-d5cb-4177-a446-7700ff7b4d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a8a086f1-09bf-4d68-a6ea-e3f9e63f8a4c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4a7cb5a5-8783-47be-9a88-19883253b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_41e96d97-e789-4018-8bc5-73be15d6153b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4a7cb5a5-8783-47be-9a88-19883253b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_503d4cb7-1a02-47e3-b161-07028ee82017" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityInvesteeWithIPOMember_c17f794e-4999-4a1c-b415-b1c6cf3b2739" xlink:href="gh-20230331.xsd#gh_EquityInvesteeWithIPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:to="loc_gh_EquityInvesteeWithIPOMember_c17f794e-4999-4a1c-b415-b1c6cf3b2739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_ab1fca40-4dbc-49a1-be55-9a3b6baa5b87" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32bb0670-97a6-498b-98d5-3fb4b6fd7ef4" xlink:to="loc_gh_GuardantHealthAMEAIncMember_ab1fca40-4dbc-49a1-be55-9a3b6baa5b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ce5d21e4-d54f-4ad7-a947-8eab12978c93" xlink:to="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_47c54044-95e9-4340-9fe7-f204bc808b42" xlink:href="gh-20230331.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c96e5bd7-2642-470e-986c-2e0fc9e7ae92" xlink:to="loc_gh_SoftBankMember_47c54044-95e9-4340-9fe7-f204bc808b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa5377e1-6df2-4a35-a0f2-be53a949ee7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SaleOfStockLockUpPeriod_5800f753-fbd7-40f9-9810-d7ae3ac34a7c" xlink:href="gh-20230331.xsd#gh_SaleOfStockLockUpPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_gh_SaleOfStockLockUpPeriod_5800f753-fbd7-40f9-9810-d7ae3ac34a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_d1b2bbc7-1cf3-4888-9c3c-62e2ec8c52ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_d1b2bbc7-1cf3-4888-9c3c-62e2ec8c52ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ccf89355-1946-4298-aaf1-b7a41303f509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ccf89355-1946-4298-aaf1-b7a41303f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a066fac2-1c6e-4d6d-ae2f-5aae0484d244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a066fac2-1c6e-4d6d-ae2f-5aae0484d244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a43401ba-ba43-4767-813a-e0c5354c4278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a43401ba-ba43-4767-813a-e0c5354c4278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_83b9d66e-c7ef-4f60-bfc8-bf2a98dc94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_83b9d66e-c7ef-4f60-bfc8-bf2a98dc94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ad27852c-e93e-4c7b-bb14-853a60312814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ad27852c-e93e-4c7b-bb14-853a60312814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_31279f9f-08e4-4435-bc70-451befc9cb5c" xlink:href="gh-20230331.xsd#gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn_31279f9f-08e4-4435-bc70-451befc9cb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_b3309fc8-c36e-4d2d-bb7a-8e6158f4d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a0a3707f-bcb3-406b-bfec-bdbfae1e91f5" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_b3309fc8-c36e-4d2d-bb7a-8e6158f4d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_94a42746-af8c-4219-8baf-6a96337d061c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_94a42746-af8c-4219-8baf-6a96337d061c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cf8519c-3c14-4d8f-8315-eac282aeedc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NoncontrollingInterestLiabilityMember_6cb51a88-fcb1-4b09-a0d4-e54fcd802361" xlink:href="gh-20230331.xsd#gh_NoncontrollingInterestLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:to="loc_gh_NoncontrollingInterestLiabilityMember_6cb51a88-fcb1-4b09-a0d4-e54fcd802361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_249102a0-a443-48c8-b41e-b6ee3d2a9621" xlink:href="gh-20230331.xsd#gh_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08296b98-b7fa-421d-b11c-a47e23fd11be" xlink:to="loc_gh_ContingentConsiderationMember_249102a0-a443-48c8-b41e-b6ee3d2a9621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c8974e45-477f-4ba5-a1da-1fb1d3939328" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0187bbf0-fc63-4255-ac12-9010dd7fbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2419d869-0109-4679-8385-756cc9dd1a14" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0187bbf0-fc63-4255-ac12-9010dd7fbdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f952de6e-a844-4ccd-95d6-2b00c8301555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3909a74a-7006-4e9d-b5b7-c2632209062e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a31fa9-d666-4dc1-944f-6be6f79df881" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3909a74a-7006-4e9d-b5b7-c2632209062e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e748741-8423-4d0e-aac5-c4e9b991078a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ad67269-3c7c-4f82-99c0-ee0b5e5046b6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_03e4b57f-3c10-4583-853e-b933c45dc64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_03e4b57f-3c10-4583-853e-b933c45dc64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_6bfe1781-7e3e-4351-aba4-65ba6af01032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_6bfe1781-7e3e-4351-aba4-65ba6af01032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5791d9d2-5d05-42ad-a0de-003a078b43c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f35c11-f575-43e6-a935-3eb625df2913" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5791d9d2-5d05-42ad-a0de-003a078b43c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a8de0ccb-9b39-4992-96dd-4cf7187121b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a8de0ccb-9b39-4992-96dd-4cf7187121b3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:to="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_da03d9e6-e2a9-4deb-a135-11b26548bd9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2f5b2cc0-c670-4e9f-ab27-4b7f0e838287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2f5b2cc0-c670-4e9f-ab27-4b7f0e838287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_fae25dad-eb79-443f-aff8-f1c6bdc8ed9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d91362d3-85c7-48be-9b43-c8b773afc6c5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_fae25dad-eb79-443f-aff8-f1c6bdc8ed9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4e3aaad8-e37e-495e-99e3-c71d47779009" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b88922fb-4e5a-42f0-ac4d-ea7e8e8baed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b88922fb-4e5a-42f0-ac4d-ea7e8e8baed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a6504a6-38aa-44f8-8f4f-6396d05338e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a6504a6-38aa-44f8-8f4f-6396d05338e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_0d15be05-fef1-48a3-842d-6c56dd3aa595" xlink:href="gh-20230331.xsd#gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost_0d15be05-fef1-48a3-842d-6c56dd3aa595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_36b58056-2475-44ec-ba61-81bc71e57751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_36b58056-2475-44ec-ba61-81bc71e57751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_adff0b25-7f10-4e7a-a516-087f5f6afca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_adff0b25-7f10-4e7a-a516-087f5f6afca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a632a73d-5506-4124-ac21-db17c6224932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a632a73d-5506-4124-ac21-db17c6224932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_44e1c103-0035-4720-924f-b9ed4191a756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_44e1c103-0035-4720-924f-b9ed4191a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_3033eb26-eb34-42a3-ad73-8d685b942cb9" xlink:href="gh-20230331.xsd#gh_CashCashEquivalentsAndDebtSecuritiesFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4631c3a2-323c-4af6-a779-84ff2fc4971e" xlink:to="loc_gh_CashCashEquivalentsAndDebtSecuritiesFairValue_3033eb26-eb34-42a3-ad73-8d685b942cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6815a3b2-e1b7-43ba-9e80-b510097f6656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6815a3b2-e1b7-43ba-9e80-b510097f6656" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffb06a96-e9fb-4664-809d-f6d6356d84d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_20b1ac20-5cf6-451e-a43e-6bc9f1fb85ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51492a91-a60a-419a-b165-c812c9c2700b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_20b1ac20-5cf6-451e-a43e-6bc9f1fb85ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e745c9b-1b98-409b-bc0c-5ba3124a8163" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1a3b58e-adfb-459c-9a56-424f98df7110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e1a3b58e-adfb-459c-9a56-424f98df7110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bc376c7c-641c-4813-bbc8-1e7f11bc347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bc376c7c-641c-4813-bbc8-1e7f11bc347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2a6eace4-ab24-4ad4-9037-def416cc67cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_a051becd-34e7-4386-97ac-e313563d2d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2a6eace4-ab24-4ad4-9037-def416cc67cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d7f25cf-ca1f-4e2d-ac08-56d9be4cf8a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d1cb89a6-3068-4cf5-88eb-59d3791ac665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d1cb89a6-3068-4cf5-88eb-59d3791ac665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_aba09a18-eb0b-4698-8fc0-99129012f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_aba09a18-eb0b-4698-8fc0-99129012f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a540cfd4-89a9-4ce4-be90-cf8150bc76fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc028cef-48a0-4191-8edf-924e9fefd416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a540cfd4-89a9-4ce4-be90-cf8150bc76fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e8e75380-9acf-40a5-a441-568785980aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e8e75380-9acf-40a5-a441-568785980aa4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3154bb9e-f347-4371-bf45-51813e4a4866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b1285d9c-70c5-4fe8-be28-75be3c2b43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_LicensingAgreementsMember_b1285d9c-70c5-4fe8-be28-75be3c2b43e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4054c220-316f-4697-a238-41d2a1c1399a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4054c220-316f-4697-a238-41d2a1c1399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_44b3f6ed-6609-41c8-a41b-9233b69ddcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f40f0a-d20f-4f85-a226-cea735106fd2" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_44b3f6ed-6609-41c8-a41b-9233b69ddcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0f7e86ad-ee19-4c78-9680-0d9173ee04c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bc45e6e-5e74-43f7-b142-f2079f3a9633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bc45e6e-5e74-43f7-b142-f2079f3a9633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_489b9d4d-3f28-4590-bda8-d4cd5fc3ce82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_489b9d4d-3f28-4590-bda8-d4cd5fc3ce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0c06f37-eee8-420a-9ac7-016d266a6445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0c06f37-eee8-420a-9ac7-016d266a6445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8da5d1a9-510a-45b6-a2d3-e534f442909a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8da5d1a9-510a-45b6-a2d3-e534f442909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_efee0265-6602-4bec-9887-bfcbb1dc1067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_Goodwill_efee0265-6602-4bec-9887-bfcbb1dc1067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_e97043bc-7bcd-4a02-974e-779e25aeb977" xlink:href="gh-20230331.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_e97043bc-7bcd-4a02-974e-779e25aeb977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8ec8be86-220d-460d-af81-7a1508f35e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4488a2d-8b25-4cd4-93cc-8409c7df57e8" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8ec8be86-220d-460d-af81-7a1508f35e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5631c32a-8586-47d1-b544-f814848be146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_42e43411-370e-45c7-83cd-742985892cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5631c32a-8586-47d1-b544-f814848be146" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_42e43411-370e-45c7-83cd-742985892cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_86a04a43-2835-4b2c-95b1-bf2493851aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_86a04a43-2835-4b2c-95b1-bf2493851aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c6aad1d-e9a6-461e-95a7-68c08300d530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c6aad1d-e9a6-461e-95a7-68c08300d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_055fcb17-18c7-49c3-ab5b-d984dec5455c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_055fcb17-18c7-49c3-ab5b-d984dec5455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5fd3346f-076f-4173-a30e-e19a7e6fe0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5fd3346f-076f-4173-a30e-e19a7e6fe0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_251c0a12-73cb-4594-8665-515c183dde0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_251c0a12-73cb-4594-8665-515c183dde0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_e7a64f3c-e564-4109-bbd3-3b1f2abb426d" xlink:href="gh-20230331.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_e7a64f3c-e564-4109-bbd3-3b1f2abb426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08593a9c-6823-4cf6-a943-6d6311d05450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85378d3e-d3cd-4a5b-975c-4b605b27465a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08593a9c-6823-4cf6-a943-6d6311d05450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3356f7c3-ff82-4d7a-83e8-3638e5945f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3356f7c3-ff82-4d7a-83e8-3638e5945f9d" xlink:to="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_63d257f4-c699-4fcf-b86a-a2b0ba324b49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_4c6e00dc-0ea7-4d67-b538-af4ea5d68269" xlink:href="gh-20230331.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421ead59-eb18-47ae-bb64-b8353217fb3f" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_4c6e00dc-0ea7-4d67-b538-af4ea5d68269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_42327bae-f00d-46ae-89ed-1680282edfc9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_96dd0ab3-cf1b-4d14-ad9d-7774047f9f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_96dd0ab3-cf1b-4d14-ad9d-7774047f9f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3045d0a1-9934-4a70-b8eb-21450068e962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1405b3ac-3910-4cd3-94cb-62fadeafcd6a" xlink:to="loc_us-gaap_SeniorNotesMember_3045d0a1-9934-4a70-b8eb-21450068e962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionAxis_94b98e34-3975-4f97-8ce3-071f8e6a2f64" xlink:to="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember_338917d3-b2cf-4dc3-8202-a73f7297fa72" xlink:href="gh-20230331.xsd#gh_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodOneMember_338917d3-b2cf-4dc3-8202-a73f7297fa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember_5bce407b-3ea9-4fd7-aa41-69593e4e0da0" xlink:href="gh-20230331.xsd#gh_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodTwoMember_5bce407b-3ea9-4fd7-aa41-69593e4e0da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember_8128510f-bfdb-409b-8536-d441d28269b7" xlink:href="gh-20230331.xsd#gh_ConversionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_625dbf92-9769-4a88-994d-0e95acd85c8d" xlink:to="loc_gh_ConversionPeriodThreeMember_8128510f-bfdb-409b-8536-d441d28269b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad433f2a-8abf-4c0b-8a9e-e78f074b99d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_cdaea583-4919-4234-8a86-85a6e0b3464b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_e531181b-9df0-481b-be9d-a8e69ef47309" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_cdaea583-4919-4234-8a86-85a6e0b3464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d882756-81c0-47c5-98e7-563a258b393b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputQuotedPriceMember_976c5d13-4fe5-425b-b573-01ff7cbba20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputQuotedPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_22cf72bf-7ae9-4b38-a0d8-bf72459a544a" xlink:to="loc_us-gaap_MeasurementInputQuotedPriceMember_976c5d13-4fe5-425b-b573-01ff7cbba20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_138e8685-9d89-438f-873b-db6bd91078e0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ae98d4e0-233f-46aa-a0ba-c81a82340230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ae98d4e0-233f-46aa-a0ba-c81a82340230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aa75bb1c-e8cb-4145-9899-d92fb3b1ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aa75bb1c-e8cb-4145-9899-d92fb3b1ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_f7fa6582-beac-42f1-8003-a1d9ea08edb5" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_f7fa6582-beac-42f1-8003-a1d9ea08edb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e25cd6b2-b3c2-451e-a23e-d3752133bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e25cd6b2-b3c2-451e-a23e-d3752133bb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a3db7e50-b80f-4927-99c1-45f07b17b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a3db7e50-b80f-4927-99c1-45f07b17b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ce86a160-b81f-4d4f-8655-d4607a73c332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ce86a160-b81f-4d4f-8655-d4607a73c332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_4f149090-e6eb-4de7-bc40-55f7a3db54b0" xlink:href="gh-20230331.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_4f149090-e6eb-4de7-bc40-55f7a3db54b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec400260-261a-43be-a5b7-35aab17eee97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec400260-261a-43be-a5b7-35aab17eee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b021f3a-0149-439d-945d-4db0dde9b108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0b021f3a-0149-439d-945d-4db0dde9b108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6c48f22e-fc95-42a6-b059-7b6f9987ffd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6c48f22e-fc95-42a6-b059-7b6f9987ffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMeasurementInputDenominator_534f5e69-3967-4154-bdea-05f7378e2a5e" xlink:href="gh-20230331.xsd#gh_DebtInstrumentMeasurementInputDenominator"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_DebtInstrumentMeasurementInputDenominator_534f5e69-3967-4154-bdea-05f7378e2a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0eb08024-3ebf-4308-b5d9-8a8cbfb13fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0eb08024-3ebf-4308-b5d9-8a8cbfb13fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_88f1e97d-282c-4e8c-9979-4cec9dc3acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_88f1e97d-282c-4e8c-9979-4cec9dc3acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice_667431ed-0684-48d7-875a-35e27d715170" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_ConvertibleDebtHedgeStrikePrice_667431ed-0684-48d7-875a-35e27d715170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_0dc64711-45e7-4afa-97df-1692e5beca09" xlink:href="gh-20230331.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_0dc64711-45e7-4afa-97df-1692e5beca09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a635cc50-69f2-4b37-b54e-6df117876dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_us-gaap_SharePrice_a635cc50-69f2-4b37-b54e-6df117876dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_2f45d359-94c8-4603-aea2-7d72ffa09eb0" xlink:href="gh-20230331.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6829299b-0f8c-41a6-8fa5-a7f915e0068e" xlink:to="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_2f45d359-94c8-4603-aea2-7d72ffa09eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2bb7f380-7a68-490c-8fd7-4b147c6f6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2bb7f380-7a68-490c-8fd7-4b147c6f6d29" xlink:to="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04015def-a045-4f74-9224-51fbd69a3d13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a10fb808-d569-4a81-9819-c05bf1408a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1ecfca69-b97f-4f41-9544-c51291c76b0e" xlink:to="loc_us-gaap_ConvertibleDebtMember_a10fb808-d569-4a81-9819-c05bf1408a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:to="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_972a326a-5df4-4ccd-b1bc-dfb8f1cfabb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_fab23968-5364-44ea-bffe-302afc924e27" xlink:href="gh-20230331.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88d769eb-717a-41a1-ac34-af231f21741f" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_fab23968-5364-44ea-bffe-302afc924e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5481c964-a5da-458d-9fff-2cca5f4a9452" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e61bf31-1e42-4322-87de-73d2edcbfc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e61bf31-1e42-4322-87de-73d2edcbfc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ae4c707f-b2a3-4974-843d-eed84cee78ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ae4c707f-b2a3-4974-843d-eed84cee78ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d49915f-371c-450e-ae2b-bd2df495b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fca4c6dd-9315-4aca-b69a-0417d46b3cfb" xlink:to="loc_us-gaap_LongTermDebt_6d49915f-371c-450e-ae2b-bd2df495b5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8606a90f-724d-45db-b3fc-2f26a200facb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8606a90f-724d-45db-b3fc-2f26a200facb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:to="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dcdb8c86-e47f-4f4e-bd08-1ae5aab5ace5" xlink:to="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_79cda434-ea73-4cbd-b9f0-0d5a7bb8250f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:to="loc_srt_MinimumMember_79cda434-ea73-4cbd-b9f0-0d5a7bb8250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0fa0a930-38ac-4c32-8e9c-36f4d10b17d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f478071-c532-48d6-8f94-2a416d139589" xlink:to="loc_srt_MaximumMember_0fa0a930-38ac-4c32-8e9c-36f4d10b17d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6747f9d6-ad17-4590-b4df-23313f71ca87" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ead16d98-d7fe-4876-92f0-86064a0bbc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ead16d98-d7fe-4876-92f0-86064a0bbc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e615630a-17b5-4cab-8a6d-22795af338fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0cb81e3d-c2ae-4599-b986-759e112b0b06" xlink:to="loc_us-gaap_OperatingLeaseExpense_e615630a-17b5-4cab-8a6d-22795af338fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_808c5924-33fc-4142-b7bc-9a29c7383923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fe9992b-c5d0-4f5d-b26a-ca9c08a3762f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_808c5924-33fc-4142-b7bc-9a29c7383923" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fe9992b-c5d0-4f5d-b26a-ca9c08a3762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a5eb266-0872-4609-a43d-9a1d328e7114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_808c5924-33fc-4142-b7bc-9a29c7383923" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a5eb266-0872-4609-a43d-9a1d328e7114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9b5ad55c-0aa6-4370-8944-2d35d4f6829b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9b5ad55c-0aa6-4370-8944-2d35d4f6829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7e509a8c-5239-4f09-a418-a3c16619fa99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7e509a8c-5239-4f09-a418-a3c16619fa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3d7dcd39-10c0-47a4-bfef-cf1ac83e3ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3d7dcd39-10c0-47a4-bfef-cf1ac83e3ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1ab33dd-ac05-4001-a0a8-1b11844cfb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1ab33dd-ac05-4001-a0a8-1b11844cfb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fd531a44-3b10-4397-8d9c-551050cf3ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fd531a44-3b10-4397-8d9c-551050cf3ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_64bb01c7-b86f-42c6-89e9-18e2dd6895b0" xlink:href="gh-20230331.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_64bb01c7-b86f-42c6-89e9-18e2dd6895b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96a7117f-34b0-41b9-b1b7-557834ec3703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96a7117f-34b0-41b9-b1b7-557834ec3703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6df6994-e8ce-4eba-b2b7-c0d2f54a16cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6df6994-e8ce-4eba-b2b7-c0d2f54a16cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a686b360-b30f-4759-8e36-4aba498391fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae8b18fa-53d6-4e22-a1db-2b79e93c65f0" xlink:to="loc_us-gaap_OperatingLeaseLiability_a686b360-b30f-4759-8e36-4aba498391fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20230331.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1fe818-60f3-48ec-9f21-a04cca097764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1fe818-60f3-48ec-9f21-a04cca097764" xlink:to="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:to="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e8b6c897-a976-48f6-994c-cfaca1a770aa" xlink:to="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_c4c0a3f7-7e8c-4d9c-84b9-9715f34e1b09" xlink:href="gh-20230331.xsd#gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bd889fce-0267-400d-a82f-41d674800256" xlink:to="loc_gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember_c4c0a3f7-7e8c-4d9c-84b9-9715f34e1b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99900cdc-0cd7-4287-b491-9ffcb494a2a6" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_9b6b3d6a-5e5e-4b60-98c2-e21fe66030e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6390ba65-b2b9-4d35-bc35-514be9260c5d" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_9b6b3d6a-5e5e-4b60-98c2-e21fe66030e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6ec7f0fe-c21c-484a-9983-3c190fa787f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ec7f0fe-c21c-484a-9983-3c190fa787f7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:to="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_687172ff-316e-48cd-b1b0-04321b2fb301" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_879463f0-aff1-4db3-aa39-e53cd28f5917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_879463f0-aff1-4db3-aa39-e53cd28f5917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb90357e-9f6d-45c8-9574-7c8d2645c6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb90357e-9f6d-45c8-9574-7c8d2645c6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_301f9a22-e8a9-4b72-be7f-710757d9526c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_PerformanceSharesMember_301f9a22-e8a9-4b72-be7f-710757d9526c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_25bec2f4-10ac-4959-bc12-4b81e1e1e7bf" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_25bec2f4-10ac-4959-bc12-4b81e1e1e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_331e9b66-6b2c-4a16-a855-b1b7e3cf008c" xlink:href="gh-20230331.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_331e9b66-6b2c-4a16-a855-b1b7e3cf008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bbd2af65-3872-44fb-9a9e-56da348792aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863ea61-1841-4391-a409-60d532dda5d7" xlink:to="loc_us-gaap_EmployeeStockMember_bbd2af65-3872-44fb-9a9e-56da348792aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51e196e6-e8de-4c92-bf9a-696aaa1de717" xlink:to="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_1812fec8-659d-42f1-b580-dfcb3ab9db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:to="loc_us-gaap_DividendsCommonStock_1812fec8-659d-42f1-b580-dfcb3ab9db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e537e37-e9df-43b2-bb26-c5fb77c68ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0be64f7f-fd05-41f9-9c7e-a244f481f97e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e537e37-e9df-43b2-bb26-c5fb77c68ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f3d3e775-05cb-4079-9391-84a6f1b4966e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f3d3e775-05cb-4079-9391-84a6f1b4966e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:to="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_eec4a81f-c0c2-4a15-b9a4-1536c6284dc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3994fb55-b893-4e55-b208-e8b51f0f77ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_us-gaap_StockOptionMember_3994fb55-b893-4e55-b208-e8b51f0f77ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d5dbfc0c-82fd-41e5-a4b7-ccc2e3c33d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_us-gaap_RestrictedStockMember_d5dbfc0c-82fd-41e5-a4b7-ccc2e3c33d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_5f306092-2195-4990-a263-6896e24894ad" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0990876c-263f-4e89-9f37-a0b78fc0495b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_5f306092-2195-4990-a263-6896e24894ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_919408c7-c2ec-49a9-9ec2-943174f6d804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:href="gh-20230331.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_232ee9a0-99de-4398-a9f4-3abf3514bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_232ee9a0-99de-4398-a9f4-3abf3514bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_ac90dcdf-0684-456f-b52f-85f15e97e09f" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_ac90dcdf-0684-456f-b52f-85f15e97e09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_0a24dfa7-7edb-451a-9da3-c76b7d7e970a" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_0a24dfa7-7edb-451a-9da3-c76b7d7e970a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_299e7588-375a-409d-bb7a-75d9ec95beae" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_299e7588-375a-409d-bb7a-75d9ec95beae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_212e521c-a71d-4b65-bf07-2a59a0e3ab67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_04823f67-3580-4184-8586-17dec053344d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_212e521c-a71d-4b65-bf07-2a59a0e3ab67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463b9a44-fc18-45e5-ab02-a4e356cb476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463b9a44-fc18-45e5-ab02-a4e356cb476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ace5be57-2648-4ec8-8f73-27ee8aa8de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ace5be57-2648-4ec8-8f73-27ee8aa8de13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91bbac0c-1d5e-425b-a078-7d84239b98ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91bbac0c-1d5e-425b-a078-7d84239b98ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9759db58-f519-4ad1-bf28-6e8068d7e90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9759db58-f519-4ad1-bf28-6e8068d7e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1849e033-f71b-483e-b718-40919e894f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79372b17-503c-468a-9be6-e538b17873d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1849e033-f71b-483e-b718-40919e894f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7ab2b3b-5b56-4741-b77e-8fc8def14d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7ab2b3b-5b56-4741-b77e-8fc8def14d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb126d20-4d8f-47d8-9ed0-23da843b7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb126d20-4d8f-47d8-9ed0-23da843b7731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_214280db-16fb-4b9e-bd2d-e9504e7c8ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_214280db-16fb-4b9e-bd2d-e9504e7c8ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d093f422-a3f3-4f96-8409-57a555e2eb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d093f422-a3f3-4f96-8409-57a555e2eb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cfec9f1c-bef0-47c7-b5f6-108eec628bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cfec9f1c-bef0-47c7-b5f6-108eec628bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d2d8dcc-fe53-4a29-b15f-d0c6335fe5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e4d7ce85-fcf9-4fe7-970b-4d556cf50c64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d2d8dcc-fe53-4a29-b15f-d0c6335fe5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1660c1a4-e76d-4794-85cf-aadc5e9edc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1660c1a4-e76d-4794-85cf-aadc5e9edc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_570749c6-27a8-4dce-99b6-d053c9dbfe43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_570749c6-27a8-4dce-99b6-d053c9dbfe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c9d87c52-06f7-47be-b07f-a158e0d06f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c9d87c52-06f7-47be-b07f-a158e0d06f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad2dd11a-258e-4eb2-8c94-6b9eff7a2853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad2dd11a-258e-4eb2-8c94-6b9eff7a2853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_18a050d6-f5b0-487f-88f3-1786dfaaff15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82de5957-607a-4b4b-a3cc-1ba976ddab77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_18a050d6-f5b0-487f-88f3-1786dfaaff15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_679a4bab-1b62-4ee3-8f40-d06d4f72bf92" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b0e3f6-ed0c-4225-8a46-a31c6ab41c92" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_679a4bab-1b62-4ee3-8f40-d06d4f72bf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9285c453-8022-47d4-bab7-5c766e5b33c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9285c453-8022-47d4-bab7-5c766e5b33c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83f3a044-786a-4274-b48d-58c7ae8b0b26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f4082f1f-2959-401e-a53f-ecaf885cc795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f4082f1f-2959-401e-a53f-ecaf885cc795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_68fb9410-bdc8-4fea-a91f-9599f81d7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_68fb9410-bdc8-4fea-a91f-9599f81d7ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_64a62753-d825-4609-aa49-9da7b2a3dea7" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_64a62753-d825-4609-aa49-9da7b2a3dea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_b08f4fc5-55e4-4e6d-82ad-4d14d45f1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_b08f4fc5-55e4-4e6d-82ad-4d14d45f1a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d7bfdeb1-6949-447d-91e8-db0af4a34c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_PerformanceSharesMember_d7bfdeb1-6949-447d-91e8-db0af4a34c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5aa6a0e3-649f-4a07-a79a-8b8ec4d53d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8666a4-2f49-4d0d-b579-d38b69166b26" xlink:to="loc_us-gaap_EmployeeStockMember_5aa6a0e3-649f-4a07-a79a-8b8ec4d53d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_afe8b550-c30c-4218-9b37-4c805a77a92d" xlink:to="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb85d48f-ace2-4205-b97b-c103de7895c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:to="loc_srt_MinimumMember_fb85d48f-ace2-4205-b97b-c103de7895c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89428a8d-78e7-4526-b8b7-d59a1bd79d68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c29bbb2-1332-420b-95e4-5f47fb2ebbbb" xlink:to="loc_srt_MaximumMember_89428a8d-78e7-4526-b8b7-d59a1bd79d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_246ba26f-8862-4097-b7a6-4af3e2e36650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_3cc7a3b6-75a0-4f55-a549-81b3d462541b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e31b369b-d578-4a75-901f-04b6bb5dc647" xlink:to="loc_srt_ChiefExecutiveOfficerMember_3cc7a3b6-75a0-4f55-a549-81b3d462541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d5aa29f5-1d61-4434-b004-635a3250004c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_2f295ce4-cc41-4427-8c75-fc06472e3745" xlink:href="gh-20230331.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7784822d-04df-4030-892b-e398cbbd6388" xlink:to="loc_gh_GuardantHealthAMEAIncMember_2f295ce4-cc41-4427-8c75-fc06472e3745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae202ab1-d029-49c4-99f9-d13d7c5ae3ec" xlink:to="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_dc091edb-cb64-46c7-8a3e-0e2b5cd56a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2c164aa7-fe50-4080-995f-638394cdcc0a" xlink:to="loc_us-gaap_CommonClassBMember_dc091edb-cb64-46c7-8a3e-0e2b5cd56a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0482ec43-ed81-414a-8593-0a718b367977" xlink:to="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a080c76d-9346-4b44-a77e-b0fca77bdffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2530dbf8-6e74-4b28-8803-7acde6179b79" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a080c76d-9346-4b44-a77e-b0fca77bdffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_84e3e593-15af-4dc6-b531-b34c39ad5bfe" xlink:to="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_bb1e9d8f-7448-489a-b61c-aa46730806c6" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:to="loc_gh_AMEA2020PlanMember_bb1e9d8f-7448-489a-b61c-aa46730806c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018EmployeeStockPurchasePlanMember_a0b49125-10e9-4a1c-8c55-590b441482c2" xlink:href="gh-20230331.xsd#gh_A2018EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_85813411-743b-4fd2-bb51-11461866ec40" xlink:to="loc_gh_A2018EmployeeStockPurchasePlanMember_a0b49125-10e9-4a1c-8c55-590b441482c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deab3334-ba7c-4ac1-be6b-cdf5b1e6db3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ce1d6a4-e3fe-461f-bef4-d0806eeb2684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ce1d6a4-e3fe-461f-bef4-d0806eeb2684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_424491ea-25ac-4af9-8207-bc019476e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_424491ea-25ac-4af9-8207-bc019476e4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9b5649ca-7f36-4bf6-b3a8-d66c4507eb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9b5649ca-7f36-4bf6-b3a8-d66c4507eb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e33d3956-736a-46d5-899a-14998779bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e33d3956-736a-46d5-899a-14998779bc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a20fd105-e541-4117-b079-a6d326ff72d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a20fd105-e541-4117-b079-a6d326ff72d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ee45ab2-4044-49d4-95eb-2c8e409e68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ee45ab2-4044-49d4-95eb-2c8e409e68b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c7374987-de1c-4a75-821a-f2f4091d9ca0" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c7374987-de1c-4a75-821a-f2f4091d9ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52824ee3-4813-4e1e-9901-861c7ab4e866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52824ee3-4813-4e1e-9901-861c7ab4e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2708bf2d-13ad-4178-8b00-5c20ada13a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2708bf2d-13ad-4178-8b00-5c20ada13a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d505bf49-4f94-4f56-acb8-74daa4d55dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d505bf49-4f94-4f56-acb8-74daa4d55dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_693d17a0-f785-467c-91b8-4668a5f8031f" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_693d17a0-f785-467c-91b8-4668a5f8031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_08ce7a30-879d-4b81-9b28-1cddbb53377d" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_08ce7a30-879d-4b81-9b28-1cddbb53377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_cd1b5408-403f-4dc2-8c40-3a6d3c2d837e" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_cd1b5408-403f-4dc2-8c40-3a6d3c2d837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_3b5accbb-22d2-4352-9226-405173ab6a24" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_3b5accbb-22d2-4352-9226-405173ab6a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ac07f6-d7fd-42ec-a9f5-850e99ce86c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ac07f6-d7fd-42ec-a9f5-850e99ce86c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_b435dcb9-60d3-4f81-88e1-10b532d1eb44" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_b435dcb9-60d3-4f81-88e1-10b532d1eb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa30df73-aad5-46b8-8b88-968eca7114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa30df73-aad5-46b8-8b88-968eca7114f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f860098-a9a1-42b7-8c42-6dfea7b1b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f860098-a9a1-42b7-8c42-6dfea7b1b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35b2fc1b-cc58-4b22-b761-2a86a67aeb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35b2fc1b-cc58-4b22-b761-2a86a67aeb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ea6cd6e8-7992-4125-b34b-1630f14d338b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ea6cd6e8-7992-4125-b34b-1630f14d338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6d270406-8393-40d2-a738-30ecb5ae6e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6d270406-8393-40d2-a738-30ecb5ae6e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94665ae-3a60-4848-af86-ff4aa2e3ad38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94665ae-3a60-4848-af86-ff4aa2e3ad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ac739c8-5a84-41ce-8a9c-11930665123c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ac739c8-5a84-41ce-8a9c-11930665123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_839545e2-8462-4970-a520-27c3ebc3e06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_839545e2-8462-4970-a520-27c3ebc3e06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_42a09f5d-dbd0-48b0-9f54-795482963fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_42a09f5d-dbd0-48b0-9f54-795482963fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c27f0a53-a18b-483a-94a9-7621342d0509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c27f0a53-a18b-483a-94a9-7621342d0509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfa233e0-95a1-40d0-8b00-7caca2763345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfa233e0-95a1-40d0-8b00-7caca2763345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9847f232-5269-47ee-bb21-a5cda998e064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9847f232-5269-47ee-bb21-a5cda998e064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aee8b4fa-7ff6-4122-82b9-511f0cbee32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aee8b4fa-7ff6-4122-82b9-511f0cbee32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7e21b9d6-91c1-4a98-8035-521bfe7d68ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7e21b9d6-91c1-4a98-8035-521bfe7d68ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_808935fd-8072-4f93-abb5-3c82dfda8f6a" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_808935fd-8072-4f93-abb5-3c82dfda8f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a67705b-a2d4-4501-adb6-b942f7f7096c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27482b10-e8cb-4878-a7f5-cc254f7a3ccf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a67705b-a2d4-4501-adb6-b942f7f7096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66e45113-f7be-47be-8606-fd63a622573c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66e45113-f7be-47be-8606-fd63a622573c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:to="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1f9dc804-a6b5-467c-8f94-97209ac2e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1cbe82f1-ce18-458a-9d4a-9b80f40fd71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1cbe82f1-ce18-458a-9d4a-9b80f40fd71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_90dfa5c0-106b-44f5-8df7-f6c434f37765" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c4b5ab9-ac01-4795-a716-9349dac046a7" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_90dfa5c0-106b-44f5-8df7-f6c434f37765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b52351b1-8733-41a4-9fae-7c3cec771ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2cf675b2-a48d-4018-a268-1110904c61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2cf675b2-a48d-4018-a268-1110904c61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae04e08e-fb43-4baf-bee4-4a48fbeb4834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ae04e08e-fb43-4baf-bee4-4a48fbeb4834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7580ac1c-2d58-43e6-990f-795e23f6e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7580ac1c-2d58-43e6-990f-795e23f6e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dea9ee03-2d8b-4fb7-bf4e-61d93c8fd56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dea9ee03-2d8b-4fb7-bf4e-61d93c8fd56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45faa0d5-64ee-4f66-9b49-b7a0700addd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf50c06b-378b-404f-b8fb-a3f2fdc09168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45faa0d5-64ee-4f66-9b49-b7a0700addd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76095ac9-79a3-4162-a3b4-7d47ed9447a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa953573-9bb6-4d35-b46c-386203e65ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa953573-9bb6-4d35-b46c-386203e65ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738e7457-0efe-4be9-af12-155a8e29e020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738e7457-0efe-4be9-af12-155a8e29e020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_142ed2af-e809-4242-8ea2-50530a4de5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_142ed2af-e809-4242-8ea2-50530a4de5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a361d93c-52b4-4fd4-8170-641c9298bb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a361d93c-52b4-4fd4-8170-641c9298bb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_746be12d-4740-4e2e-a243-88d58b79dae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_09baa797-5267-4182-b629-33d287c9c312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_746be12d-4740-4e2e-a243-88d58b79dae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed8fb632-ebaa-4708-80fe-00e2a60b6292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed8fb632-ebaa-4708-80fe-00e2a60b6292" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:to="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d932e9ee-cb3c-4aa2-989c-7063abea3bab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_872f26e2-14bd-4017-b0b8-a2e08b547de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e4cdab8-ca84-412a-bdc6-d85625352ce7" xlink:to="loc_us-gaap_PerformanceSharesMember_872f26e2-14bd-4017-b0b8-a2e08b547de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:to="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_f90b8dfe-f107-42d1-b4c2-b0debec75efc" xlink:to="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_88f88a4e-11d8-4eab-bc2a-da029e193423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_88f88a4e-11d8-4eab-bc2a-da029e193423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8dbc92ea-6494-46f2-842b-6ba3f44e5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8dbc92ea-6494-46f2-842b-6ba3f44e5aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b06c3f37-305c-4c5c-828a-6ba6a647d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a65c4e89-9f46-4244-8be3-a9f97d0ced63" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b06c3f37-305c-4c5c-828a-6ba6a647d7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc34a7e6-97c5-4d1c-8fb4-c421fb07ffa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_76b4ee81-1c0f-4c1f-b2ac-d72d11b3424e" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal_76b4ee81-1c0f-4c1f-b2ac-d72d11b3424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_1a047c99-a4e8-428b-94e9-6b9b7a2028e6" xlink:href="gh-20230331.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af32ed5f-80d2-4a1b-9c00-23c8834a530f" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_1a047c99-a4e8-428b-94e9-6b9b7a2028e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6666af3-f9cf-42a2-8e23-b3a2dd7b9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6666af3-f9cf-42a2-8e23-b3a2dd7b9d84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e36e7b4-d618-4858-8c4c-062e7da9bcec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_e1138e48-522d-482f-b70e-2f466a3229f2" xlink:href="gh-20230331.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_gh_PrecisionOncologyTestingMember_e1138e48-522d-482f-b70e-2f466a3229f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostOfDevelopmentServicesAndOtherMember_5eb3394e-461d-4da2-b60d-96e84f0fcd51" xlink:href="gh-20230331.xsd#gh_CostOfDevelopmentServicesAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_gh_CostOfDevelopmentServicesAndOtherMember_5eb3394e-461d-4da2-b60d-96e84f0fcd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f1bdba08-96f7-4008-9112-7f1e81a9d262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f1bdba08-96f7-4008-9112-7f1e81a9d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_0605393b-5d48-4b0c-9d4e-32c51645b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_0605393b-5d48-4b0c-9d4e-32c51645b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89b15c16-a52f-45be-a9b1-66bc671a7a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b3c4d20-368b-4507-a120-a4ffd0d58f20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89b15c16-a52f-45be-a9b1-66bc671a7a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57cfdd70-2fad-462e-9a24-23ff4f16e1f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_814d6acf-305f-4a27-b2eb-a0ee3882fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_527bafbd-8ad0-4eb4-9fbb-53682eeefb08" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_814d6acf-305f-4a27-b2eb-a0ee3882fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf5c704-de15-4988-a375-73467392a357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf5c704-de15-4988-a375-73467392a357" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:to="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4f9cc371-28d9-4113-ad8f-ecb9939ff7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cc285174-1113-4cae-9e86-1589a751878b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cc285174-1113-4cae-9e86-1589a751878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_76bd35f8-7a29-4f96-9d1d-c1a9850ae1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d8bfdf-7bb6-49f1-891b-bfc689790fe9" xlink:to="loc_us-gaap_EmployeeStockMember_76bd35f8-7a29-4f96-9d1d-c1a9850ae1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:to="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cd6c24ce-50b2-4a48-b937-a951c06ade06" xlink:to="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_805c7277-7c5c-4c7d-bf70-8c9c9740f7f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:to="loc_srt_MinimumMember_805c7277-7c5c-4c7d-bf70-8c9c9740f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f5f2952-3418-4a08-9ede-fa931c1a06e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa1e1866-9d0d-4b2d-92b0-5f8be6669e0f" xlink:to="loc_srt_MaximumMember_8f5f2952-3418-4a08-9ede-fa931c1a06e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab5b802c-4100-4420-8942-8ab8e0547a31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6bf7b513-a72f-4985-8a14-d9d4baca89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6bf7b513-a72f-4985-8a14-d9d4baca89d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cad91474-10d6-4ec6-851b-13243fd24a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cad91474-10d6-4ec6-851b-13243fd24a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0648a2d6-08bd-4150-a908-b73616c7500c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0648a2d6-08bd-4150-a908-b73616c7500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfcd52c4-8278-4d1d-b647-181e44068f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e78a6656-2be9-476c-ae43-854b0e61ed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfcd52c4-8278-4d1d-b647-181e44068f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#NetLossPerShareScheduleofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_47c42e25-a05c-4c0b-87ab-19145c775db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_47c42e25-a05c-4c0b-87ab-19145c775db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc726b90-df45-4f72-b103-895d4663a9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc726b90-df45-4f72-b103-895d4663a9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1917775d-79cd-4cbb-9744-c37b248db54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_EarningsPerShareBasic_1917775d-79cd-4cbb-9744-c37b248db54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_da09dd41-20cb-4cd4-b47d-a702a1e3050c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_da09dd41-20cb-4cd4-b47d-a702a1e3050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_603ef93a-c0ff-43c2-b60d-1e56ea563001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_603ef93a-c0ff-43c2-b60d-1e56ea563001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ecf212a-a103-43ac-aefb-a72748cad151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bd603d0-be4b-4902-8a55-43dc9f5069a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ecf212a-a103-43ac-aefb-a72748cad151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e643fbc-cce7-4d60-aa82-a8a6b02b9ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e643fbc-cce7-4d60-aa82-a8a6b02b9ea8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b7283f0-083f-411d-9054-1c37f7a59e40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76543f72-41b7-48c6-af6b-86d2c9085a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76543f72-41b7-48c6-af6b-86d2c9085a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8557fcf6-f700-4114-b9ee-8b950b15bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8557fcf6-f700-4114-b9ee-8b950b15bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d833dcfc-c832-44c9-b5f8-de7719552623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_PerformanceSharesMember_d833dcfc-c832-44c9-b5f8-de7719552623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_8042bdb3-778f-4580-a142-6f58912eda6d" xlink:href="gh-20230331.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_8042bdb3-778f-4580-a142-6f58912eda6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_19722e24-2ecd-4823-a90f-a7a1f52e431c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_EmployeeStockMember_19722e24-2ecd-4823-a90f-a7a1f52e431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5bd177d8-0c17-41c0-a4f3-6f941e2f61e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4017808f-9d39-4026-85c1-ec9f5142c5ce" xlink:to="loc_us-gaap_SeniorNotesMember_5bd177d8-0c17-41c0-a4f3-6f941e2f61e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_06f61f2b-4118-4331-a102-2643b4b2fa40" xlink:to="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_b64f2bc7-938b-4d39-accd-3fd84835caa2" xlink:href="gh-20230331.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3bc43135-9499-47d2-ad91-4dc31dfaca59" xlink:to="loc_gh_AMEA2020PlanMember_b64f2bc7-938b-4d39-accd-3fd84835caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b876cfc1-c31f-492c-b796-fb7897d51b36" xlink:to="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_27b9cf9c-0f46-4666-beb9-f9f419b06511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_801fb8bf-5ff7-467f-8d79-14ab8d2d44ca" xlink:to="loc_us-gaap_CommonClassBMember_27b9cf9c-0f46-4666-beb9-f9f419b06511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d74a012a-d6a3-4cfd-a90a-4d213a37340d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1382e9-6f2a-4cd8-84f1-1c3880dda618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1382e9-6f2a-4cd8-84f1-1c3880dda618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12a9bcb2-fda3-4a08-9d7d-787f825a5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_446b4d26-1d06-4267-8d2f-2ae9642fd739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12a9bcb2-fda3-4a08-9d7d-787f825a5b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20230331.xsd#SegmentandGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_40c6cd8d-0009-423e-8eb9-668b4d4af564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_40c6cd8d-0009-423e-8eb9-668b4d4af564" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_743d8ba9-2b9f-4495-b5bc-29e216e370a1" xlink:to="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9aae61a-f288-4cd5-8b5a-21a0e657c4bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:to="loc_country_US_a9aae61a-f288-4cd5-8b5a-21a0e657c4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_285966f2-123c-4b07-9cc1-95a3d3ae7a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_add619b5-b5aa-4d78-ab55-078ee74b54ef" xlink:to="loc_us-gaap_NonUsMember_285966f2-123c-4b07-9cc1-95a3d3ae7a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6cde60c3-8329-408e-9ae2-34fea4a46d05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_1691c55a-4852-4541-9888-9a702f9be654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e3cc6e4-3a55-4c90-ad91-00bbb445358d" xlink:to="loc_us-gaap_AssetsMember_1691c55a-4852-4541-9888-9a702f9be654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a00c7895-a38f-4a03-9adc-b7292ef655f8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_07a9d455-8832-4fd3-9962-3710480f89db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_736d610f-c1d1-4595-9df1-a052b4cca0df" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_07a9d455-8832-4fd3-9962-3710480f89db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6b377246-0036-40cc-bd87-ec783bc5ff1e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_19010e5f-92da-436e-b8cb-9f9c811dc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86afbc05-f5ae-42c4-a01f-cc3af29f8057" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_19010e5f-92da-436e-b8cb-9f9c811dc0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_832bf2ed-a77e-42d2-ae2a-ec62b6bad2f2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b43f4aa0-7a9f-491a-9a38-e659f4deb648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b43f4aa0-7a9f-491a-9a38-e659f4deb648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_878c5acb-092a-49bb-9872-8e405ca861a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_Revenues_878c5acb-092a-49bb-9872-8e405ca861a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a8ec1e4d-0ad3-4835-bb8e-afb36ceeb333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f88788e8-46e2-4b3e-8ce3-148d2e27fd9a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a8ec1e4d-0ad3-4835-bb8e-afb36ceeb333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126346256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GUARDANT HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4139254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3100 Hanover Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">698-8887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,764,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126395680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 223,640<span></span>
</td>
<td class="nump">$ 141,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">713,380<span></span>
</td>
<td class="nump">869,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">87,204<span></span>
</td>
<td class="nump">97,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">46,474<span></span>
</td>
<td class="nump">51,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="nump">33,762<span></span>
</td>
<td class="nump">31,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,104,460<span></span>
</td>
<td class="nump">1,191,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">163,229<span></span>
</td>
<td class="nump">167,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">170,651<span></span>
</td>
<td class="nump">174,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">11,047<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">58,954<span></span>
</td>
<td class="nump">61,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,511,631<span></span>
</td>
<td class="nump">1,609,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">190,534<span></span>
</td>
<td class="nump">175,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">13,621<span></span>
</td>
<td class="nump">17,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">204,155<span></span>
</td>
<td class="nump">193,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">1,138,034<span></span>
</td>
<td class="nump">1,137,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">204,857<span></span>
</td>
<td class="nump">210,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">9,136<span></span>
</td>
<td class="nump">9,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,556,182<span></span>
</td>
<td class="nump">1,549,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March&#160;31, 2023, and December&#160;31, 2022; 102,708,305 and 102,619,383 shares issued and outstanding as of March&#160;31, 2023, and December&#160;31, 2022, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,763,544<span></span>
</td>
<td class="nump">1,742,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12,150)<span></span>
</td>
<td class="num">(19,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,795,946)<span></span>
</td>
<td class="num">(1,662,413)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; (Deficit) Equity</a></td>
<td class="num">(44,551)<span></span>
</td>
<td class="nump">60,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; (Deficit) Equity</a></td>
<td class="nump">$ 1,511,631<span></span>
</td>
<td class="nump">$ 1,609,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891128121040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">102,708,305<span></span>
</td>
<td class="nump">102,619,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">102,708,305<span></span>
</td>
<td class="nump">102,619,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126377264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_RevenueFromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="nump">$ 113,393<span></span>
</td>
<td class="nump">$ 84,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_RevenueFromDevelopmentServices', window );">Development services and other</a></td>
<td class="nump">15,321<span></span>
</td>
<td class="nump">11,963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">128,714<span></span>
</td>
<td class="nump">96,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_CostsOfPrecisionOncologyTesting', window );">Cost of precision oncology testing</a></td>
<td class="nump">45,106<span></span>
</td>
<td class="nump">30,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_CostOfDevelopmentServices', window );">Cost of development services and other</a></td>
<td class="nump">7,967<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">93,128<span></span>
</td>
<td class="nump">81,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">76,123<span></span>
</td>
<td class="nump">64,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">40,445<span></span>
</td>
<td class="nump">41,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">262,769<span></span>
</td>
<td class="nump">219,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(134,055)<span></span>
</td>
<td class="num">(123,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,654)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for (benefit from) income taxes</a></td>
<td class="num">(133,293)<span></span>
</td>
<td class="num">(123,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">240<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,533)<span></span>
</td>
<td class="num">$ (123,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in usd per share)</a></td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in usd per share)</a></td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share , basic (in shares)</a></td>
<td class="nump">102,663<span></span>
</td>
<td class="nump">101,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</a></td>
<td class="nump">102,663<span></span>
</td>
<td class="nump">101,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostOfDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostOfDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsOfPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs Of Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsOfPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenueFromDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenueFromDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenueFromPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenueFromPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126336768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,533)<span></span>
</td>
<td class="num">$ (123,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">7,535<span></span>
</td>
<td class="num">(12,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">7,372<span></span>
</td>
<td class="num">(13,550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (126,161)<span></span>
</td>
<td class="num">$ (136,778)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124313984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,767,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 645,005<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,657,593<span></span>
</td>
<td class="num">$ (4,764)<span></span>
</td>
<td class="num">$ (1,007,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Vesting of common stock exercised early</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(13,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(123,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123,228)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,895,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">533,040<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,682,406<span></span>
</td>
<td class="num">(18,314)<span></span>
</td>
<td class="num">(1,131,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,619,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 60,180<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,742,114<span></span>
</td>
<td class="num">(19,522)<span></span>
</td>
<td class="num">(1,662,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">21,049<span></span>
</td>
<td class="nump">21,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">7,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(133,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,533)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,708,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (44,551)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,763,544<span></span>
</td>
<td class="num">$ (12,150)<span></span>
</td>
<td class="num">$ (1,795,946)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127689424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,533)<span></span>
</td>
<td class="num">$ (123,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">10,345<span></span>
</td>
<td class="nump">7,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_NonCashOperatingLeaseCosts', window );">Operating lease costs</a></td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">6,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">2,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">22,266<span></span>
</td>
<td class="nump">24,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (discount) premium on marketable debt securities</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains on marketable equity securities</a></td>
<td class="num">(3,882)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of non-marketable equity securities</a></td>
<td class="nump">5,485<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">13,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">5,125<span></span>
</td>
<td class="num">(5,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, net</a></td>
<td class="num">(3,354)<span></span>
</td>
<td class="nump">21,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets, net</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">13,886<span></span>
</td>
<td class="nump">20,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(7,422)<span></span>
</td>
<td class="num">(3,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(4,145)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(74,441)<span></span>
</td>
<td class="num">(28,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable debt securities</a></td>
<td class="num">(63,252)<span></span>
</td>
<td class="num">(163,742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturity of marketable debt securities</a></td>
<td class="nump">228,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of non-marketable equity securities and other related investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(7,524)<span></span>
</td>
<td class="num">(22,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">157,224<span></span>
</td>
<td class="nump">110,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments made on finance lease obligations</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(993)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">81,766<span></span>
</td>
<td class="nump">81,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;Beginning of period</a></td>
<td class="nump">141,948<span></span>
</td>
<td class="nump">492,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;End of period</a></td>
<td class="nump">223,714<span></span>
</td>
<td class="nump">573,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">1,964<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">8,016<span></span>
</td>
<td class="nump">19,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">223,640<span></span>
</td>
<td class="nump">573,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; included in other assets, net</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 223,714<span></span>
</td>
<td class="nump">$ 573,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accounts Payable, Accrued and Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NonCashOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Operating Lease Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NonCashOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131482656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guardant Health, Inc., or the Company, is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company believes its tests can transform cancer care by unlocking insights that will help patients at all stages of the disease, including at its earliest stages, when it&#8217;s most treatable. For patients with advanced stage cancer, the Company has commercially launched Guardant360 LDT and Guardant360 CDx, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, and breast cancer. The Company has also launched the Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. In addition, the Company has developed Guardant Galaxy suite of advanced analytical technologies to enhance the performance and clinical utility of its portfolio of cancer tests, and to power the next generation of biomarker and drug discovery.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also collaborates with biopharmaceutical companies in clinical studies by providing the above-mentioned tests, as well as the GuardantOMNI blood test for advanced-stage cancer, and the GuardantINFINITY blood test, a next-generation smart liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. Using data collected from its tests, the Company has also developed its GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For early cancer detection, the Company has launched the Shield LDT test to address the needs of individuals eligible for colorectal cancer screening. From a simple blood draw, Shield uses a novel multimodal approach to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors. In December 2022, the Company announced that the ECLIPSE study, an over 20,000 patient registrational study evaluating the performance of its Shield blood test for detecting colorectal cancer in average-risk adults, met co-primary endpoints. In addition, in March 2023, the Company submitted a premarket approval application for its Shield blood test to the FDA in March 2023. </span></div>The Company was incorporated in Delaware in December 2011 and is headquartered in Palo Alto, California.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131584800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts were made to conform with the current period presentation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable debt securities as of March&#160;31, 2023, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended, or the Securities Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of payroll withholding related to the Company's enrollment in a voluntary disability insurance plan. Restricted cash balance was $0.1 million and $0.3 million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, which was included in other assets, net in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investees. One of the investees is concluded to be a variable interest entity, or VIE, but the Company is deemed not to be the primary beneficiary as the Company does not have the power to direct the activities that most significantly impact the VIE&#8217;s economic performance. The Company's non-marketable equity and other related investments totaled $19.6&#160;million and $25.0&#160;million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, and are included in other assets, net on the accompanying condensed consolidated balance sheets. Non-marketable securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. As a result of the evaluation, the Company recorded an impairment of $5.5&#160;million for one of its non-marketable equity security investments for the three months ended March&#160;31, 2023 based on an independent third-party valuation. In addition, pursuant to one of the investments in non-marketable securities purchased by the Company, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. In September 2022, the Company decided not to exercise such rights to purchase the investee and recorded an impairment of $5.3&#160;million based on an independent third-party valuation. No other impairment or downward adjustments to the carrying value of non-marketable securities have been otherwise recorded. In addition, pursuant to another investment in non-marketable securities purchased by the Company in October 2022, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the Company, on or before October 1, 2023.  </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, 2021 and 2022, the Company received the first, second and third installment payments of $1.0&#160;million, $1.1&#160;million and $1.1&#160;million, respectively. The Company has evaluated and recorded a credit loss for the remaining $4.8&#160;million considering the third-party's credit worthiness and lack of financial history. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the receivable and the related credit loss amounts:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allowance for credit losses activities for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against commercial and governmental payers, biopharmaceutical companies, research institutes, international laboratory partners and distributors, including unbilled receivables, and royalty payments due from third parties for licensing the Company&#8217;s technologies. Unbilled receivables include balances due from biopharmaceutical customers related to development services and other revenues that are recognized upon the achievement of performance-based milestones but prior to the achievement of contractual billing rights. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had unbilled receivables of $4.3 million and $5.4 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had an immaterial allowance for credit losses related to its accounts receivable.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs, or IPR&amp;D, acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In connection with the launch of Shield LDT in May 2022, the Company's IPR&amp;D of $1.6&#160;million was reclassified as an intangible asset with a useful life of 2 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill is not amortized but is tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate its value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level. As of&#160;March&#160;31, 2023, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 2&#8212;12 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-acquisition Contingent Consideration </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-acquisition contingent consideration is recognized over the service period, subject to meeting the respective service requirements and performance metrics. For the three months ended March 31, 2023, and 2022, the Company recorded post-acquisition contingent consideration expense of $0.6 million and $2.1 million, respectively, in research and development expenses on the Company's condensed consolidated statement of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use, or ROU, assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible senior notes are accounted for as a liability and measured at their amortized cost. Transaction costs related to the issuance of the notes are netted with the liability and are amortized to interest expense over the term of the notes, using an effective interest rate method.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services, as well as from development services and other. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing the Company's technologies, kit fulfillment and screening services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes, international laboratory partners and distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its test to a clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s testing panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For the companion diagnostic development and regulatory approval services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of these contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other revenue includes amounts derived from licensing the Company's digital sequencing technologies to its domestic customers and international laboratory partners, kit fulfillment and screening services. For the licensed technology, the Company is compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Kit fulfillment related revenues are recognized when such products are delivered. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers and international laboratory partners may include multiple distinct performance obligations, such as provision of precision oncology testing, the above-mentioned development services, and digital sequencing technology licensing, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers and international laboratory partners to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of March&#160;31, 2023 and December&#160;31, 2022, the deferred revenue balance was $17.1 million and $21.2 million, respectively, of which $3.4 million and $3.8 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets. Revenue recognized in the three months ended March 31, 2023 that was included in the deferred revenue balance as of December&#160;31, 2022 was $6.4 million, and revenue recognized in the three months ended March 31, 2022 that was included in the deferred revenue balance as of December&#160;31, 2021 was $3.5 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 1-2 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Precision Oncology Testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing generally consists of cost of materials, cost of labor, including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing test samples (including sample accessioning, library preparation, sequencing, and quality control analyses), freight, curation of test results for physicians, phlebotomy, and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, lease costs, amortization of leasehold improvements, and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers, and costs associated with the Company's partnership agreements and screening services. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan (as amended and restated), or the 2012 Plan, and the 2018 Incentive Award Plan, or the 2018 Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics, or PSUs, is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. No stock-based compensation expense is recorded for PSUs, unless it is determined to be probable that the related performance metrics will be met. Any PSUs that remain unvested at the end of the performance period will be forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891132137152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text">Joint VentureIn May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc., the Joint Venture, for the sale, marketing and distribution of the Company&#8217;s tests generally outside the Americas and Europe, and to accelerate commercialization of its products in Asia, the Middle East and Africa. Under the terms of the joint venture agreement, each party held an approximately 50% ownership interest in the Joint Venture and two seats on the board of the Joint Venture. In June 2022, the Company purchased all of the shares of the Joint Venture, or the Joint Venture Acquisition, held by SoftBank and its affiliates in consideration for a cash payment of the aggregate purchase price of $177.8&#160;million, which resulted in $99.8&#160;million of fair value adjustments to the noncontrolling interest liability. In connection with the Joint Venture Acquisition, the Company also issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options held by the Joint Venture's employees. Prior to the completion of the Joint Venture Acquisition, the Joint Venture was deemed to be a VIE, and the Company had been identified as the VIE&#8217;s primary beneficiary. As the primary beneficiary, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation. Upon completion of the Joint Venture Acquisition and the tender offer, Guardant Health AMEA, Inc. became the Company's wholly owned subsidiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131401280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Condensed Consolidated Balance Sheet Components</a></td>
<td class="text">Condensed Consolidated Balance Sheet Components<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $9.6 million and $6.7 million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214">Operating lease liabilities</span></span></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131615024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements, Cash Equivalents and Marketable Securities</a></td>
<td class="text">Fair Value Measurements, Cash Equivalents and Marketable Securities <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, and accounts payable and accrued liabilities. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, and accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, one of the Company's equity investees completed its IPO, subsequent to which, the Company started to account for the investment at fair value on a recurring basis, and classified the investment within Level 1 of the fair value hierarchy as the investment is valued using the quoted market price. The Company is subject to a 2-year lock-up period from the IPO date, during which the Company shall not transfer the investee's shares between accounts, establish or cancel pledges, sell, or withdraw such shares, without approval from the local securities and exchange commission. As of March&#160;31, 2023 and December&#160;31, 2022, the balance of the investment was $22.2 million and $18.3 million, respectively, included in other assets, net on the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's contingent consideration liability was $6.1 million and $6.4 million, respectively, of which $4.6 million and $4.9 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the Joint Venture Acquisition in June 2022, the fair value of the noncontrolling interest liability was considered to be a Level 3 measurement and was determined based on an annual internal rate of return of 20% on the initial amount of $41.0&#160;million invested by SoftBank in May 2018, to the date of Company's exercising the call right in November 2021. The noncontrolling interest liability was fully paid by June 30, 2022 (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interest Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in fair value </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the Convertible Notes as of March&#160;31, 2023, and December&#160;31, 2022, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to the fair value of the Convertible Notes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash equivalents and marketable debt securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the estimated fair values and gross unrealized losses of the Company's marketable debt securities that have been in a continuous unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,193)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,958)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,821)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>There have been no material realized gains or losses on marketable debt securities for the periods presented. The Company determined that it did have the ability and intent to hold all marketable debt securities that have been in a continuous loss position until maturity or recovery and the loss position was temporary due to market volatility, thus there has been no recognition of credit losses in the three months ended March&#160;31, 2023, and 2022, respectively. The Company recorded $3.9 million unrealized gains on marketable equity securities for the three months ended March 31, 2023, included in other income (expense), net on the Company's condensed consolidated statement of operations. The Company did not record any unrealized gains or losses on marketable equity securities for the three months ended March 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131511456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net and Goodwill</a></td>
<td class="text">Intangible Assets, Net and Goodwill<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets was $0.7 million and $0.5 million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets, net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131564032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company issued $1.15&#160;billion principal amount of its 0% Convertible Senior Notes due 2027, or the 2027 Notes. The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter, or the sale price condition;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the five consecutive business days immediately after any ten consecutive trading day period, or the measurement period, if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon the occurrence of specified corporate events</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#8217;s election. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $139.82 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#8220;Make-Whole Fundamental Change&#8221; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&#8217;s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain corporate events that constitute a &#8220;Fundamental Change&#8221; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#8217;s common stock.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the 2027 Notes were not convertible as of March&#160;31, 2023 and December&#160;31, 2022, the net carrying amount of the 2027 Notes was classified as a long-term liability.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net carrying amounts of the 2027 Notes as of March&#160;31, 2023, and December&#160;31, 2022: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of the 2027 Notes was $0.8 billion and $0.7 billion as of March&#160;31, 2023, and December&#160;31, 2022, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, which represented an effective interest rate of 0.2% and 0.2% for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Hedges</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions, or the 2027 Note Hedges, with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $182.60 per share, which represents a premium of 75% over the last reported sale price of the Company&#8217;s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#8217; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0&#160;million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131455776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements for office space, data center, lab and warehouse use, with remaining terms ranging from 1 year to 11 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense was $7.3 million and $6.9 million for the three months ended March 31, 2023, and 2022, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). </span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:71.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March&#160;31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131345184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Disputes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, TwinStrand Biosciences, Inc., or TwinStrand Biosciences, and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#8217; allegations and asserted counterclaims of invalidity, unenforceability due to inequitable conduct and infringement of four of the Company&#8217;s patents. Discovery in the case is ongoing and trial is scheduled to commence in November 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Illumina Inc., or Illumina, filed suit in the United States District Court for the District of Delaware against the Company and its Co-Chief Executive Officers, Drs. Helmy Eltoukhy and AmirAli Talasaz, or collectively, the Defendants, alleging that Illumina is the owner of certain of the Company&#8217;s patents and patent applications, and that the Defendants allegedly misappropriated Illumina trade secrets. Illumina also alleges that Drs. Eltoukhy and Talasaz breached various Illumina employment contracts, company policies, and implied covenants of good faith and fair dealing as part of their former employment with Illumina prior to starting the Company. Illumina is requesting unspecified compensatory and punitive damages, attorneys&#8217; fees, and specific performance in the form of a declaration of ownership and assignment of intellectual property filed for or obtained by the Defendants that derives from the alleged misuse of Illumina confidential information. The Defendants deny the allegations of misconduct, and in March 2023, the District Court granted in part the Defendants&#8217; motion to dismiss the complaint, without prejudice to amend, effectively staying discovery on the dismissed allegations.  In April 2023, Illumina filed an amended complaint to which Defendants will respond by June 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Advertising Dispute</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company also filed a lawsuit against Natera, Inc., or Natera, in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#8217;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#8217;s Signatera assay. The Company is seeking an injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. The Company moved to dismiss Natera&#8217;s counterclaims, and in January 2022, the court granted in part and denied in part the Company's motion to dismiss. The Company and Natera have both moved for summary judgment on various claims, with the court granting in part non-dispositive motions brought by each party. Trial is scheduled to commence in July 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Investigative Demand</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company received a Civil Investigative Demand, or CID, from the United States Attorney for the Northern District of California in connection with an investigation under the False Claims Act. The CID requests information and documents regarding billing of government-funded programs for the Company&#8217;s panel of genetic tests known as Guardant360. The Company is fully cooperating with the investigation. At this time, the Company is unable to predict the outcome of this investigation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131564032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common StockThe Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors, or the Board of Directors. As of March&#160;31, 2023, and December&#160;31, 2022, no dividends on the Company's common stock had been declared by the Board of Directors.<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372,561</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402,574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430,821</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687,888</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,713</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333,892</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438,296</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144,505</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,311</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875,818</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,249,546</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131335776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438,296</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402,574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,091)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,091</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,049)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,055</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,055)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,717)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,911</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333,892</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372,561</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2023, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $0.4 million and $7.3 million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $19.82 and $36.32 per share for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested options as of March&#160;31, 2023 was $39.7 million, which is expected to be recognized over a weighted-average period of 2.9 years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,873)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,911)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested restricted stock units as of March&#160;31, 2023 was $161.5 million, which is expected to be recognized over a weighted-average period of 2.8 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant PSUs, under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of 1.5 years to 4 years and an additional service period requirement of six months to one year after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of 4 years. The PSUs are expected to be expensed over a period of approximately 2.5 years to 4.5 years subject to meeting the respective performance metrics and service requirements. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, and as part of these PSU programs, the Company granted restricted stock units with certain performance metrics consisting of a performance period of 4 years combined with an additional service period requirement of six months should the vesting criteria be met. As of March&#160;31, 2023, these PSUs had a grant-date fair value of approximately $28.0&#160;million, net of forfeitures, however no compensation expense for these PSUs has been recorded to-date since the achievement of the performance metrics was not determined to be probable as of that point time. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,713</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,438)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation recorded for the PSUs was $0.3 million and $0.3 million for the three months ended March 31, 2023, and 2022, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of March&#160;31, 2023 was $2.6 million, which is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units, or MSUs, under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYxNw_60b18dda-66c2-4999-b9be-3ed7aa5e2977">six</span> to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration. The following table presents additional information relating to each MSU award:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche was recognized based on an accelerated attribution method over the estimated derived service period. The derived service period was the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model used assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU. The weighted-average grant date fair value of the MSUs was $67.00 per share and the weighted-average derived service period was estimated to be in the range of 0.83 &#8211; 2.07 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2021, Tranche 1 of the MSUs became vested because it had met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of 30 consecutive calendar days. As of March&#160;31, 2023 and December&#160;31, 2022, 2,260,764 shares of market-based restricted stock units, with a weighted-average grant date fair value of $65.20 per share, were outstanding under the 2018 Plan. No MSUs were granted, vested or canceled during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All three tranches of the MSUs were fully expensed as of June 30, 2022. Stock-based compensation for the MSUs was $8.5 million for the three months ended March&#160;31, 2022, which was recorded in general and administrative expenses on the Company's condensed consolidated statement of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMEA 2020 Equity Incentive Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan, or the AMEA 2020 Plan, under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, in connection with the Joint Venture Acquisition, the Company issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options, at a price of $4.44 per share determined pursuant to an independent valuation. In July 2022, the Company settled the tender offer with the 39 grantees for a total amount of $13.7&#160;million. In addition, in connection with the Joint Venture Acquisition, the unvested Joint Venture's stock options were cancelled and such grantees received replacement awards covering a number of shares of the Company's common stock. The replacement awards, valued at $4.1&#160;million, are subject to the same vesting schedule that applied to the unvested Joint Venture's stock option immediately prior to the close of the Joint Venture Acquisition transaction, to be recognized over a weighted-average period of 2.2 years. The Company accounted for this as a modification which resulted in an immaterial incremental stock-based compensation expense. After the settlement of the tender offer in July 2022, the Company cancelled the AMEA 2020 Plan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of development services and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,266&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1% &#8211; 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan, or the ESPP. A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020 and March 2, 2023, an additional 942,614&#160;and 1,026,194 shares of common stock became available for issuance under the ESPP.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No ESPP shares were granted or purchased for the three months ended March 31, 2023, and 2022. The total compensation expense related to the ESPP was $1.6 million&#160;and $1.0 million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to the ESPP was $0.8 million, which is expected to be recognized over the remaining term of the offering period of 0.1 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131408576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:64.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,961</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Excludes stock options of 2,995,200 shares of the Joint Venture's Class B common stock granted under the AMEA 2020 Plan as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131615024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three months ended March&#160;31, 2023 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three months ended March&#160;31, 2023, and 2022, relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131390688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three months ended March&#160;31, 2023,&#160;and&#160;2022, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, and December&#160;31, 2022, 98% and 99%, respectively, of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131564032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. Prior to the completion of the Joint Venture Acquisition in June 2022, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124492016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts were made to conform with the current period presentation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable debt securities as of March&#160;31, 2023, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. </span></div>The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended, or the Securities Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash consists of payroll withholding related to the Company's enrollment in a voluntary disability insurance plan.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_NonMarketableSecuritiesPolicyTextBlock', window );">Non-Marketable Securities</a></td>
<td class="text">Non-Marketable SecuritiesThe Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investees. One of the investees is concluded to be a variable interest entity, or VIE, but the Company is deemed not to be the primary beneficiary as the Company does not have the power to direct the activities that most significantly impact the VIE&#8217;s economic performance. The Company's non-marketable equity and other related investments totaled $19.6&#160;million and $25.0&#160;million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, and are included in other assets, net on the accompanying condensed consolidated balance sheets. Non-marketable securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. As a result of the evaluation, the Company recorded an impairment of $5.5&#160;million for one of its non-marketable equity security investments for the three months ended March&#160;31, 2023 based on an independent third-party valuation. In addition, pursuant to one of the investments in non-marketable securities purchased by the Company, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. In September 2022, the Company decided not to exercise such rights to purchase the investee and recorded an impairment of $5.3&#160;million based on an independent third-party valuation. No other impairment or downward adjustments to the carrying value of non-marketable securities have been otherwise recorded. In addition, pursuant to another investment in non-marketable securities purchased by the Company in October 2022, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the Company, on or before October 1, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div>The Company is also subject to credit risk from its other receivables and other assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against commercial and governmental payers, biopharmaceutical companies, research institutes, international laboratory partners and distributors, including unbilled receivables, and royalty payments due from third parties for licensing the Company&#8217;s technologies. Unbilled receivables include balances due from biopharmaceutical customers related to development services and other revenues that are recognized upon the achievement of performance-based milestones but prior to the achievement of contractual billing rights. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had unbilled receivables of $4.3 million and $5.4 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had an immaterial allowance for credit losses related to its accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_AssetAcquisitionPolicyTextBlock', window );">Asset Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs, or IPR&amp;D, acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In connection with the launch of Shield LDT in May 2022, the Company's IPR&amp;D of $1.6&#160;million was reclassified as an intangible asset with a useful life of 2 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill is not amortized but is tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate its value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level. As of&#160;March&#160;31, 2023, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 2&#8212;12 years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_PostAcquisitionCompensationPolicyPolicyTextBlock', window );">Post-acquisition Contingent Consideration</a></td>
<td class="text">Post-acquisition Contingent Consideration Post-acquisition contingent consideration is recognized over the service period, subject to meeting the respective service requirements and performance metrics.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use, or ROU, assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible senior notes are accounted for as a liability and measured at their amortized cost. Transaction costs related to the issuance of the notes are netted with the liability and are amortized to interest expense over the term of the notes, using an effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services, as well as from development services and other. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing the Company's technologies, kit fulfillment and screening services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes, international laboratory partners and distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its test to a clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s testing panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For the companion diagnostic development and regulatory approval services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of these contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other revenue includes amounts derived from licensing the Company's digital sequencing technologies to its domestic customers and international laboratory partners, kit fulfillment and screening services. For the licensed technology, the Company is compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Kit fulfillment related revenues are recognized when such products are delivered. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers and international laboratory partners may include multiple distinct performance obligations, such as provision of precision oncology testing, the above-mentioned development services, and digital sequencing technology licensing, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers and international laboratory partners to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of March&#160;31, 2023 and December&#160;31, 2022, the deferred revenue balance was $17.1 million and $21.2 million, respectively, of which $3.4 million and $3.8 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets. Revenue recognized in the three months ended March 31, 2023 that was included in the deferred revenue balance as of December&#160;31, 2022 was $6.4 million, and revenue recognized in the three months ended March 31, 2022 that was included in the deferred revenue balance as of December&#160;31, 2021 was $3.5 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 1-2 years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock', window );">Costs of Precision Oncology Testing</a></td>
<td class="text">Costs of Precision Oncology TestingCost of precision oncology testing generally consists of cost of materials, cost of labor, including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing test samples (including sample accessioning, library preparation, sequencing, and quality control analyses), freight, curation of test results for physicians, phlebotomy, and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, lease costs, amortization of leasehold improvements, and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_CostOfDevelopmentServicesPolicyTextBlock', window );">Cost of Development Services and Other</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers, and costs associated with the Company's partnership agreements and screening services. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan (as amended and restated), or the 2012 Plan, and the 2018 Incentive Award Plan, or the 2018 Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics, or PSUs, is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. No stock-based compensation expense is recorded for PSUs, unless it is determined to be probable that the related performance metrics will be met. Any PSUs that remain unvested at the end of the performance period will be forfeited.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, and accounts payable and accrued liabilities. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, and accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostOfDevelopmentServicesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostOfDevelopmentServicesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsOfPrecisionOncologyTestingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsOfPrecisionOncologyTestingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NonMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Marketable Securities Policy Text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NonMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PostAcquisitionCompensationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-Acquisition Compensation, Policy Text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PostAcquisitionCompensationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Condensed Financial Statements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131327648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock', window );">Schedule of Contractual Receivables and Related Credit Loss</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the receivable and the related credit loss amounts:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Gross Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for Credit Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allowance for credit losses activities for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;Beginning of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Reclassification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Allowance for credit losses&#8212;End of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891132130112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214">Operating lease liabilities</span></span></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126420976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable debt securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Level 3 Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interest Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in fair value </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities'</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash equivalents and marketable debt securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the estimated fair values and gross unrealized losses of the Company's marketable debt securities that have been in a continuous unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,193)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,958)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,821)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,779)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126280432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets, net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131355376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instrument Components</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net carrying amounts of the 2027 Notes as of March&#160;31, 2023, and December&#160;31, 2022: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131305312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:71.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March&#160;31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131615024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372,561</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402,574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430,821</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687,888</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,713</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333,892</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438,296</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144,505</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,311</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875,818</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,249,546</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124518352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438,296</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402,574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,091)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,091</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,049)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,055</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,055)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,717)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,911</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,333,892</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372,561</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2023, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,873)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,911)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,713</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,438)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of Performance-based Restricted Stock Units Vesting Conditions</a></td>
<td class="text">The following table presents additional information relating to each MSU award:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of development services and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,266&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1% &#8211; 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891128120640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:64.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:<div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,961</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Excludes stock options of 2,995,200 shares of the Joint Venture's Class B common stock granted under the AMEA 2020 Plan as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131395168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three months ended March&#160;31, 2023,&#160;and&#160;2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131366464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_NumberOfPatients', window );">Number of patients</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126827008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Non-marketable equity and other investments</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_EquitySecurityFVNIImpairmentOfPurchaseRights', window );">Impairment of non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue', window );">Impairment or adjustments of non-marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLoss', window );">Other receivables and other assets due from a third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesTerm', window );">Other receivables and other assets, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ProceedsFromContractualReceivable', window );">Contractual receivables, installment payment</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent', window );">Contractual receivables, credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">11,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_PostAcquisitionContingentConsiderationExpense', window );">Post-acquisition contingent consideration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue long term</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration', window );">Remaining performance obligation, expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration', window );">Remaining performance obligation, expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquitySecurityFVNIImpairmentOfPurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Impairment Of Purchase Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquitySecurityFVNIImpairmentOfPurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PostAcquisitionContingentConsiderationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-Acquisition Contingent Consideration Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PostAcquisitionContingentConsiderationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ProceedsFromContractualReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contractual Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ProceedsFromContractualReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891125650544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerCMember', window );">Customer C | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerDMember', window );">Customer D | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127893552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent', window );">Financing receivable, gross amount, current</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent', window );">Financing receivable, allowance for credit losses, current</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent', window );">Financing receivable, net amount, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent', window );">Financing receivable, net amount, noncurrent</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent', window );">Financing receivable, allowance for credit losses, noncurrent</a></td>
<td class="num">(3,700)<span></span>
</td>
<td class="num">(4,800)<span></span>
</td>
<td class="num">(4,800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent', window );">Financing receivable, net amount, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward', window );"><strong>Financing Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent', window );">Beginning balance, financing receivable, allowance for credit loss, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossReclassificationCurrent', window );">Reclassification, allowance for credit loss, current</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent', window );">Ending balance, financing receivable, allowance for credit loss, current</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent', window );">Beginning balance, financing receivable, allowance for credit loss, noncurrent</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossReclassificationNoncurrent', window );">Reclassification, allowance for credit loss, noncurrent</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent', window );">Ending balance, financing receivable, allowance for credit loss, noncurrent</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, After Allowance For Credit Loss Net, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossReclassificationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Reclassification, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossReclassificationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossReclassificationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Reclassification, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossReclassificationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124653408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>seat</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,875,818<span></span>
</td>
<td class="nump">16,249,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring | Noncontrolling Interest Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement</a></td>
<td class="nump">$ 177,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Increase in fair value</a></td>
<td class="nump">$ 99,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard', window );">Number of seats | seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Number Of Seats Each Party Holds On The Board</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_NoncontrollingInterestLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_NoncontrollingInterestLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126401840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 260,981<span></span>
</td>
<td class="nump">$ 256,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(97,752)<span></span>
</td>
<td class="num">(88,131)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">163,229<span></span>
</td>
<td class="nump">167,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">100,688<span></span>
</td>
<td class="nump">95,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">99,951<span></span>
</td>
<td class="nump">99,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">31,442<span></span>
</td>
<td class="nump">29,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,560<span></span>
</td>
<td class="nump">20,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,543<span></span>
</td>
<td class="nump">8,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,797<span></span>
</td>
<td class="nump">$ 1,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126504416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126418048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 67,320<span></span>
</td>
<td class="nump">$ 68,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation</a></td>
<td class="nump">69,423<span></span>
</td>
<td class="nump">55,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 23,619<span></span>
</td>
<td class="nump">$ 21,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
<td class="text">Accounts payable and accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">$ 30,172<span></span>
</td>
<td class="nump">$ 29,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 190,534<span></span>
</td>
<td class="nump">$ 175,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126916992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 129,087<span></span>
</td>
<td class="nump">$ 18,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">713,380<span></span>
</td>
<td class="nump">869,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">22,174<span></span>
</td>
<td class="nump">18,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">864,641<span></span>
</td>
<td class="nump">905,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">54,389<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">22,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">76,563<span></span>
</td>
<td class="nump">21,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">74,698<span></span>
</td>
<td class="nump">14,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">713,380<span></span>
</td>
<td class="nump">869,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">788,078<span></span>
</td>
<td class="nump">884,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">713,380<span></span>
</td>
<td class="nump">869,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">713,380<span></span>
</td>
<td class="nump">869,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">54,389<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">54,389<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">74,698<span></span>
</td>
<td class="nump">14,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">74,698<span></span>
</td>
<td class="nump">14,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127218720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gain (loss) on marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease', window );">Recognition of credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (loss) gain on marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=gh_SoftBankMember', window );">SoftBank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_EquityInvesteeWithIPOMember', window );">Equity Investee With IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_SaleOfStockLockUpPeriod', window );">Lock up period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | SoftBank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue', window );">Redeemable noncontrolling interest, redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Measurements, Recurring | Equity Investee With IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SaleOfStockLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Lock Up Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SaleOfStockLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value That Is No Less Than Internal Rate of Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 24(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_EquityInvesteeWithIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_EquityInvesteeWithIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126502448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details) - Fair Value, Measurements, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_NoncontrollingInterestLiabilityMember', window );">Noncontrolling Interest Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Increase in fair value</a></td>
<td class="nump">$ 99,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Increase in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">2,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,130<span></span>
</td>
<td class="nump">$ 6,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_NoncontrollingInterestLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_NoncontrollingInterestLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891130005504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortization cost, cash and cash equivalents</a></td>
<td class="nump">$ 223,640<span></span>
</td>
<td class="nump">$ 141,647<span></span>
</td>
<td class="nump">$ 573,604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost', window );">Amortized cost, cash and cash equivalents and debt securities available-for-sale</a></td>
<td class="nump">851,703<span></span>
</td>
<td class="nump">904,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(9,257)<span></span>
</td>
<td class="num">(16,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_CashCashEquivalentsAndDebtSecuritiesFairValue', window );">Cash, cash equivalents and debt securities, fair value</a></td>
<td class="nump">842,467<span></span>
</td>
<td class="nump">887,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortization cost, cash and cash equivalents</a></td>
<td class="nump">54,389<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value, cash and cash equivalents</a></td>
<td class="nump">54,389<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="nump">797,314<span></span>
</td>
<td class="nump">901,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(9,257)<span></span>
</td>
<td class="num">(16,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value, debt securities</a></td>
<td class="nump">$ 788,078<span></span>
</td>
<td class="nump">$ 884,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CashCashEquivalentsAndDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Debt Securities, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CashCashEquivalentsAndDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, And Cash And Cash Equivalents Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891128048608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 99,537<span></span>
</td>
<td class="nump">$ 170,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater</a></td>
<td class="nump">590,849<span></span>
</td>
<td class="nump">685,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">690,386<span></span>
</td>
<td class="nump">856,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(2,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater</a></td>
<td class="num">(9,193)<span></span>
</td>
<td class="num">(13,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(9,257)<span></span>
</td>
<td class="num">(16,779)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">99,537<span></span>
</td>
<td class="nump">170,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater</a></td>
<td class="nump">590,849<span></span>
</td>
<td class="nump">685,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">690,386<span></span>
</td>
<td class="nump">856,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(2,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater</a></td>
<td class="num">(9,193)<span></span>
</td>
<td class="num">(13,821)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (9,257)<span></span>
</td>
<td class="num">$ (16,779)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124323872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 18,586<span></span>
</td>
<td class="nump">$ 18,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(7,539)<span></span>
</td>
<td class="num">(6,859)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">11,047<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_IntangibleAssetsGrossIncludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">21,876<span></span>
</td>
<td class="nump">21,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">14,337<span></span>
</td>
<td class="nump">15,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">11,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(3,852)<span></span>
</td>
<td class="num">(3,579)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 8,034<span></span>
</td>
<td class="nump">$ 8,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted-Average Useful Life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements and other covenant rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(2,954)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 2,146<span></span>
</td>
<td class="nump">$ 2,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted-Average Useful Life</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(733)<span></span>
</td>
<td class="num">(533)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 867<span></span>
</td>
<td class="nump">$ 1,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted-Average Useful Life</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127591760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891130738544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 2,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 11,047<span></span>
</td>
<td class="nump">$ 11,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Amortization Expense After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127138128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644,000<span></span>
</td>
<td class="nump">$ 642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ConvertibleDebtHedgeStrikePrice', window );">Strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ConvertibleDebtHedgeSharePricePremiumPercentage', window );">Share price, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges', window );">Purchase of convertible senior note hedges | $</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="nump">1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage', window );">Maximum special interest rate percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.0071523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 139.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Valuation, Market Approach | Measurement Input, Quoted Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_DebtInstrumentMeasurementInputDenominator', window );">Debt, measurement input denominator | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days | d</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Conversion Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConvertibleDebtHedgeSharePricePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Hedge, Share Price, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConvertibleDebtHedgeSharePricePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConvertibleDebtHedgeStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Hedge, Strike Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConvertibleDebtHedgeStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentMeasurementInputDenominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Measurement Input Denominator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentMeasurementInputDenominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputQuotedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputQuotedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127880896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Convertible Senior Notes (Details) - Convertible Debt - Senior Notes Due 2027 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: debt issuance costs, net of amortization</a></td>
<td class="num">(11,966)<span></span>
</td>
<td class="num">(12,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 1,138,034<span></span>
</td>
<td class="nump">$ 1,137,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891130778432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891131349328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127192944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Liability Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 23,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">33,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">32,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">27,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">24,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">125,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">267,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(38,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 228,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124520336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2021 </div>
<div>patent</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember', window );">TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, patents allegedly infringed upon, number</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891124328576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">20,875,818<span></span>
</td>
<td class="nump">16,249,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares underlying outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,372,561<span></span>
</td>
<td class="nump">3,402,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,430,821<span></span>
</td>
<td class="nump">3,687,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,260,764<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">333,275<span></span>
</td>
<td class="nump">341,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember', window );">Shares available for issuance under the 2018 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,333,892<span></span>
</td>
<td class="nump">5,438,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,144,505<span></span>
</td>
<td class="nump">1,118,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127059472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,438,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable', window );">2018 Plan annual increase (in shares)</a></td>
<td class="nump">3,689,000<span></span>
</td>
<td class="nump">3,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,333,892<span></span>
</td>
<td class="nump">5,438,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,372,561<span></span>
</td>
<td class="nump">3,402,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.08<span></span>
</td>
<td class="nump">$ 34.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,766<span></span>
</td>
<td class="nump">$ 39,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable', window );">2018 plan annual increase (in shares)</a></td>
<td class="nump">3,689,000<span></span>
</td>
<td class="nump">3,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Available For Grant, Forfeitures In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Annual Increase In Shares Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891049363216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>grantee</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, grants in period (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.82<span></span>
</td>
<td class="nump">$ 36.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized, options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,266<span></span>
</td>
<td class="nump">$ 24,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,875,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,249,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized, options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Issuance of exercise of vested stock option granted | grantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Settled of tender, amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,372,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,687,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,687,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod', window );">Additional service period requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod', window );">Additional service period requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod', window );">Market-based restricted stock share price goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Tranche 1 - $120 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal', window );">Price goal (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Total market-based restricted stock units approved and granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (as a percent of the fair value of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,144,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">1,026,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate, ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan | 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares approved (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891129190272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">3,687,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">176,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(67,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(365,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">3,430,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 60.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share) | $ / shares</a></td>
<td class="nump">30.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in usd per share) | $ / shares</a></td>
<td class="nump">67.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">57.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 59.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">341,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(8,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">333,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 110.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">122.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 110.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891129242768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Market-based Restricted Stock Units (Details) - MSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 1 - $120 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal', window );">Price goal (in dollars per share)</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 2 - $150 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal', window );">Price goal (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 3 - $200 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal', window );">Price goal (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891125657024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22,266<span></span>
</td>
<td class="nump">$ 24,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember', window );">Cost of precision oncology testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gh_CostOfDevelopmentServicesAndOtherMember', window );">Cost of development services and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,678<span></span>
</td>
<td class="nump">5,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,409<span></span>
</td>
<td class="nump">$ 12,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gh_CostOfDevelopmentServicesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gh_CostOfDevelopmentServicesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891132480192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation of Stock Options (Details) - Stock options issued and outstanding<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.50%<span></span>
</td>
<td class="nump">63.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891127095136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss, basic</a></td>
<td class="num">$ (133,533)<span></span>
</td>
<td class="num">$ (123,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss, diluted</a></td>
<td class="num">$ (133,533)<span></span>
</td>
<td class="num">$ (123,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share , basic (in usd per share)</a></td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share , diluted (in usd per share)</a></td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share , basic (in shares)</a></td>
<td class="nump">102,663<span></span>
</td>
<td class="nump">101,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share , diluted (in shares)</a></td>
<td class="nump">102,663<span></span>
</td>
<td class="nump">101,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891126808736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">18,015,000<span></span>
</td>
<td class="nump">14,961,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">3,372,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember', window );">AMEA 2020 Plan | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,995,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,378,000<span></span>
</td>
<td class="nump">2,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,550,000<span></span>
</td>
<td class="nump">1,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">MSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,261,000<span></span>
</td>
<td class="nump">2,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">337,000<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,225,000<span></span>
</td>
<td class="nump">8,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139891049352592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 128,714<span></span>
</td>
<td class="nump">$ 96,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets | Geographic Concentration Risk | Net Assets, Geographic Area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 118,911<span></span>
</td>
<td class="nump">90,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 9,803<span></span>
</td>
<td class="nump">$ 5,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>gh-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:gh="http://guardanthealth.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gh-20230331.xsd" xlink:type="simple"/>
    <context id="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic63eda5373a64e0b98a90b18ccae37eb_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6506cad5ab63497db74f92ba4f91d108_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id314243f2ead4456aa30110c9be601cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9b4fdb150214c56afcbdbb322033b7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i061c59efe2d945519dfb0e5134ddbbfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08422884f60b4434b3801e044a34720c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i65627937720c45f5af483254a1fe5f4b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia281fcd22cc54accbefe8d9b460bd5cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae9eaada43ef4cfd925883681dcbc4c2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i234915b13fca42879cd971070e15ee06_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia2f8f14dc64d49c6be419158cec74a14_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie23b9007cc9d4791bd36771afacf5634_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c902d77713c48f9b6c55bb637b64351_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i004e4666a5184be996fa4c7ddf054bc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b965e37113409d8d7d5afef90e67b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18bad5d6e63649409643e7d759322b03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i837fd30e88e14cca94ef2ffcde2af73e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6340409bc504436ca385dbfa0f3ec40c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61824cd12b914964a5a603b514d2a3de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i49ecdc52faa648b9851cd7fd4d341e4d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idaeefd32a5fc49089e432e6ef771b042_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i10781cf49c274a30b77473e1ab3caaa8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2401cae2c40e42969858a2d39f106f28_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd26156a544941a48ee279e2b62c8c3f_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id35cadfe3a234269bcb1f5e099b19840_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70f9229bf0864d9e814f7520f6d69d7d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6f93c12cead4d2c895bca577a25be67_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5cfb22333f754690bd602bfaec6d0504_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3f4f6ec0d8c49d09f2cbdc348b5a7c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i966b9062789c40178998266340270e67_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5fb596e53d6d4e77aa67b76c30c717a5_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i251adc25d68b484abdc116bdcad141c8_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iaa6502eac62f4edfbd8f440e52695d9f_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28ecc6c83a29450f8f6715df23f4d2d3_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id85a3adbc9da44018010d9f2fcd08a6c_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ieb5caeb66ee94198aa9cd342c3f706e3_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i6691016ad5b34d59883ed1923b33bed4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i604eb9f9835e4c13814c14e8654cb3e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39a86681777f4f5a97cdce262db9a555_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7810d83be2d148339c6e185649dcccc3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17dac8c118b84995ab3b80232dab1573_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ia536ff2c58f1448390655c51b679d617_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia40dd21d206c406fb998d0a9b6cd895f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecd08dde4eb843418c0ae87833fedcdf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibbcb14cec5f44c8289340eb8d4348692_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id1670651f92b400b9f911d06867002b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic021058209134f95a1e8e10b009c7ace_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i246a5d493f5c473b88cd065c03268005_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a29ac54766d4a0f8b2b24b51cdb55b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60b5561c4b114d22bafce063538c856e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d186d3354934b5a8f8bbe42c4c14495_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6bdcfada3cd4a2cbbe095e2aa5e702a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ca178fdb5534ed4b35053a5ba325f0d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae2f9a0766ce44c6af97879837c1db9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d5c289384e245aa892095bbc5f2ab2b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i73f279ce6f9246c4848f2a4e3e17128a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iacc566dc53fa4e07bf56f8a8aabdb279_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3168dac582d49e69c1516251fd3e0dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i42e3cdcf1bbe4a9b81b4b8bdc2e6ab64_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3214563d103944fcad24fe9145d19d95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f02aa3d8ed8418682e04a58b2a857df_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92a924e51c984ac7b0fbc1fd9ad60d4d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieb852a9ed67d4316a04d75194f6818e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b835cd88e044426b718c40c4b445c18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1a5558266daa4fd5803cd22934821259_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9af15fbc37d84fa1955e0848cbda5aaa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52d01132e1c54427979eb175a61dff09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1963c0481247479c9f779e03f6b467ab_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i698a971f2120433494d66c1f389aa846_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i645a895f548a4ff28015517f297d96a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20c5fb94fc744d39b9304cf6183f81e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie641c330319e42cb920c03007560f205_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecfd089f28904d93b229f01b003d873a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d21756670fa4cdd8e4365d35747d8c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58665cb260e34ed2974fba4c7d288b91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia63bc9236559423696b0059bb44368a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6cc878b77cc41ffae86c8b04609a610_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4a34db6e72349e9af6fc43f300a4276_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b6d2513d70d4e718e77e46a90e3914f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2ed47738cd74c8e8c229d9ce44342ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c04821a302247519fa063baf7a9e04a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4c4a003031e4fc18e276dd67fb04ae3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i293edf8bd4704d8884ce7ede54eb1f69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b77f5413426453b85bf391a9398dbb7_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i967d903179d741649abf3b3123b84ae7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:EquityInvesteeWithIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6d8629622e1d44fb9a12b229ec47a1f7_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ib473620977be4b178565e23e78583e12_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ied9f5b8c565a4dca904ac822c40abf74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7491d2ac94a0486e8c65beb38d59a2ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32cd2d2a717f448ca58407271970c8e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3f16d72a05843cbbd0a5e1691d4c754_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb285d391a2d4b938bbb5a745115ea97_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i379830d644434dba8ff6a21e1c68f858_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icebfefb0eb874a23853e2e48b2069dc0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:NoncontrollingInterestLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf1e2b5f8f4a47bca104f021c60c4860_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d73083e0eca473a97a807ca5c0d2592_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i926f66c4f4dc49b7a001e9143083c137_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5bc2aa61097449da810dfe20cd6df079_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i482b6cd7778c438ba3a971ad9a5511c0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea8dad0b65c142c5b15551bf9029a808_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i63d00e5d8314401f9793acf9cd87f30d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3add32afcf0e47928bccc0d9a1e4ab89_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i47c2c3e9fc144decaddb722e0a2f7ce2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98ffab5486f140f2bc284e765264afc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d450e08fff545ebb9a7c77e00ca86e1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1ad0ce630064286a222741120078585_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ef1b08124ca422d8c5fde0b52484dbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac2ed04947454c96b49ed77c531cc5bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20def10aa5d14802a5363d3f0e99bcb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32ad1fbc3dfd4b90ba560b118b576125_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ic4afdaf1a32649acbb00d349e86393cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1e7530b179b2482daf26e93a3433f2d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie06cffa6cd1640db8649a5e4f20e89f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputQuotedPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iafd5c38886184fd6af5573e63dd61acd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c8b26b7ee69436e81522ee5db3fb810_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6a0869ad8ec4e6aa0ab8611139bf5b8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i73765d8c5b9c47e49e769314e9a95216_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="ifa6e61cb42a24541ada6ecb600b9aafe_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i4a3c1288310f43a4abefc9f3326e5f24_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1e94bdae869e4b2a9849b1c8d02651a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6cdfb5a23124fe8acf8a056dc1ce503_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c7c95d575374df5873ad5d340d429dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i471e1119a5c84de99cc7a66a9091e4b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24e6708f9c264d729a87143b05a29523_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5419e29cd3674106abc793e0ae7a5a7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b6c755d9322493ea937d75411cca741_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b801579905e486f9d16da0424368dea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67005148159d4de98f4625a633c07616_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b3f42809445495ba7ea570bf865bb5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12acc1844c7547209359a2ebd3bbac18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2888bc5ff0cd47c1b681eb96ef6bc6c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8b85720538549e793c0ea411f6d2926_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4744fe70bd24460bded39c69c9e72eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i09bde5cb1e9146c78e36910bd9edc42c_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i167512a61ade446cb826830cb9b48a43_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="id371f8b5f52a447a988f5108d595d824_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="if79268d66ccd4c498d88b492e67d4b78_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90f4b6d3e1a44b50bca2cfe317198cd9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="iad577482d6c44d62a1d8638eab07b300_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="if0ae71f8bf884fe38ffe82c44c115460_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i31a0dc3163854d6cb56d919865f28f0f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8355f22e8d444065acdca383af614973_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie817ff3c12124b78a03fdb6de0e8038d_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="iab8405ea1a894bd49c95fae94c570714_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9210d17c359d4a029aa0d629f68b0d32_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia06f00d018a84185bf63dbd26b8fcf13_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i5f314cba04f147aaa5a0130ab210f819_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i32e84c2df8114b2ca174af7f12413df9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i22845a3df5054db690d00e20e26e9de7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2aa36b882d6a4a99b4d65b78a2f7f31f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:CostOfDevelopmentServicesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2eb41fcfde104edeb7f180200c669ff1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:CostOfDevelopmentServicesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i257ec7f3adfd447980af46db25d249da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i525b368da8b94090b710ab4a0286430d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1e6b4f53ad9427188ba1f105f093cba_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0babdde2fcb4400f8a4240d151c2273f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5f08d30f39d4fd18d425c922f9e450a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5740f52d90ea487290d3e3b20b00fe62_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic749eee03b16467aa70909df615b2c86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf899f29153c4ae48025cc44a9774ca0_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ie2e087e17e0e420b8c053b525bbb7093_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i8d35aee771524865b1b3cd4a8ec1d0ac_D20230302-20230302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib07e4ec43ccf4868a95b7cba38569e07_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8405bc3396f043d38ac107f7e621ea0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia1dfcb8b82cc435bafa0737693ff7b95_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96a7782cf20244b492722ced02d556d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i018eca720b2b4bee988fdb517bb09d46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i784a2015beb447b480ff240ec2998829_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i90b84667fc3047d39ba495dfdb6af2a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0c434d2375a64859af229e0a8a1a79c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f00602410084027a24ca5b4c50e87c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i436487de8e484b5891dc7aaa105cc2dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92d27c009cdc4d3c997e7de9fc339551_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c5f7a63f9954f08adb2cdcc6eafb151_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d27e6a526f14a71b27f8d0b9f9a0f23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9213a2532134ae5b9a645905cc1fbad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if3794fca71da4bfdaa6a037250b08ea1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4a0c4f0823b457fb2f4cda5edce7d8f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9e06c37d3dbd437d892d43f95983c3c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25302361b67443c4a5fa5c0994f68a46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9cbb23a4c4404fd09cf2220d10bbfd76_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>gh:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="seat">
        <measure>gh:seat</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="patent">
        <measure>gh:patent</measure>
    </unit>
    <unit id="tranche">
        <measure>gh:tranche</measure>
    </unit>
    <unit id="grantee">
        <measure>gh:grantee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8xLTEtMS0xLTY4MDIy_823ab805-2e29-4c4e-a2e0-a58919aa9cdd">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8yLTEtMS0xLTY4MDIy_e16aaedd-bde9-4e02-94fa-10f18e5911de">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl8zLTEtMS0xLTY4MDIy_b466da8c-94d7-45ca-93b9-9eedd0018a29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl80LTEtMS0xLTY4MDIy_2178446d-7509-4a1b-b5f9-f73946382204">0001576280</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80L2ZyYWc6N2MzYWI5MTM4OTcwNGIzYmE4MDkxYzAyYmNkZTQ0MzMvdGFibGU6NDFlYTBhM2FjMTg5NGI2N2FjZDkxMTM1ZDZkNjBiMGIvdGFibGVyYW5nZTo0MWVhMGEzYWMxODk0YjY3YWNkOTExMzVkNmQ2MGIwYl81LTEtMS0xLTY4MDIy_88ef61b3-0497-49c4-8331-8febc4a64dcd">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4a3c1288310f43a4abefc9f3326e5f24_D20201101-20201130"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82Ny9mcmFnOmEwN2RiMjA5N2Q3ZjRhMjhiOGY2NjU5NjAxZjllNmFkL3RleHRyZWdpb246YTA3ZGIyMDk3ZDdmNGEyOGI4ZjY2NTk2MDFmOWU2YWRfMTA5_6a036bc5-dd78-4844-9fae-f6bc09ce9254"
      unitRef="number">0.0071523</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="iad577482d6c44d62a1d8638eab07b300_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYxNw_60b18dda-66c2-4999-b9be-3ed7aa5e2977">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <dei:DocumentType
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI0_a0f72873-3919-4722-a106-338df7f27a32">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMw_f8f0c47a-eb29-4f66-a997-710f6a43adaf">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yNjQ_f6b47afb-c54d-426c-820f-c678408bbb42">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM3_1ac216ce-c9ac-44be-843d-df60f45ac2f6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMx_7712473a-d9ab-480c-ab34-acafc0a02efd">001-38683</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI1_e9c084d9-67b9-4ef5-9f2c-064f71b0b357">GUARDANT HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6OTAzYzY3OGE2YTc0NDdhOTg5MjFjNGQ3NjhjNDI3ZTQvdGFibGVyYW5nZTo5MDNjNjc4YTZhNzQ0N2E5ODkyMWM0ZDc2OGM0MjdlNF8wLTAtMS0xLTY4MDIy_d421a498-f56b-4c13-a2c5-c61ef063cf19">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6OTAzYzY3OGE2YTc0NDdhOTg5MjFjNGQ3NjhjNDI3ZTQvdGFibGVyYW5nZTo5MDNjNjc4YTZhNzQ0N2E5ODkyMWM0ZDc2OGM0MjdlNF8wLTItMS0xLTY4MDIy_feeb1c7b-d6c7-4aea-a42e-3570a4f1936d">45-4139254</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI3_0efb6352-3142-433e-8c16-93fdc36a926c">3100 Hanover Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMy_d4cd0699-7ee3-4590-9885-cfb4380b6d11">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzMz_50d8c7d3-e527-459b-8ff6-cdea8a35ee0b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI4_1d5226be-709f-4d59-b65a-45a631301a88">94304</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI2_5cbb83bd-62d3-4005-ab0e-d3af23caf2f8">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM0_8377b53d-3c4d-4f84-8961-c8d8b70bb97f">698-8887</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTAtMS0xLTY4MDIy_87d98880-1345-4bd7-a9d9-71f2a319cd9d">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTEtMS0xLTY4MDIy_9f688192-8be6-46d6-9c96-f6b67e78ae9b">GH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6YzhiMTM3ZTNlYTc5NDdlY2I2ODY0NmQzMzNjYzc2ZTYvdGFibGVyYW5nZTpjOGIxMzdlM2VhNzk0N2VjYjY4NjQ2ZDMzM2NjNzZlNl8xLTItMS0xLTY4MDIy_7096c3a9-1755-4385-800f-ac6ca41e564d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzI5_d879cd72-23f1-4e63-b551-e3d357dd0a14">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM1_02b58445-87cb-43a4-979d-de2c1f38e67c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl8wLTAtMS0xLTY4MDIy_86b677ef-a603-4dd6-852b-7b601a915a34">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl8yLTMtMS0xLTY4MDIy_b30a6818-4801-4ae8-8117-d71f96489f38">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGFibGU6NTlmODk1YTEwNWU4NDk2ODlhMGE0NTVlZTcwZjJmNmYvdGFibGVyYW5nZTo1OWY4OTVhMTA1ZTg0OTY4OWEwYTQ1NWVlNzBmMmY2Zl80LTEtMS0xLTY4MDIy_8e7f0757-77e8-4c82-b9ad-fc12789253c7">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMzM2_ba0aba2e-16cb-463a-9157-962ed39bfa56">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic63eda5373a64e0b98a90b18ccae37eb_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xL2ZyYWc6MGQ4NjJmM2M0MTNjNDBlMzk1NDA1NTc1OGViOWI5ZTEvdGV4dHJlZ2lvbjowZDg2MmYzYzQxM2M0MGUzOTU0MDU1NzU4ZWI5YjllMV8yMjYw_822bce53-32bc-4595-8564-0b6830b2bfeb"
      unitRef="shares">102764840</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMy0xLTEtMS02ODAyMg_ecb3ac89-c854-4cae-9a3f-efbc5d3fcb5d"
      unitRef="usd">223640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMy0zLTEtMS02ODAyMg_32023592-a215-4166-9e4a-6bf631a7fd0f"
      unitRef="usd">141647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNC0xLTEtMS02ODAyMg_3738f449-aa6c-46a2-a0e9-bd2e80a7a279"
      unitRef="usd">713380000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNC0zLTEtMS02ODAyMg_2d198eb8-6592-4028-b4b9-0bebb53d1dc0"
      unitRef="usd">869584000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNS0xLTEtMS02ODAyMg_477faa97-56fe-49b2-bd97-71f4c7efcea2"
      unitRef="usd">87204000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNS0zLTEtMS02ODAyMg_7f4228a2-edad-4497-9a94-bc3e9c113367"
      unitRef="usd">97256000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNi0xLTEtMS02ODAyMg_6901337a-cddd-40ff-974d-1a02da63d6d5"
      unitRef="usd">46474000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNi0zLTEtMS02ODAyMg_bb5606e2-e3c9-4751-af09-bd27b4cda6f2"
      unitRef="usd">51598000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNy0xLTEtMS02ODAyMg_e17fb377-87f4-4120-86cd-533517b55ef6"
      unitRef="usd">33762000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfNy0zLTEtMS02ODAyMg_4ea4adef-ab8c-422c-8266-0cc8bd9c835f"
      unitRef="usd">31509000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfOC0xLTEtMS02ODAyMg_7cecd297-6693-42e4-8b63-f79d206c9c81"
      unitRef="usd">1104460000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfOC0zLTEtMS02ODAyMg_4be1f910-4083-4d98-a706-96db94dbc443"
      unitRef="usd">1191594000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTAtMS0xLTEtNjgwMjI_a3a8ed3e-b683-4bac-9437-3ec630c9d04e"
      unitRef="usd">163229000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTAtMy0xLTEtNjgwMjI_4244ef18-e0f4-4d46-bfda-49b0f7bff0d6"
      unitRef="usd">167920000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTEtMS0xLTEtNjgwMjI_a0abad74-ca89-4b5f-8ec6-afc0004fe047"
      unitRef="usd">170651000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTEtMy0xLTEtNjgwMjI_18e981a7-9b4d-472d-880a-4c604396a0f0"
      unitRef="usd">174001000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTItMS0xLTEtNjgwMjI_8d72ad3b-c4e0-4f36-9d6f-47f064543cb6"
      unitRef="usd">11047000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTItMy0xLTEtNjgwMjI_bc7ae66b-693f-44be-b867-0b857b2bb540"
      unitRef="usd">11727000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTMtMS0xLTEtNjgwMjI_ed63741a-9436-4529-8e85-f3b78f8abd10"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTMtMy0xLTEtNjgwMjI_f0ff77be-1083-4a2a-9326-2c6361428c85"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTUtMS0xLTEtNjgwMjI_480c3208-557b-4d62-93b2-93458d0713b3"
      unitRef="usd">58954000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTUtMy0xLTEtNjgwMjI_c58ea46f-f878-4cc9-a500-7b1878af9baf"
      unitRef="usd">61453000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTYtMS0xLTEtNjgwMjI_d9def67a-0fc8-4510-b041-86ca873fd7b1"
      unitRef="usd">1511631000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTYtMy0xLTEtNjgwMjI_6069f237-3e3f-49cb-ac0e-f141d8b7d96e"
      unitRef="usd">1609985000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTktMS0xLTEtNjgwMjI_2ab5a984-3026-480d-b774-a65c1e3b27d2"
      unitRef="usd">190534000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMTktMy0xLTEtNjgwMjI_80530f22-e840-492e-b9b2-d46c69c6be1e"
      unitRef="usd">175817000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjEtMS0xLTEtNjgwMjI_9ccb8be1-f8b1-401c-90b0-83cb99ec0cbc"
      unitRef="usd">13621000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjEtMy0xLTEtNjgwMjI_a19d80ab-b954-4a0c-ae66-4032fbea12d1"
      unitRef="usd">17403000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjMtMS0xLTEtNjgwMjI_d4f3feb3-8ae7-4bdf-a148-76ea1c3c960b"
      unitRef="usd">204155000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjMtMy0xLTEtNjgwMjI_2cd62f6c-5837-4e4d-87a8-b298e81e1f12"
      unitRef="usd">193220000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjQtMS0xLTEtNjgwMjI_be755334-2ecc-4d0b-b222-cf6f516ed1ba"
      unitRef="usd">1138034000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjQtMy0xLTEtNjgwMjI_33e4645a-d244-4192-bd36-1a071a0b5d9a"
      unitRef="usd">1137391000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjUtMS0xLTEtNjgwMjI_07218f33-f33d-484a-a33f-5b1d1344528e"
      unitRef="usd">204857000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjUtMy0xLTEtNjgwMjI_89c39988-5f55-41d7-944f-a42f8b97ae11"
      unitRef="usd">210015000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjctMS0xLTEtNjgwMjI_a94ab9cd-9bbe-4a3b-ab7b-35c10a83408d"
      unitRef="usd">9136000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjctMy0xLTEtNjgwMjI_3d4ee115-aa96-40d7-8356-7129158657c2"
      unitRef="usd">9179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjgtMS0xLTEtNjgwMjI_eb5655bb-a32b-44c1-ba30-f5fd87aa07e8"
      unitRef="usd">1556182000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjgtMy0xLTEtNjgwMjI_72ac2880-fa32-4f70-a8ea-b79048953cf2"
      unitRef="usd">1549805000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjktMS0xLTEtNzYxODI_2f9bd128-9ee5-4288-817c-0db84552cd8f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMjktMy0xLTEtNzYxODI_e4306d16-79fc-4b38-96b0-284d7aa5d4b7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF8zNA_09d3977c-393a-4ff8-9fd6-5ff97ec408ab"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF8zNA_5a5ad465-fa0a-4d59-a590-7e7d7648733b"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF80OA_13a3bf16-8227-4036-bb64-d6185f7913d1"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF80OA_9b95daba-dbdf-49cd-a741-6e5d947efaf6"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_2fddb157-4a92-4d60-a7e4-62c4c3117b55"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_941b0371-1a58-4d4e-9535-f86dd679cf4e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_c1b980d0-00d0-4378-b294-1bbfd773b8dc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjphZTlmZWE3YWVmZmU0YTM2OTNlMGQzYmJmZmM2MjIwZF83MA_f46d9922-550f-4f3e-8088-06eacc87490f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMS0xLTEtNjgwMjI_049f2d83-6193-40d6-8b37-fa4d11a45212"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzItMy0xLTEtNjgwMjI_7508dd6e-74f3-4044-8f17-6acf1336af2e"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl8zMg_b091af7a-d0d3-4f0b-840d-3069fed0e536"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl8zMg_bac0a932-a70e-44cc-bc1f-207289f31ae3"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl80Ng_b2644ad6-3f37-4b34-8717-65e874eb74e1"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl80Ng_da4a39e2-30b6-493f-9885-91b4239bd985"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl84NQ_7ea8e92b-10a8-4452-834e-ad277e812ed7"
      unitRef="shares">102708305</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl84NQ_c7d5f05c-8859-4bde-b785-87a27cd1ff92"
      unitRef="shares">102708305</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl85Mg_38ecb38d-986c-485f-b42e-928e31e2bcfd"
      unitRef="shares">102619383</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMC0xLTEtNjgwMjIvdGV4dHJlZ2lvbjpiNjhlZTAwNjQ4MjU0N2UzOTYwY2VjNTA1Zjg0ZTM4Yl85Mg_caa2bdd7-7415-44df-b6c2-2f9da7bcbc3e"
      unitRef="shares">102619383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMS0xLTEtNjgwMjI_b0608dc3-933a-44c0-92aa-9b5146de3346"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzMtMy0xLTEtNjgwMjI_033bcdf4-5f81-4370-9b75-83bcf2c85436"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzQtMS0xLTEtNjgwMjI_e651810e-399f-4e45-8f39-e82eb64b5cc7"
      unitRef="usd">1763544000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzQtMy0xLTEtNjgwMjI_b96be258-53a0-4555-b616-a049021bd0c2"
      unitRef="usd">1742114000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzUtMS0xLTEtNjgwMjI_49222629-04a4-423a-a186-a941154bd80c"
      unitRef="usd">-12150000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzUtMy0xLTEtNjgwMjI_752ef535-f37d-4083-b7cc-333589af7454"
      unitRef="usd">-19522000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzYtMS0xLTEtNjgwMjI_ef943ffd-7a40-4569-93f5-29477874ce26"
      unitRef="usd">-1795946000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzYtMy0xLTEtNjgwMjI_42b8ec88-cffb-4e90-aeb5-6f4105076e73"
      unitRef="usd">-1662413000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzctMS0xLTEtNjgwMjI_1e6aebbe-5c61-4bf4-b58b-d6ce716c6d8a"
      unitRef="usd">-44551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzctMy0xLTEtNjgwMjI_09fb76db-5ad8-4d52-b34c-6793c95b276e"
      unitRef="usd">60180000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzgtMS0xLTEtNjgwMjI_b509c590-689a-4263-ad43-9ebe58da4e3c"
      unitRef="usd">1511631000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xNi9mcmFnOjM0NWM4YzMxNThjZDQ0OGE5YjE1MTAyNTI2YTMyZmM2L3RhYmxlOjZmNzI5YmEwNjk1YzQxYzM4NDg0YjJlOGQ5OTBlODA3L3RhYmxlcmFuZ2U6NmY3MjliYTA2OTVjNDFjMzg0ODRiMmU4ZDk5MGU4MDdfMzgtMy0xLTEtNjgwMjI_15914222-1e9d-474d-a2e5-5aa43c704451"
      unitRef="usd">1609985000</us-gaap:LiabilitiesAndStockholdersEquity>
    <gh:RevenueFromPrecisionOncologyTesting
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNC02LTEtMS02ODAyMg_ba8ecc28-80aa-484e-a1c9-0a4d2b542610"
      unitRef="usd">113393000</gh:RevenueFromPrecisionOncologyTesting>
    <gh:RevenueFromPrecisionOncologyTesting
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNC04LTEtMS02ODAyMg_5468a2ea-b41a-4c17-ad1e-08143c8abd87"
      unitRef="usd">84136000</gh:RevenueFromPrecisionOncologyTesting>
    <gh:RevenueFromDevelopmentServices
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNS02LTEtMS02ODAyMg_bc14e140-178a-4dfa-8b6d-807bf4a00bd9"
      unitRef="usd">15321000</gh:RevenueFromDevelopmentServices>
    <gh:RevenueFromDevelopmentServices
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNS04LTEtMS02ODAyMg_63823d7f-bebe-4df9-804f-9d3ec288d1ba"
      unitRef="usd">11963000</gh:RevenueFromDevelopmentServices>
    <us-gaap:Revenues
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNi02LTEtMS02ODAyMg_4ddd3220-21c2-4e54-be29-b34aa8c0ed25"
      unitRef="usd">128714000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfNi04LTEtMS02ODAyMg_810e9361-67cd-4fc6-9c23-d79db19e3a05"
      unitRef="usd">96099000</us-gaap:Revenues>
    <gh:CostsOfPrecisionOncologyTesting
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOC02LTEtMS02ODAyMg_d485602b-c4f6-452b-b229-df5a6eab2dbe"
      unitRef="usd">45106000</gh:CostsOfPrecisionOncologyTesting>
    <gh:CostsOfPrecisionOncologyTesting
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOC04LTEtMS02ODAyMg_aa993c53-46ce-4966-bed3-a7e999a62e4d"
      unitRef="usd">30684000</gh:CostsOfPrecisionOncologyTesting>
    <gh:CostOfDevelopmentServices
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOS02LTEtMS02ODAyMg_14d6f26b-fabf-4ba5-8a54-84f1b01eb418"
      unitRef="usd">7967000</gh:CostOfDevelopmentServices>
    <gh:CostOfDevelopmentServices
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfOS04LTEtMS02ODAyMg_eae54503-58ec-438b-b75e-81d1e3417d18"
      unitRef="usd">1297000</gh:CostOfDevelopmentServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTAtNi0xLTEtNjgwMjI_78b60f73-92d4-4913-85df-09134d1eba95"
      unitRef="usd">93128000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTAtOC0xLTEtNjgwMjI_01da086b-07aa-4d4f-bb6b-23d4f0e55359"
      unitRef="usd">81757000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTEtNi0xLTEtNjgwMjI_2b66a199-27b6-4a85-84d9-dd7d5f2b1b1a"
      unitRef="usd">76123000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTEtOC0xLTEtNjgwMjI_9e503580-bb3b-4961-b605-9c89632f4388"
      unitRef="usd">64432000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTItNi0xLTEtNjgwMjI_c92e129f-2dd5-48da-978a-1c72b2135a44"
      unitRef="usd">40445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTItOC0xLTEtNjgwMjI_dbf03db0-f594-42b0-b72d-8ee3877ccf96"
      unitRef="usd">41267000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTMtNi0xLTEtNjgwMjI_fdb0daf5-b7f7-414a-af10-4daf5ca95615"
      unitRef="usd">262769000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTMtOC0xLTEtNjgwMjI_7827da45-c341-4156-b85d-d28b4f6b6fd9"
      unitRef="usd">219437000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTQtNi0xLTEtNjgwMjI_e5715f74-d1ec-413c-8cc6-fbd7c7ef07e1"
      unitRef="usd">-134055000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTQtOC0xLTEtNjgwMjI_05a9c526-8c6c-468b-9a6f-0a29c45a4b4d"
      unitRef="usd">-123338000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTUtNi0xLTEtNjgwMjI_ce0fade1-26b8-473a-9256-0b24aa7eced0"
      unitRef="usd">3060000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTUtOC0xLTEtNjgwMjI_4a6f9486-b1c9-49b7-bb39-a64f76f9d6ec"
      unitRef="usd">778000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTYtNi0xLTEtNjgwMjI_bb74fff4-43ef-43a7-be70-5eb4cb1a5f78"
      unitRef="usd">644000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTYtOC0xLTEtNjgwMjI_7a04794a-62d8-4b7a-b257-615502838c1a"
      unitRef="usd">644000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTctNi0xLTEtNjgwMjI_6fc22521-77f8-4994-9eea-1e1015e61703"
      unitRef="usd">-1654000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTctOC0xLTEtNjgwMjI_2c1e2170-89f9-42a8-b9b0-c4bc0e0c9d63"
      unitRef="usd">-48000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTktNi0xLTEtNjgwMjI_3aef2887-108c-4b0b-9fff-d7ad7454caa9"
      unitRef="usd">-133293000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMTktOC0xLTEtNjgwMjI_bc63573a-208b-4e77-ab15-66915e41d2e5"
      unitRef="usd">-123252000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjAtNi0xLTEtNjgwMjI_26237e99-067a-42fe-8123-6d7e7b0d8b25"
      unitRef="usd">240000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjAtOC0xLTEtNjgwMjI_d1410565-c997-4273-a636-570a9bc0dbc3"
      unitRef="usd">-24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjMtNi0xLTEtNjgwMjI_3f31189f-26e9-4498-b74f-b790ba957612"
      unitRef="usd">-133533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjMtOC0xLTEtNjgwMjI_df1fda21-cd5b-4dbf-addf-bc97f2012670"
      unitRef="usd">-123228000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtNi0xLTEtNjgwMjI_220036eb-9cb2-4229-997c-f75a3a4187bc"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtNi0xLTEtNjgwMjI_99ba037c-76cf-43f9-a1b9-381b75d4c261"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtOC0xLTEtNjgwMjI_bc0d5ead-d3f6-42e7-a0c1-952d25e72d13"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjQtOC0xLTEtNjgwMjI_be5e8e7d-8d03-40d1-9338-20aba2d1fd32"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtNi0xLTEtNjgwMjI_2ec3080a-ff39-47e6-b71a-e8f38512eece"
      unitRef="shares">102663000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtNi0xLTEtNjgwMjI_cf495f91-7a1a-4287-a035-a4f8e9cf1a39"
      unitRef="shares">102663000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtOC0xLTEtNjgwMjI_42d4f00a-5bc5-4667-a29f-4a0ee6c05d64"
      unitRef="shares">101853000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xOS9mcmFnOjFkZGMyNDhlZWEzMzQ5MjI5ZjNjZTdkOGE4ZDhiNjRhL3RhYmxlOmY2MTYwN2MxNmIwODQ2M2U5NDg3ZmY2MWY3Y2JiNjU3L3RhYmxlcmFuZ2U6ZjYxNjA3YzE2YjA4NDYzZTk0ODdmZjYxZjdjYmI2NTdfMjUtOC0xLTEtNjgwMjI_8508b8c9-90da-4c65-b52c-d97143f69c4a"
      unitRef="shares">101853000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfMy02LTEtMS02ODAyMg_67e1bb7e-e7a4-4792-90d4-4c9f8dffd9a7"
      unitRef="usd">-133533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfMy04LTEtMS02ODAyMg_333ddad9-4f7b-43f4-89ef-3c9f810d1a98"
      unitRef="usd">-123228000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNS02LTEtMS02ODAyMg_42067375-b0d3-4609-ad11-6a7e5fa6adc5"
      unitRef="usd">7535000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNS04LTEtMS02ODAyMg_e7b09f65-d57e-4b1e-9e14-ad1339bb5367"
      unitRef="usd">-12758000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNi02LTEtMS02ODAyMg_20518eab-a052-4cd2-b7a1-0d7bd9966a2c"
      unitRef="usd">-163000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNi04LTEtMS02ODAyMg_48f376bf-3ff0-42c5-9859-0f53a258b4da"
      unitRef="usd">-792000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNy02LTEtMS02ODAyMg_9beb1ab3-afe0-4886-88f9-8dd2cde1045e"
      unitRef="usd">7372000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfNy04LTEtMS02ODAyMg_ee68f5c1-09b4-4bc7-a614-beb1ac969b31"
      unitRef="usd">-13550000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfOC02LTEtMS02ODAyMg_a6cb0556-7816-4f79-833d-3a2bcf122225"
      unitRef="usd">-126161000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yMi9mcmFnOjIxNTA3MWQ1ZmQzZDRiMjI4ZTM1MGU2ZDA5MzU3YzlhL3RhYmxlOmQ4N2Q3YTU1MDZjNzQ5Njc4YjZiYTQ2NDU0MjYxNDc4L3RhYmxlcmFuZ2U6ZDg3ZDdhNTUwNmM3NDk2NzhiNmJhNDY0NTQyNjE0NzhfOC04LTEtMS02ODAyMg_4d9ca77e-7bbd-4a8a-8f82-25edd476b606"
      unitRef="usd">-136778000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id314243f2ead4456aa30110c9be601cb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0zLTEtMS02ODAyMg_99c3bcb1-afcc-4a1a-906d-57b1d3b483f7"
      unitRef="shares">102619383</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id314243f2ead4456aa30110c9be601cb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy01LTEtMS02ODAyMg_ad3d94e7-dd3d-440e-83f7-1c160839a0db"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9b4fdb150214c56afcbdbb322033b7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy03LTEtMS02ODAyMg_e421f413-5ffb-4467-ac13-ff1b0e31f028"
      unitRef="usd">1742114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i061c59efe2d945519dfb0e5134ddbbfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy05LTEtMS02ODAyMg_5c265692-8887-4cc1-a7db-a4d8a421f5f3"
      unitRef="usd">-19522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08422884f60b4434b3801e044a34720c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0xMS0xLTEtNjgwMjI_75492170-6250-4caa-ab99-67a2454f312b"
      unitRef="usd">-1662413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMy0xMy0xLTEtNjgwMjI_44b5de4c-aba7-4612-966d-53a1d4077b0e"
      unitRef="usd">60180000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS0zLTEtMS02ODAyMg_c8f9ef3c-57fd-49ac-953e-575a5a77eb5a"
      unitRef="shares">21049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS03LTEtMS02ODAyMg_0974470c-6f73-4abb-87f5-9d625e41cc0a"
      unitRef="usd">157000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNS0xMy0xLTEtNjgwMjI_86d5d4ca-21d7-4364-a068-1ef4ea12e5ef"
      unitRef="usd">157000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8413ca00be4f42a3b4524ae4bf583424_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfNi0zLTEtMS02ODAyMg_f8f91bbc-359d-4aae-867d-f234d0c2ff4f"
      unitRef="shares">67873</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfOS03LTEtMS02ODAyMg_d8d3a641-006d-4cc2-980c-54cbf264d828"
      unitRef="usd">993000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfOS0xMy0xLTEtNjgwMjI_dd0177ff-490d-4217-acfc-1c42ef22ebce"
      unitRef="usd">993000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica54ad6239b249a1a56fcad5f296b873_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTAtNy0xLTEtNjgwMjI_a42fc83a-1915-492f-8133-9de40c3282dd"
      unitRef="usd">22266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTAtMTMtMS0xLTY4MDIy_84035139-c022-49d9-a64a-c07cfa505f55"
      unitRef="usd">22266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i65627937720c45f5af483254a1fe5f4b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTMtOS0xLTEtNjgwMjI_b697266c-b0dd-494d-9928-a9973ba2646e"
      unitRef="usd">7372000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTMtMTMtMS0xLTY4MDIy_bbe09162-1f34-485e-bdda-f018de041da3"
      unitRef="usd">7372000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia281fcd22cc54accbefe8d9b460bd5cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTQtMTEtMS0xLTY4MDIy_6e141829-6084-4927-b534-e1e356e74f7a"
      unitRef="usd">-133533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTQtMTMtMS0xLTY4MDIy_a41243a1-733e-494d-b968-5962060b3f78"
      unitRef="usd">-133533000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iae9eaada43ef4cfd925883681dcbc4c2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMy0xLTEtNjgwMjI_eba77059-30e2-426f-aac9-057c67da0a2c"
      unitRef="shares">102708305</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iae9eaada43ef4cfd925883681dcbc4c2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtNS0xLTEtNjgwMjI_e3a425cc-85fe-4dd2-96ec-de572967b6aa"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i234915b13fca42879cd971070e15ee06_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtNy0xLTEtNjgwMjI_3ad6307a-c786-4aa0-8211-4c1cc81b1a34"
      unitRef="usd">1763544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2f8f14dc64d49c6be419158cec74a14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtOS0xLTEtNjgwMjI_dfbf4665-a5e8-4af8-870d-a74cff5bd00c"
      unitRef="usd">-12150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie23b9007cc9d4791bd36771afacf5634_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMTEtMS0xLTY4MDIy_0e29a059-3749-475a-a564-290df27bff2c"
      unitRef="usd">-1795946000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOmVjOTliODBmNTEyNDRlMWViOTFjZTY5YTRiODdiOWQzL3RhYmxlcmFuZ2U6ZWM5OWI4MGY1MTI0NGUxZWI5MWNlNjlhNGI4N2I5ZDNfMTUtMTMtMS0xLTY4MDIy_430967fa-bfef-4554-9158-5b279625c961"
      unitRef="usd">-44551000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0zLTEtMS02ODAyMg_2c2571d3-1dd1-4ca4-8788-9bcd336562c1"
      unitRef="shares">101767446</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i63da5e92a9b84f0d93e9513d7c29fb14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy01LTEtMS02ODAyMg_237e09ac-9ecc-4137-b924-698a7c5371a9"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c902d77713c48f9b6c55bb637b64351_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy03LTEtMS02ODAyMg_7a77179c-767d-43b0-ae85-81d78f42ef0c"
      unitRef="usd">1657593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i004e4666a5184be996fa4c7ddf054bc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy05LTEtMS02ODAyMg_5e4aec98-b8a1-4792-9f7d-865d956a3972"
      unitRef="usd">-4764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49b965e37113409d8d7d5afef90e67b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0xMS0xLTEtNjgwMjI_078de641-fdf7-4211-bde8-0f782d5f7617"
      unitRef="usd">-1007825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18bad5d6e63649409643e7d759322b03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMy0xMy0xLTEtNjgwMjI_b1d7d358-7f60-44e1-a8c8-f772b81229d0"
      unitRef="usd">645005000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi0zLTEtMS02ODAyMg_499fddf9-616b-4aac-be06-aded0e6213fe"
      unitRef="shares">105218</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi03LTEtMS02ODAyMg_c5d7a8dc-d7ec-49bc-a709-3c8d481a747b"
      unitRef="usd">963000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNi0xMy0xLTEtNjgwMjI_9bdff7ba-5f9b-4f41-a82e-b6ba30ca164f"
      unitRef="usd">963000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib6abd5e7fcb540a280ba7355e04e36c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfNy0zLTEtMS02ODAyMg_14c34d6a-3fab-45b3-ab4a-5cd662398795"
      unitRef="shares">23171</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfOC03LTEtMS02ODAyMg_dd1249b2-a884-4968-96b1-0cbe944e6e69"
      unitRef="usd">8000</gh:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <gh:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfOC0xMy0xLTEtNjgwMjI_54bcb811-72f0-4e13-90cb-14454c266d30"
      unitRef="usd">8000</gh:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTAtNy0xLTEtNjgwMjI_635d1db8-0538-4bac-9f84-1d7dff0cd9ba"
      unitRef="usd">957000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTAtMTMtMS0xLTY4MDIy_5d4fd916-5d1f-4842-bfb4-33fe21501d5e"
      unitRef="usd">957000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id53d1a8d7c3741399fe857293053ddcf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTEtNy0xLTEtNjgwMjI_d5c7e147-b389-406c-9f6d-afe0674b20b7"
      unitRef="usd">24799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTEtMTMtMS0xLTY4MDIy_e1ba93d9-b8d0-4bf9-89e7-5973a25a8cb4"
      unitRef="usd">24799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i837fd30e88e14cca94ef2ffcde2af73e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTMtOS0xLTEtNjgwMjI_22120f99-35ba-4cee-8d8c-c52ed877397f"
      unitRef="usd">-13550000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTMtMTMtMS0xLTY4MDIy_a2617989-774d-4ff0-89ab-a086a7e428b2"
      unitRef="usd">-13550000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i6340409bc504436ca385dbfa0f3ec40c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTQtMTEtMS0xLTY4MDIy_7a38bda4-6049-4d83-91e1-50dd37e35cb4"
      unitRef="usd">-123228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTQtMTMtMS0xLTY4MDIy_802c26ca-00cc-4c7b-833d-34935c5be43d"
      unitRef="usd">-123228000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i61824cd12b914964a5a603b514d2a3de_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMy0xLTEtNjgwMjI_27af6f4e-ffc5-4838-a531-43cf326e326e"
      unitRef="shares">101895835</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61824cd12b914964a5a603b514d2a3de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtNS0xLTEtNjgwMjI_5a3ad51d-4d5d-4a88-83c2-9145ccfdd213"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49ecdc52faa648b9851cd7fd4d341e4d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtNy0xLTEtNjgwMjI_ce7e4590-16c8-4c27-a2b6-7b49b0f6ae30"
      unitRef="usd">1682406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaeefd32a5fc49089e432e6ef771b042_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtOS0xLTEtNjgwMjI_3cfea41d-5e1e-4015-a0e3-d55bf280edf9"
      unitRef="usd">-18314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10781cf49c274a30b77473e1ab3caaa8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMTEtMS0xLTY4MDIy_0cc145cf-a151-43f2-ba94-e432a8c89707"
      unitRef="usd">-1131053000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8yNS9mcmFnOmFiNTg1MDdkYzdiNzQ1NGE5NTI3ZTg0YjA2MzI3OTUyL3RhYmxlOjU5MDc1NTRkNWFjZDRlZTZhNGFjNmJhZDUxZGQwZTM2L3RhYmxlcmFuZ2U6NTkwNzU1NGQ1YWNkNGVlNmE0YWM2YmFkNTFkZDBlMzZfMTUtMTMtMS0xLTY4MDIy_ce783f0d-0afe-4d10-9698-6742a2b7b0f5"
      unitRef="usd">533040000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNC0xLTEtMS02ODAyMg_5d48b267-19da-450c-90b9-f3c253d171ae"
      unitRef="usd">-133533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNC0zLTEtMS02ODAyMg_54b9200f-bc2d-4c9d-81d3-af65499a4817"
      unitRef="usd">-123228000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNi0xLTEtMS02ODAyMg_9190cce2-d93d-4524-a0aa-78ca3b0704c6"
      unitRef="usd">10345000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNi0zLTEtMS02ODAyMg_1598e7bd-2420-4e9c-ba98-37679973f3b3"
      unitRef="usd">7201000</us-gaap:DepreciationDepletionAndAmortization>
    <gh:NonCashOperatingLeaseCosts
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNy0xLTEtMS02ODAyMg_89bea0cf-4e67-4032-bdd5-d4491eb4aff1"
      unitRef="usd">7339000</gh:NonCashOperatingLeaseCosts>
    <gh:NonCashOperatingLeaseCosts
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNy0zLTEtMS02ODAyMg_f754a81a-2c1e-4a64-94c8-a1266ceb68c7"
      unitRef="usd">6949000</gh:NonCashOperatingLeaseCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTAtMS0xLTEtNjgwMjI_2219f0a9-8896-40ce-bc05-b60000411be0"
      unitRef="usd">-300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTAtMy0xLTEtNjgwMjI_f22e4225-e68c-4f2f-aa8f-17df865bbf14"
      unitRef="usd">2390000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTEtMS0xLTEtNjgwMjI_fedda806-e5b4-4175-92b4-37118ab05d39"
      unitRef="usd">22266000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTEtMy0xLTEtNjgwMjI_4fddec9c-d295-4eaf-aef1-b1b16ae74b10"
      unitRef="usd">24799000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTItMS0xLTEtNjgwMjI_ee493627-59c1-4352-9ddc-8e32fdc522f0"
      unitRef="usd">644000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTItMy0xLTEtNjgwMjI_773a4386-4c65-42f4-890d-7a0e6bb72d0c"
      unitRef="usd">642000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTMtMS0xLTEtNjgwMjI_78f1a41c-2da9-4f57-b839-2911d9b026ba"
      unitRef="usd">1009000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTMtMy0xLTEtNjgwMjI_62d6444c-a945-493e-aad2-06710c5003f2"
      unitRef="usd">-2449000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTQtMS0xLTEtNjgwMjI_c8a1b819-8d34-4a2a-b6d5-b6d6892caa1e"
      unitRef="usd">3882000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTQtMy0xLTEtNjgwMjI_bf38384a-b696-474b-a209-ce77820e3ffd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTUtMS0xLTEtNjgwMjI_bc377ff7-f737-49cd-9887-10f5f51bb091"
      unitRef="usd">5485000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTUtMy0xLTEtNjgwMjI_155155f9-8de7-4970-b2b4-a3339b6ddb5b"
      unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTctMS0xLTEtNjgwMjI_1100dcae-15ea-48b7-97ac-5cedfd4a8157"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTctMy0xLTEtNjgwMjI_b0bbc2d2-aa00-44f7-8bfc-dfcb8ffd378c"
      unitRef="usd">-21000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTktMS0xLTEtNjgwMjI_093fe345-3a63-4248-aba7-443c8a6a132a"
      unitRef="usd">-12349000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMTktMy0xLTEtNjgwMjI_c4c308ee-f67c-49a4-9d6e-b5a03c3a6d5d"
      unitRef="usd">-13299000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjAtMS0xLTEtNjgwMjI_7e1d8009-a98c-474b-beb2-a49247a7897d"
      unitRef="usd">-5125000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjAtMy0xLTEtNjgwMjI_642531b3-7e36-4f3b-8a03-eb30514c7131"
      unitRef="usd">5937000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjEtMS0xLTEtNjgwMjI_e15839b8-b4df-44ff-9c1b-c27c2d15fcd5"
      unitRef="usd">3354000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjEtMy0xLTEtNjgwMjI_98e89721-7454-421e-bb30-040aad1ca784"
      unitRef="usd">-21882000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjItMS0xLTEtNjgwMjI_86be599b-cbce-461d-bb83-e8f3b12100c4"
      unitRef="usd">-1765000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjItMy0xLTEtNjgwMjI_03c519a1-8f19-4833-adfe-e4e0c38bd8c2"
      unitRef="usd">-3846000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjMtMS0xLTEtNjgwMjI_875e0d44-f1b5-4548-96fe-c159670fc25f"
      unitRef="usd">13886000</gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities>
    <gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjMtMy0xLTEtNjgwMjI_55642a31-3e83-4682-8b09-f521b041b1e9"
      unitRef="usd">20931000</gh:IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjQtMS0xLTEtNjgwMjI_d9d341ef-2a7c-4cac-bfff-9e8a246c673b"
      unitRef="usd">-7422000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjQtMy0xLTEtNjgwMjI_2a015415-9ea9-43c4-af2c-7e59d8fc9dbc"
      unitRef="usd">-3106000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjUtMS0xLTEtNjgwMjI_4b0a290b-5ae5-42e2-9338-c3dbd233fee4"
      unitRef="usd">-4145000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjUtMy0xLTEtNjgwMjI_d7bf302e-8efd-47f6-bf58-fa57cdccaec5"
      unitRef="usd">-757000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjYtMS0xLTEtNjgwMjI_1d0d70de-282f-4c05-b727-f70b3c68c71a"
      unitRef="usd">-74441000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjYtMy0xLTEtNjgwMjI_baf08f15-7e45-418c-a7cc-8095ea9c7f71"
      unitRef="usd">-28619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjgtMS0xLTEtNjgwMjI_46f0857e-13ab-449d-bd84-a0b1c6031ff8"
      unitRef="usd">63252000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjgtMy0xLTEtNjgwMjI_e42dc2b4-63c1-4872-9a92-746b29b77d44"
      unitRef="usd">163742000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjktMS0xLTEtNjgwMjI_97b93850-a44b-4250-b31b-90eca3c189fc"
      unitRef="usd">228000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMjktMy0xLTEtNjgwMjI_78338e36-c52c-4e0f-98f2-a062b16cb343"
      unitRef="usd">310000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzAtMS0xLTEtNjgwMjI_ebc4f4aa-3825-49f2-8935-bdd945a78611"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzAtMy0xLTEtNjgwMjI_80cbbf2e-5de6-40f0-9faf-98e275201573"
      unitRef="usd">12750000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzEtMS0xLTEtNjgwMjI_fda2527f-9fd6-4512-b945-c355adc8b8eb"
      unitRef="usd">7524000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzEtMy0xLTEtNjgwMjI_7f3c7b13-6c7d-4c39-9570-63c1468ec549"
      unitRef="usd">22700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzQtMS0xLTEtNjgwMjI_462e70c9-3deb-4865-a717-e1f39e5bce81"
      unitRef="usd">157224000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzQtMy0xLTEtNjgwMjI_f1e94dc2-edc2-4e3c-a870-ccabd8f25f4e"
      unitRef="usd">110808000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzctMS0xLTEtNjgwMjI_408508b6-00ef-47b0-85ce-2f9808c0524e"
      unitRef="usd">18000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzctMy0xLTEtNjgwMjI_877f46d4-4afa-4d9d-b499-1de64740a8ee"
      unitRef="usd">18000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzgtMS0xLTEtNjgwMjI_b12afa69-0912-4622-ac6d-fcc3f8d3ae4e"
      unitRef="usd">157000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfMzgtMy0xLTEtNjgwMjI_068b17a3-f076-4231-b3e9-235a3eaf9411"
      unitRef="usd">963000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDAtMS0xLTEtNjgwMjI_c95c3645-b563-44a1-ba05-a8c0a2a350f8"
      unitRef="usd">993000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDAtMy0xLTEtNjgwMjI_5f5b2641-bc98-4952-9ec2-b00cc66450d3"
      unitRef="usd">957000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDgtMS0xLTEtNjgwMjI_64ab9104-71ab-4d8d-b89b-8f47f8231912"
      unitRef="usd">-854000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDgtMy0xLTEtNjgwMjI_c4e2def3-34de-44cc-9377-2b3476697c7b"
      unitRef="usd">-12000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDktMS0xLTEtNjgwMjI_ce67c5c4-cbd3-4efe-a3bc-483e379c2cc4"
      unitRef="usd">-163000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNDktMy0xLTEtNjgwMjI_818bccc3-9870-4876-a34a-e4750fbd9b2d"
      unitRef="usd">-792000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTAtMS0xLTEtNjgwMjI_d05cce5e-16ee-47ce-bd19-fc7db0caf709"
      unitRef="usd">81766000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTAtMy0xLTEtNjgwMjI_9ec557a5-809b-4310-81eb-8625d393ef32"
      unitRef="usd">81385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTEtMS0xLTEtNjgwMjI_291693f2-386e-4529-ba58-e1f5fbf02bc3"
      unitRef="usd">141948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i18bad5d6e63649409643e7d759322b03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTEtMy0xLTEtNjgwMjI_2aab32a9-70a8-4992-a596-bca48654cf8f"
      unitRef="usd">492288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTItMS0xLTEtNjgwMjI_c0669881-f725-462c-8e0a-28c09c83da16"
      unitRef="usd">223714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTItMy0xLTEtNjgwMjI_d2bffe8e-7051-4630-ae7b-8d8fab587023"
      unitRef="usd">573673000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTQtMS0xLTEtNjgwMjI_c8834f99-bb14-4219-a402-5c136423c854"
      unitRef="usd">1964000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTQtMy0xLTEtNjgwMjI_f488e921-262a-40b0-9ac0-ddd205af3c67"
      unitRef="usd">3940000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTgtMS0xLTEtNjgwMjI_73cb4a2d-3cd2-4e0b-bcb3-bb799bfc44e9"
      unitRef="usd">8016000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNTgtMy0xLTEtNjgwMjI_b2e22001-e87a-40db-938b-df4ae8e18410"
      unitRef="usd">19751000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjUtMS0xLTEtNjgwMjI_97b58389-fc3f-4bee-9095-30a6fa69d14b"
      unitRef="usd">223640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjUtMy0xLTEtNjgwMjI_9d962c51-7646-4e93-a796-b073e1fc8bb7"
      unitRef="usd">573604000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjctMS0xLTEtNjgwMjI_ad3bbb25-0928-4725-80b1-b429567fffbb"
      unitRef="usd">74000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjctMy0xLTEtNjgwMjI_23a1ed06-02c9-400f-bfff-f7c836a7d102"
      unitRef="usd">69000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjgtMS0xLTEtNjgwMjI_73311fa9-05a2-436d-b2a1-125cd7a5e45f"
      unitRef="usd">223714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zMS9mcmFnOjNjNTc3NGRlNWFiNjQyZDhiNTYzZTViYjJmYjY5ZDk2L3RhYmxlOjY1ZTEzYjQwMTgwMDRmNzk4MmViOTU3N2Q4MzQwMDk1L3RhYmxlcmFuZ2U6NjVlMTNiNDAxODAwNGY3OTgyZWI5NTc3ZDgzNDAwOTVfNjgtMy0xLTEtNjgwMjI_6215dc20-5f9e-407c-821b-be9bd81a9e71"
      unitRef="usd">573673000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zNy9mcmFnOjJhYTRjNjJlODllODRjZGE4ZmNhNWVhMzU4MThlNjRmL3RleHRyZWdpb246MmFhNGM2MmU4OWU4NGNkYThmY2E1ZWEzNTgxOGU2NGZfMzc4Mg_01603f7a-4664-4ae4-8f83-d2d7b1b5db9f">Description of Business&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Guardant Health, Inc., or the Company, is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company believes its tests can transform cancer care by unlocking insights that will help patients at all stages of the disease, including at its earliest stages, when it&#x2019;s most treatable. For patients with advanced stage cancer, the Company has commercially launched Guardant360 LDT and Guardant360 CDx, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, and breast cancer. The Company has also launched the Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. In addition, the Company has developed Guardant Galaxy suite of advanced analytical technologies to enhance the performance and clinical utility of its portfolio of cancer tests, and to power the next generation of biomarker and drug discovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also collaborates with biopharmaceutical companies in clinical studies by providing the above-mentioned tests, as well as the GuardantOMNI blood test for advanced-stage cancer, and the GuardantINFINITY blood test, a next-generation smart liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. Using data collected from its tests, the Company has also developed its GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For early cancer detection, the Company has launched the Shield LDT test to address the needs of individuals eligible for colorectal cancer screening. From a simple blood draw, Shield uses a novel multimodal approach to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors. In December 2022, the Company announced that the ECLIPSE study, an over 20,000 patient registrational study evaluating the performance of its Shield blood test for detecting colorectal cancer in average-risk adults, met co-primary endpoints. In addition, in March 2023, the Company submitted a premarket approval application for its Shield blood test to the FDA in March 2023. &lt;/span&gt;&lt;/div&gt;The Company was incorporated in Delaware in December 2011 and is headquartered in Palo Alto, California.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <gh:NumberOfPatients
      contextRef="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8zNy9mcmFnOjJhYTRjNjJlODllODRjZGE4ZmNhNWVhMzU4MThlNjRmL3RleHRyZWdpb246MmFhNGM2MmU4OWU4NGNkYThmY2E1ZWEzNTgxOGU2NGZfMTY0OTI2NzQ0OTExOQ_9d058b64-bbdc-47d1-a804-002466ec9bf4"
      unitRef="segment">20000</gh:NumberOfPatients>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjQ_db397346-537c-43de-abde-ecc2e715c25a">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts were made to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents and marketable debt securities as of March&#160;31, 2023, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended, or the Securities Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of payroll withholding related to the Company's enrollment in a voluntary disability insurance plan. Restricted cash balance was $0.1 million and $0.3 million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, which was included in other assets, net in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investees. One of the investees is concluded to be a variable interest entity, or VIE, but the Company is deemed not to be the primary beneficiary as the Company does not have the power to direct the activities that most significantly impact the VIE&#x2019;s economic performance. The Company's non-marketable equity and other related investments totaled $19.6&#160;million and $25.0&#160;million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, and are included in other assets, net on the accompanying condensed consolidated balance sheets. Non-marketable securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. As a result of the evaluation, the Company recorded an impairment of $5.5&#160;million for one of its non-marketable equity security investments for the three months ended March&#160;31, 2023 based on an independent third-party valuation. In addition, pursuant to one of the investments in non-marketable securities purchased by the Company, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. In September 2022, the Company decided not to exercise such rights to purchase the investee and recorded an impairment of $5.3&#160;million based on an independent third-party valuation. No other impairment or downward adjustments to the carrying value of non-marketable securities have been otherwise recorded. In addition, pursuant to another investment in non-marketable securities purchased by the Company in October 2022, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the Company, on or before October 1, 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, 2021 and 2022, the Company received the first, second and third installment payments of $1.0&#160;million, $1.1&#160;million and $1.1&#160;million, respectively. The Company has evaluated and recorded a credit loss for the remaining $4.8&#160;million considering the third-party's credit worthiness and lack of financial history. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the receivable and the related credit loss amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Gross Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Net Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Gross Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Net Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allowance for credit losses activities for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent valid claims against commercial and governmental payers, biopharmaceutical companies, research institutes, international laboratory partners and distributors, including unbilled receivables, and royalty payments due from third parties for licensing the Company&#x2019;s technologies. Unbilled receivables include balances due from biopharmaceutical customers related to development services and other revenues that are recognized upon the achievement of performance-based milestones but prior to the achievement of contractual billing rights. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had unbilled receivables of $4.3 million and $5.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had an immaterial allowance for credit losses related to its accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to in-process research and development costs, or IPR&amp;amp;D, acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts. In connection with the launch of Shield LDT in May 2022, the Company's IPR&amp;amp;D of $1.6&#160;million was reclassified as an intangible asset with a useful life of 2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill is not amortized but is tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate its value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level. As of&#160;March&#160;31, 2023, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 2&#x2014;12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Post-acquisition Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Post-acquisition contingent consideration is recognized over the service period, subject to meeting the respective service requirements and performance metrics. For the three months ended March 31, 2023, and 2022, the Company recorded post-acquisition contingent consideration expense of $0.6 million and $2.1 million, respectively, in research and development expenses on the Company's condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use, or ROU, assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible senior notes are accounted for as a liability and measured at their amortized cost. Transaction costs related to the issuance of the notes are netted with the liability and are amortized to interest expense over the term of the notes, using an effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives revenue from the provision of precision oncology testing services, as well as from development services and other. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing the Company's technologies, kit fulfillment and screening services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes, international laboratory partners and distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. FASB ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its test to a clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development services and other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#x2019;s testing panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For the companion diagnostic development and regulatory approval services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of these contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, other revenue includes amounts derived from licensing the Company's digital sequencing technologies to its domestic customers and international laboratory partners, kit fulfillment and screening services. For the licensed technology, the Company is compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Kit fulfillment related revenues are recognized when such products are delivered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts with biopharmaceutical customers and international laboratory partners may include multiple distinct performance obligations, such as provision of precision oncology testing, the above-mentioned development services, and digital sequencing technology licensing, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers and international laboratory partners to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of March&#160;31, 2023 and December&#160;31, 2022, the deferred revenue balance was $17.1 million and $21.2 million, respectively, of which $3.4 million and $3.8 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets. Revenue recognized in the three months ended March 31, 2023 that was included in the deferred revenue balance as of December&#160;31, 2022 was $6.4 million, and revenue recognized in the three months ended March 31, 2022 that was included in the deferred revenue balance as of December&#160;31, 2021 was $3.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 1-2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of precision oncology testing generally consists of cost of materials, cost of labor, including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing test samples (including sample accessioning, library preparation, sequencing, and quality control analyses), freight, curation of test results for physicians, phlebotomy, and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, lease costs, amortization of leasehold improvements, and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Development Services and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of development services and other primarily includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers, and costs associated with the Company's partnership agreements and screening services. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan (as amended and restated), or the 2012 Plan, and the 2018 Incentive Award Plan, or the 2018 Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics, or PSUs, is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#x2019;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. No stock-based compensation expense is recorded for PSUs, unless it is determined to be probable that the related performance metrics will be met. Any PSUs that remain unvested at the end of the performance period will be forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjU_5f152a86-2538-464a-8f20-7ee680f2246b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts were made to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents and marketable debt securities as of March&#160;31, 2023, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzM_d3291347-8ce5-43be-a083-26472fa0363c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. &lt;/span&gt;&lt;/div&gt;The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.</us-gaap:UseOfEstimates>
    <gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjc_bc5b2133-4b5a-430d-8282-6936078b0997">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended, or the Securities Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwODU_3aab49b0-01b1-4135-a9d2-fbcc9ba9c17a">Restricted CashRestricted cash consists of payroll withholding related to the Company's enrollment in a voluntary disability insurance plan.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTk4MQ_dcb51ba1-8110-444a-a076-ef112ebda124"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTk4OA_888b2dc4-79e1-4b69-85dc-9950ac9b3f37"
      unitRef="usd">300000</us-gaap:RestrictedCash>
    <gh:NonMarketableSecuritiesPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzE_46576de5-3ea1-4653-b457-269542a4ad59">Non-Marketable SecuritiesThe Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investees. One of the investees is concluded to be a variable interest entity, or VIE, but the Company is deemed not to be the primary beneficiary as the Company does not have the power to direct the activities that most significantly impact the VIE&#x2019;s economic performance. The Company's non-marketable equity and other related investments totaled $19.6&#160;million and $25.0&#160;million&#160;as of March&#160;31, 2023, and December&#160;31, 2022, respectively, and are included in other assets, net on the accompanying condensed consolidated balance sheets. Non-marketable securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. As a result of the evaluation, the Company recorded an impairment of $5.5&#160;million for one of its non-marketable equity security investments for the three months ended March&#160;31, 2023 based on an independent third-party valuation. In addition, pursuant to one of the investments in non-marketable securities purchased by the Company, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. In September 2022, the Company decided not to exercise such rights to purchase the investee and recorded an impairment of $5.3&#160;million based on an independent third-party valuation. No other impairment or downward adjustments to the carrying value of non-marketable securities have been otherwise recorded. In addition, pursuant to another investment in non-marketable securities purchased by the Company in October 2022, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the Company, on or before October 1, 2023.</gh:NonMarketableSecuritiesPolicyTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNjQ5NQ_67e3a3e3-0b04-496b-9bc2-d2e231b9e415"
      unitRef="usd">19600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNjUwMg_e9c50f51-c45b-4256-8972-c3c652ad057c"
      unitRef="usd">25000000</us-gaap:EquitySecuritiesFvNi>
    <gh:EquitySecurityFVNIImpairmentOfPurchaseRights
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTY0OTI2NzQ4OTI1MA_fcd50c9f-01f2-4760-8071-163c1e448dc8"
      unitRef="usd">5500000</gh:EquitySecurityFVNIImpairmentOfPurchaseRights>
    <gh:EquitySecurityFVNIImpairmentOfPurchaseRights
      contextRef="idd26156a544941a48ee279e2b62c8c3f_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTY0OTI2NzQ4NzMyMQ_8164103e-cac6-4118-ab86-0d4ef158d4b6"
      unitRef="usd">5300000</gh:EquitySecurityFVNIImpairmentOfPurchaseRights>
    <gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzI_c462091a-ace8-4c6b-abf0-027b29de2b0e"
      unitRef="usd">0</gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTI_7754cb0f-2d0d-4a32-83e4-a5a1d3feeb83">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.&lt;/span&gt;&lt;/div&gt;The Company is also subject to credit risk from its other receivables and other assets.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTM_58a24d38-0843-45bc-b753-dd581e672eea">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNS0xMi0xLTEtNjgwMjI_8a1d3224-683a-4c10-a2ea-842169dd4425"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id35cadfe3a234269bcb1f5e099b19840_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi02LTEtMS02ODAyMg_4f34697c-1e71-4118-b831-1bc9c10493c2"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70f9229bf0864d9e814f7520f6d69d7d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi04LTEtMS02ODAyMg_e141945e-1498-4d1f-9b61-eaffb6fe655e"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib6f93c12cead4d2c895bca577a25be67_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi0xMC0xLTEtNjgwMjI_66a78fb0-8de4-47c8-90d1-d447aacb1598"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5cfb22333f754690bd602bfaec6d0504_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfNi0xMi0xLTEtNjgwMjI_f9cfeeee-ccb8-47f0-851e-28203997752f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3f4f6ec0d8c49d09f2cbdc348b5a7c7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfOS0xMC0xLTEtNjgwMjI_2bdb4241-8b93-492e-a203-fd76219d8654"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i966b9062789c40178998266340270e67_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOmJmOWJmMjg5NTgxYTQ4MjRiMmIyZTRlOTNhODc3NTJiL3RhYmxlcmFuZ2U6YmY5YmYyODk1ODFhNDgyNGIyYjJlNGU5M2E4Nzc1MmJfMTAtMTAtMS0xLTY4MDIy_b552e418-7334-4d43-a5d7-24e39bf9ebab"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLoss
      contextRef="i5fb596e53d6d4e77aa67b76c30c717a5_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTA5ODU_862e7de2-d2d5-4dcf-90c6-dcf2f39c77f0"
      unitRef="usd">8000000</gh:ContractualReceivablesBeforeAllowanceForCreditLoss>
    <gh:ContractualReceivablesTerm
      contextRef="i251adc25d68b484abdc116bdcad141c8_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEwMTM_8d538621-c60b-4904-8659-7cc976c6e134">P6Y</gh:ContractualReceivablesTerm>
    <gh:ProceedsFromContractualReceivable
      contextRef="iaa6502eac62f4edfbd8f440e52695d9f_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEwODk_8f6b10fa-4b58-4ae9-9ac4-fd2e06193854"
      unitRef="usd">1000000</gh:ProceedsFromContractualReceivable>
    <gh:ProceedsFromContractualReceivable
      contextRef="i28ecc6c83a29450f8f6715df23f4d2d3_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTExNzA_e535a625-b3ce-4842-a1ba-4e34342cd76a"
      unitRef="usd">1100000</gh:ProceedsFromContractualReceivable>
    <gh:ProceedsFromContractualReceivable
      contextRef="i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODU1MDM1_1f973501-9619-42f3-9a63-7bd470fc9b1d"
      unitRef="usd">1100000</gh:ProceedsFromContractualReceivable>
    <gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTEyNDU_8903036a-b268-4d05-a2f7-2948a47965ae"
      unitRef="usd">4800000</gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzY_d85afd54-21c0-4636-802a-2122205f3e69">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the receivable and the related credit loss amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Gross Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Net Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Gross Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Net Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allowance for credit losses activities for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;Beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Allowance for credit losses&#x2014;End of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNS0yLTEtMS02ODAyMg_e76da631-2845-4ab6-9f0a-ae7afad61578"
      unitRef="usd">1100000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNS00LTEtMS02ODAyMg_170fab12-b462-4f54-972f-286f6e992feb"
      unitRef="usd">0</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNi0yLTEtMS02ODAyMg_3a55da01-429c-4613-8a1c-0f53ed4d37c5"
      unitRef="usd">1100000</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNi00LTEtMS02ODAyMg_bfd6c67a-11c4-468c-b817-104195eef011"
      unitRef="usd">0</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNy0yLTEtMS02ODAyMg_e8d90811-3aa6-4610-aba0-2ff3a1951751"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfNy00LTEtMS02ODAyMg_939be085-5f74-46d1-824d-c0058f26efcb"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfOS0yLTEtMS02ODAyMg_e65112ec-05b5-49d6-b463-b556b32253fa"
      unitRef="usd">3700000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfOS00LTEtMS02ODAyMg_d6a6df52-d39f-4cd4-b334-93984af04e86"
      unitRef="usd">4800000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTAtMi0xLTEtNjgwMjI_c76b3f6c-1db1-44d9-b547-14d82067d4c7"
      unitRef="usd">3700000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTAtNC0xLTEtNjgwMjI_d62ec513-1c5a-4bee-8e79-fd8ffa57a8c5"
      unitRef="usd">4800000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTEtMi0xLTEtNjgwMjI_a683c17f-4dcc-4462-aabc-6c18c85eca64"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjEyOGQxOWQzNDZjYjQwNDE4MjdhZThjODJlOTZlNDc4L3RhYmxlcmFuZ2U6MTI4ZDE5ZDM0NmNiNDA0MTgyN2FlOGM4MmU5NmU0NzhfMTEtNC0xLTEtNjgwMjI_4d6a32ab-5c2d-4934-befe-c46d5695a327"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfNi0yLTEtMS02ODAyMg_d9681402-1dbc-49db-ad3e-771f2aee38c9"
      unitRef="usd">0</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i18bad5d6e63649409643e7d759322b03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfNi00LTEtMS02ODAyMg_728d2210-592a-42ab-8ca3-55690fafd17f"
      unitRef="usd">0</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesCreditLossReclassificationCurrent
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOC0yLTEtMS02ODAyMg_48346bac-a47f-4d80-9b8f-25cfc62d9cf0"
      unitRef="usd">1100000</gh:ContractualReceivablesCreditLossReclassificationCurrent>
    <gh:ContractualReceivablesCreditLossReclassificationCurrent
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOC00LTEtMS02ODAyMg_29c82dfc-8508-4e6e-b222-970572bed60c"
      unitRef="usd">1100000</gh:ContractualReceivablesCreditLossReclassificationCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOS0yLTEtMS02ODAyMg_a01bc6ae-2e88-489f-90cb-bea7acd69a2f"
      unitRef="usd">1100000</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfOS00LTEtMS02ODAyMg_4ac0838c-98f7-423b-aff4-157ea64e0086"
      unitRef="usd">1100000</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTEtMi0xLTEtNjgwMjI_6c145f5e-e92e-4fa3-8c39-d422ed53b1b5"
      unitRef="usd">4800000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i18bad5d6e63649409643e7d759322b03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTEtNC0xLTEtNjgwMjI_5c339cce-2950-431a-842a-2b2206c81a36"
      unitRef="usd">5900000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesCreditLossReclassificationNoncurrent
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTMtMi0xLTEtNjgwMjI_b9909d39-1337-45a3-838f-c6a1fd3ae27d"
      unitRef="usd">-1100000</gh:ContractualReceivablesCreditLossReclassificationNoncurrent>
    <gh:ContractualReceivablesCreditLossReclassificationNoncurrent
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTMtNC0xLTEtNjgwMjI_78951f1f-0637-45fc-9988-2933adec4da2"
      unitRef="usd">-1100000</gh:ContractualReceivablesCreditLossReclassificationNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTQtMi0xLTEtNjgwMjI_3ee95280-2d0f-42ca-acc2-b29a7b8d5734"
      unitRef="usd">3700000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i2401cae2c40e42969858a2d39f106f28_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RhYmxlOjIwMDgxMGNiMzcxMTQ4YmZiNWIyMjA5ZjRkNmEwNjU2L3RhYmxlcmFuZ2U6MjAwODEwY2IzNzExNDhiZmI1YjIyMDlmNGQ2YTA2NTZfMTQtNC0xLTEtNjgwMjI_10e7e070-162b-40c2-87cf-d0a44a7c8f62"
      unitRef="usd">4800000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzM_7e15eae1-4ddd-4f1a-a7c7-08107ef1ea51">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent valid claims against commercial and governmental payers, biopharmaceutical companies, research institutes, international laboratory partners and distributors, including unbilled receivables, and royalty payments due from third parties for licensing the Company&#x2019;s technologies. Unbilled receivables include balances due from biopharmaceutical customers related to development services and other revenues that are recognized upon the achievement of performance-based milestones but prior to the achievement of contractual billing rights. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had unbilled receivables of $4.3 million and $5.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of March&#160;31, 2023, and December&#160;31, 2022, the Company had an immaterial allowance for credit losses related to its accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTIyMzk_8f3b278f-9afa-43b5-9cd3-a9d6207f1166"
      unitRef="usd">4300000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTIyNDY_b089d966-c011-47c5-8ec4-a9eaa6a7a3c8"
      unitRef="usd">5400000</us-gaap:ContractWithCustomerAssetNet>
    <gh:AssetAcquisitionPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNTQ_3ab70e2a-8dda-46a3-9ef2-47ba6b068d68">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;</gh:AssetAcquisitionPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzQ_8f4bb92d-2b0a-4dae-9ec9-cff07d723676">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to in-process research and development costs, or IPR&amp;amp;D, acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts. In connection with the launch of Shield LDT in May 2022, the Company's IPR&amp;amp;D of $1.6&#160;million was reclassified as an intangible asset with a useful life of 2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill is not amortized but is tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate its value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level. As of&#160;March&#160;31, 2023, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 2&#x2014;12 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id85a3adbc9da44018010d9f2fcd08a6c_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ0NzM_956782d2-635e-4fae-a42e-4829fca8ee94"
      unitRef="usd">1600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ieb5caeb66ee94198aa9cd342c3f706e3_D20220501-20220531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ1Mzg_83940b6b-682f-4d64-966b-eb4edc611704">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTQ4Nzc_1043fe8d-d635-4099-be3e-8f72665f5ffd"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUwMzk_46fb3b00-890f-4c64-8c6f-bde2c9be3b2f"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6691016ad5b34d59883ed1923b33bed4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUzNDY_f0d3f085-fd4c-4071-911d-10258555a632">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i604eb9f9835e4c13814c14e8654cb3e8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMTUzNDk_a9084c15-6fc7-428c-b9e7-92b382448388">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <gh:PostAcquisitionCompensationPolicyPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNDk_f541c02c-9ced-4a99-890a-9a2510ea3a34">Post-acquisition Contingent Consideration Post-acquisition contingent consideration is recognized over the service period, subject to meeting the respective service requirements and performance metrics.</gh:PostAcquisitionCompensationPolicyPolicyTextBlock>
    <gh:PostAcquisitionContingentConsiderationExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODU1MTYw_b83f4b39-61a5-49cb-9ec6-042c5663eefb"
      unitRef="usd">600000</gh:PostAcquisitionContingentConsiderationExpense>
    <gh:PostAcquisitionContingentConsiderationExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxMDU2_dcab9950-618e-45f6-9b30-84d4a0ee49c8"
      unitRef="usd">2100000</gh:PostAcquisitionContingentConsiderationExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNDY_6f5f7212-69e6-449e-bf6f-210244075e32">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use, or ROU, assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNjI_23058f9d-fe9e-4733-8433-6e7e12c3ccad">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible senior notes are accounted for as a liability and measured at their amortized cost. Transaction costs related to the issuance of the notes are netted with the liability and are amortized to interest expense over the term of the notes, using an effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzA_e4d0f3d8-95a2-4259-ac14-6d0bc8782f50">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives revenue from the provision of precision oncology testing services, as well as from development services and other. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing the Company's technologies, kit fulfillment and screening services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes, international laboratory partners and distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. FASB ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its test to a clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development services and other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#x2019;s testing panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For the companion diagnostic development and regulatory approval services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of these contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, other revenue includes amounts derived from licensing the Company's digital sequencing technologies to its domestic customers and international laboratory partners, kit fulfillment and screening services. For the licensed technology, the Company is compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Kit fulfillment related revenues are recognized when such products are delivered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts with biopharmaceutical customers and international laboratory partners may include multiple distinct performance obligations, such as provision of precision oncology testing, the above-mentioned development services, and digital sequencing technology licensing, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers and international laboratory partners to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of March&#160;31, 2023 and December&#160;31, 2022, the deferred revenue balance was $17.1 million and $21.2 million, respectively, of which $3.4 million and $3.8 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets. Revenue recognized in the three months ended March 31, 2023 that was included in the deferred revenue balance as of December&#160;31, 2022 was $6.4 million, and revenue recognized in the three months ended March 31, 2022 that was included in the deferred revenue balance as of December&#160;31, 2021 was $3.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 1-2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzAyODM_43a47230-1bcc-4fe2-b2d5-da0294d77754"
      unitRef="usd">17100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxNDE4_cbd643fe-a846-485c-b3ca-af4f493d9bac"
      unitRef="usd">21200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzAyOTY_48edecbc-e531-4f9d-a93a-e77bcfe07a9e"
      unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNTQ5NzU1ODUxNDM5_57be3c91-f39c-432a-a5b0-dba30368bccb"
      unitRef="usd">3800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzA1NzM_ef2a7154-4faa-4aeb-8e06-af24ad781e96"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzA2NzM_e0ad5d8d-f948-45c8-8455-74857a5d7837"
      unitRef="usd">3500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration
      contextRef="i39a86681777f4f5a97cdce262db9a555_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNDM5ODA0NjU1NDA3OQ_ba7809a9-7188-48e1-96bd-6e31985c75a1">P1Y</us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration>
    <us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration
      contextRef="i7810d83be2d148339c6e185649dcccc3_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfNDM5ODA0NjU1NDA3Ng_23a3d9d8-2bba-4e33-ba43-f156e6216adc">P2Y</us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration>
    <gh:CostsOfPrecisionOncologyTestingPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzU_c3189e98-99ca-46e8-98c9-a3e0c3cd63b7">Costs of Precision Oncology TestingCost of precision oncology testing generally consists of cost of materials, cost of labor, including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing test samples (including sample accessioning, library preparation, sequencing, and quality control analyses), freight, curation of test results for physicians, phlebotomy, and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, lease costs, amortization of leasehold improvements, and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.</gh:CostsOfPrecisionOncologyTestingPolicyTextBlock>
    <gh:CostOfDevelopmentServicesPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzE_03702fbd-59f2-44e6-bd53-bd53cc796b14">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Development Services and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of development services and other primarily includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers, and costs associated with the Company's partnership agreements and screening services. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.&lt;/span&gt;&lt;/div&gt;</gh:CostOfDevelopmentServicesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwMzg_ddacc6e7-cf69-4136-b34a-d149d7c99a34">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzY_6d45892a-0771-4907-bf8d-71683ad00838">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan (as amended and restated), or the 2012 Plan, and the 2018 Incentive Award Plan, or the 2018 Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics, or PSUs, is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#x2019;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. No stock-based compensation expense is recorded for PSUs, unless it is determined to be probable that the related performance metrics will be met. Any PSUs that remain unvested at the end of the performance period will be forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80MC9mcmFnOmM0ZmEwZjQ4MjE3ODQ4YmRhMmYxN2ZkYzJkZmQyODQ3L3RleHRyZWdpb246YzRmYTBmNDgyMTc4NDhiZGEyZjE3ZmRjMmRmZDI4NDdfMzcwNzI_7c5325cb-c0e3-4e2e-a726-b1f7b3ab105a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNTQ3OQ_bf56d26a-8417-4699-b169-7b387daecaa9">Joint VentureIn May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc., the Joint Venture, for the sale, marketing and distribution of the Company&#x2019;s tests generally outside the Americas and Europe, and to accelerate commercialization of its products in Asia, the Middle East and Africa. Under the terms of the joint venture agreement, each party held an approximately 50% ownership interest in the Joint Venture and two seats on the board of the Joint Venture. In June 2022, the Company purchased all of the shares of the Joint Venture, or the Joint Venture Acquisition, held by SoftBank and its affiliates in consideration for a cash payment of the aggregate purchase price of $177.8&#160;million, which resulted in $99.8&#160;million of fair value adjustments to the noncontrolling interest liability. In connection with the Joint Venture Acquisition, the Company also issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options held by the Joint Venture's employees. Prior to the completion of the Joint Venture Acquisition, the Joint Venture was deemed to be a VIE, and the Company had been identified as the VIE&#x2019;s primary beneficiary. As the primary beneficiary, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation. Upon completion of the Joint Venture Acquisition and the tender offer, Guardant Health AMEA, Inc. became the Company's wholly owned subsidiary.</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i17dac8c118b84995ab3b80232dab1573_I20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNjIw_ff685ffa-d6cb-4dd7-96db-eef1ae21b291"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <gh:EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard
      contextRef="i17dac8c118b84995ab3b80232dab1573_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNTQ5NzU1ODE5ODA5_0266522f-7d5e-4704-bb24-bbf15f43a488"
      unitRef="seat">2</gh:EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ia536ff2c58f1448390655c51b679d617_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNDkzNA_599adc1a-700b-4b2d-8f54-49c655867e04"
      unitRef="usd">177800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="ia536ff2c58f1448390655c51b679d617_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80My9mcmFnOjI4MzAxMDc0YzI4ODRmMWE4M2EwZGYzZmIwMTY0MDNkL3RleHRyZWdpb246MjgzMDEwNzRjMjg4NGYxYTgzYTBkZjNmYjAxNjQwM2RfNDk1Ng_af1e28a0-e0be-4fe0-882b-64bfb6b84a37"
      unitRef="usd">99800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzMx_d5dda5e1-20a4-4b7a-bc60-e133bcd6dab4">Condensed Consolidated Balance Sheet Components&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $9.6 million and $6.7 million for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzI2_912a9be6-f491-4f3d-99ad-bf85ae83f533">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia40dd21d206c406fb998d0a9b6cd895f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMy0xLTEtMS02ODAyMg_ba501e8e-ac3f-41a6-8f1f-d429eefde67f"
      unitRef="usd">100688000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iecd08dde4eb843418c0ae87833fedcdf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMy0zLTEtMS02ODAyMg_39a846e2-4442-45e2-b26f-0d65d19837d7"
      unitRef="usd">95764000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibbcb14cec5f44c8289340eb8d4348692_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNC0xLTEtMS02ODAyMg_910eb21d-5918-40d7-849e-ab20cf3f38b4"
      unitRef="usd">99951000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1670651f92b400b9f911d06867002b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNC0zLTEtMS02ODAyMg_f2152d5c-1b14-45a1-8917-88aad2c721fb"
      unitRef="usd">99781000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic021058209134f95a1e8e10b009c7ace_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNS0xLTEtMS02ODAyMg_72ef6f34-0df8-4515-b78b-ab218ffc2fe0"
      unitRef="usd">31442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i246a5d493f5c473b88cd065c03268005_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNS0zLTEtMS02ODAyMg_38179a0e-89cf-46db-a078-ae4ecab5f3ce"
      unitRef="usd">29744000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2a29ac54766d4a0f8b2b24b51cdb55b4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNi0xLTEtMS02ODAyMg_363efbdc-a497-495a-86ae-f91f03929034"
      unitRef="usd">18560000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i60b5561c4b114d22bafce063538c856e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNi0zLTEtMS02ODAyMg_90537237-d9a2-448d-9d8c-5e6e4280a688"
      unitRef="usd">20598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6d186d3354934b5a8f8bbe42c4c14495_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNy0xLTEtMS02ODAyMg_6a34b41f-b03f-4556-815c-797e12bf36e3"
      unitRef="usd">8543000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic6bdcfada3cd4a2cbbe095e2aa5e702a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfNy0zLTEtMS02ODAyMg_fccb4885-f5ff-43d9-801f-013896f5217a"
      unitRef="usd">8367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ca178fdb5534ed4b35053a5ba325f0d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOC0xLTEtMS02ODAyMg_f3723144-a94d-45d5-a845-720f51b25b57"
      unitRef="usd">1797000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iae2f9a0766ce44c6af97879837c1db9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOC0zLTEtMS02ODAyMg_298bdfc2-666a-4bbc-8b99-9ab8e736a1dc"
      unitRef="usd">1797000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOS0xLTEtMS02ODAyMg_d81eec26-586c-4041-8026-179727380923"
      unitRef="usd">260981000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfOS0zLTEtMS02ODAyMg_70f756c6-87e1-4405-84d6-1218f1a84e4d"
      unitRef="usd">256051000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTAtMS0xLTEtNjgwMjI_c8f3b5c4-18a4-4888-b1ea-032197a049cd"
      unitRef="usd">97752000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTAtMy0xLTEtNjgwMjI_ca2c6125-e568-4295-b01d-433855222ab0"
      unitRef="usd">88131000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTEtMS0xLTEtNjgwMjI_fb75aff2-20ec-41d3-839e-f00bad8103b2"
      unitRef="usd">163229000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjczNWNmNGViMTRhZDQ0MThhODk5ZWMzMTJlYjI5MWRiL3RhYmxlcmFuZ2U6NzM1Y2Y0ZWIxNGFkNDQxOGE4OTllYzMxMmViMjkxZGJfMTEtMy0xLTEtNjgwMjI_4f56bb6a-a448-4ed4-99c9-d97339768fcc"
      unitRef="usd">167920000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNTI1_58373af8-4cdd-4dbc-bce1-d48eda9c893d"
      unitRef="usd">9600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNTMy_6b15f511-423d-4142-a3ea-b33bae10224e"
      unitRef="usd">6700000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RleHRyZWdpb246NjkzMWM4ZDE3OWFkNGJjNThjZTAzMzRmYzc0MTgwZmJfNzI5_0ab2e7d0-37f8-4d60-97c3-843dde7fe20d">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_a277a36a-542e-4806-bfc4-dc56d6d882cc"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0wLTEtMS02ODAyMg_ca97845a-2590-4d09-86dd-ee89356f9214"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfMy0xLTEtMS02ODAyMg_0a01990f-26fd-42eb-b89b-1c2a38e337d8"
      unitRef="usd">67320000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfMy0zLTEtMS02ODAyMg_9d95d056-4fc1-4518-8d78-d7be9c1da9fd"
      unitRef="usd">68911000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNC0xLTEtMS02ODAyMg_30583b9f-b65e-4206-9e27-ef5b045ad92d"
      unitRef="usd">69423000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNC0zLTEtMS02ODAyMg_238559c2-a11e-4fe2-84bf-35a07a3d8c1b"
      unitRef="usd">55788000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0xLTEtMS02ODAyMg_76cd82f0-0544-4205-9ec4-1ae806399ab4"
      unitRef="usd">23619000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNS0zLTEtMS02ODAyMg_85ee27f1-8caf-40f2-aa48-c02dd9ce492d"
      unitRef="usd">21878000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNi0xLTEtMS02ODAyMg_63a65f5b-d448-420e-bdd4-4130768c3ee8"
      unitRef="usd">30172000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNi0zLTEtMS02ODAyMg_89e725fa-178a-4403-9d8e-bed74f091432"
      unitRef="usd">29240000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNy0xLTEtMS02ODAyMg_91d0871e-62ca-40f9-9c73-d38fbe6db39e"
      unitRef="usd">190534000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF80Ni9mcmFnOjY5MzFjOGQxNzlhZDRiYzU4Y2UwMzM0ZmM3NDE4MGZiL3RhYmxlOjlhMWU2NjkxNWNiNzQwNDA4OTk2OTQxMDkyNWQwNGEzL3RhYmxlcmFuZ2U6OWExZTY2OTE1Y2I3NDA0MDg5OTY5NDEwOTI1ZDA0YTNfNy0zLTEtMS02ODAyMg_92279d6c-3cce-4b74-9c37-5dadc3997337"
      unitRef="usd">175817000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3MA_530ba4c1-8760-4adb-ac5c-c3134cea1414">Fair Value Measurements, Cash Equivalents and Marketable Securities &lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, and accounts payable and accrued liabilities. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, and accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Long-term marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, one of the Company's equity investees completed its IPO, subsequent to which, the Company started to account for the investment at fair value on a recurring basis, and classified the investment within Level 1 of the fair value hierarchy as the investment is valued using the quoted market price. The Company is subject to a 2-year lock-up period from the IPO date, during which the Company shall not transfer the investee's shares between accounts, establish or cancel pledges, sell, or withdraw such shares, without approval from the local securities and exchange commission. As of March&#160;31, 2023 and December&#160;31, 2022, the balance of the investment was $22.2 million and $18.3 million, respectively, included in other assets, net on the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's contingent consideration liability was $6.1 million and $6.4 million, respectively, of which $4.6 million and $4.9 million is considered long-term and was recorded within other long-term liabilities on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the Joint Venture Acquisition in June 2022, the fair value of the noncontrolling interest liability was considered to be a Level 3 measurement and was determined based on an annual internal rate of return of 20% on the initial amount of $41.0&#160;million invested by SoftBank in May 2018, to the date of Company's exercising the call right in November 2021. The noncontrolling interest liability was fully paid by June 30, 2022 (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities for the Level 3 financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Noncontrolling Interest Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the fair value of the Convertible Notes as of March&#160;31, 2023, and December&#160;31, 2022, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information related to the fair value of the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable debt securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the estimated fair values and gross unrealized losses of the Company's marketable debt securities that have been in a continuous unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;There have been no material realized gains or losses on marketable debt securities for the periods presented. The Company determined that it did have the ability and intent to hold all marketable debt securities that have been in a continuous loss position until maturity or recovery and the loss position was temporary due to market volatility, thus there has been no recognition of credit losses in the three months ended March&#160;31, 2023, and 2022, respectively. The Company recorded $3.9 million unrealized gains on marketable equity securities for the three months ended March 31, 2023, included in other income (expense), net on the Company's condensed consolidated statement of operations. The Company did not record any unrealized gains or losses on marketable equity securities for the three months ended March 31, 2022.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3Ng_c15827de-82fc-4dac-bc1a-05af92a1693b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, and accounts payable and accrued liabilities. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, and accounts payable and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3OA_c2871a12-64dd-43ae-9174-9e6a8fd9d78a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Long-term marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7d5c289384e245aa892095bbc5f2ab2b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi0xLTEtMS02ODAyMg_c3423b91-d3eb-4ddb-aea7-44a018bb9d94"
      unitRef="usd">54389000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i73f279ce6f9246c4848f2a4e3e17128a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi0zLTEtMS02ODAyMg_4fd26b0b-b1f5-4581-92a7-0c5b27d79f9b"
      unitRef="usd">54389000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iacc566dc53fa4e07bf56f8a8aabdb279_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi01LTEtMS02ODAyMg_3d22846f-048a-4a93-aefb-5c76444367d4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3168dac582d49e69c1516251fd3e0dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNi03LTEtMS02ODAyMg_98cf980d-976e-4aa0-8bd1-56527ad0b1bd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i42e3cdcf1bbe4a9b81b4b8bdc2e6ab64_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0xLTEtMS03MTc3MQ_a8579a40-b80b-424f-9409-28e03562be5b"
      unitRef="usd">74698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3214563d103944fcad24fe9145d19d95_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0zLTEtMS03MTc3Mw_aa7b33ac-94a0-4150-b136-4c03585ada25"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5f02aa3d8ed8418682e04a58b2a857df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy01LTEtMS02OTcxNQ_56fe025c-8141-4262-87a5-a49119b5d86e"
      unitRef="usd">74698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92a924e51c984ac7b0fbc1fd9ad60d4d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy03LTEtMS03MTc3NQ_e31729e4-d169-453d-bb52-d58c036838de"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0xLTEtMS02ODAyMg_6e24a9ea-2084-4d0e-a92b-415f7202f155"
      unitRef="usd">129087000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy0zLTEtMS02ODAyMg_6115e9ab-1620-42ae-b070-a8d1f2d55ffc"
      unitRef="usd">54389000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy01LTEtMS02ODAyMg_94534add-ffcf-4d04-a90a-a103c50084a6"
      unitRef="usd">74698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfNy03LTEtMS02ODAyMg_05f679ab-22e1-453d-bdb7-70b85bbeaf6e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i1a5558266daa4fd5803cd22934821259_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtMS0xLTEtNjgwMjI_da37c488-1b60-4f85-bd54-a493b21686c2"
      unitRef="usd">713380000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i9af15fbc37d84fa1955e0848cbda5aaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtMy0xLTEtNjgwMjI_23a5ebd1-6f49-4331-a54c-5e96a6cc525d"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i52d01132e1c54427979eb175a61dff09_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtNS0xLTEtNjgwMjI_e3ee1a6b-c5f0-4e3c-a679-81cb5db16866"
      unitRef="usd">713380000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i1963c0481247479c9f779e03f6b467ab_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTAtNy0xLTEtNjgwMjI_b60ebfd6-4cf2-4249-8566-8e5a84c0b4bd"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtMS0xLTEtNjgwMjI_9c6a9145-ec8b-4678-9605-31c28582ab6d"
      unitRef="usd">713380000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtMy0xLTEtNjgwMjI_e49a5b61-f874-49b3-af03-73d52f498eae"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtNS0xLTEtNjgwMjI_1035f60c-0466-4dce-b249-d3a430ad412e"
      unitRef="usd">713380000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTEtNy0xLTEtNjgwMjI_02d6d6e0-4028-4646-b24e-2f26340344ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtMS0xLTEtNjgwMjI_a8e4b38d-ea1a-431b-9f9d-918626467a77"
      unitRef="usd">22174000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtMy0xLTEtNjgwMjI_8747907f-0232-4e11-8aaf-86ea00f0cad4"
      unitRef="usd">22174000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtNS0xLTEtNjgwMjI_65ba2a0b-170d-49fb-9349-8017a2bfcac5"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTYtNy0xLTEtNjgwMjI_24f64aa5-e35d-4fb7-bb01-d4d21985ccbe"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctMS0xLTEtNjgwMjI_6b9a4903-9d0e-4fe2-9abf-59aeb54fa18d"
      unitRef="usd">864641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctMy0xLTEtNjgwMjI_af81f1df-5f9d-4d99-8669-576c082e05b6"
      unitRef="usd">76563000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctNS0xLTEtNjgwMjI_9846e70b-a878-46c2-b9cf-1332b7b41e7a"
      unitRef="usd">788078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMTctNy0xLTEtNjgwMjI_89b0fcce-85f7-4a1d-8b2d-2bc82215e32c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtMS0xLTEtNjgwMjI_e9b013e6-f13b-4f45-a67b-97e0405a3a14"
      unitRef="usd">6130000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtMy0xLTEtNjgwMjI_aeb05bd1-2168-44a8-a769-1bedb8fb77d9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtNS0xLTEtNjgwMjI_45cd8e6d-54a4-45eb-9151-c134c96ca8af"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjAtNy0xLTEtNjgwMjI_2cef0cdc-24d1-42a6-a28f-f4f3f28063c3"
      unitRef="usd">6130000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ieb852a9ed67d4316a04d75194f6818e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtMS0xLTEtNjgwMjI_a20d5086-043a-48f4-9965-d3619a1f45e9"
      unitRef="usd">6130000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2b835cd88e044426b718c40c4b445c18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtMy0xLTEtNjgwMjI_4b0f2317-b9da-4602-9efb-9abb4e88cdd9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i42c4c1ff2f6f4f8fafb8cd6f612d75b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtNS0xLTEtNjgwMjI_1790d579-4c1f-4139-a918-4ef3af3d94fc"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmIzM2ViNzdmZGIyODRkYWY5MTgzMzFmOTJiZTQxNzU5L3RhYmxlcmFuZ2U6YjMzZWI3N2ZkYjI4NGRhZjkxODMzMWY5MmJlNDE3NTlfMjEtNy0xLTEtNjgwMjI_a8c147cb-e741-4a58-9ced-999a8654256a"
      unitRef="usd">6130000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i698a971f2120433494d66c1f389aa846_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS0xLTEtMS02ODAyMg_6809708a-a376-49eb-ade4-219d46ab249a"
      unitRef="usd">3104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i645a895f548a4ff28015517f297d96a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS0zLTEtMS02ODAyMg_d7986061-72a3-495c-a116-ccf7ac5a215e"
      unitRef="usd">3104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20c5fb94fc744d39b9304cf6183f81e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS01LTEtMS02ODAyMg_cd4b8c38-76b4-473a-9c91-a560032ee71b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie641c330319e42cb920c03007560f205_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNS03LTEtMS02ODAyMg_97b2ee2e-08a2-4680-99fe-9cf66ea78231"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iecfd089f28904d93b229f01b003d873a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0xLTEtMS03MTc3Nw_ead55eb5-aa1c-4d9a-9258-f73a6e851ec7"
      unitRef="usd">14987000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d21756670fa4cdd8e4365d35747d8c9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0zLTEtMS03MTc3OQ_03736727-8465-4df6-a7e9-6a9486054edc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i58665cb260e34ed2974fba4c7d288b91_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi01LTEtMS02OTY4Nw_75451b96-99ab-4645-8863-164d2b9163e0"
      unitRef="usd">14987000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia63bc9236559423696b0059bb44368a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi03LTEtMS03MTc4Mg_a47cdf8c-3f71-461d-a673-e0ba0e532113"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0xLTEtMS02ODAyMg_9992642a-881e-44ca-8249-01c46f1d63d7"
      unitRef="usd">18091000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi0zLTEtMS02ODAyMg_7d8cb44b-f36f-4ae6-a01e-298a47162fca"
      unitRef="usd">3104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi01LTEtMS02ODAyMg_7591809e-ad3c-445c-b9f5-885e88fb82a9"
      unitRef="usd">14987000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfNi03LTEtMS02ODAyMg_38e3017f-fa7f-446d-8598-2ee873d35244"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i2b6d2513d70d4e718e77e46a90e3914f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS0xLTEtMS02ODAyMg_a43b4859-8cf1-4a20-aa4f-cf52c20cece1"
      unitRef="usd">869584000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ic2ed47738cd74c8e8c229d9ce44342ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS0zLTEtMS02ODAyMg_3c53e2a8-e37b-4925-ac87-0b5e796c3790"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i2c04821a302247519fa063baf7a9e04a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS01LTEtMS02ODAyMg_24df1f3e-c28d-406e-a9fb-f11f2df45d67"
      unitRef="usd">869584000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ia4c4a003031e4fc18e276dd67fb04ae3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfOS03LTEtMS02ODAyMg_0b631294-454a-4c9f-8594-bb2bbfb2ed2c"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtMS0xLTEtNjgwMjI_1e2302cb-9073-4aab-bd84-b8b71975079a"
      unitRef="usd">869584000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtMy0xLTEtNjgwMjI_5aa78c8d-772e-4453-ba53-7b5e95bd6096"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtNS0xLTEtNjgwMjI_c02987e9-386d-4cf2-8827-749306de6dea"
      unitRef="usd">869584000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTAtNy0xLTEtNjgwMjI_8c3a385f-9dfb-4781-8eec-71317a070b8a"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtMS0xLTEtNzE3ODQ_11d6b435-1048-40a0-84d1-7aa1136c1e0f"
      unitRef="usd">18291000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i293edf8bd4704d8884ce7ede54eb1f69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTUtMy0xLTEtNjk2NzM_1bc2d96b-ef5e-4b2f-9315-dc991b610b95"
      unitRef="usd">18291000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtNS0xLTEtNzE3ODY_a95fe609-3e5f-4add-9cab-7264e52249e1"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTYtNy0xLTEtNzE3ODg_8be608fe-abc2-4c5d-9ed3-260dee8348bf"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtMS0xLTEtNjgwMjI_6a847554-76c6-468f-9422-ae435281a2df"
      unitRef="usd">905966000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtMy0xLTEtNjgwMjI_6f19a4b9-0181-4c4d-9390-2bf34dd76f1c"
      unitRef="usd">21395000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtNS0xLTEtNjgwMjI_53799d5a-07f1-4ddd-a15c-7bf99f813cc2"
      unitRef="usd">884571000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTQtNy0xLTEtNjgwMjI_e5c49f5e-1d62-4a10-a5a1-0498400ae82b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctMS0xLTEtNjgwMjI_896faebb-ef88-4432-b0b1-aa94699521e0"
      unitRef="usd">6430000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctMy0xLTEtNjgwMjI_94287d72-625c-412b-8f6e-aadb4628dd18"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctNS0xLTEtNjgwMjI_a9991d42-6c84-428d-93bc-d589dedce4f4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTctNy0xLTEtNjgwMjI_c84a5841-d4e8-4710-8007-9bf405a79af9"
      unitRef="usd">6430000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic6cc878b77cc41ffae86c8b04609a610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtMS0xLTEtNjgwMjI_28e95d1d-e09a-4d50-976c-e0f994512acb"
      unitRef="usd">6430000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie07fa9240cef4fa6a34a33ea43e2bda5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtMy0xLTEtNjgwMjI_b7f3945a-9462-4d4e-b3e6-48f300b1b7e2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4cbc4c492b564ebcbc67541f9edbecc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtNS0xLTEtNjgwMjI_d5d913af-a062-473e-ae5b-5fed6bc921d0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzOGNhNDUzOWVlZjQ5NmFiNDc0YmFjMzQ5NmZmMDJiL3RhYmxlcmFuZ2U6NTM4Y2E0NTM5ZWVmNDk2YWI0NzRiYWMzNDk2ZmYwMmJfMTgtNy0xLTEtNjgwMjI_fb6f57c6-a69d-4683-a73c-d1b35f368483"
      unitRef="usd">6430000</us-gaap:LiabilitiesFairValueDisclosure>
    <gh:SaleOfStockLockUpPeriod
      contextRef="i8b77f5413426453b85bf391a9398dbb7_D20220701-20220731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMzE2NA_3e3a4664-83ce-438e-bc04-f4b8693cd0ed">P2Y</gh:SaleOfStockLockUpPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i967d903179d741649abf3b3123b84ae7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMzQ1Mw_25b869d6-a0d3-4aab-83b1-fcccd1a03fc5"
      unitRef="usd">22200000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i293edf8bd4704d8884ce7ede54eb1f69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMTA5OTUxMTYzNzk5Mg_0842d5fe-620f-4122-8236-09acb79f4f24"
      unitRef="usd">18300000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDYwNg_67986701-9c77-4f37-85e1-106f706fbaa2"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfMTA5OTUxMTYzODAwMA_3b435553-0aa9-4256-aad8-73b7961551a7"
      unitRef="usd">6400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia8ab4bf2a705463dbc04e086f2591ac6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDY0Ng_15597675-801b-4fb8-a331-dd8b3bc081a5"
      unitRef="usd">4600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic4a34db6e72349e9af6fc43f300a4276_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNTQ5NzU1ODIxODcy_5b5e3108-3950-48c3-95b0-4dab146ed433"
      unitRef="usd">4900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <gh:VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn
      contextRef="i6d8629622e1d44fb9a12b229ec47a1f7_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNjA0NzMxMzk2Mjk3Nw_1d82b4f3-0256-4b28-bd2c-bba83834a566"
      unitRef="number">0.20</gh:VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn>
    <us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue
      contextRef="ib473620977be4b178565e23e78583e12_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNDM5ODA0NjUyMTI5OA_904d0da6-70fe-46ef-9ffc-67a219ac20c3"
      unitRef="usd">41000000</us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY3Mw_5312b0e0-77c4-4e93-91c8-f6682f5bd832">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities for the Level 3 financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Noncontrolling Interest Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ied9f5b8c565a4dca904ac822c40abf74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi02LTEtMS02ODAyMg_35f7b7f1-c402-4dec-98ba-5593f676587a"
      unitRef="usd">78000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7491d2ac94a0486e8c65beb38d59a2ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi0xMC0xLTEtNjgwMjI_f6f2c7f9-fc22-4f78-a549-a8d8640ac64e"
      unitRef="usd">6430000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i32cd2d2a717f448ca58407271970c8e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfNi0xMi0xLTEtNjgwMjI_f109e0af-3f54-4d99-be18-7841ac9d234b"
      unitRef="usd">3625000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="ic3f16d72a05843cbbd0a5e1691d4c754_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC02LTEtMS02ODAyMg_2c1bbcf9-c583-4f38-b17c-f9e691dbf52b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="ibb285d391a2d4b938bbb5a745115ea97_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC0xMC0xLTEtNjgwMjI_f6055898-952f-4736-97b5-e72720301f3c"
      unitRef="usd">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="i379830d644434dba8ff6a21e1c68f858_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfOC0xMi0xLTEtNjgwMjI_9f9edfe2-97f7-4487-8e15-2fec16eb1037"
      unitRef="usd">2390000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icebfefb0eb874a23853e2e48b2069dc0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtNi0xLTEtNjgwMjI_130620d3-0899-478d-ada6-89104fce6641"
      unitRef="usd">78000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idf1e2b5f8f4a47bca104f021c60c4860_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtMTAtMS0xLTY4MDIy_c404a6f9-725e-4045-bb2e-503e468fca84"
      unitRef="usd">6130000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1d73083e0eca473a97a807ca5c0d2592_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjViNDEwMzk5NTk0NTQ3MWE5YzBiMTU5ZDVlYTkwYmQzL3RhYmxlcmFuZ2U6NWI0MTAzOTk1OTQ1NDcxYTljMGIxNTlkNWVhOTBiZDNfMTEtMTItMS0xLTY4MDIy_60a79ea5-9429-4faa-87f5-6286f0d8d26a"
      unitRef="usd">6015000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2NQ_d0a8c657-e87f-4452-8bb8-6ebfb8792f80">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable debt securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS0xLTEtMS02ODAyMg_838ae98c-884e-4951-aae8-44c974f4d7de"
      unitRef="usd">54389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS0zLTEtMS02ODAyMg_51348caf-5643-4af0-829b-1399209a6e15"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS01LTEtMS02ODAyMg_4e168e52-4eea-45ad-8d9e-084da7ee25a2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i926f66c4f4dc49b7a001e9143083c137_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNS03LTEtMS02ODAyMg_bc22fdcc-7ad8-4e14-ae82-a1e633b77ce0"
      unitRef="usd">54389000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy0xLTEtMS02ODAyMg_5a822125-c7d0-4b23-bd68-b972f4c498b5"
      unitRef="usd">797314000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy0zLTEtMS02ODAyMg_087849b0-8931-413f-a29d-4141c50a05e5"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy01LTEtMS02ODAyMg_6cbeec0c-dda2-44cb-9b2a-ade213517392"
      unitRef="usd">9257000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfNy03LTEtMS02ODAyMg_e82b65d8-5517-4f8e-a0b6-5f14ff35d87b"
      unitRef="usd">788078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC0xLTEtMS02ODAyMg_3cce18de-619b-4285-adae-a702b8e1b953"
      unitRef="usd">851703000</gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC0zLTEtMS02ODAyMg_338a5b14-99dd-479a-aaf8-8979556c7795"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC01LTEtMS02ODAyMg_b1faeeb4-ef55-4ebb-9a7a-d4fff82aa568"
      unitRef="usd">9257000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsAndDebtSecuritiesFairValue
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjUzYmUyMjk3NjQ1ZjQyNGRiNDI2YTdmOGU0YjkwZWIyL3RhYmxlcmFuZ2U6NTNiZTIyOTc2NDVmNDI0ZGI0MjZhN2Y4ZTRiOTBlYjJfOC03LTEtMS02ODAyMg_2dd3893b-7fcb-43fb-9bf1-ef75cc329dc0"
      unitRef="usd">842467000</gh:CashCashEquivalentsAndDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC0xLTEtMS02ODAyMg_bdc866c0-b4ab-421c-b0c2-e0429c0a1d06"
      unitRef="usd">3104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC0zLTEtMS02ODAyMg_526ae411-aae6-4aa0-ae3f-3049d31773e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC01LTEtMS02ODAyMg_cfd35fb9-1274-4e78-8494-6985eb5c22fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5bc2aa61097449da810dfe20cd6df079_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNC03LTEtMS02ODAyMg_6190c1e0-0f8d-49fd-b489-affb8f8cbdd8"
      unitRef="usd">3104000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi0xLTEtMS02ODAyMg_1adbdc69-7e94-4d7f-8d4a-0c0018d8e514"
      unitRef="usd">901342000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi0zLTEtMS02ODAyMg_8dfa80de-0c12-4780-a5f2-efd42c8e15b1"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi01LTEtMS02ODAyMg_140273f8-3a24-4acf-b3cb-109cd6a1f1af"
      unitRef="usd">16779000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNi03LTEtMS02ODAyMg_125f79e8-3fb9-414a-a827-c37eb8f4c078"
      unitRef="usd">884571000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy0xLTEtMS02ODAyMg_c5253ae5-6356-4aa2-9957-3310bf4a8ed5"
      unitRef="usd">904446000</gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy0zLTEtMS02ODAyMg_3ddc38da-89a5-4225-9f27-8223dbebf486"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy01LTEtMS02ODAyMg_088728d5-4841-41ee-b63d-a12e72834a05"
      unitRef="usd">16779000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsAndDebtSecuritiesFairValue
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjllNjBlODhmMmU0ZjRiYTg4M2E4NzJmY2YyODkxYjVkL3RhYmxlcmFuZ2U6OWU2MGU4OGYyZTRmNGJhODgzYTg3MmZjZjI4OTFiNWRfNy03LTEtMS02ODAyMg_be7375fe-8424-44d1-ae66-81da9ab1c059"
      unitRef="usd">887675000</gh:CashCashEquivalentsAndDebtSecuritiesFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MQ_a57cce32-70f2-4c81-bc09-7e5bd99c8950">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the estimated fair values and gross unrealized losses of the Company's marketable debt securities that have been in a continuous unrealized loss position as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0xLTEtMS02ODAyMg_d984d870-6015-49f8-88e2-d9c9d5d89128"
      unitRef="usd">99537000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0zLTEtMS02ODAyMg_dd96d88e-b707-481b-9fea-899f05e4a9f0"
      unitRef="usd">64000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC01LTEtMS02ODAyMg_c58e3697-1e56-4cef-bf61-0ed2e40c3fbd"
      unitRef="usd">590849000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC03LTEtMS02ODAyMg_644f40a4-14bd-405d-8923-354cd9320e97"
      unitRef="usd">9193000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC05LTEtMS02ODAyMg_80f599c9-7660-4e56-8145-3906fa797309"
      unitRef="usd">690386000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iea67017ee8da4bf7a6abbb8ca3679aa8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfOC0xMS0xLTEtNjgwMjI_36e34523-397e-4530-badc-04d61e075533"
      unitRef="usd">9257000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMS0xLTEtNjgwMjI_e90b11e0-a39e-428f-af09-8ad7f500ebb0"
      unitRef="usd">99537000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMy0xLTEtNjgwMjI_d966264a-5430-43c8-95a8-44528f617d2f"
      unitRef="usd">64000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtNS0xLTEtNjgwMjI_7d2359b1-6dce-47ad-9963-990c65661a90"
      unitRef="usd">590849000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtNy0xLTEtNjgwMjI_f49e0b70-ab86-4f4f-85c2-75a6d1fa3f6e"
      unitRef="usd">9193000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtOS0xLTEtNjgwMjI_34f67d6e-47d5-4193-80f8-646cf455ce7e"
      unitRef="usd">690386000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOmE5NTJiM2Q4MTg4NjQ4MGFhYTg1MTk5YmZiNjFmOWFhL3RhYmxlcmFuZ2U6YTk1MmIzZDgxODg2NDgwYWFhODUxOTliZmI2MWY5YWFfMTAtMTEtMS0xLTY4MDIy_1689be91-5ddd-4a82-ab22-e96bbad9e881"
      unitRef="usd">9257000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC0xLTEtMS03MDU2Ng_71bb7c83-7f97-4827-b13a-3bbc5782b50b"
      unitRef="usd">170975000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC0zLTEtMS03MDU2Ng_f2a74a35-c2c7-43e8-be24-71ccbeb9d1ae"
      unitRef="usd">2958000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC01LTEtMS03MDU2Ng_44609ff8-f367-435f-a801-d19b34fcca73"
      unitRef="usd">685754000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOC03LTEtMS03MDU2Ng_ffb766c2-7e15-431f-91a5-4dc90af2dda8"
      unitRef="usd">13821000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfNy05LTEtMS03MTgxMA_7b75c2d7-b344-46ee-b6c1-19b54a99afb4"
      unitRef="usd">856729000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ide92f0d2998b407aa0f38cfeebc5d4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfNy0xMS0xLTEtNzE4MTI_37114f0c-9ee8-4382-b56c-f46fcbb1588c"
      unitRef="usd">16779000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0xLTEtMS03MTc5Nw_13b7cb31-02a6-4682-8d47-b57b3451003b"
      unitRef="usd">170975000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0zLTEtMS03MTgwMQ_97872b33-7ffd-4191-a427-94093f76b899"
      unitRef="usd">2958000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS01LTEtMS03MTgwNA_c4a9e978-9477-4655-af71-52a312784784"
      unitRef="usd">685754000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS03LTEtMS03MTgwNw_38d63991-ed7b-4b8e-93e0-f8571d294d9b"
      unitRef="usd">13821000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS05LTEtMS03MTgxMA_76d9a294-c1f9-4751-aa5c-3a26853b0e5a"
      unitRef="usd">856729000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RhYmxlOjc2YTRjYWY5MDYxNjQ4Y2ZhMzY3NjI5YzIwZDk1ZDRiL3RhYmxlcmFuZ2U6NzZhNGNhZjkwNjE2NDhjZmEzNjc2MjljMjBkOTVkNGJfOS0xMS0xLTEtNzE4MTI_b194d5c9-a02b-420d-8ae0-9e7b9889cc8d"
      unitRef="usd">16779000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MA_c1849d97-63c5-4a2a-be26-5259e4756cde"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzY2MA_d4dfeb6c-5a73-44b9-9010-8d5f25028474"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzE1Mw_149ac3fd-0090-40b2-bae1-7f727a2bac60"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzE1Mw_e3793cac-f4a0-4a90-86ee-6d89a1c40bfc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzM1NA_41f90a03-c717-4530-9373-50623f441ebe"
      unitRef="usd">3900000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfNzM1NA_4e20a0c5-f7ec-489d-b565-ca5fc4a559c1"
      unitRef="usd">3900000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF81Mi9mcmFnOjIwYmExMWVkMDlkOTQ5NTE4Yjk0Y2ExZTJiMDM0ZGEyL3RleHRyZWdpb246MjBiYTExZWQwOWQ5NDk1MThiOTRjYTFlMmIwMzRkYTJfOTIyMg_af2e1f3d-e04f-490f-a7fe-a947cdfb853e"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzky_8883f287-28bf-4684-9469-c09a4e2591bc">Intangible Assets, Net and Goodwill&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived intangible assets was $0.7 million and $0.5 million for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzg5_de0c9b8c-af1d-4400-9f4e-342f4468d439">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzk1_36478b91-1c4d-4512-ac8a-dada5f79a120">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;March&#160;31, 2023,&#160;and&#160;December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi0yLTEtMS02ODAyMg_463b79c7-8fa4-4346-abc5-b8a9e2112003"
      unitRef="usd">11886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi00LTEtMS02ODAyMg_02e254d3-b779-424d-acc7-37982f67c983"
      unitRef="usd">3852000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i482b6cd7778c438ba3a971ad9a5511c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi02LTEtMS02ODAyMg_4b87680d-f220-44f0-8699-2f0d74472c24"
      unitRef="usd">8034000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iea8dad0b65c142c5b15551bf9029a808_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNi04LTEtMS02ODAyMg_d86c4f0c-03e9-46c5-9fe7-ec099052fa40">P7Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy0yLTEtMS02ODAyMg_a4592bdc-c559-4c03-94ea-8fae493b521d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy00LTEtMS02ODAyMg_7c735f04-aff7-42a4-b698-9909771a574b"
      unitRef="usd">2954000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i63d00e5d8314401f9793acf9cd87f30d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy02LTEtMS02ODAyMg_0baf9f84-657a-489c-bd15-eece47a7a030"
      unitRef="usd">2146000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3add32afcf0e47928bccc0d9a1e4ab89_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfNy04LTEtMS02ODAyMg_b86e4359-73da-4a45-be1e-3ce8cbd38217">P2Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC0yLTEtMS02ODAyMg_8b431c18-dc67-4dca-9850-74fdd72add0b"
      unitRef="usd">1600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC00LTEtMS02ODAyMg_f018bc34-ad36-4b46-9973-343f8ae33033"
      unitRef="usd">733000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2eddcaeafe4e42668ad2d2e8336dcc6b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC02LTEtMS02ODAyMg_0f138e65-d90f-4750-91e0-7a43ebcc0887"
      unitRef="usd">867000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i47c2c3e9fc144decaddb722e0a2f7ce2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOC04LTEtMS02ODAyMg_9fefe373-ea9d-4000-a74c-af8ae55843ff">P1Y1M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS0yLTEtMS02ODAyMg_6c635c11-1aa0-40be-834d-02111128e11b"
      unitRef="usd">18586000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS00LTEtMS02ODAyMg_78fda6d6-8972-4970-a79f-08c2f884b09b"
      unitRef="usd">7539000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfOS02LTEtMS02ODAyMg_685a8820-b287-43b5-9d1b-08ed29f3a5e5"
      unitRef="usd">11047000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTItMi0xLTEtNjgwMjI_1ce88628-cea3-47d4-aa0d-f4c2f0779c7e"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTItNi0xLTEtNjgwMjI_23bd963b-2ad2-40c1-89da-23759e65fd38"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtMi0xLTEtNjgwMjI_4ffdc897-65ae-4c8d-ba4d-194ef7a73112"
      unitRef="usd">21876000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtNC0xLTEtNjgwMjI_768cbe47-72cf-49d5-947b-6723ac00c129"
      unitRef="usd">7539000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjY4ZDEzNjhmYzU5MTQzZjBhNjE4YTExY2JiMWJmYzA4L3RhYmxlcmFuZ2U6NjhkMTM2OGZjNTkxNDNmMGE2MThhMTFjYmIxYmZjMDhfMTMtNi0xLTEtNjgwMjI_932b4959-0586-40d3-a2b5-0501378c3cb4"
      unitRef="usd">14337000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS0yLTEtMS02ODAyMg_daafa59b-28b4-47df-84ad-15cca77fca5a"
      unitRef="usd">11886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS00LTEtMS02ODAyMg_fbf2a6e0-391f-49fb-bd7f-321ac0d12f90"
      unitRef="usd">3579000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i98ffab5486f140f2bc284e765264afc3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS02LTEtMS02ODAyMg_b8f7c52c-9f12-4b31-8915-3793ddf163a8"
      unitRef="usd">8307000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8d450e08fff545ebb9a7c77e00ca86e1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNS04LTEtMS02ODAyMg_8b78345d-7376-4b87-9b1b-8aafda5c2077">P7Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib1ad0ce630064286a222741120078585_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi0yLTEtMS02ODAyMg_5b390804-fabd-44cb-a3b6-fbd3e6cae43b"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1ad0ce630064286a222741120078585_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi00LTEtMS02ODAyMg_cfdd375a-c8ae-4ba1-b0ab-98245c908bb0"
      unitRef="usd">2747000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib1ad0ce630064286a222741120078585_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi02LTEtMS02ODAyMg_1bf07a35-9ac2-48ca-ba00-4c0c73fafefd"
      unitRef="usd">2353000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2ef1b08124ca422d8c5fde0b52484dbe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNi04LTEtMS02ODAyMg_2c292515-f9e6-4a83-897c-52adeb5f2a47">P2Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy0yLTEtMS03MDY5MA_77126bca-3e40-4393-bb70-f7fbedcf4f06"
      unitRef="usd">1600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy00LTEtMS03MDY5Mw_04a54c4e-f3ae-4baf-a3ae-e1f2e8e52327"
      unitRef="usd">533000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iac2ed04947454c96b49ed77c531cc5bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy02LTEtMS03MDY5Ng_2b766914-2f89-44d3-89ac-1242500a3211"
      unitRef="usd">1067000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i20def10aa5d14802a5363d3f0e99bcb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy04LTEtMS03MDcwNQ_4f6dbf8a-ceda-48f9-b5be-002e76034a95">P1Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy0yLTEtMS02ODAyMg_b157e23c-a420-40a1-b080-7ac363369c6e"
      unitRef="usd">18586000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy00LTEtMS02ODAyMg_445520cf-00fd-470a-ad00-6254a8936bd4"
      unitRef="usd">6859000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfNy02LTEtMS02ODAyMg_a70d7d58-1422-4987-890f-092f1c490f4e"
      unitRef="usd">11727000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTAtMi0xLTEtNjgwMjI_623169ff-2bf4-4e29-aa6b-e40045dce4c0"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTAtNi0xLTEtNjgwMjI_66409dbc-9475-4450-bfa4-83d601bdc019"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtMi0xLTEtNjgwMjI_9c197ee2-f64f-4db3-9cba-5d0bd21c3e17"
      unitRef="usd">21876000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtNC0xLTEtNjgwMjI_16b76b3f-0cb7-45e0-956a-90471b4e9c7d"
      unitRef="usd">6859000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOjcyZWNjZTkwMjkyMTQ3Y2ZiNWVkN2U3OTZmNTk3OTY2L3RhYmxlcmFuZ2U6NzJlY2NlOTAyOTIxNDdjZmI1ZWQ3ZTc5NmY1OTc5NjZfMTEtNi0xLTEtNjgwMjI_1cc2e71e-82f4-4fd8-bb39-82214915c86f"
      unitRef="usd">15017000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMTg3_90794f00-f1e5-4230-9ea0-c2e0d069fc76"
      unitRef="usd">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMTk0_fdc17767-7a27-4867-ae6b-fc0712a10e05"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RleHRyZWdpb246ZGY5NTljZDA3NGE0NGQ3MThhZjlmNGM2M2U4N2RhYmNfMzk2_3e4512b9-e51b-4b1b-85a0-42a34a831d46">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfMy0yLTEtMS02ODAyMg_13e2df80-51d8-4182-bc21-83ff40679b55"
      unitRef="usd">2067000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNC0yLTEtMS02ODAyMg_6d650449-0312-44ef-bf25-3428eed7f6fd"
      unitRef="usd">2219000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNS0yLTEtMS02ODAyMg_c1cdf6bd-92a0-4b3c-80c4-e9fb408d2c7b"
      unitRef="usd">1670000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNi0yLTEtMS02ODAyMg_e8650912-76e7-47ca-991e-fa7f926a4c40"
      unitRef="usd">1212000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfNy0yLTEtMS02ODAyMg_8e677392-9a9b-487f-880c-48ebc681cb52"
      unitRef="usd">1107000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfOC0yLTEtMS02ODAyMg_fa242fec-26ab-4315-a6ee-17afc4c48421"
      unitRef="usd">2772000</gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82MS9mcmFnOmRmOTU5Y2QwNzRhNDRkNzE4YWY5ZjRjNjNlODdkYWJjL3RhYmxlOmMwY2M5ZGE1YWUwYTRmY2E5ZjY5NDg4ZTU4Nzk3ZGNhL3RhYmxlcmFuZ2U6YzBjYzlkYTVhZTBhNGZjYTlmNjk0ODhlNTg3OTdkY2FfOS0yLTEtMS02ODAyMg_f0ceaa85-a6eb-41e8-816e-c785de9ac645"
      unitRef="usd">11047000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjYyNw_0716eef7-c612-46af-b733-56cefc1cdd9d">Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company issued $1.15&#160;billion principal amount of its 0% Convertible Senior Notes due 2027, or the 2027 Notes. The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter, or the sale price condition;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;during the five consecutive business days immediately after any ten consecutive trading day period, or the measurement period, if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;upon the occurrence of specified corporate events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#x2019;s election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $139.82 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#x201c;Make-Whole Fundamental Change&#x201d; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#x2019;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&#x2019;s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If certain corporate events that constitute a &#x201c;Fundamental Change&#x201d; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the 2027 Notes were not convertible as of March&#160;31, 2023 and December&#160;31, 2022, the net carrying amount of the 2027 Notes was classified as a long-term liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net carrying amounts of the 2027 Notes as of March&#160;31, 2023, and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability component:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair value of the 2027 Notes was $0.8 billion and $0.7 billion as of March&#160;31, 2023, and December&#160;31, 2022, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, which represented an effective interest rate of 0.2% and 0.2% for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions, or the 2027 Note Hedges, with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $182.60 per share, which represents a premium of 75% over the last reported sale price of the Company&#x2019;s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#x2019; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0&#160;million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNzY_7a898682-6296-4a98-89c0-d16af71cdedb"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTAz_19e0410b-9d6a-4529-afcd-19681680edc4"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage
      contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzY2_37a0e470-9d4a-40b9-a66b-33dcd12e5e7c"
      unitRef="number">0.0050</gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTAxOQ_78761599-3c12-4555-9d01-adcc261b98f2"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTA2Nw_b6d932ac-6042-452f-be62-ebd564feb738"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="if7ae0f6e1d18431fb7ce859e2b072551_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTEyMw_48c289b8-2e5a-4b8c-87c9-2d8709b72a78"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTI2OQ_b8df7575-8458-48f4-93a5-2ceef0d360e1"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTMyMA_46c93d42-7629-402e-9837-a037d9a74516"
      unitRef="d">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate
      contextRef="i709636ebb2804c8aa1c1ebaf71b56a29_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTUwMA_7e58a211-3d9e-49b0-96b7-e579f1312a10"
      unitRef="number">0.98</gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i32ad1fbc3dfd4b90ba560b118b576125_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMjI3OA_5cf62606-bf0b-40e1-82e2-ee351885c97a"
      unitRef="usdPerShare">139.82</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzIzOQ_4a390f50-3832-408a-a578-26a5774b49fa"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzI5MA_c5241be3-24e5-4371-800d-97bc0313e36e"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia3f0b4de61c34e4cb8a990ae57b687b3_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMzM0Ng_c4274377-bfcc-49a4-bef4-2f729aa443da"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjYyNA_7a8ce495-6d25-4603-8304-5f2a025c9030">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net carrying amounts of the 2027 Notes as of March&#160;31, 2023, and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability component:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNC0yLTEtMS02ODAyMg_d44ce159-c5b8-4117-b17c-d07166b1139d"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNC00LTEtMS02ODAyMg_0aca490b-a4d9-4d4c-9755-be88e76d6d26"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNi0yLTEtMS02ODAyMg_9e78a488-9fb1-43b9-8682-e19b1125784a"
      unitRef="usd">11966000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNi00LTEtMS02ODAyMg_45d36f81-70ed-4111-80b0-7b86469e4b82"
      unitRef="usd">12609000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNy0yLTEtMS02ODAyMg_5f7c3a4b-e017-4d5b-8898-096e4c39c629"
      unitRef="usd">1138034000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RhYmxlOjMyZmRhZjc5YjliNjRjNjRhZGI3N2RiNzBiOWFlMjk1L3RhYmxlcmFuZ2U6MzJmZGFmNzliOWI2NGM2NGFkYjc3ZGI3MGI5YWUyOTVfNy00LTEtMS02ODAyMg_84b1ecf2-3a00-48be-b7e2-c6d5d4ebd47a"
      unitRef="usd">1137391000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDc3NA_4eb6d2bf-b484-4cec-b5b3-95edaec07cd0"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1e7530b179b2482daf26e93a3433f2d3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDc4MQ_edb36214-537b-4c59-9dbb-7db118c5359b"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFairValue>
    <gh:DebtInstrumentMeasurementInputDenominator
      contextRef="ie06cffa6cd1640db8649a5e4f20e89f0_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNDg4NQ_7c999bd8-5e96-4aa7-bc7d-8749479e23bf"
      unitRef="usd">100</gh:DebtInstrumentMeasurementInputDenominator>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iafd5c38886184fd6af5573e63dd61acd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTAzOQ_010cd4b2-a9ff-4ee4-ba3e-35ddfecf3ab1"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7c8b26b7ee69436e81522ee5db3fb810_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfMTY0OTI2NzQ0ODMwNQ_abbf718a-14ad-46ac-abe9-eec3989e66d5"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic4afdaf1a32649acbb00d349e86393cd_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTE0OQ_44144867-c83c-450c-9a84-2b0501395a53"
      unitRef="number">0.002</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib6a0869ad8ec4e6aa0ab8611139bf5b8_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTE1Ng_343a8ce6-4418-4957-b259-fba4de1dbda4"
      unitRef="number">0.002</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <gh:ConvertibleDebtHedgeStrikePrice
      contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTY4MA_c9b5650d-b9a7-4203-90de-8ae45b98e066"
      unitRef="usdPerShare">182.60</gh:ConvertibleDebtHedgeStrikePrice>
    <gh:ConvertibleDebtHedgeSharePricePremiumPercentage
      contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTcyNA_87be85e6-c598-4e75-aefa-c75474ba8bbd"
      unitRef="number">0.75</gh:ConvertibleDebtHedgeSharePricePremiumPercentage>
    <us-gaap:SharePrice
      contextRef="i73765d8c5b9c47e49e769314e9a95216_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNTc5NA_e86ac494-cfcb-444b-b4be-521cf2cdcca9"
      unitRef="usdPerShare">104.34</us-gaap:SharePrice>
    <gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
      contextRef="ifa6e61cb42a24541ada6ecb600b9aafe_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF82NC9mcmFnOjM0NGNkM2Q0NjZkMDRkYzhiMzU4ODg0YzI4N2U4ODgxL3RleHRyZWdpb246MzQ0Y2QzZDQ2NmQwNGRjOGIzNTg4ODRjMjg3ZTg4ODFfNjUwMA_e8454abc-5c8b-46b5-9c35-f48ed4291e10"
      unitRef="usd">90000000</gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIyMA_cab18179-7e12-4b64-ad4e-3f3f24d7e132">Leases&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various operating lease agreements for office space, data center, lab and warehouse use, with remaining terms ranging from 1 year to 11 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense was $7.3 million and $6.9 million for the three months ended March 31, 2023, and 2022, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are not material to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1e94bdae869e4b2a9849b1c8d02651a5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTY4_39f740a1-9e9b-47f3-9f8c-7e948e6d8ee8">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie6cdfb5a23124fe8acf8a056dc1ce503_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc0_3e92cbfc-9f4a-4003-99a0-cb27a172c7c7">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc4Mw_7c98f67c-3e0e-4cd9-a411-4c343e642095"
      unitRef="usd">7300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMTc5MA_8527f98c-73d9-4030-a4f3-06a504ae0a0d"
      unitRef="usd">6900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIyMg_16c3c471-e8b3-42da-8c37-a9d4e5086e09">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMi0yLTEtMS02ODAyMg_eb97213c-6445-46e6-acfd-493a1832b1f8">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMi00LTEtMS02ODAyMg_3f918c5a-798b-43c8-85b2-ee6422c51828">P9Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMy0yLTEtMS02ODAyMg_43d54edc-5a7c-48bb-8d85-0292bf7c0ac6"
      unitRef="number">0.0393</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjVmNTQ0ZDIzZjNjZDQ2Zjc5NDlmZWVmZTI2NDhjNGFhL3RhYmxlcmFuZ2U6NWY1NDRkMjNmM2NkNDZmNzk0OWZlZWZlMjY0OGM0YWFfMy00LTEtMS02ODAyMg_6c51c488-011b-4d48-9f7b-cec6a32011c9"
      unitRef="number">0.0393</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RleHRyZWdpb246MjliZThiNjI4YzZjNDkyN2I4YmQwM2E2NmJiYmUyODhfMjIxOQ_b2e43640-9657-4bfb-a2c7-b45eabe93d86">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMy0xLTEtMS02ODAyMg_53c87d47-a219-4fd7-9ad7-568b1088545b"
      unitRef="usd">23612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNC0xLTEtMS02ODAyMg_fb3eb627-30d4-45d9-a6cc-46bb1a622cf9"
      unitRef="usd">33668000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNS0xLTEtMS02ODAyMg_3b9ac785-5607-4030-9cb5-ced3989ca98e"
      unitRef="usd">32655000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNi0xLTEtMS02ODAyMg_96690855-bc31-401b-b4ad-9fbe20f2c909"
      unitRef="usd">27799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfNy0xLTEtMS02ODAyMg_c6c7eef6-e6d6-4e0a-bd4c-e1d8de87c2f0"
      unitRef="usd">24479000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfOC0xLTEtMS02ODAyMg_7f51cb20-fbfe-4270-b2d6-d0eae2d6fc92"
      unitRef="usd">125157000</gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfOS0xLTEtMS02ODAyMg_6ee09f0e-afa8-440e-9ace-44e8bcfe77ee"
      unitRef="usd">267370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMTAtMS0xLTEtNjgwMjI_00ef1e3a-2a16-4d24-9289-a4f9291c6c65"
      unitRef="usd">38894000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83MC9mcmFnOjI5YmU4YjYyOGM2YzQ5MjdiOGJkMDNhNjZiYmJlMjg4L3RhYmxlOjIyM2NlYWNhMjJlODQ1YzdhNjY2ZWUwMDkzN2JlMjJiL3RhYmxlcmFuZ2U6MjIzY2VhY2EyMmU4NDVjN2E2NjZlZTAwOTM3YmUyMmJfMTItMS0xLTEtNjgwMjI_46ada688-6336-44a7-8979-1a1ece8d0cc8"
      unitRef="usd">228476000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83Ni9mcmFnOmUzNzFlYzRhMGJkYjRjNjI5ZTQzYWVmYWM4MTQ0ZTMxL3RleHRyZWdpb246ZTM3MWVjNGEwYmRiNGM2MjllNDNhZWZhYzgxNDRlMzFfNjI4OA_3d9a4e2a-b695-414a-912b-3615e7ce9dbd">Commitments and Contingencies &lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intellectual Property Disputes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, TwinStrand Biosciences, Inc., or TwinStrand Biosciences, and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#x2019; allegations and asserted counterclaims of invalidity, unenforceability due to inequitable conduct and infringement of four of the Company&#x2019;s patents. Discovery in the case is ongoing and trial is scheduled to commence in November 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Illumina Inc., or Illumina, filed suit in the United States District Court for the District of Delaware against the Company and its Co-Chief Executive Officers, Drs. Helmy Eltoukhy and AmirAli Talasaz, or collectively, the Defendants, alleging that Illumina is the owner of certain of the Company&#x2019;s patents and patent applications, and that the Defendants allegedly misappropriated Illumina trade secrets. Illumina also alleges that Drs. Eltoukhy and Talasaz breached various Illumina employment contracts, company policies, and implied covenants of good faith and fair dealing as part of their former employment with Illumina prior to starting the Company. Illumina is requesting unspecified compensatory and punitive damages, attorneys&#x2019; fees, and specific performance in the form of a declaration of ownership and assignment of intellectual property filed for or obtained by the Defendants that derives from the alleged misuse of Illumina confidential information. The Defendants deny the allegations of misconduct, and in March 2023, the District Court granted in part the Defendants&#x2019; motion to dismiss the complaint, without prejudice to amend, effectively staying discovery on the dismissed allegations.  In April 2023, Illumina filed an amended complaint to which Defendants will respond by June 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;False Advertising Dispute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company also filed a lawsuit against Natera, Inc., or Natera, in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#x2019;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#x2019;s Signatera assay. The Company is seeking an injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. The Company moved to dismiss Natera&#x2019;s counterclaims, and in January 2022, the court granted in part and denied in part the Company's motion to dismiss. The Company and Natera have both moved for summary judgment on various claims, with the court granting in part non-dispositive motions brought by each party. Trial is scheduled to commence in July 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Civil Investigative Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company received a Civil Investigative Demand, or CID, from the United States Attorney for the Northern District of California in connection with an investigation under the False Claims Act. The CID requests information and documents regarding billing of government-funded programs for the Company&#x2019;s panel of genetic tests known as Guardant360. The Company is fully cooperating with the investigation. At this time, the Company is unable to predict the outcome of this investigation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF83Ni9mcmFnOmUzNzFlYzRhMGJkYjRjNjI5ZTQzYWVmYWM4MTQ0ZTMxL3RleHRyZWdpb246ZTM3MWVjNGEwYmRiNGM2MjllNDNhZWZhYzgxNDRlMzFfMzQ5NA_07f16d0c-f785-4f40-8466-c32ae23350cd"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMzY1_b923c4fd-30e8-4cf6-9f22-c9b7234d95db">Common StockThe Company&#x2019;s common stockholders are entitled to dividends if and when declared by the Company&#x2019;s Board of Directors, or the Board of Directors. As of March&#160;31, 2023, and December&#160;31, 2022, no dividends on the Company's common stock had been declared by the Board of Directors.&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying outstanding stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372,561&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402,574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687,888&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438,296&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,311&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875,818&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,249,546&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DividendsCommonStock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMTg1_285140bf-3616-4c88-852b-13554776516c"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMTg1_7fe81e41-d2f8-45ca-a210-038460ababe5"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RleHRyZWdpb246OWQyNjZiOTEzZDJmNGU3M2FmMTZkOWQ2YzdlZDU2NTNfMzY4_866c7d2d-94db-4842-95f0-6fc477971526">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying outstanding stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372,561&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402,574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687,888&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438,296&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,311&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875,818&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,249,546&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9c7c95d575374df5873ad5d340d429dc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMi0xLTEtMS02ODAyMg_4f745229-5f08-4cb1-a692-c26aac6ac3f8"
      unitRef="shares">3372561</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i471e1119a5c84de99cc7a66a9091e4b6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMi0zLTEtMS02ODAyMg_726e185d-844b-431c-a92a-2c1012772b9e"
      unitRef="shares">3402574</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i24e6708f9c264d729a87143b05a29523_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMy0xLTEtMS02ODAyMg_396031a5-307a-4620-8e49-b49d39be7db0"
      unitRef="shares">3430821</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfMy0zLTEtMS02ODAyMg_d3fb09d2-cd95-4196-97d6-a9dd203ac625"
      unitRef="shares">3687888</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4b6c755d9322493ea937d75411cca741_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNC0xLTEtMS02ODAyMg_516787d0-d553-42ff-bbb0-e166e206f922"
      unitRef="shares">2260764</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3b801579905e486f9d16da0424368dea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNC0zLTEtMS02ODAyMg_f5c45211-7be6-4c54-b26a-a52c96b067cc"
      unitRef="shares">2260764</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i67005148159d4de98f4625a633c07616_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNS0xLTEtMS02ODAyMg_134437c2-1f6d-4203-b533-2ca5346976e6"
      unitRef="shares">333275</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNS0zLTEtMS02ODAyMg_7146dfc5-a608-49e1-b2a5-ed5d87183647"
      unitRef="shares">341713</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i12acc1844c7547209359a2ebd3bbac18_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNi0xLTEtMS02ODAyMg_096d6ffc-4c68-46e3-9ec9-4ba4007ce9d9"
      unitRef="shares">9333892</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2888bc5ff0cd47c1b681eb96ef6bc6c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNi0zLTEtMS02ODAyMg_e46cdb4c-9d60-4687-83fc-f32fe4a7b02e"
      unitRef="shares">5438296</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id8b85720538549e793c0ea411f6d2926_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNy0xLTEtMS02ODAyMg_21ffc150-76d6-4daf-9414-38d9eb82ca20"
      unitRef="shares">2144505</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia4744fe70bd24460bded39c69c9e72eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfNy0zLTEtMS02ODAyMg_6706cb40-64c3-4fc4-8b77-4e16efa429c4"
      unitRef="shares">1118311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfOC0xLTEtMS02ODAyMg_9f0dae77-aafd-48b0-9911-230ef68ce911"
      unitRef="shares">20875818</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84Mi9mcmFnOjlkMjY2YjkxM2QyZjRlNzNhZjE2ZDlkNmM3ZWQ1NjUzL3RhYmxlOmEzZjBjMjcxNjU2ZTQwMzE4NWQwMmUwZDUwZjIyODVjL3RhYmxlcmFuZ2U6YTNmMGMyNzE2NTZlNDAzMTg1ZDAyZTBkNTBmMjI4NWNfOC0zLTEtMS02ODAyMg_aa642cc6-eab6-4fc2-9eb3-a2e79ef2d2e3"
      unitRef="shares">16249546</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODE_9e4aaa19-3776-4528-8945-cf3a2828bc59">Stock-Based Compensation&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Plan annual increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,091)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,091&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,049)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,055)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,717)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372,561&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Effective as of January 1, 2023, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $0.4 million and $7.3 million for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted was $19.82 and $36.32 per share for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future stock-based compensation for unvested options as of March&#160;31, 2023 was $39.7 million, which is expected to be recognized over a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,873)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,911)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future stock-based compensation for unvested restricted stock units as of March&#160;31, 2023 was $161.5 million, which is expected to be recognized over a weighted-average period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant PSUs, under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of 1.5 years to 4 years and an additional service period requirement of six months to one year after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of 4 years. The PSUs are expected to be expensed over a period of approximately 2.5 years to 4.5 years subject to meeting the respective performance metrics and service requirements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, and as part of these PSU programs, the Company granted restricted stock units with certain performance metrics consisting of a performance period of 4 years combined with an additional service period requirement of six months should the vesting criteria be met. As of March&#160;31, 2023, these PSUs had a grant-date fair value of approximately $28.0&#160;million, net of forfeitures, however no compensation expense for these PSUs has been recorded to-date since the achievement of the performance metrics was not determined to be probable as of that point time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,438)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation recorded for the PSUs was $0.3 million and $0.3 million for the three months ended March 31, 2023, and 2022, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of March&#160;31, 2023 was $2.6 million, which is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units, or MSUs, under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYxNw_60b18dda-66c2-4999-b9be-3ed7aa5e2977"&gt;six&lt;/span&gt; to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration. The following table presents additional information relating to each MSU award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$120 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche was recognized based on an accelerated attribution method over the estimated derived service period. The derived service period was the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model used assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU. The weighted-average grant date fair value of the MSUs was $67.00 per share and the weighted-average derived service period was estimated to be in the range of 0.83 &#x2013; 2.07 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 1, 2021, Tranche 1 of the MSUs became vested because it had met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of 30 consecutive calendar days. As of March&#160;31, 2023 and December&#160;31, 2022, 2,260,764 shares of market-based restricted stock units, with a weighted-average grant date fair value of $65.20 per share, were outstanding under the 2018 Plan. No MSUs were granted, vested or canceled during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All three tranches of the MSUs were fully expensed as of June 30, 2022. Stock-based compensation for the MSUs was $8.5 million for the three months ended March&#160;31, 2022, which was recorded in general and administrative expenses on the Company's condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AMEA 2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan, or the AMEA 2020 Plan, under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, in connection with the Joint Venture Acquisition, the Company issued a tender offer to purchase the Joint Venture's Class B common stock issued and issuable upon exercise of vested Joint Venture's stock options, at a price of $4.44 per share determined pursuant to an independent valuation. In July 2022, the Company settled the tender offer with the 39 grantees for a total amount of $13.7&#160;million. In addition, in connection with the Joint Venture Acquisition, the unvested Joint Venture's stock options were cancelled and such grantees received replacement awards covering a number of shares of the Company's common stock. The replacement awards, valued at $4.1&#160;million, are subject to the same vesting schedule that applied to the unvested Joint Venture's stock option immediately prior to the close of the Joint Venture Acquisition transaction, to be recognized over a weighted-average period of 2.2 years. The Company accounted for this as a modification which resulted in an immaterial incremental stock-based compensation expense. After the settlement of the tender offer in July 2022, the Company cancelled the AMEA 2020 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of development services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1% &#x2013; 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the commencement of trading of the Company&#x2019;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan, or the ESPP. A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020 and March 2, 2023, an additional 942,614&#160;and 1,026,194 shares of common stock became available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#x2019;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No ESPP shares were granted or purchased for the three months ended March 31, 2023, and 2022. The total compensation expense related to the ESPP was $1.6 million&#160;and $1.0 million for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to the ESPP was $0.8 million, which is expected to be recognized over the remaining term of the offering period of 0.1 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzE_d4c4019e-d4f3-44b4-8e78-c4af83a40c84">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,438,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Plan annual increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,091)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,091&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,049)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,055)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,717)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,333,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372,561&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Effective as of January 1, 2023, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS0xLTEtMS02ODAyMg_c73defe8-4e51-413c-9483-6e7215ab91e8"
      unitRef="shares">5438296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS0zLTEtMS02ODAyMg_4ae728af-e78b-4dc3-b367-2651d6e2ef37"
      unitRef="shares">3402574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS01LTEtMS02ODAyMg_9946ff22-8035-4cc2-a8b8-fd0a890bfb46"
      unitRef="usdPerShare">34.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i65b1aa8a365f42e29ff4898d461d4dc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS03LTEtMS02ODAyMg_e289ad41-46f7-4508-889f-398d1a7c3f81">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6506cad5ab63497db74f92ba4f91d108_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNS05LTEtMS02ODAyMg_e84872f5-2427-4ff7-88f6-3c7a8e7f824b"
      unitRef="usd">39749000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNi0xLTEtMS02ODAyMg_f5e48a4d-c8f1-42fa-a634-3e5b4f8a1367"
      unitRef="shares">3689000</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy0xLTEtMS02ODAyMg_44f929ff-76a2-4fd5-8dbd-9ea12d216969"
      unitRef="shares">40091</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy0zLTEtMS02ODAyMg_26e011ff-65f6-43af-8ff3-c37c8e15031a"
      unitRef="shares">40091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfNy01LTEtMS02ODAyMg_9fd1cc47-ab11-4bf1-b1b2-1ab2ecbdc72a"
      unitRef="usdPerShare">30.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfOS0zLTEtMS02ODAyMg_1856da11-67dd-419c-9bc6-72436955b030"
      unitRef="shares">21049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfOS01LTEtMS02ODAyMg_acc53d07-6dbc-4cc8-a894-b3651913a766"
      unitRef="usdPerShare">7.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="id30f4f4ab6224baf807524e0477cfd7f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtMS0xLTEtNjgwMjI_0886f721-ff31-4928-b5fc-f4075df5271f"
      unitRef="shares">49055</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtMy0xLTEtNjgwMjI_f0841487-214b-4507-b6fb-8837cb88b092"
      unitRef="shares">49055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTAtNS0xLTEtNjgwMjI_eff7df11-1994-4ae3-abc2-79a76e3a91a2"
      unitRef="usdPerShare">60.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTEtMS0xLTEtNjgwMjI_f61dd4c5-33c6-4c89-ba79-c7adf6b93a51"
      unitRef="shares">176717</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i65223fda005149b5b460fbf6312c2d82_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTItMS0xLTEtNjgwMjI_95fddfda-f360-4e6c-b452-6c5e6018d638"
      unitRef="shares">365911</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTYtMS0xLTEtNjgwMjI_ec262df2-a4d3-426c-9535-ac84008ec80b"
      unitRef="shares">8438</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctMS0xLTEtNjgwMjI_53cbfc84-1cbd-42d5-acab-249801a7fedf"
      unitRef="shares">9333892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctMy0xLTEtNjgwMjI_42c1fd2a-ff68-4ece-9e71-5d38596c5bd8"
      unitRef="shares">3372561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctNS0xLTEtNjgwMjI_13eed666-b7f7-44cd-9afd-00348bad316b"
      unitRef="usdPerShare">34.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctNy0xLTEtNjgwMjI_fe55bd57-57cb-4cef-8b35-6476efa510f6">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTctOS0xLTEtNjgwMjI_cbfa6a4c-b88b-4d54-bccd-c00b32ae2b3d"
      unitRef="usd">32766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtMy0xLTEtNjgwMjI_a6f21e44-2f05-43ba-ac94-801a9a750cad"
      unitRef="shares">2091671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtNS0xLTEtNjgwMjI_a38f265c-32ce-4ec0-beed-039db4007dcb"
      unitRef="usdPerShare">21.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtNy0xLTEtNjgwMjI_ddc61e18-858f-47ad-841e-70f7925ddcfd">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjdkZGRkNzFjZDVlOTRiZjQ5N2Y4MzgwMjdiNjBlYmRkL3RhYmxlcmFuZ2U6N2RkZGQ3MWNkNWU5NGJmNDk3ZjgzODAyN2I2MGViZGRfMTgtOS0xLTEtNjgwMjI_a8d0bd3b-395c-490d-844b-82ef5c42726d"
      unitRef="usd">32077000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="i09bde5cb1e9146c78e36910bd9edc42c_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzE4_d490a2d4-4f47-406c-9841-cbea1bb9bedd"
      unitRef="shares">3689000</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzA3_05c8a5c6-4bd0-4f91-a9af-fd800a221abe"
      unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzE0_646341e0-dde3-475e-8438-4504b7115d59"
      unitRef="usd">7300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODY1_607a5f79-8416-4e36-8a3e-e239affb1e67"
      unitRef="usdPerShare">19.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODcy_b46bce6e-10ba-4b59-967f-702ac9b839a4"
      unitRef="usdPerShare">36.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i83d00be36d6c415b8e0fe3afc59a41a8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTA0Mw_e678590c-e8d4-4c8f-b5ef-38884cef820a"
      unitRef="usd">39700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTExNg_d65463c2-7384-42ae-a2aa-8248820c6284">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODM_2ecc133e-e7dd-4dab-8782-59e1c64f1bd7">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,873)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,911)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,438)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfMy0yLTEtMS02ODAyMg_d4a9f458-854e-4988-9478-1fe5e9ebdb47"
      unitRef="shares">3687888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5419e29cd3674106abc793e0ae7a5a7d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfMy00LTEtMS02ODAyMg_298fcdd8-2172-4cb4-b423-0a81742398e6"
      unitRef="usdPerShare">60.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNC0yLTEtMS02ODAyMg_3e9eb232-1f33-4a6c-a875-5401f976ab73"
      unitRef="shares">176717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNC00LTEtMS02ODAyMg_a0de7918-ee9f-49fa-9d1a-d45842bfca46"
      unitRef="usdPerShare">30.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNi0yLTEtMS02ODAyMg_51bf24c1-99a1-4d7a-9ebc-3c3be61f117b"
      unitRef="shares">67873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNi00LTEtMS02ODAyMg_98565a34-4a7a-4dff-8b8d-0fd5acf0ff0c"
      unitRef="usdPerShare">67.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNy0yLTEtMS02ODAyMg_7d0f36e8-47fb-4065-b13f-cd4b719be544"
      unitRef="shares">365911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfNy00LTEtMS02ODAyMg_90674272-4638-4c0f-a2fb-1ea68daf9988"
      unitRef="usdPerShare">57.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i24e6708f9c264d729a87143b05a29523_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfOC0yLTEtMS02ODAyMg_5720fb7f-9d96-441d-be25-ddde2a9f12e7"
      unitRef="shares">3430821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i24e6708f9c264d729a87143b05a29523_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjJiNzlhYTk1YjVlZTQ1MDNhZjVlOGYyNzlhMmFmODhmL3RhYmxlcmFuZ2U6MmI3OWFhOTViNWVlNDUwM2FmNWU4ZjI3OWEyYWY4OGZfOC00LTEtMS02ODAyMg_a2372c42-0b14-4fdf-8674-89c0c286810c"
      unitRef="usdPerShare">59.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i24e6708f9c264d729a87143b05a29523_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQzMw_defccea7-f93f-4809-a63c-156a5b703a5d"
      unitRef="usd">161500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4a217ce041e141b09264af36dd335cb8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTUwNg_e7add42e-2435-4d85-9b24-9fbf03d054af">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2MjcxMA_4394cecc-b6c8-4ae8-98dd-4c20cfacb632">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTg3MA_39f1ed31-2753-4d46-b808-81597e5e1b31">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod
      contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTkyMQ_ea75319a-50a0-41a7-a0ba-5ea60db791d7">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod
      contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2MjcxNw_b7b3a207-ac56-4ee4-a53d-1a4932706523">P1Y</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjA3NQ_51b76bfa-e143-4768-839e-43a1aa713cdd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i03a4c407d20849f2ac33f0b0cd4ffe0e_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjE0Nw_6600c810-01ce-4c9e-8512-18f3d490faf3">P2Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i167512a61ade446cb826830cb9b48a43_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjE1Mw_a67cd013-6de9-4868-b26e-88230c47ba1f">P4Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="id371f8b5f52a447a988f5108d595d824_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNjA0NzMxMzk3NTYwNA_66297644-5d0e-4bed-95b9-363ecbe0f48f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id371f8b5f52a447a988f5108d595d824_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNjA0NzMxMzk3NTYxOA_4cb47e2e-d050-4c39-8f7a-c4f58e730fc6">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="if79268d66ccd4c498d88b492e67d4b78_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2NDQ1Mw_61ad685d-4058-4e79-8cd1-229ba88566bf"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib558b81d3e2c4bd28c787815b2a68bef_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTY0OTI2NzQ2NDQ2Nw_3403a52d-9a5f-44fb-849f-76f6dcf086a8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfMy0yLTEtMS02ODAyMg_0e774255-55e0-4630-af34-cd3e93acfefe"
      unitRef="shares">341713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2b3f42809445495ba7ea570bf865bb5e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfMy00LTEtMS02ODAyMg_5dd04892-9447-4b57-a15b-0129867b90c9"
      unitRef="usdPerShare">110.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNi0yLTEtMS02ODAyMg_4fb65497-a413-48a8-b291-c0827183252c"
      unitRef="shares">8438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNi00LTEtMS02ODAyMg_9e0906e0-3363-4e1b-a607-adacc7c8eef0"
      unitRef="usdPerShare">122.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i67005148159d4de98f4625a633c07616_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNy0yLTEtMS02ODAyMg_6c0d1d74-aeb9-4620-8900-0c78e60c55b4"
      unitRef="shares">333275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i67005148159d4de98f4625a633c07616_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjljNzEyYmRkNmJkMTQzYzE4Zjc0MjIzMjY0MDI4ODFiL3RhYmxlcmFuZ2U6OWM3MTJiZGQ2YmQxNDNjMThmNzQyMjMyNjQwMjg4MWJfNy00LTEtMS02ODAyMg_9bc86504-87d4-40e7-983a-02a1c4756a76"
      unitRef="usdPerShare">110.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjY0MA_ea4d8e83-4bcb-42a9-b53b-d37cc19d6a84"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i90f4b6d3e1a44b50bca2cfe317198cd9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjY0Nw_40625594-a2f2-4c7e-bfbd-fbec9ed4fab7"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i67005148159d4de98f4625a633c07616_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjgyMQ_d8c4aaf2-8d72-44db-973a-652a02440d8b"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9c8a883928394ceab9ef7ed1a98a41da_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjg5NA_54686555-a3f6-45d2-9719-22f7ee00a608">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMjk5MQ_17f655c2-0423-4b17-b519-4e4e127767ab"
      unitRef="shares">1695574</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches
      contextRef="ia22f89a3471c4a37a16fa3ed3f2760cf_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODQ_c1ffff8a-4244-4ed5-a412-cb1965ab9eb4"
      unitRef="tranche">3</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod
      contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzQzMg_5e9c8a8c-7b00-4af9-98b7-68259df99b25">P30D</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzI_1147d4c8-e077-4a38-9fd0-3d30e4cd75a7">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="if0ae71f8bf884fe38ffe82c44c115460_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMzYyMw_244c8512-e051-4864-86dd-49ac317d2822">P12M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NjQ_53b0fb12-369b-45bd-a3bb-12e15b5a1ef5">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODU_e4f9dd2c-eb39-4438-81eb-9767739bc734">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NTk_bdd2b6fe-dc7b-45aa-ab18-33f14a568abe">The following table presents additional information relating to each MSU award:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$120 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal
      contextRef="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMS0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOmQ4Mjg2ZWFkNTA3ODRhZTI4OWU2YTBhM2UzMjY3ZWZlXzQ_bafc6cfe-84be-4cd0-b0d0-584a444c3cba"
      unitRef="usdPerShare">120</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMS00LTEtMS02ODAyMg_1728d4e5-1089-42fd-8f22-87b0d6ed86f2"
      unitRef="shares">565192</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal
      contextRef="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMi0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOmUzNjY1NjY2MTUyYzQyNmI4YzZlYWRkY2Y0MDcxYjQ0XzQ_cded186e-a862-4d99-a1fd-6f6eaadfd3cf"
      unitRef="usdPerShare">150</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="i4b1e39d2685d4e9aa871f2fe5a246297_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMi00LTEtMS02ODAyMg_19c706ab-0ddd-4a41-8562-47a3eae8e380"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal
      contextRef="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMy0yLTEtMS02ODAyMi90ZXh0cmVnaW9uOjM5ZTFjZDIwZmMwNTRmZmE4NmRiMzI5NmI0NmUzN2Y1XzQ_641dd72b-27ed-42d1-9c80-4895f989eb32"
      unitRef="usdPerShare">200</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="i6d9045c971f24a02933bc1c62321fc35_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjgzNTdmNjI1YjBhOTQ0NDNiODMwYzI4NTExOGRmODI5L3RhYmxlcmFuZ2U6ODM1N2Y2MjViMGE5NDQ0M2I4MzBjMjg1MTE4ZGY4MjlfMy00LTEtMS02ODAyMg_0bcd1e00-a4f5-434c-9773-423a49368e7e"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTA4OA_c6abb5d3-ef6c-42cf-84c0-29d64d5ae5a3"
      unitRef="usdPerShare">67.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i31a0dc3163854d6cb56d919865f28f0f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTE4NQ_74995172-4d60-4f86-bf3e-757239c227cb">P0Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i8355f22e8d444065acdca383af614973_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTE5MA_f3c3cc13-181d-4111-8351-3e44f7e9f60a">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal
      contextRef="ie817ff3c12124b78a03fdb6de0e8038d_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTM3Mw_d6ebdd59-bc0e-472b-801a-deb90f65559a"
      unitRef="usdPerShare">120</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod
      contextRef="id2cfd4fd803842ae8b0807df3cbae68c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQxNQ_5e9c8a8c-7b00-4af9-98b7-68259df99b25">P30D</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4b6c755d9322493ea937d75411cca741_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ2Mg_131d5784-957e-403e-9290-9fd7a31ee5dc"
      unitRef="shares">2260764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3b801579905e486f9d16da0424368dea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ2Mg_e9a6cf5e-111c-4c55-a6a3-3c56b1177eaf"
      unitRef="shares">2260764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4b6c755d9322493ea937d75411cca741_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTU2MQ_0ac28a4c-3a7b-4408-ac23-325f05c93a31"
      unitRef="usdPerShare">65.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_aa18a1a7-907a-4d31-93e0-8a983f45874e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_c6b660d3-ae00-4412-84f1-4765ab253440"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib0dcea7b690f4e599e02e792a2c11c14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTYxMw_d4129b22-80d9-453b-a04e-17e1a3fdbc3c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches
      contextRef="iab8405ea1a894bd49c95fae94c570714_D20220630-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTA5OTUxMTY0OTE4MQ_cf25d4b1-df86-4dc4-b7be-eacac09322d5"
      unitRef="tranche">3</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9210d17c359d4a029aa0d629f68b0d32_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTc1OA_07216b30-1f5d-41f5-a87a-9d5b55cb82c2"
      unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia06f00d018a84185bf63dbd26b8fcf13_D20220601-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNzkxMg_ca0806ee-42e0-4f44-accb-74884525c308"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODAyNw_fd6855bb-93d8-46c9-95fd-2feac47d7fd4"
      unitRef="grantee">39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODA2MQ_6836bd9b-42c6-4de7-b6b1-91930a43500f"
      unitRef="usd">13700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5f314cba04f147aaa5a0130ab210f819_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODMyNQ_7e89d3d0-19ff-4b0e-8501-5c3d123b823c"
      unitRef="usd">4100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibf9198643e4345d7aafb78c91a7567ae_D20220701-20220731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfODU1Ng_2e1fdf9e-574f-489b-95c9-c3eaf5cd7aea">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzM_c6ea910a-c912-4f7f-b717-23b322de5a9a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of development services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i32e84c2df8114b2ca174af7f12413df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNS02LTEtMS02ODAyMg_1f7f1307-f589-4b80-bd53-934cb7ce68fd"
      unitRef="usd">1202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22845a3df5054db690d00e20e26e9de7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNS04LTEtMS02ODAyMg_1adfe862-ca5b-4374-8376-6f7c38704919"
      unitRef="usd">1164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2aa36b882d6a4a99b4d65b78a2f7f31f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi02LTEtMS03MzM4MQ_7cf7eb35-3be1-44bb-897a-830378e27f7c"
      unitRef="usd">474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2eb41fcfde104edeb7f180200c669ff1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi04LTEtMS03MzM4OQ_4c2ea273-132f-42be-80d7-8e89ec2b6089"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i257ec7f3adfd447980af46db25d249da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi02LTEtMS02ODAyMg_54623d23-33bd-4229-8bc1-1730d7e6aca8"
      unitRef="usd">8678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i525b368da8b94090b710ab4a0286430d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNi04LTEtMS02ODAyMg_bd1a78ab-f323-4c31-aa71-e4dd2c7f0ca4"
      unitRef="usd">5343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1e6b4f53ad9427188ba1f105f093cba_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNy02LTEtMS02ODAyMg_725adcda-5dde-4d75-9620-fb5a015aa6df"
      unitRef="usd">7503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0babdde2fcb4400f8a4240d151c2273f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfNy04LTEtMS02ODAyMg_7d70f09a-50e4-4da6-8f9e-4c957a9ab497"
      unitRef="usd">5525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5f08d30f39d4fd18d425c922f9e450a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOC02LTEtMS02ODAyMg_18456223-95ab-4409-9293-ecfc40c1ab38"
      unitRef="usd">4409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5740f52d90ea487290d3e3b20b00fe62_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOC04LTEtMS02ODAyMg_3e636e2f-3bc8-4e80-9eec-7b53d2e357e5"
      unitRef="usd">12767000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOS02LTEtMS02ODAyMg_10f6f770-b521-40e5-b673-4c0af51ad3b4"
      unitRef="usd">22266000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjc2NjIxMGI0MDlkNDQyOTZiMTI0ZjFlYTIyMjYwYmIyL3RhYmxlcmFuZ2U6NzY2MjEwYjQwOWQ0NDI5NmIxMjRmMWVhMjIyNjBiYjJfOS04LTEtMS02ODAyMg_c6c4e586-d6e2-497d-90c3-b896eb987835"
      unitRef="usd">24799000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1ODc_8f0a4a10-c41a-4489-89b3-cbc786800294">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1% &#x2013; 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjdiNGYyMjNiNDM4ODQyMWJiMjAyNTczYTgzY2Q4OWY5XzQ_521ccb2e-9681-4829-93fb-9f12a9839cd2">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjdiNGYyMjNiNDM4ODQyMWJiMjAyNTczYTgzY2Q4OWY5Xzk_11e07d63-f669-45ed-a0fe-ff7a281ff946">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNC04LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQwZWY0OGEyZmRjNDQxNzc4YWFmNjA5M2NjMTY0ZTM3XzQ_8f9dc973-a735-4a8b-9ee3-ff688f359306">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNS02LTEtMS02ODAyMi90ZXh0cmVnaW9uOmZjZjlhMjAwZDg0NTQ0MzdhNmVlOTVkZDZkYWJiNGZkXzQ_7deae766-a9d8-4cc0-ad5b-c0f3fb1e34a6"
      unitRef="number">0.695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNS04LTEtMS02ODAyMi90ZXh0cmVnaW9uOmY3ZTlkMGVlOGY0NTQ5NmNiMWE4ZTFlZDZlNmM4Y2U4XzQ_e0c92e09-18af-439c-86a4-f61a0198505f"
      unitRef="number">0.633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQ1NDQ5YzZlYzEyNDRjNzY4ZmFjMDhiZmEwYzkyNGViXzQ_01f89353-ac59-4e80-8f57-b986e4ba4b8b"
      unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5d3eea331b924df08ecf3b1dd89ebde0_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi02LTEtMS02ODAyMi90ZXh0cmVnaW9uOjQ1NDQ5YzZlYzEyNDRjNzY4ZmFjMDhiZmEwYzkyNGViXzk_539cf65d-cd3f-44cf-b263-6598f2ed3e62"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic749eee03b16467aa70909df615b2c86_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNi04LTEtMS02ODAyMi90ZXh0cmVnaW9uOjhjNjhlMDMxOGEzOTRiNzhiMmE5Y2Q5N2I2MDExOTg0XzQ_e18b0bab-9f09-4a02-8ed5-29c132f62de9"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNy02LTEtMS02ODAyMi90ZXh0cmVnaW9uOmJkNTIwNDlhMDg2ZTRjMmE4ZDAwZDkzNTZmYWEwYzY4XzQ_11b68cf4-1f19-4fec-8aae-71489bf881d9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idd87a164b7414d629f78c60cc37c4b3a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RhYmxlOjRlNjI5YjQyZGUyZTQ4NjI5MTZjOTE1NDU5NzViYjMxL3RhYmxlcmFuZ2U6NGU2MjliNDJkZTJlNDg2MjkxNmM5MTU0NTk3NWJiMzFfNy04LTEtMS02ODAyMi90ZXh0cmVnaW9uOmZlMjk1YjU4YmZjNjQ1NDhhOTY5ZjQ0NjY2NjQ4MDBhXzQ_4b70733b-ac01-4e73-9105-721d21db99d6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI2MDA_9aaffe29-8578-4537-b6a4-98b74896956c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibf899f29153c4ae48025cc44a9774ca0_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI3OTE_cbdf7b1d-f68e-43a9-9935-5ef57fc49669"
      unitRef="shares">922250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ie2e087e17e0e420b8c053b525bbb7093_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTI5MDQ_87a35cc2-e98d-4143-a2ca-291632c89bc9"
      unitRef="shares">942614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8d35aee771524865b1b3cd4a8ec1d0ac_D20230302-20230302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODM0ODg4_832c45b0-f72d-4d03-93bf-d5d8777a9a47"
      unitRef="shares">1026194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="id8b85720538549e793c0ea411f6d2926_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTMxMDI_1d148564-353d-4d8b-bbea-3c95a09533fc"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTMyNzU_4ce4cb59-598a-4bae-84af-9c8f6b6aaf72"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NzA_25595991-34c2-4553-bc2e-4cbec66bb001">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1OTI_5b775613-debe-4f8a-b905-9762e4dc6aef"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1OTI_79887490-844c-40b0-8054-b1dbb8e22dac"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODI5MzQz_de0ae7e7-c422-46ec-b3c7-d1db4c9866eb"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i963faee6e3fa4927a9157769b2f74953_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfNTQ5NzU1ODI5MzUx_f99a4771-6085-432d-a7b5-65b04cc25a24"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id8b85720538549e793c0ea411f6d2926_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ0Njg_1fa81ee9-7316-4613-8121-7e80df8bbfa9"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if0104cdb888d4846b002224ba300cf0c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF84NS9mcmFnOjgzNDZiNjU2YjllODRhNjNiOTg0ZTNmMzVkOGQwMGJiL3RleHRyZWdpb246ODM0NmI2NTZiOWU4NGE2M2I5ODRlM2YzNWQ4ZDAwYmJfMTQ1NTc_57e5f38b-f166-445a-bd67-76ba69036819">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODM1_8f97338f-69ed-41af-8804-90a96d43dbca">Net Loss Per Share &lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,961&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Excludes stock options of 2,995,200 shares of the Joint Venture's Class B common stock granted under the AMEA 2020 Plan as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODQx_72343d9d-28ae-4a52-85bf-ce92073f9302">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy02LTEtMS02ODAyMg_45eafcd1-7cee-4f26-a12f-d58578e5356f"
      unitRef="usd">-133533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy02LTEtMS02ODAyMg_4adeca11-df28-4384-833b-20a4a4612f60"
      unitRef="usd">-133533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy04LTEtMS02ODAyMg_22d03f21-ecc0-4a63-aa2f-286b73e39074"
      unitRef="usd">-123228000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfNy04LTEtMS02ODAyMg_91ca3818-983e-4b46-930e-cbc2178326fb"
      unitRef="usd">-123228000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC02LTEtMS02ODAyMg_36c91bd9-fdc6-4245-837c-13ee687b6942"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC02LTEtMS02ODAyMg_c9348b6b-4b66-4ea2-9d5c-fa70b1db7ba3"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC04LTEtMS02ODAyMg_774d9a86-4071-4daf-b516-040e797b28cb"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOC04LTEtMS02ODAyMg_81760556-6b90-4b14-a081-d4dd7a807781"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS02LTEtMS02ODAyMg_2ec3080a-ff39-47e6-b71a-e8f38512eece"
      unitRef="shares">102663000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS02LTEtMS02ODAyMg_cf495f91-7a1a-4287-a035-a4f8e9cf1a39"
      unitRef="shares">102663000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS04LTEtMS02ODAyMg_42d4f00a-5bc5-4667-a29f-4a0ee6c05d64"
      unitRef="shares">101853000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjRhMTE5NjFkZmUxMTQ2YWVhZTYyZWY0Y2NmYjIwNWYzL3RhYmxlcmFuZ2U6NGExMTk2MWRmZTExNDZhZWFlNjJlZjRjY2ZiMjA1ZjNfOS04LTEtMS02ODAyMg_8508b8c9-90da-4c65-b52c-d97143f69c4a"
      unitRef="shares">101853000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfODMy_d3f8ad3a-ad7c-4cb6-8ffe-e0b3f90cd284">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,961&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Excludes stock options of 2,995,200 shares of the Joint Venture's Class B common stock granted under the AMEA 2020 Plan as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib07e4ec43ccf4868a95b7cba38569e07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNS02LTEtMS02ODAyMg_2bfe2c4e-037b-494a-821f-320fb8ad8231"
      unitRef="shares">3378000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8405bc3396f043d38ac107f7e621ea0b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNS04LTEtMS02ODAyMg_4283be41-b25d-47c6-a6ce-5981f0a3a07c"
      unitRef="shares">2550000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1dfcb8b82cc435bafa0737693ff7b95_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNi02LTEtMS02ODAyMg_42616d87-2264-46a5-bf91-e9ead2151f2b"
      unitRef="shares">3550000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96a7782cf20244b492722ced02d556d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNi04LTEtMS02ODAyMg_6a908396-2997-460a-b022-49f75f3ef0b0"
      unitRef="shares">1484000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i018eca720b2b4bee988fdb517bb09d46_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNy02LTEtMS02ODAyMg_4238ad1f-7e7a-4170-b0b6-f9cd9836e3ad"
      unitRef="shares">2261000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i784a2015beb447b480ff240ec2998829_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfNy04LTEtMS02ODAyMg_82ad7f53-8490-4e0c-97b7-c9eea3132f78"
      unitRef="shares">2261000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i90b84667fc3047d39ba495dfdb6af2a5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOC02LTEtMS02ODAyMg_c2bef0f1-dd20-4f72-80d9-029544c80d67"
      unitRef="shares">337000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c434d2375a64859af229e0a8a1a79c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOC04LTEtMS02ODAyMg_dcc2f4bc-7e76-42e9-abf6-b2506f9e9612"
      unitRef="shares">357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f00602410084027a24ca5b4c50e87c8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOS02LTEtMS02ODAyMg_0e2f52a0-fa58-4f70-b391-c76e9936e199"
      unitRef="shares">264000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i436487de8e484b5891dc7aaa105cc2dd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfOS04LTEtMS02ODAyMg_55ba8d2f-b9c8-4687-801a-dc686eda2ebb"
      unitRef="shares">84000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i92d27c009cdc4d3c997e7de9fc339551_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTEtNi0xLTEtNjgwMjI_8f08098d-6991-4829-8965-ed9e3318aa58"
      unitRef="shares">8225000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c5f7a63f9954f08adb2cdcc6eafb151_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTEtOC0xLTEtNjgwMjI_80d36ec3-00cb-4f33-8f20-bd2f592b8a95"
      unitRef="shares">8225000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTItNi0xLTEtNjgwMjI_5cc85ce7-bb2b-456f-9cc0-fe6e9d55aa80"
      unitRef="shares">18015000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RhYmxlOjllM2JmZjBhNTUzMDQ0NmM5NzQzM2ViYWMzY2Q0ZGJiL3RhYmxlcmFuZ2U6OWUzYmZmMGE1NTMwNDQ2Yzk3NDMzZWJhYzNjZDRkYmJfMTItOC0xLTEtNjgwMjI_ca0286c4-fe2b-4f32-955e-00756ace7568"
      unitRef="shares">14961000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3d27e6a526f14a71b27f8d0b9f9a0f23_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85NC9mcmFnOmYwZDM2ZmY4NzA4MjRlZDE5MDJiZGM3NmU0ZmI1NjkyL3RleHRyZWdpb246ZjBkMzZmZjg3MDgyNGVkMTkwMmJkYzc2ZTRmYjU2OTJfNTQ5NzU1ODE0OTA0_4bda7cbd-881d-4ff2-839a-4281d10cdab8"
      unitRef="shares">2995200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF85Ny9mcmFnOmQxMmU4MzViNzM4YTQxMzQ5MWIzMGI0MWI5M2E2NjUwL3RleHRyZWdpb246ZDEyZTgzNWI3MzhhNDEzNDkxYjMwYjQxYjkzYTY2NTBfNjI3_25e1e24d-e4c7-404e-a1c0-7d88670c0b14">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the three months ended March&#160;31, 2023 was determined based upon estimates of the Company&#x2019;s effective income tax rates in various jurisdictions. The difference between the Company&#x2019;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the three months ended March&#160;31, 2023, and 2022, relates primarily to state minimum income tax and income tax on the Company&#x2019;s earnings in foreign jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0MQ_9f7613b0-9bc9-448a-9d96-2ce1e29d398d">Segment and Geographic Information&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three months ended March&#160;31, 2023,&#160;and&#160;2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, and December&#160;31, 2022, 98% and 99%, respectively, of the Company&#x2019;s long-lived assets and right-of-use assets are located in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0Mg_ca687bce-3c50-43c7-bbc9-f6ebec46f048"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzc0NQ_bd733364-037c-4b8d-9873-9b390825c8eb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three months ended March&#160;31, 2023,&#160;and&#160;2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="ie9213a2532134ae5b9a645905cc1fbad_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzUtNi0xLTEtNjgwMjI_98bbc68e-bcb5-44ad-8b58-aa4cf224ce54"
      unitRef="usd">118911000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3794fca71da4bfdaa6a037250b08ea1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzUtOC0xLTEtNjgwMjI_77eee094-d874-41ae-ac3d-306658d2b03d"
      unitRef="usd">90871000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4a0c4f0823b457fb2f4cda5edce7d8f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzYtNi0xLTEtNjgwMjI_bb90a37e-f07a-41f0-9011-22a763a3047c"
      unitRef="usd">9803000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e06c37d3dbd437d892d43f95983c3c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzYtOC0xLTEtNjgwMjI_9699ab7c-1947-430f-b68d-7eedf7d9cfbd"
      unitRef="usd">5228000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzctNi0xLTEtNjgwMjI_370840dc-b19f-43e4-9163-223feb578507"
      unitRef="usd">128714000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i153e4ea1593a42e8aa4272c4bf133847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90YWJsZTo0NDY2NjgxZDMzM2Y0ZDU1YTUyMjViNTQwMTVlY2IxNi90YWJsZXJhbmdlOjQ0NjY2ODFkMzMzZjRkNTVhNTIyNWI1NDAxNWVjYjE2XzctOC0xLTEtNjgwMjI_56cec516-e33a-4583-952c-4bae223fc493"
      unitRef="usd">96099000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i25302361b67443c4a5fa5c0994f68a46_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzYyMw_36d935e8-6773-4d96-9805-8d2633d1072d"
      unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9cbb23a4c4404fd09cf2220d10bbfd76_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDAvZnJhZzo4YzFlNGE5M2I2NzQ0Y2Q1OGQzNmEwY2RlZTc2MDVlMi90ZXh0cmVnaW9uOjhjMWU0YTkzYjY3NDRjZDU4ZDM2YTBjZGVlNzYwNWUyXzYzMA_a2018df2-017d-43b4-a56e-0c5d2944b03c"
      unitRef="number">0.99</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxODA4YmM1NjQ3ZTQ1YzBiNDg3ZWNlYTJlOWU1MGIwL3NlYzpkMTgwOGJjNTY0N2U0NWMwYjQ4N2VjZWEyZTllNTBiMF8xMDMvZnJhZzo0OTMxYjAxMTI4NzE0NjEzOWQ3ZjFjMWMwZWI4MjI4ZC90ZXh0cmVnaW9uOjQ5MzFiMDExMjg3MTQ2MTM5ZDdmMWMxYzBlYjgyMjhkXzEwNzE_a1c389c9-3a12-4cb4-9c58-9853af1f02c9">Related Party Transactions&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. Prior to the completion of the Joint Venture Acquisition in June 2022, the Company had consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances had been eliminated in consolidation.&lt;/span&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@/M+ 2IC=V*^/;3?FA;_ 5!+ P04    "  (B*E6U)UQ]O\"  !9"@  &
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M!5ZA0%D#_#Z7TCQ,[ ^Z2UGZ!U!+ P04    "  (B*E6VC\8V\(&  !"+@
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M,'=G=&+V!8.>RP#490B%IOZ)VRH&Q*P8_&<IU8P_^F_<OC[@^7._^XL#U&D
MBA9"H:F$MFH#,:L-/TJ\(YIB?M']?W9I[MS8=!SD,P#U&4*AJ?0=G:HPBQ%C
M%#S2K\0)(9[7Y014FACF- !U&D*AJ:2TP@0Q"Q/_2L$C?0'!MWW2)0>RVE^!
MH@6#1A!"^52Y:14&8E883.H=T97KMNW:O64+]/@$*%H BA8."(E*1"M@$+.
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M2)532 K4E6 936.I;FZE^J>\)05@2S"/Q1I\5AX7X%U9Q&5*E<Q[< 2^W5Z
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M.5Z [PMKP^:!-^C_U^#L7U!+ P04    "  (B*E6_Q8?6:DF  "OA0  &
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M-<[K!^3N1#D8O)Z40J 6$&@+O-&@>J]H4=")H/OH&0TLVHIJ.'5[NT)%AC:
MOP TV!M4UR/TEIW21 VJ"?!\'3 .ZA?0!B+(J[)=]3O  BK;A>(AE,_>L6IU
ML J8*?S,>-,!&\ZS9=\1>Z,B1DQU3>XW)GQW PJ>'DD24%CFR.%5*[": +"7
M<@2G,!7J'?""*S&:B!'0;:S&O0'SJI\<'\?,N@._%NTK$H.<?T1FLZS*#5N
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MV#FY-NCUA:(R 8-^I\'=8"G6/<J<65MQQ:6[(J@%:08P7(HH2G3K0JV:$AS
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M2['T^$=3?!&-0;6/!BS#@9=4%/ 3W;HYB>U]OX=]H>,GIQ^,FF5SJA4 SX&
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MQAPKL.@MT-\1^GV?P-'6UH*)O(R[F4?0K0EI@>G?]NO?/&T]C^)I=\36L%1
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M7!JEE$=>*WN1*ABR]6=9%R-.;CCGJ#*R=@6M46U0P6D5PJD(3;Y+)%%YLB8
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;,56;6_;-A#^*P<U*!)
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MW@Z58>VFLD)BG[#20Q%X3)9E7?!YZB%5*M/E0HR&I_#$H:MG?P!.A#<BA4N
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M\*O%OG1Y[;O.)G@Y1:5=HZZ]2]:MC:NMB:]/$HZ@A2=U%O=6Q"V>$'>N?H"
M353?N,8TT_TG4&W0;U'T>[OXK, ?=)BK\[-*+4X7YY^1=S[8>\[RSO\;>]6-
MC77K8Q^,^N?5,J8 T/SK,2_((<\>/X02Z:NXU;5Y,T.F1!-V9G;YQ5_.+DZ_
M_HP)SP83GGU.^I\/V?\@3OW=K'6KW@=?&]/@<52W2*6FL9Q3R:OZWG:_;.U:
MTZ]165?W(9@&'U3:&.4#1"#UL:D/$=]7:ME'Z!-CI5;!=RHAX4FJ_,46:+?5
M[@#(']32@#N6OR*?:8E6.QVL20<24[?:=J) RQIOCQI7I$?;T^>RCL^2[#)!
MMNV,:WS 8M =+Z6'6Y]@F(4\D:IK,0QDJ!K=@;6P8>UW)CCR %98MS,Q#1Y@
MC\".  -2PEES!3)1YI/NMJVI)B9N= 3-U08LU52\DXS.KEOUB5!9<W!Z]E%>
M"]58<E6,@WP$98LO%!,VE56 -BW,(-M6NH7[=0/%DT4 UC!;DZDX;A4H^F1.
MI7;6MVP)^=A IC_0#_ N>:(V8B#2I$&I"'>3W7/U\SWC<*C'$K@G]>EI&X<5
MU0"T(0"CL)(+C$,D:FR!H8'X5Q2*QMS!/1T64H!B7V\4SN^\,XG@-X3.NE][
MQW4!RUMK5KR],?!DT,ECJ3R>VE)KYSPY ?()BQO:'5$&(KF)5O")C8U;6!&K
M+#1N;1)0'V&%,HE8T1IZ;C[9B%]J7A4,A)%W-AKJ:2?A0MB )!-HLX4Z.-^[
M"8R6IM:])%=C:4<.7Z>=ELA(=I%2A$DGU3&J/4HC_>50($]! #BD]I&<:X #
M)#+#+OIV1RB:6#EU$0FGH.C5RK866_$1H=UJX,UPZ.@4B>DH=\?AA</J8)<X
M=$FMPU2^C<#FV@??Q_9 53@G+<XT+6*PUH0B'.+AB=$!C#1Z-CIIKC[8M;,K
MB[@FR-KAN*T0VK \9R\;\4"QV]4D -"M=_ -TB.N>J*$HX(59:==04\\@\2.
MR(_<$9'$1 @DP+.\XZD5+<\$&,QOO0T2B:TFI*%,:0$3&BNLG;)D03B%V#4G
M.!V_<]*PB'JCD:YJ@PJ$,]#J!8X5A>[(S/N-1:#!V6V3P7C$8 'E$8NT]PB?
MK8]2*G#R*$GD)*+(N?KH6APC'+6WD 6#F!X>.%4OV\Q\.GKZ=E!$MJ2,X,E'
MIC^M IN%@W!^M+2-?R/>IH4EG ]"^>,*"<'^QH&4Y*.C!E%%2M$-&@W!Q \Z
M00$^#C* LZ4NF[1 D4'P&3-TYWL@$=H_8A ]JL9)SH9;U&"NL]*F<[AWVK9\
M-'/TA';,:@5\<"0RZ0+UI8*#_FSDZK6$;1L;FI*W1RJE IZ7![/N6R)+)C$8
MO[?@D;%#C$+8Q3PFC[Y4%/J)/3)7/QR!_TAT*.TT,RY9RBT$0,(4'C1!QJ$&
MM[39!^(7\I/52U /M0=!"@(HU+JB%RES]',N"$CE(?#(&G0VT),"EQD$,5MF
M&U"C%=5]A,;UW1(?(.9@=+A'A,'L:)"02-:3U@H&M4! 4K_U<*\)[3TD[3>&
M.X<!V8(E,8KJJ21OPU$HBX%<T!A<>$=I.B#,'!&6G3Q-#,K.,<+FZI>-F=:5
M,5^-,,[]10;V!/""C7L(7Q+'64JK&LU@)"%#G'(7<(P*,<F@=DFZ 4JBYJ3H
M4'^!\W<6R*'"5'KY/=DB.?U8/H_-R30[=*XX]8_LGBJ>97$BF$]49Z1#8:/Q
M9; 9@',)91?)V$N;#5Z$*VYR4:5F^ZI?HU&E^0=3T,][Z]"\DV_?6A^!(W0+
MR();5\^95IY:4#C@HY.>0-KF7W3< )")8&Y;@M)C?2"RGLQW10 QS8?$A0**
MID!-T#41PA"DX3'.N$'KL.<$+MWGX+&!W/-A47V<?YBK]Z+".X_XGIU6BY<O
MJHOSLZ_I\\7+5]7%JU?\^<7S1?7J.9Z3;?3]XK0Z6[RXWXC$O>%Z25Q3VF(R
MYL<Z><I;<6QCW(%T>]Q_7_SEY>+LQ==BPJBUUQ'#';FCIM";4#KP%<T!NK7H
M7@\5J"3WJ07IC33PR"44\\39 FIH>CA,FI21[XFBX=N2MMFNK%#,X8*C:'0E
M0AKRJ-94EJ&,6_LRSR3I&Z.BRYVF;W,3 *+CKA,[WT%&E]UR3O $,P=P/KXN
M +.V[8D\CW@K3ZH,H/\35(;^[6%+>>V_O-Y0J_[-)U/WW+O_B"ZSYD;IAOCW
M.]-V!_5-FWQ_MY&-5YT-5ZU5/^M61_WO2H8D3CP(: _2;-QPFX9NBA)F@M;!
M<"O]L=\[H7P<FZ#K[X1'FEN!M=YN6[2:#**2ESD?CN?+\:8!T70V8@N8(5AN
MP0=5>.Q"::N#(0 ,SYD&97^F:O;*Q!_9#VH)1B,H\"R-9OHH933M4=FB@8]&
MS!R,K8<-MA +FC],290%Z")8?;AC[7V#0=.F#:_!)\S,!DE!6(S<4F2OX0=J
M6^#0T:%[VCAH ^.E9T+9#TG",GA[/@D/=<A4-; &;?@6S<Q*=.LPV4>9ZC@<
M/>!)Z!FF0;0=/CAS&-)]98J%64ZMP,_<8N5TX5D)WX7UR^"8VQL&"0AV6[@"
M8T;):3OF_6WA?<DA2@WZMR1D46]ZN(\.CFJ##GQG<@7F B28(<3DWG#P"T*X
M0E64[F_4)0I9CB03#QZ%9:JCZ9'HA2FJ*H/40 SGU323)<'7(%'I22764Q.*
MBSM?+I)0KW%(G!)UQ3C E$R]WZ\]YFUF3@TW8D"0-I83F(#!!-X,/)CGXBR7
MBMO1)&:V*Z"JS08,GLIUT,D9&3A2-'"PC$(C?W&-1T>XA7,H4-^#[#-W?LN7
M+%?'2Y92UH55#[GRI/L=3*G$X$)FTT*&[VCFTJ-:7Q[\&;I]YP/UB6["N]?(
M2BQP5M.PAW)IW3VU!%@,.SF5,@UN10/+<_<&B9TV-<_XTH#1L+RDP'&S.<J:
M)YC2F3TB!D[V:P 0"5RIOZ$O)B^KGS"=Z+8B_\9^O<[935)H(:F"R-7HV+BK
MES$7+J-7!X2.@MB5*2PB-@QGT_PO5B%)]>'!50.-#U)"Q_,T3>"!YZ;B$[E6
ME"LZUM!+(YZOVUPS=AE/N<=[4YX'>;8OTNB2A':C:0P"\W+_."]+^%;MR1[D
M=XZM'KL&[!U@1[<64EVF%WV]8Q9G*DWVR!_#):W?24=1<OF>GR<:#CSRO78]
M37328DCZ/T8@,ILZ>X]3\N%_C0^YY.&=U. W.'/I46%$9<J._%I*@676PM)N
MJ(I%8RY*]S3D:Z>LC_/N2[H0\P*\K!$&Z>#[]281@*G>\F*"V>^V8]_W[2'3
MR;7=@:UNC_?+.^+3CJRZ?<R)QPE4KI3!*$^+8#ZYOKVICM5D2B=7N3;^42(A
MY9$)+K]\VTL;,+T>!YZ:/-\*5UX+=*_J<GE\>U/*>9S>;1 4?-U+^@2P>F!P
MH[_F_H+;CW(K_^6J9R(',2%@7;Q_?S-JUIQI>:]QP'?-[!+5G4,AIY:E\-'Y
MQ>D#BD#*M/1>(U]L08<!*Q.;Y_ D7:I$OH3]S!W7^'8YWQ(+=3+;C24^]DKI
M9/1&$(W5FM][Y@24EX/#T^'5ZI6\43PNE_>R*//H@Z-JS0I;3^<OGL_DKKU\
M27[+[Q>13\EW_!'E )&E!?A]Y7TJ7^B X87SY7\ 4$L#!!0    (  B(J59=
M54(@> ,  /D'   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)5538_;
M-A#]*P,%2%N 74F4;&LWM@'O1]$< AC9M#T4/=#2V"*6(A62LN-_WZ%DNT[C
M==J+/1S.>WPSI&:F.V-?7(WHX4NCM)M%M??M71R[LL9&N!O3HJ:=M;&-\+2T
MF]BU%D75@QH5\R09QXV0.II/>]_2SJ>F\TIJ7%IP7=,(N[]'97:S*(V.CH]R
M4_O@B.?35FSP&?UO[=+2*CZQ5+)![:318'$]BQ;IW7T>XON WR7NW)D-(9.5
M,2]A\;Z:14D0A I+'Q@$_6WQ 94*1"3C\X$S.AT9@.?VD?V7/G?*924</ACU
MAZQ\/8N*""I<BT[YCV;W*Q[R&06^TBC7_\)NB$TIN.R<-\T!3 H:J8=_\>50
MAS- D;P"X < [W4/!_4J'X47\ZDU.[ AFMB"T:?:HTF<U.%2GKVE74DX/W\P
M34/%>?:F?)G&GAB#/RX/Z/L!S5]!9_#!:%\[>-(55E_C8U)RDL./<N[Y5<(/
MPMY EC+@"<^N\&6G]+*>+WN%[^ES)_T>_ERLG+?T OZZE.- D5^F"%_%G6M%
MB;.(GKU#N\5H_O9-.D[>71&8GP3FU]B_6___COY4(]"Z%7K_]DW!T\D[!^6P
M[\)^;52%UH&P"*B]] HK\ 8JN945ZLJ!7(/0%>QJU/2P2T61%:SVX"\PWQMA
M*S!K>)26/C!C'0-C^]!OMVY@X8*#;K>L3]?+^M,>L<1FA?;HY@STN2B2?W;^
M#U_G!+4@A7A![R41WZL0L;F![7#/%:P/.:V-HO8E]09:XT/UA()UYSNJI72N
M$[I$=_>O_+Y-#7[LM.@JZ;'Z"9YKTNN@HR_'JGV@II[I/-4DV(,@TX;6Y2!C
MV82ST3@E*T_(FN07\)W>HB/N(-];609SX.FT]($ESQ)&B9,U+B:L*(H@^07]
MSZ&QO8KCC(\3-AGG9]82;3\1*/'KX"S+&)^,(,M3-DFSHVRQ%5*)E<*^Q,<:
M#MGT%>=)6L![\NG0MF&Q"_>Y5$+#+0N<Q2V'$254,'X[_G^L3TVKS!YQ^&Y@
MV=&M40H#.V=IGK-1,H*4I6G!LC2%3\;3?7.JW63$"F)(QXSGMVR4CR^U@/BL
M'3=H-_W0"4^MTW[HS"?O::XMAG;^3_@P%.EZ-I(>@,(U09.;R2@".PR:8>%-
MVS?WE?$T*GJSIMF,-@30_MK0>STLP@&G:3__&U!+ P04    "  (B*E6[LI)
MV/X1   1.   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RU6VMSVSBR
M_2LH;[(WJ:)I/O2<25+E/&8V6S<35YS)UM;6_4"1D,0-16H(,H[FU]_3#8 $
M];*3S7ZQ*0IH=#>Z3S\ /;NKZL]J+64COFZ*4CV_6#?-]J>K*Y6NY291?K65
M);Y95O4F:?"Q7EVI;2V3C"=MBJLH""97FR0O+UX\XW<W]8MG5=L4>2EO:J':
MS2:I=R]E4=T]OP@O[(L/^6K=T(NK%\^VR4K>RN;W[4V-3U<=E2S?R%+E52EJ
MN7Q^<1W^]')$XWG IUS>*>=9D"2+JOI,']YFSR\"8D@6,FV(0H)_7^0K611$
M"&S\86A>=$O21/?94O^%98<LBT3)5U7QCSQKUL\O9A<BD\ND+9H/U=W?I)%G
M3/32JE#\5]SIL:/X0J2M:JJ-F0P.-GFI_R=?C1Z<";/@Q(3(3(B8;[T0<_DZ
M:9(7S^KJ3M0T&M3H@47EV6 N+VE3;IL:W^:8U[RX;:KT\^5+R)6)5]4&>ZT2
M4M>SJP;4:<Q5:BB]U)2B$Y1B\:XJF[42;\I,9L/Y5^"J8RVRK+V,SA)\E]2^
MB$-/1$$4GZ$7=Z+&3"\^)>HZJ:41]2;9P;(:<5W72;F2_/ROZX5J:IC)_QT3
M7M,>':=-KO.3VB:I?'X!WU"R_B(O7OSU+^$D^/D,YZ..\]$YZM^T2=]'2? 7
MXOV6/UR3J^3-3EQ;9Q754C1KR7.2<O?7O\RB</JS$HJG5=O>PVA:"PNH>7P4
MA)&X*1)\66;VS:Q_4\LB:<!+7FI\(3*Y$HD2RZH 8*B?#$]*O&\;U6!.7JX$
M;Z7J_K6+?\/)15,='?P/]DR975Y_D36 1KSY*NLT5U+<U'DJ#[__( G-:.HK
M6#191)L4XG_SI11/_BF36CT5UZM5+5=@7;S%B!P8E8I/2=%B1%LF;9:#WE/Q
M)"\A<]4J<())+Q.(C04A'=3Y]Z1L2;/&P,78&\4S+YI/1.R-@L@;3T?BD8A'
M?CP2$W]&SW-O.IH/-%@29WF9 H\ASY/P*29/9G,O" +!FQ3]+'Z%B9..GXP"
M+YACB/XOXL"/@TX963?^211ZP6C^5$S]42Q>$<L%OAZ!ZG@,*OS_J9@$_B2
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M$=G(+,>:L)NNX\/&TX()I99M86Q?V]TV,6DQ98,ZQ ]->B CEE#YIK7!5&_
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MN)*@<3,)9LG5O._DO<!7CCMS- 87R5JI.S?YO9@$L7,(!>;6(3#ZW>,U"N&
MR(WO'69P,.D4C\=[](\^=HIES0Q>*_&-%[:<!*, "MRP1MA;M?L-NW@&#B]7
MPO@O[%K9+ X@;XQ55:=,'E1<MG_VT/%PI# ZI9!V"JGWNS7DO?R5638=:[4#
M[:0)S0U\J%Z;G./2)65E->URTK/33Y3W/Y4QL$0-JY)I'$>6<-UNE'<8\Q8C
M/8&1P8V2MC2PD 46S_4C\N?@5+IW:IZ^"WC#= ^R)(0T3K-W\+)#D)G'RT[@
M+9B67&Z/@H2_9FMC-=7$WV_%V\+UWX9SY^3*U"S'24 'P:"^QV#ZTP_),/[E
M'6?[!V?[[Z'_RXS\5PSX7")LE*!#2$R 96N!8- :6M2V!$O;N:KJQC)_6M3&
M+U'!\QR8+*#@HK%8@"1HX:!K@C8.^HJP->*S(O"9<Y\4SAK)FH*3[CF<<4FP
MJC&$:$+ AQQK^X0$!97P.7SJ3(1OF/\1SI(L"P=9=N[':1:FZ>A)YPGLE'8O
MBUO57IJ<PS=_;+'XP.Y1TRW4ZAIH#(F3MRTGCK+7@;]E(8G3<#C,Z)^$HT$&
M*RYS]%1>$Q*3C[!CQ@&S#DP9[@FG-  3PJ%S5="&JRQ)D'LKK^T#-Q[9L J!
M4$^G*'3;3I2\$8WI$NS-*4M6.!/[P&F=8JY(@NZ>_ [H(C>6(G04[%0C"BB)
M*E@C4@RD^<%;I9NU]Z+$=B^9?0:+WQM^SP39-B1)L5 MB,95SD:KJBU')O)&
M',KQ='2>.Z?QBKLN[$?RF<8O' ;<;*@W_-_R/8=52U#M/*2<&M,XBU0,QYR=
M49%E878Q@C0<#&*X1;IW>.Z<:YEH)"<.,K^9A/U1'VY67PQ)I\.D^R[=0I9=
M0#:X@,5JN02U%GS;4I,.^T!*UTH2SY:WYUIRHD12;@V,Z( ,NN]G92G3R2B,
MDP$D_?"2P)V#BY9\L\]Y%Q*QGH:7EX.06OQ1?3BJ_U!<6OA*+#<:?S9P+1BE
M9/X\R5O-?!8:XK3-T.QF,7.\QK 4+A\>CZ[[O-S?]VGOK3LT.NIP%>JM[^.&
MK#72MLWNL'IX*LS:#ODDWKXSR-J64W "-Z0:]RX& >BV=[<3JVK?+]?*4O?U
MPY*>.ZB= .UO%/':39R!PP-J^@]02P,$%     @ "(BI5EQR2S$  P  (0<
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MY%.$G46[@>,MOQ/'ICSN' YV*C9TE5R5_E:<T4L72;)WZ]/V6(>WS?5B]P_
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MYNSR45W8QYT><"S]ES(Y":)(ZA\;6BGF#)OZ,9P35\_K$33:D])(X3[531-
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M@CO" /WIR&@R-:UW$/NX+SELR(UZK'N_$]DIC\OY#$@J@DCG?5$%;=0;)M0
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MK\FAM\_[](H:-:L(M%S &1?<X-%[8OJ.?'8AW^M[-_+K'&$A"^IG+I9@+#G
M/154L@P-XX6V8%:52G/JF SX/1)65Y8Y#3K.-&_.TW.G<(HIEG-4V^UP])T:
MO%-2:SAA2MU9 +-25L+ +$VKLBJ8H7BTI0S_QESC6SY_KWR)=F#9C<^N;S$[
MFMV@HC$$GS0NJ@+>\P5"NQ*LRJBBV2&TN0"3RTH32%TO[Y I$L^?9*>K^9\T
M=L!(8 ^@C CDUXHK0ECPE"8;P@$$@3<8]$EH1]X@#@])&GA^U(.D$\-'*8Y2
M6:[0D.^E0BQ=D6V=I,FI2*F\0<$H(V73T!![@>]#._2&<>\00B_H]2'L)/>!
M#::YD(5<WD'@]:UN$D6',.@G$'0"N):&%3O.ZYF,(!AX,:%O)UX<#0]M,GXO
MV5$1(<WS56FZ,/+"H0^O7PW"('RS6=6(]G'I $*J8>)JN,%!9>UY490\9=//
M9,]/8$R<#&O&1'Y"C!G\"\8DO<0R)HHC8LQP'V-BRQ@Z:<>9WC_F3)_X7G,F
M"?]/SFQP4&%CSP\2V#.3XV8FQS\\D\_IW;?XVW-YK_^7N?PREU_F\LM<?IG+
MF[G<;^9R_S_ZK>S!667L#_]'K'M[N[*'O6M@[PW\XP.[OAWS;Z@!M>&E8_ZB
MAO+HM+"&8C/9O%T*E\F3FGH@T(S@-Z*XO8?94(^Z;\\PK1LJ(T6*XF8\G8_C
M%RUZ)(;!T(JQ96#B6[%/(IVX%8F%Q&&G.W!$MSQ'MC#DCVB=A!L^'&S'TZX#
M[CZXVY:HENX&KZE;J.'K:VZSV_Q),*OOQO?J]3\,]+I:<J&AP 69^IV$WK&J
MOK77"R-7[J8\EX;NW4[,D5'Z5H&>+Z0TVX4-T/QU,OT+4$L#!!0    (  B(
MJ5:T^6B2SP(  !$&   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;'U5
M;4_;,!#^*Z=LFJB4D;=2H&LK4=@T)$ (V/9AV@<WN386CIW9#H7]^IV=-(-1
M^J4YG^]Y[CG;=YVLE;XW):*%QTI(,PU*:^MQ%)F\Q(J9?56CI)VETA6SM-2K
MR-0:6>%!E8C2.!Y%%>,RF$V\[UK/)JJQ@DN\UF":JF+Z:8Y"K:=!$FP<-WQ5
M6N>(9I.:K? 6[;?Z6M,JZED*7J$T7$G0N)P&)\EX/G3Q/N [Q[5Y9H.K9*'4
MO5N<%],@=H)08&X= Z// YZB$(Z(9/SN.(,^I0,^MS?L7WSM5,N"&3Q5X@<O
M;#D-C@(H<,D:86_4^BMV]1PXOEP)XW]AW<8.CP/(&V-5U8%)0<5E^V6/W3D\
M QS%;P#2#I!ZW6TBK_*,63:;:+4&[:*)S1F^5(\F<5RZ2[FUFG8YX>SL#!<6
M]N[80J 93")+E&XCRCOXO(6G;\ SN%32E@8^RP*+E_B(I/1ZTHV>>;J3\)+I
M?<B2$-(XS7;P97U]F>?+=M5WQDTNE&DTPL^3A;&:WL*O;<6V7,/M7*X_QJ9F
M.4X#:@"#^@&#V8=WR2C^M$/IL%<ZW,4^NZ5^*QJ!H)9PH>3JHT5=@==_+DES
M0ZU@X515M9)DF6WZ=V;8KO^N1%@J0<W)Y0JL>PA@T!IR:EN"I6U)LR%G6C^Y
M"%:IAK([E6Z/KND0KI1% \P[Z0+SLK_!$)@LJ(@<JP7JC3L=_Q?V.@+V&LF:
M@ELL!K#')253C2$R,X +SA9<</L$^>8TQG"MN<QYS02\AR1,#N(PCN,7]@4:
M,Z:.I0/EQC1,YD@$QIK05TC:J39M^1_FY\5>DH3'HQ%E3])P%!\/X.KU.;0)
MLJ,PSH:=?1AFQPEL>Q#1LS:M4*_\,#*D@8C:CNV]_;P[:=O\7W@[+.GX5EP:
M$+@D:+Q_>!" ;@=0N["J]DV_4)9&B#=+FMFH70#M+Q7=6;=P"?I_@=E?4$L#
M!!0    (  B(J5:0E-IU30,  &<'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;'U566_C-A#^*P/U2@#7LB7?M0TDV19=8(,&2=I%4?2!ED86L3Q4
MDHK7^^MW2,FJTSIZD8;'?//-R?5!FT^V1'3P60IE-U'I7+6*8YN5*)D=Z@H5
MG13:2.9H:?:QK0RR/"A)$2>CT2R6C*MHNPY[#V:[UK437.&# 5M+R<SQ%H4^
M;*)Q=-IXY/O2^8UXNZ[8'I_0_5X]&%K%'4K.)2K+M0*#Q2:Z&:]NI_Y^N/ '
MQX,]D\%[LM/ZDU^\SS?1R!-"@9GS"(Q^+WB'0G@@HO%/BQEU)KWBN7Q"_R7X
M3K[LF,4[+3[RW)6;:!%!C@6KA7O4AU^Q]2<0S+2PX0N'YNYD&4%66Z=EJTP,
M)%?-GWUNXW"FL!B]H9"T"DG@W1@*+-\QQ[9KHP]@_&U"\T)P-6@3.:Y\4IZ<
MH5-.>F[[ <DE"U?/;"?07J]C1Z#^*,Y:@-L&('D#((5[K5QIX6>58_Y:/R8R
M':/DQ.@VZ06\9V8(Z7@ R2A)>_#2SL,TX*7]'OYUL[/.4!'\?<G'!F)R&<(W
MQLI6+,--1)5OT;Q@M/W^F_%L]%,/P4E'<-*'WA"$]ZKI,"K52P3[(2AF6=D%
M#=YAAG*'YK23P%6M6)USA_DU? R5BOF/[ 4--1[UEN]>KO8@ A6'1L(55W!$
M9NPU+(9+6 ['_U?,N<UTK1P8YA#2X3*%[]I?3URF75RFO4X]T0#*:X&@"_BM
M(HO.4VRB]8&S'1?<'>&>N=IPQ]%>"ENOA<MY?2X1"BUH6GESSO=%.[+X%ZHC
M1\=W6E9,'7^P4-1D':$R7&6\8@(R:@9?937)>B?X/F24+FH#NG.BB7.FI>2.
M)IRSP*QW\W4>5_ G)< WEM=YE=3S?/I,N5+7EJF<LO48LIG310(,Y? M).E@
M-D[\:@(IR;.%EZ>0)H/9=.KE&23SP7RY]/(<DLE@,@_R @C5.TT3OZ#"@'$R
M'8RG<WC6SKOX'Y<J=FS\(9NS^2"=CRAAUJZ RZHFML 5@:!U<)4N!HOEY/H-
M(-$FF/+JL9(%$9K!I:J*SX:?1+,/(]Y"*,QF#G:[W2MRTPS/?Z\W3Q"%?\\I
M60(+4AT-YU0^IAGKS<+I*HS2G78TF(-8TDN(QE^@\T)K=UIX ]W;NOT*4$L#
M!!0    (  B(J59<2^="-@,  .(&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;)55WX^;.!#^5T94JEJ)6\! 8+=)I-WMGJX/E:)F>_=PN@<')L%:
M8U/;;)K__L:0<*F4C70O,#;S??[&\X/Y7IL7VR Z^-E*91=!XUQW%T6V:K#E
M]D9WJ.C+5IN6.UJ:760[@[P>0*V,6!S/HI8+%2SGP][*+.>Z=U(H7!FP?=MR
M<WA J?>+( E.&]_$KG%^(UK..[[#-;KOW<K0*II8:M&BLD(K,+A=!/?)W4/F
M_0>'/P7N[9D-/I*-UB]^\:5>!+$7A!(KYQDXO5[Q$:7T1"3CQY$SF([TP'/[
MQ/[[$#O%LN$6'[7\2]2N601E #5N>2_=-[W_ X_QY)ZOTM(.3]B/OJP(H.JM
MT^T13 I:H<8W_WF\AS- &;\!8$< &W2/!PTJ/W/'EW.C]V"\-[%Y8PAU0),X
MH7Q2UL[05T$XMWS4;4N7LW:Z>H$/SWPCT7Z<1XZHO4-4'6D>1AKV!DT*7[5R
MC84G56/]*SXB29,N=M+UP*X2?N7F!M(D!!:S] I?.L69#GSI&WQ//WKA#O#W
M_<8Z0Z7PSZ481XKL,H5OCSO;\0H7 =6_1?.*P?+]NV06?[HB,)L$9M?8EVMJ
MM[J7"'I[S,;F (^26WM)Z76NYP:!$MMQ=7C_KF1)\<E"-2;:#M0-M[!!]&TU
MQ%$#M3<X@FVUI#X5:@>==JB<X!*VO>L-@K"VYZI">P>4G:J9T@.?L<)V@^:T
MP^!#KWA?"X?U1U@WG(Z!GBK#R(.GIN%@'5>UMT=!NO,]:B$-TX*%^2PA*XO)
M*K(+^%Z]HB5N+]\947ESY.F5<)XE2^.0 B=K5A9A699>\@NZWWP'OXEC(9O%
M83'+SJP5FF'T4>#7P6F:AJS((<V2L$C2DVS^RH7T;35<\>D.QVB&&V=Q4L(7
MVE-^/L']GIL:5I(KN T]9WG+(*> RI#=SOX?ZU/;27U /!;4JJ>L40@C.PN3
M+ OS.(<D3)(R3),$GK6C?#.ZNR(/2V)(9B'+;L,\FUTJ\>AL[K1H=L-T]:76
M*S>.H&EW&N#WX]SZSWV<_I2>G: "D+@E:'Q3Y &8<:*."Z>[88IMM*.9.)@-
M_830> ?ZOM54K\>%/V#ZK2W_!5!+ P04    "  (B*E6=L#JKA<'  "N$P
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M(5!9!_J^DM+L-C9 ^\^9_P502P,$%     @ "(BI5I\O#RP_ @  S 0  !D
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MWPT8ET#G>ZWM,7 %AA]8^A=02P,$%     @ "(BI5L-X"'0U"0  ?F$  !D
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M#KB7-)7$IE+5ZI?///OSK)B%==SK'_>,UC(!G:,$I=E0F@.EN5":!Z7Y4%J
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M965T,S8N>&ULK9AO;^HV%,:_BI5)TR;U-O\HM!T@E7C3KK1.%6C;BVDOW.0
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M;=X0[G(-+ -I*YCG2R'TX<8VT)RB3[\"4$L#!!0    (  B(J58#Q)8,#@0
M !@4   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+58VX[;-A#]%4(-
MB@38K"Z^;VT!MM6@!;+ PD[:AZ /M#2VB5"D2])V^O<E):UL13)]B?-BB]3,
MF3F'MQ&'>RZ^RC6 0M]2RN3(62NU>7)=&:\AQ?*1;X#I-TLN4JQT4ZQ<N1&
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MIX=:Y-=0>4/Q378QL^!*\31[7 -.0!@#_7[)N7IMF #E96#X/U!+ P04
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M_XJ555,G=<T'D$ 'D=JB;KW85)5UNYAV89(#\>K$S':@VZ_?<9)F*80PH=V
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M0&2=J:18'Q*J:3R48D.DR48V,[!F6C3*9]QL^U1+7&6(TW$",TU.R%CDA>#
MM2)B@1%?@]1LE@&9 F="DENA09'#!#1EF3JRD#])-<M.;E("";S@#.?OIPDY
M/#@B!X1Q\F4E2D7Y7 U=C0),&6Y:%WM9%1N\4.QG*D])Z!\;WK %/NZ&)Y V
M\* %GG3#;\4:X9Z%>[MP%UUOK \:ZP/+%W99?\V5EB6>(TV^WV "N=:0JQ]M
MWE1L43N;:0\#5= 41@Z>?P5R#4[\_IW?]SZT.?669,D;D>VX&#8NAEWL\40R
MGK*"9FV65="^A9H&N(Y]O^?A9^BNM]UX95[R][P=#5&C(>K4< -*#;!;X>^!
M*552G@))A=+JF'#L_'@B:2[PJ/VBIE>V":WX>UN%G?C^1;^_I[,M+>A[%WLR
M.ZO]S_WL-5[T.KVX1<$IE?*)\:6177+=)KC7LA/AN1=&>XI;\\[""W]/<F=1
M_RK9W>K'YO+$OK5D7)$,%DCOG9[AVV1U(56!%H5MT3.AL>';X0KO<) F =<7
M EMJ'9BNW_PKB'\#4$L#!!0    (  B(J5;L86&IX0(  "@+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;+56:T_;,!3]*U:&)I!8\^J#LC82;8>&
M1#<$8OLP[8-);UN+Q,YL]\&_W[63AA:EV=C*E]9V[CF^Y_@FOKV5D(]J#J#)
M.DVXZCMSK;-SUU7Q'%*J&B(#CD^F0J94XU3.7)5)H!,+2A,W\+RVFU+&G:AG
MUVYDU!,+G3 .-Y*H19I2^32 1*SZCN]L%F[9;*[-@AOU,CJ#.]#WV8W$F5NR
M3%@*7#'!B81IW[GPSX>^9P VXAN#E=H:$R/E08A',[F:]!W/9 0)Q-I04/Q;
MPA"2Q#!A'K\*4J?<TP"WQQOV2RL>Q3Q0!4.1?&<3/>\[9PZ9P)0N$GTK5I^A
M$-0R?+%(E/TEJSRV%3HD7B@MT@*,&:2,Y_]T71BQ!4">:D!0 (*7@.8>0%@
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MTFMT\+,J\[8LGVB1V<[F06CLD^QPCJTL2!. SZ="Z,W$;% VQ]%O4$L#!!0
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MP/R&[DDIWVPI*["0MVQG\STC.*F3BMQ&CA/8!<Y*:SFOGZW9<DXKD6<E63/
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MI@3+I:("Y/LMI>+U1A7H3O.7_P%02P,$%     @ "(BI5CVU^JC_!@  G2\
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M8GUD[6K5VF:5Q'P2$R0F24R16$!BX?!@[>IYWF"PMW9M>%1O.![O;=62"Y9
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MUVO-]5YSK?.X?7@\"W<5'^+3=>*-L3^ O)4::->:H<)^+S[<Q1>$8V]Z^C>
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M(ME"=U)C)K$OT\,9ML[ U09\/V%,;B?J V4SWOL'4$L#!!0    (  B(J59
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M;CC#QQPH:X#[$RG->F(/J)^'Z1]02P,$%     @ "(BI5O*4938/ P  S0D
M !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULM99K;]HP%(;_BI554RNU
MY,:U@TBE[;1)ZX3*NGZ8]L$DAEA-[,QVH/OW.W9"&I!!3-J^@"_GO'E>W\<;
M+EYD2HA"KWG&Y,1)E2JN75?&*<FQ[/"",.A9<I%C!56Q<F4A"$Y,4IZY@>?U
MW1Q3YD1CTS83T9B7*J.,S 2299YC\7M*,KZ9.+ZS;7BDJU3I!C<:%WA%YD0]
M%3,!-;=126A.F*2<(4&6$^?&O[X=Z7@3\)V2C6R5D7:RX/Q%5SXG$\?30"0C
ML=(*&/[6Y)9DF18"C%^UIM-\4B>VRUOUC\8[>%E@26YY]DP3E4Z<H8,2LL1E
MIA[YYA.I_?2T7LPS:7[1IH[U'!274O&\3@:"G++J'[_6X]!* !U[0E G!/L)
MW0,)89T0&J,5F;%UAQ6.QH)OD-#1H*8+9FQ,-KBA3,_B7 GHI9"GHJ^P4+YP
M*=&,"#1/L2#H"LUAK21E1A!?(DO ^1U1F&;R D*?YG?H_.P"G2$72=TK$67H
MB5$E+UL-WU)>2LP2:#S;J8]=!2XTBQO7Q-.*.#A '*('SE0JT3U+2+*;[X+[
M9@B"[1!,@Z."#UAT4.A?HL +0@O/[>GIP1&<L)F1T.B%!_3NL6"4K=H#_N-F
M(96 %?_3-ER57-<NIT^!:UG@F$P<V.:2B#5QHO?O_+[WP>;U'XGM..\VSKO'
MU,U:S&"I7>J-26.;UTJ@;P3T ;6.KOPP[(4P;^NV#5M<$ ;!L(G;(>PUA+T3
M"1.:E6I_^56,O1,9;7%'&/L-8_\D1E3 ^C$[$-4#BLYAYY4R>>NYL/%7\L,=
MKLX^O#4H\.WH@P9]\/?H]4B?"#\X!=X:= A^V, /C\(_FQN#)%=X301<@-O3
MKY0 #^PQSXM2P<Y&[/@,57E6=Q5!KP7N>T&_O^_/%N8/>Z'=X*@Q./J?!MOS
M>,3BZ#2+MC"+1;=U,^9$K,R#00)JR51U0S2MS9ODQES%>^U3>*M43XLWF>JA
M ^?_BC*),K($2:\S "A1/1ZJBN*%N7\77,%M;HHIO+>(T '0O^1<;2OZ \T+
M+OH#4$L#!!0    (  B(J59O+X?U] 0   HD   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;,V:[V_B-AC'_Q4KDZ8[:6L2A_"C Z06=]I)UPD5W?9B
MV@LW&+ NB9GME$[:'S\[I DAQE<J7\6;-@E^OO;S<1XG7_!XQ_A7L2%$@N<L
MS<7$VTBYO?9]D6Q(AL45VY)<?;)B/,-2G?*U+[:<X&49E*4^#(*^GV&:>]-Q
M>6W.IV-6R)3F9,Z!*+(,\W]O2<IV$R_T7BX\T/5&Z@O^=+S%:[(@\LMVSM69
M7ZLL:49R05D..%E-O)OP&L&^#BA;_$')3AP< YW*(V-?]<FGY<0+](A(2A*I
M);#Z]T1F)$VUDAK'/Y6H5_>I P^/7]1_+9-7R3QB068L_9,NY6;B#3VP)"M<
MI/*![7XC54*QUDM8*LJ_8%>U#3R0%$*RK I6(\AHOO^/GRL0!P%*QQP JP!X
M'- [$1!5 =%K WI50*\DLT^EY("PQ-,Q9SO =6NEI@]*F&6T2I_F>MX7DJM/
MJ8J3T]_5K?69"0'FA(/%!G,"?@8+=7<MBY0 M@(WN:1+FA9Z>L"") 6GDA(!
M/B B,4W%1]5>Z#@Q]J4:D);UDZKSVWWG\$3G$;AGN=P(<)<OR;(=[ZM$ZFS@
M2S:WT"IXC_D5B,*?  Q@9!C/[/7AT!".[.&()*?"6]E$]=Q$I5YT0N\4^KOG
M)"T4,+#B+ ,SEFT+B<LJ4O-UAWE.\_7AA/[U60F#3Y)DXF_3).U'T3./0B\\
MUV*+$S+QU,HB"'\BWO3''\)^\(N)L$LQY$BL1;]7T^_9U-OT14.?M.@G;?KD
MA?Y6T2_+ GR@>54@'TWP]X.(RT'H1?II&@Z#, Z"8.P_'8(U-.R-^F&G(;*F
M]49H<0TMMD);2)9\!6RK>0B@GC-"XGRIB'P+0]S)+HH&,.Z'1Q2LW9][>QDZ
M[04P'O3J3EL0^C6$OOW.N;^[T6M  .8ISL%_8)9BM<+>FO*V*IU;>R[%D".Q
M%L%!37!P$2O?P"5]EV+(D5B+_K"F/_P^16R5/1?GL%.<<#2*86>Y<]1IB]2H
M)C4Z@Q05HE#WIF)U",T$RJIZ+BB78LB16(MF&#0OH\%%U'TU#$<3X%0-N5)K
M3\&!'P@OX;6G&L71 W_8?>TQ-(2Q?CTZ7@?L>;V5&VRX02NW!R(DIXE4A$2Y
M*A0YE69/9!4Z^^9SJ89<J;4A-H8GO S'$SJU/$[5D"NU]A0TKB>\"-L3=NU,
M9"KKF:%AV!OV#/7_/7Q/V!B?T.Y\[A=?S-7NTK',G*HA5VIM9(U-"ON74>U.
M3993->1*K3T%C<\*K4;BW:I]T'V(0\-W%[/7-D3VO-[*K7%(H=TBS4]5NU,+
MY%0-N5)K(VNL4CBZC&IW:JZ<JB%7:NTOQQM[!:W>X;VJO1K%T;M]M]A-[>)N
M.V3/ZJW4&D<$[8[H;C&? _:8TG7)Q)BQ(^]1<7&IAERIM>DUO@C"BRA[Z-15
M.55#KM3:4]"X*FBU#.]6]E'WV=WOOJC/#.U,[_/VI-X*K?%!T.Z#9BQ_(ES2
MQU0SRRGC(&?2_"NG7>KL>\^E&G*EUL;8V"(87T;Y.[593M60*[7V%#0V"W[C
MYZAW*O]^MZPA-/R0^=J&R)[7N=S\@TT2&>'K<K.)4'D7N=SO,*BOUAM:;LIM
M'$?7;\/KV7Y;2B.SWR5SC_F:Y@*D9*4D@ZN!RI'O-Y[L3R3;EELQ'IF4+"L/
M-P0O"=<-U.<KII:8ZD1W4&__F?X/4$L#!!0    (  B(J59ZV$Y9TP,  /,2
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;+58V6[C-A3]%4(=%#-
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M\C$%G !3 ?+]AE)Q*J@&FGNN\%]02P,$%     @ "(BI5G5O^9=+ P  VA0
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M17L$8<2)1X^1OY8$!A+<;?F#5Z4_VW)8DK!NFV$_*^2Z>R+B'"8+S5GP2,6
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M">O+:][6UX:%G]WG(449EGN7V[8]\V7?U*7FS<NGFR^?G9[\ U!+ P04
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M&^IM!'H;ZFT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^V2SFT!O1[V=0&]'O9U
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "(BI5L\EQ]3O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M"(BI5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  (B*E6+6BZF,T%  #*'@  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M"(BI5F"7M^.'!@  =QH  !@              ("!$0X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    (  B(J5;4G7'V_P(  %D*   8
M          " @<X4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  (B*E6<DK41$L%  !\%   &               @($#&   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "(BI5AO<%B0X P  H D
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M965T.2YX;6Q02P$"% ,4    "  (B*E63"UH(<D$   @"P  &0
M    @('57@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M  B(J59;;R0X[ ,  "()   9              " @=5C  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ "(BI5IAJRJ52#0  <RD  !D
M             ("!^&<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  (B*E6B@LQVTP$  "%"P  &0              @(&!=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  B(J5:_-AN(W0H
M $P@   9              " @01Z  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ "(BI5J902.CH!   M@H  !D              ("!
M&(4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  (B*E6
M\MV3@?L+  !\'@  &0              @($WB@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    (  B(J59=54(@> ,  /D'   9
M      " @6F6  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ "(BI5N[*2=C^$0  $3@  !D              ("!&)H  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  (B*E6Y5TD8PP$  !,"0
M&0              @(%-K   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    (  B(J59<<DLQ  ,  "$'   9              " @9"P  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ "(BI5IZGX]/!
M P  8 @  !D              ("!Q[,  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  (B*E6P-6:"/$"  "S!@  &0
M@(&_MP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  B(
MJ58X< K<!BH  #J5   9              " @>>Z  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ "(BI5G/#/\JB!   Z@P  !D
M         ("!).4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  (B*E6B:&\IL4#  "]"   &0              @(']Z0  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  B(J5;HPN&:808  (\5
M   9              " @?GM  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ "(BI5BXE9K!N!   1A$  !D              ("!D?0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  (B*E6M/EH
MDL\"   1!@  &0              @($V^0  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    (  B(J5:0E-IU30,  &<'   9
M  " @3S\  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M"(BI5EQ+YT(V P  X@8  !D              ("!P/\  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  (B*E6=L#JKA<'  "N$P  &0
M            @($M P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    (  B(J59OK*F?_0,  %()   9              " @7L* 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "(BI5MR)NOT) P
M?P8  !D              ("!KPX! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  (B*E6GR\/+#\"  #,!   &0              @('O
M$0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  B(J5;#
M> AT-0D  'YA   9              " @644 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ "(BI5LN6'W7  P  41<  !D
M     ("!T1T! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B(J5;\/1:=-0,  "\)   9              "
M@;PQ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ "(BI
M5BCWV6:;!P  9SX  !D              ("!*#4! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  (B*E6Q*9:)  '  #[.P  &0
M        @('Z/ $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   (  B(J595FA;K]@,  #(1   9              " @3%$ 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ "(BI5@I%&HU[!   RA<
M !D              ("!7D@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  (B*E6W>E-EK\#   ;$   &0              @($030$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  B(J59;Z(.K
M%P4  .X9   9              " @091 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ "(BI5E3C?5ER @  X04  !D
M ("!5%8! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  (
MB*E61<^_EO4"  #5"0  &0              @(']6 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  B(J5;/'&-Q_ <  *1)   9
M          " @2E< 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#
M%     @ "(BI5K2%(O'% @  (0@  !D              ("!7&0! 'AL+W=O
M<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  (B*E6[&%AJ>$"   H
M"P  &0              @(%89P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM
M;%!+ 0(4 Q0    (  B(J581\A<^4 (  /8%   9              " @7!J
M 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ "(BI5K?5
MWAC6 @  ]P<  !D              ("!]VP! 'AL+W=O<FMS:&5E=',O<VAE
M970U-"YX;6Q02P$"% ,4    "  (B*E6=A&;?'D"  "A!0  &0
M    @($$< $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M  B(J5;KPF!\= 0  -D7   9              " @;1R 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ "(BI5CVU^JC_!@  G2\  !D
M             ("!7W<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    "  (B*E6V*I-;4$7  "=:P$ &0              @(&5?@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  B(J59T+3VG- 0
M -H1   9              " @0V6 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ "(BI5N9=LO1F P  F \  !D              ("!
M>)H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  (B*E6
M0%,^O/X#  "!%   &0              @($5G@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    (  B(J59]AJ,7<P,  "H.   9
M      " @4JB 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ "(BI5O*4938/ P  S0D  !D              ("!]*4! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  (B*E6;R^']?0$   *)
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M+G)E;'-02P$"% ,4    "  (B*E6HWIWN]8$  #Z*@  #P
M@ '.M@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "(BI5K5Q8'P6 @
MJB8  !H              ( !T;L! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ "(BI5M(T9!3L 0  !R8  !,              ( !
M'[X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $D 20#V$P  /, !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? (Deficit) Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? (Deficit) Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/JointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Intangible Assets, Net and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</Role>
      <ShortName>Intangible Assets, Net and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables</Role>
      <ShortName>Intangible Assets, Net and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/NetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/DescriptionofBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/JointVentureDetails</Role>
      <ShortName>Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/JointVenture</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Debt - Components of Convertible Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails</Role>
      <ShortName>Debt - Components of Convertible Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Leases - Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesLeaseInformationDetails</Role>
      <ShortName>Leases - Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails</Role>
      <ShortName>Leases - Schedule of Operating Liability Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStockTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Market-based Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationDetails</Role>
      <ShortName>Segment and Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting, us-gaap:DebtInstrumentConvertibleConversionRatio1 -  gh-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="gh-20230331.htm">gh-20230331.htm</File>
    <File>gh-03312023x10qxex311.htm</File>
    <File>gh-03312023x10qxex312.htm</File>
    <File>gh-03312023x10qxex313.htm</File>
    <File>gh-03312023x10qxex321.htm</File>
    <File>gh-03312023x10qxex322.htm</File>
    <File>gh-03312023x10qxex323.htm</File>
    <File>gh-20230331.xsd</File>
    <File>gh-20230331_cal.xml</File>
    <File>gh-20230331_def.xml</File>
    <File>gh-20230331_lab.xml</File>
    <File>gh-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="726">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gh-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 726,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "gh-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gh-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gh-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gh-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gh-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gh-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 556,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://guardanthealth.com/20230331": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 55,
   "keyStandard": 297,
   "memberCustom": 20,
   "memberStandard": 50,
   "nsprefix": "gh",
   "nsuri": "http://guardanthealth.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://guardanthealth.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Joint Venture",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://guardanthealth.com/role/JointVenture",
     "shortName": "Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Intangible Assets, Net and Goodwill",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill",
     "shortName": "Intangible Assets, Net and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://guardanthealth.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://guardanthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://guardanthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://guardanthealth.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://guardanthealth.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://guardanthealth.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://guardanthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Segment and Geographic Information",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformation",
     "shortName": "Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables",
     "shortName": "Condensed Consolidated Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Intangible Assets, Net and Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables",
     "shortName": "Intangible Assets, Net and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://guardanthealth.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://guardanthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://guardanthealth.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://guardanthealth.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://guardanthealth.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Segment and Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationTables",
     "shortName": "Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Description of Business (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://guardanthealth.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i4fd5436f59444ce687ed0189efa7463f_D20221201-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i6506cad5ab63497db74f92ba4f91d108_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i6506cad5ab63497db74f92ba4f91d108_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i7e65589a00cc4191b7198e0d03acf479_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Joint Venture (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://guardanthealth.com/role/JointVentureDetails",
     "shortName": "Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ia536ff2c58f1448390655c51b679d617_D20220601-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenueFromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
     "shortName": "Condensed Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenueFromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ieb852a9ed67d4316a04d75194f6818e6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ieb852a9ed67d4316a04d75194f6818e6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesRealizedGainLoss",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesRealizedGainLoss",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ied9f5b8c565a4dca904ac822c40abf74_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ied9f5b8c565a4dca904ac822c40abf74_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "gh:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Schedule of Unrealized Loss Position, Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://guardanthealth.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i73765d8c5b9c47e49e769314e9a95216_I20201116",
      "decimals": "2",
      "lang": "en-US",
      "name": "gh:ConvertibleDebtHedgeStrikePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ic4afdaf1a32649acbb00d349e86393cd_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Debt - Components of Convertible Senior Notes (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
     "shortName": "Debt - Components of Convertible Senior Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ic4afdaf1a32649acbb00d349e86393cd_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://guardanthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Leases - Lease Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://guardanthealth.com/role/LeasesLeaseInformationDetails",
     "shortName": "Leases - Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails",
     "shortName": "Leases - Schedule of Operating Liability Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://guardanthealth.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "idccc5081d04f48319c21aeaeeb9692b0_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://guardanthealth.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i6506cad5ab63497db74f92ba4f91d108_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i83d00be36d6c415b8e0fe3afc59a41a8_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i5419e29cd3674106abc793e0ae7a5a7d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i4a217ce041e141b09264af36dd335cb8_D20230101-20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i63da5e92a9b84f0d93e9513d7c29fb14_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 (Deficit) Equity (unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 (Deficit) Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i63da5e92a9b84f0d93e9513d7c29fb14_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ie817ff3c12124b78a03fdb6de0e8038d_D20200501-20200531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i6f7831f66bf24d07b9a37f3bf04460d1_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i32e84c2df8114b2ca174af7f12413df9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "ia40c9dfe7a204b459542dce8ca3a4052_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i667290ec4cc3455698d2cc3f2246ca74_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Segment and Geographic Information (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
     "shortName": "Segment and Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "i25302361b67443c4a5fa5c0994f68a46_D20230101-20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://guardanthealth.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20230331.htm",
      "contextRef": "id4c7e55434984b3fb92dff3a7b136af1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://guardanthealth.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gh_A2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Employee Stock Purchase Plan [Member]",
        "label": "2018 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_A2018IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Incentive Award Plan [Member]",
        "label": "2018 Incentive Award Plan [Member]",
        "verboseLabel": "Shares available for issuance under the 2018 Incentive Award Plan"
       }
      }
     },
     "localname": "A2018IncentiveAwardPlanMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AMEA2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMEA 2020 Plan",
        "label": "AMEA 2020 Plan [Member]",
        "terseLabel": "AMEA 2020 Plan"
       }
      }
     },
     "localname": "AMEA2020PlanMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges",
        "terseLabel": "Purchase of convertible senior note hedges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AssetAcquisitionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Policy Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CashCashEquivalentsAndDebtSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Debt Securities, Fair Value",
        "label": "Cash, Cash Equivalents And Debt Securities, Fair Value",
        "terseLabel": "Cash, cash equivalents and debt securities, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesFairValue",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, After Allowance For Credit Loss Net, Current",
        "label": "Contractual Receivables, After Allowance For Credit Loss Net, Current",
        "totalLabel": "Financing receivable, net amount, current"
       }
      }
     },
     "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent",
        "label": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent",
        "totalLabel": "Financing receivable, net amount, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 1.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss, Current",
        "label": "Contractual Receivables, Allowance For Credit Loss, Current",
        "negatedLabel": "Financing receivable, allowance for credit losses, current",
        "periodEndLabel": "Ending balance, financing receivable, allowance for credit loss, current",
        "periodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossCurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 2.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss, Noncurrent",
        "label": "Contractual Receivables, Allowance For Credit Loss, Noncurrent",
        "negatedLabel": "Financing receivable, allowance for credit losses, noncurrent",
        "periodEndLabel": "Ending balance, financing receivable, allowance for credit loss, noncurrent",
        "periodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossNoncurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss",
        "label": "Contractual Receivables, Allowance For Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Contractual Receivables and Related Credit Loss"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss",
        "label": "Contractual Receivables, Before Allowance For Credit Loss",
        "terseLabel": "Other receivables and other assets due from a third-party"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLoss",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 2.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current",
        "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current",
        "terseLabel": "Financing receivable, gross amount, current"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 1.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent",
        "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent",
        "terseLabel": "Financing receivable, net amount, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent",
        "label": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent",
        "terseLabel": "Contractual receivables, credit loss"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossExpenseReversalNoncurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossReclassificationCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Reclassification, Current",
        "label": "Contractual Receivables, Credit Loss, Reclassification, Current",
        "terseLabel": "Reclassification, allowance for credit loss, current"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossReclassificationCurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossReclassificationNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent",
        "label": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent",
        "terseLabel": "Reclassification, allowance for credit loss, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossReclassificationNoncurrent",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Term",
        "label": "Contractual Receivables, Term",
        "terseLabel": "Other receivables and other assets, term"
       }
      }
     },
     "localname": "ContractualReceivablesTerm",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConversionPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Three",
        "label": "Conversion Period Three [Member]",
        "terseLabel": "Conversion Period Three"
       }
      }
     },
     "localname": "ConversionPeriodThreeMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConvertibleDebtHedgeSharePricePremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Hedge, Share Price, Premium Percentage",
        "label": "Convertible Debt, Hedge, Share Price, Premium Percentage",
        "terseLabel": "Share price, premium"
       }
      }
     },
     "localname": "ConvertibleDebtHedgeSharePricePremiumPercentage",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_ConvertibleDebtHedgeStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Hedge, Strike Price",
        "label": "Convertible Debt, Hedge, Strike Price",
        "terseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "ConvertibleDebtHedgeStrikePrice",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gh_ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2027",
        "label": "Convertible Senior Notes Due 2027 [Member]",
        "terseLabel": "Senior Notes Due 2027"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CostOfDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Development Services",
        "label": "Cost Of Development Services",
        "terseLabel": "Cost of development services and other"
       }
      }
     },
     "localname": "CostOfDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostOfDevelopmentServicesAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Development Services And Other",
        "label": "Cost Of Development Services And Other [Member]",
        "terseLabel": "Cost of development services and other"
       }
      }
     },
     "localname": "CostOfDevelopmentServicesAndOtherMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CostOfDevelopmentServicesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Development Services [Policy Text Block]",
        "label": "Cost Of Development Services [Policy Text Block]",
        "terseLabel": "Cost of Development Services and Other"
       }
      }
     },
     "localname": "CostOfDevelopmentServicesPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CostsOfPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs Of Precision Oncology Testing",
        "label": "Costs Of Precision Oncology Testing",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "CostsOfPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostsOfPrecisionOncologyTestingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing [Policy Text Block]",
        "label": "Costs Of Precision Oncology Testing [Policy Text Block]",
        "terseLabel": "Costs of Precision Oncology Testing"
       }
      }
     },
     "localname": "CostsOfPrecisionOncologyTestingPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer D",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate",
        "label": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage",
        "label": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage",
        "terseLabel": "Maximum special interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_DebtInstrumentMeasurementInputDenominator": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Measurement Input Denominator",
        "label": "Debt Instrument, Measurement Input Denominator",
        "terseLabel": "Debt, measurement input denominator"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInputDenominator",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gh_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, And Cash And Cash Equivalents Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, And Cash And Cash Equivalents Amortized Cost",
        "totalLabel": "Amortized cost, cash and cash equivalents and debt securities available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_EquityInvesteeWithIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investee With IPO",
        "label": "Equity Investee With IPO [Member]",
        "terseLabel": "Equity Investee With IPO"
       }
      }
     },
     "localname": "EquityInvesteeWithIPOMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Number Of Seats Each Party Holds On The Board",
        "label": "Equity Method Investment, Number Of Seats Each Party Holds On The Board",
        "terseLabel": "Number of seats"
       }
      }
     },
     "localname": "EquityMethodInvestmentNumberOfSeatsEachPartyHoldsOnTheBoard",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_EquitySecurityFVNIImpairmentOfPurchaseRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Security, FV-NI, Impairment Of Purchase Rights",
        "label": "Equity Security, FV-NI, Impairment Of Purchase Rights",
        "terseLabel": "Impairment of non-marketable equity securities"
       }
      }
     },
     "localname": "EquitySecurityFVNIImpairmentOfPurchaseRights",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value",
        "label": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value",
        "terseLabel": "Impairment or adjustments of non-marketable securities"
       }
      }
     },
     "localname": "EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_GuardantHealthAMEAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guardant Health AMEA, Inc [Member]",
        "label": "Guardant Health AMEA, Inc [Member]",
        "terseLabel": "Guardant Health AMEA, Inc"
       }
      }
     },
     "localname": "GuardantHealthAMEAIncMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Accounts Payable, Accrued and Other Liabilities",
        "label": "Increase (Decrease) in Accounts Payable, Accrued and Other Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_NonCashOperatingLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Operating Lease Costs",
        "label": "Non Cash Operating Lease Costs",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCosts",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_NonMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Marketable Securities Policy Text block",
        "label": "Non-Marketable Securities [Policy Text Block]",
        "terseLabel": "Non-Marketable Securities"
       }
      }
     },
     "localname": "NonMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_NoncontrollingInterestLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Liability Member",
        "label": "Noncontrolling Interest Liability [Member]",
        "terseLabel": "Noncontrolling Interest Liability"
       }
      }
     },
     "localname": "NoncontrollingInterestLiabilityMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_NumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patients",
        "label": "Number Of Patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatients",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Restricted Stock Units",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PostAcquisitionCompensationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-Acquisition Compensation, Policy Text block",
        "label": "Post-Acquisition Compensation, Policy [Policy Text Block]",
        "terseLabel": "Post-acquisition Contingent Consideration"
       }
      }
     },
     "localname": "PostAcquisitionCompensationPolicyPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_PostAcquisitionContingentConsiderationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-Acquisition Contingent Consideration Expense",
        "label": "Post-Acquisition Contingent Consideration Expense",
        "terseLabel": "Post-acquisition contingent consideration expense"
       }
      }
     },
     "localname": "PostAcquisitionContingentConsiderationExpense",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PrecisionOncologyTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Oncology Testing [Member]",
        "label": "Precision Oncology Testing [Member]",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "PrecisionOncologyTestingMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ProceedsFromContractualReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Contractual Receivable",
        "label": "Proceeds From Contractual Receivable",
        "terseLabel": "Contractual receivables, installment payment"
       }
      }
     },
     "localname": "ProceedsFromContractualReceivable",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RevenueFromDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Development Services",
        "label": "Revenue From Development Services",
        "terseLabel": "Development services and other"
       }
      }
     },
     "localname": "RevenueFromDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RevenueFromPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Precision Oncology Testing",
        "label": "Revenue From Precision Oncology Testing",
        "terseLabel": "Precision oncology testing"
       }
      }
     },
     "localname": "RevenueFromPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_SaleOfStockLockUpPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Lock Up Period",
        "label": "Sale Of Stock, Lock Up Period",
        "terseLabel": "Lock up period"
       }
      }
     },
     "localname": "SaleOfStockLockUpPeriod",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period",
        "terseLabel": "Additional service period requirement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Available For Grant, Forfeitures In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Available For Grant, Forfeitures In Period, Gross",
        "terseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "terseLabel": "Number of MSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest, Price Goal",
        "terseLabel": "Price goal (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestPriceGoal",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross",
        "negatedTerseLabel": "Granted (in shares)",
        "terseLabel": "Total market-based restricted stock units approved and granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "terseLabel": "Market-based stock units holding period during vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Tranches",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Annual Increase In Shares Available",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Annual Increase In Shares Available",
        "terseLabel": "2018 plan annual increase (in shares)",
        "verboseLabel": "2018 Plan annual increase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "terseLabel": "Market-based restricted stock share price goal"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_SoftBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SoftBank [Member]",
        "label": "SoftBank [Member]",
        "terseLabel": "SoftBank"
       }
      }
     },
     "localname": "SoftBankMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Exercise Of Warrants",
        "label": "Stock Issued During Period, Value, Exercise Of Warrants",
        "terseLabel": "Vesting of common stock exercised early"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.",
        "label": "TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc. [Member]",
        "terseLabel": "TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc."
       }
      }
     },
     "localname": "TwinStrandBiosciencesAndUniversityOfWashingtonVsGuardantHealthIncMember",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "label": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimCondensedFinancialStatementsPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value That Is No Less Than Internal Rate of Return",
        "label": "Variable Interest Entity, Threshold Percentage of Fair Value That Is No Less Than Internal Rate of Return",
        "terseLabel": "Threshold percentage of fair value that is no less than internal rate of return"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPercentageOfFairValueThatIsNoLessThanInternalRateOfReturn",
     "nsuri": "http://guardanthealth.com/20230331",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r286",
      "r609",
      "r669",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r409",
      "r551",
      "r569",
      "r590",
      "r591",
      "r607",
      "r613",
      "r619",
      "r667",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r409",
      "r551",
      "r569",
      "r590",
      "r591",
      "r607",
      "r613",
      "r619",
      "r667",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r286",
      "r609",
      "r669",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r402",
      "r409",
      "r439",
      "r440",
      "r441",
      "r527",
      "r551",
      "r569",
      "r590",
      "r591",
      "r607",
      "r613",
      "r619",
      "r662",
      "r667",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r402",
      "r409",
      "r439",
      "r440",
      "r441",
      "r527",
      "r551",
      "r569",
      "r590",
      "r591",
      "r607",
      "r613",
      "r619",
      "r662",
      "r667",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r618",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r577",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r618",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r647",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r617"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of (discount) premium on marketable debt securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r93",
      "r181"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r190",
      "r563",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r134",
      "r515",
      "r570",
      "r571",
      "r630",
      "r631",
      "r632",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Remaining Weighted-Average Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Balance Sheet Components"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r617"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r640",
      "r641",
      "r642",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r125",
      "r126",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r35",
      "r362",
      "r501",
      "r634"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r46",
      "r79",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r154",
      "r166",
      "r185",
      "r216",
      "r269",
      "r273",
      "r278",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r469",
      "r471",
      "r488",
      "r617",
      "r665",
      "r666",
      "r707"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r177",
      "r192",
      "r216",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r469",
      "r471",
      "r488",
      "r617",
      "r665",
      "r666",
      "r707"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Member]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r291",
      "r309"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost, debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r72",
      "r290",
      "r309",
      "r557"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated fair value, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r71",
      "r309"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r468",
      "r633"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r131",
      "r132",
      "r467"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration liability, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r48",
      "r179",
      "r593"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Amortization cost, cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Estimated fair value, cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r49",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r48",
      "r53"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014End of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014Beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r147"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r216",
      "r236",
      "r237",
      "r244",
      "r246",
      "r253",
      "r254",
      "r301",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r369",
      "r370",
      "r373",
      "r377",
      "r384",
      "r488",
      "r592",
      "r626",
      "r636",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r158",
      "r171"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r325",
      "r326",
      "r580",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r640",
      "r641",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March\u00a031, 2023, and December\u00a031, 2022; 102,708,305 and 102,619,383 shares issued and outstanding as of March\u00a031, 2023, and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r197",
      "r199",
      "r206",
      "r559",
      "r565"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r144",
      "r145",
      "r286",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r144",
      "r145",
      "r286",
      "r576",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r144",
      "r145",
      "r286",
      "r579",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r164",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r60",
      "r61",
      "r144",
      "r145",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r62",
      "r144",
      "r146",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r144",
      "r145",
      "r286",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r386",
      "r388",
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r386",
      "r387",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r386",
      "r387",
      "r399"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r386",
      "r387",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue long term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r98",
      "r340",
      "r341",
      "r352",
      "r353",
      "r354",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt",
        "verboseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r58",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r214",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r356",
      "r363",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r155",
      "r156",
      "r165",
      "r219",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r502",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r99",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r18",
      "r107",
      "r110",
      "r112",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold of consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold of common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r149",
      "r151",
      "r340",
      "r502",
      "r603",
      "r604"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r354",
      "r487",
      "r603",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r149",
      "r368",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r219",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r502",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r107",
      "r111",
      "r112",
      "r113",
      "r148",
      "r149",
      "r151",
      "r163",
      "r219",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r502",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Recognition of credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r297",
      "r313",
      "r600"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r297",
      "r313"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r297",
      "r313",
      "r600"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r297",
      "r313"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less Than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r295",
      "r310",
      "r600"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r296",
      "r311"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r294",
      "r600",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Debt securities, short-term"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on marketable debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r150",
      "r668"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: debt issuance costs, net of amortization"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r46",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r46",
      "r267"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r413",
      "r444",
      "r445",
      "r448",
      "r453",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r114",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends on common stock"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r236",
      "r244",
      "r245",
      "r246",
      "r250",
      "r476",
      "r477",
      "r560",
      "r566",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share , basic (in usd per share)",
        "verboseLabel": "Net loss per share, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r244",
      "r245",
      "r246",
      "r250",
      "r476",
      "r477",
      "r560",
      "r566",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in usd per share)",
        "verboseLabel": "Net loss per share , diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock based compensation not recognized, period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for issuance under the 2018 Employee Stock Purchase Plan",
        "verboseLabel": "ESPP obligation"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options issued and outstanding",
        "verboseLabel": "Shares underlying outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r175",
      "r200",
      "r201",
      "r202",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r252",
      "r303",
      "r385",
      "r449",
      "r450",
      "r451",
      "r458",
      "r459",
      "r475",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r515",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r186",
      "r486",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Non-marketable equity and other investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r567",
      "r655"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized gains on marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r478",
      "r479",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r354",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r479",
      "r524",
      "r525",
      "r526",
      "r603",
      "r604",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r478",
      "r479",
      "r481",
      "r482",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r354",
      "r403",
      "r408",
      "r479",
      "r524",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r354",
      "r403",
      "r408",
      "r479",
      "r525",
      "r603",
      "r604",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r354",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r479",
      "r526",
      "r603",
      "r604",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r141",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Level 3 Activity"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)",
        "terseLabel": "Increase in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Settlement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value \u2014 end of period",
        "periodStartLabel": "Fair value \u2014 beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r354",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r524",
      "r525",
      "r526",
      "r603",
      "r604",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r506",
      "r509"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments made on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r312",
      "r314",
      "r315",
      "r365",
      "r382",
      "r473",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r600",
      "r652",
      "r653",
      "r654",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r183",
      "r321"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Intangible assets subject to amortization, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r85",
      "r555"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets subject to amortization, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r80",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r85",
      "r554"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets subject to amortization, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Gain contingency, patents allegedly infringed upon, number"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r59",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r182",
      "r316",
      "r556",
      "r601",
      "r617",
      "r659",
      "r660"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 2.0,
       "parentTag": "gh_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r317",
      "r318",
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r152",
      "r159",
      "r173",
      "r269",
      "r272",
      "r277",
      "r280",
      "r561",
      "r599"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r455",
      "r456",
      "r457",
      "r460",
      "r462",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r218",
      "r231",
      "r232",
      "r268",
      "r454",
      "r461",
      "r463",
      "r568"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r552",
      "r633"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r78",
      "r83"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r150",
      "r161",
      "r203",
      "r266",
      "r500"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r191",
      "r594",
      "r617"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r38",
      "r265"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r216",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r470",
      "r471",
      "r472",
      "r488",
      "r598",
      "r665",
      "r707",
      "r708"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r157",
      "r169",
      "r617",
      "r638",
      "r656",
      "r701"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r178",
      "r216",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r470",
      "r471",
      "r472",
      "r488",
      "r617",
      "r665",
      "r707",
      "r708"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Financial and nonfinancial liabilities, fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Acquired license"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r156",
      "r167",
      "r353",
      "r367",
      "r603",
      "r604"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r19",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketApproachValuationTechniqueMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.",
        "label": "Valuation, Market Approach [Member]",
        "terseLabel": "Valuation, Market Approach"
       }
      }
     },
     "localname": "MarketApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities'"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized (loss) gain on marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputQuotedPriceMember": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using quoted price.",
        "label": "Measurement Input, Quoted Price [Member]",
        "terseLabel": "Measurement Input, Quoted Price"
       }
      }
     },
     "localname": "MeasurementInputQuotedPriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetAssetsGeographicAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Net Assets, Geographic Area [Member]",
        "terseLabel": "Net Assets, Geographic Area"
       }
      }
     },
     "localname": "NetAssetsGeographicAreaMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r47",
      "r160",
      "r172",
      "r176",
      "r195",
      "r198",
      "r202",
      "r216",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r242",
      "r269",
      "r272",
      "r277",
      "r280",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r477",
      "r488",
      "r599",
      "r665"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r233",
      "r234",
      "r243",
      "r246",
      "r269",
      "r272",
      "r277",
      "r280",
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements and other covenant rights"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r269",
      "r272",
      "r277",
      "r280",
      "r599"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r512",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r511",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r634",
      "r661"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment of non-marketable equity securities"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, net"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r24",
      "r26",
      "r489",
      "r490",
      "r492"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r106",
      "r196",
      "r199",
      "r205",
      "r493",
      "r498",
      "r499",
      "r558",
      "r564",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r40",
      "r70",
      "r208"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r211",
      "r299"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchase of non-marketable equity securities and other related investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "MSUs",
        "verboseLabel": "Market-based restricted stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded as phantom share or unit.",
        "label": "Phantom Share Units (PSUs) [Member]",
        "terseLabel": "Phantom Share Units"
       }
      }
     },
     "localname": "PhantomShareUnitsPSUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets, net"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r70",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturity of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r124"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r92",
      "r180"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r94",
      "r170",
      "r562",
      "r617"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.",
        "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value",
        "terseLabel": "Redeemable noncontrolling interest, redemption value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r127",
      "r174",
      "r715"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r627",
      "r635",
      "r716",
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r578",
      "r628",
      "r635"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash \u2013 included in other assets, net"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Shares underlying unvested restricted stock units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r114",
      "r168",
      "r573",
      "r575",
      "r617"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r175",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r303",
      "r449",
      "r450",
      "r451",
      "r458",
      "r459",
      "r475",
      "r570",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration",
        "terseLabel": "Remaining performance obligation, expected recognition period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r204",
      "r216",
      "r263",
      "r264",
      "r271",
      "r275",
      "r276",
      "r282",
      "r283",
      "r286",
      "r301",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r488",
      "r561",
      "r665"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r510",
      "r616"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r286",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r19",
      "r107",
      "r111",
      "r112",
      "r113",
      "r148",
      "r149",
      "r151",
      "r163",
      "r603",
      "r605",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instrument Components"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r76",
      "r176",
      "r216",
      "r301",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r80",
      "r84",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r80",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of Performance-based Restricted Stock Units Vesting Conditions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r116",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r101",
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r187",
      "r188",
      "r189",
      "r253",
      "r369",
      "r370",
      "r371",
      "r373",
      "r377",
      "r382",
      "r384",
      "r607",
      "r626",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r102",
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r62",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r269",
      "r270",
      "r274",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Weighted-average derivative service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Market-based stock unit vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of MSU (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending unvested balance (in shares)",
        "periodStartLabel": "Beginning unvested balance (in shares)",
        "terseLabel": "Unvested balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)",
        "terseLabel": "Weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "negatedTerseLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Settled of tender, amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate, ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares approved (in share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending number of shares, available for grant (in shares)",
        "periodStartLabel": "Beginning number of shares, available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable, weighted average exercise price per share (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, grants in period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending number of shares, outstanding (in shares)",
        "periodStartLabel": "Beginning number of shares, outstanding (in shares)",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "terseLabel": "Issuance of exercise of vested stock option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche 1 - $120 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche 3 - $200 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche 2 - $150 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r417",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (as a percent of the fair value of common stock)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r216",
      "r236",
      "r237",
      "r244",
      "r246",
      "r253",
      "r254",
      "r301",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r369",
      "r370",
      "r373",
      "r377",
      "r384",
      "r488",
      "r592",
      "r626",
      "r636",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/JointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r106",
      "r175",
      "r200",
      "r201",
      "r202",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r252",
      "r303",
      "r385",
      "r449",
      "r450",
      "r451",
      "r458",
      "r459",
      "r475",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r515",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r252",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r106",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r106",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r106",
      "r114",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r106",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "terseLabel": "Forfeitures value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r106",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r69",
      "r617",
      "r638",
      "r656",
      "r701"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofStockholdersDeficitEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 (deficit) equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r215",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r385",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "verboseLabel": "Acquired technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r365",
      "r382",
      "r473",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r652",
      "r653",
      "r654",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails",
      "http://guardanthealth.com/role/JointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities",
        "verboseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesScheduleofUnrealizedLossPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r255",
      "r256",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r235",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share , diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r233",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share , basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "24(b)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001576280-23-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001576280-23-000060-xbrl.zip
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MHMBNPO=0Y@QT KA6LEP&8 IDL RP@;!&N$NYQ&T!&?-@:=@:S/7!993()0@
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M;LPAA<5*OGRJ7(,"X)NI,([%0(JG3@\VVTO^6^50S25UF"CJYS*OY8)?<5
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MG'*L0BF=% ]W=<$[/,FDFG,8G<7*,PV]AS7 QI.4Z.K792P(7.RM.RL4$\:
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M1LG"KD_YS%MLY:=_H<Z]VG?V'U!+ P04    "  (B*E6(%LJ2T@(  "=*
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M$>!"#"3'?!,.X!U(848X \5B8%ID6[QFPH12F0SF(0=K)3V@4JU"SN"V(?N
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M23DQ<-^[;[UBZ5:G?[6%+! (N=[?\IDKVO*SN"VV]];#?P%02P,$%     @
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MD903 _>]&]<KGFYU^E=;R!R!L-+[6SYS25M^%O?%]N:Z_R]02P,$%     @
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M+L#&=P\44^E\E%&*<I[G !R-11FD! *1".R8Q6G-/[$FN@!>**?**2X6H++
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MU<BQ K=O;C,RIK#W[+V?=7LR+/7.M4>]'1;NT/3#8T^/894A?26CX6?JVI&
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MI6%?48 '8W,L_[O;^?S!>U1H\5AH(=)^(G=BQ$O3!HP(M=W#$'X:'7Y>GA4
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M%74(:<IP*KY2QC#PBP;EN.94]8;F<F4]7HT>SV9V,2@CX_<@BBWI,:5 !B0
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MRPWL+-)XCH6O<BR70_@YYK=BGG48<KAOF8A<C=XCZGC W,2E9 *@1C,@-:-
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M!WHF$ N" H=28C B%DAK.0C&B2CD (5/#3@);4-6]=O]VKC"$!D)5HH$-7#
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MKRZK:#YE7[@(XYSOOIX(=T,ZYKW@K7JJZ2KUG7#<QJ3]K F"H=FT2D><HEX
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M5Z_),P:UI@A3HA$0A/B)0],H+@%3',.(R20(V3!-KBF8/7?7-M?]>O[LZ2-
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M1=9*9) F-'5N%SR:YI1FW,RXF7&SWDA%D %19SEU5%EN/$TGP*7U5E"-Z.W
M>8M;,R/H<A%T-E?3!1,HYPQHYF5$T""!%- !+:)I$)AQ$"9S'+<1J[:(7[B.
M4$;.C)P9.4OD])@8!:&P5CDJ%#*.<"&0#MH&QDE&SJ8A9R6^"SU6NO1D"JH
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M:!7$3@B!B*4R*,,M8\9P(@RGA*&'X-;&9R6L#M1F6TT+'24FE 61=3E B8%
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M NF4KTY(FY&'Q'B:=XKO">#2?0\JLK3!+"J;IJ-5/JNX?FCU8Q:M:-QC( S
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M!KJL+2:IB-<P;&\JL>%.W[V9R&RXW__JIV<)LA%5'^(=5$B*D %IBBS 3BM
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M=#LKZTY[%B;OU$IHUR;:KX^9*_ @S'P3WW?@JGTK;6^<9' 5G2>(G8]^UH;
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MD- @8.)VR;B(*&@B\Q,/1M1<Z*JY2EH72\I*6I>2SI:I(AIY!SF V"H0Y1V
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MXE >]$Z;"?=2/<KU9]@F')*&P??WY@5L%>JFU6PD N_T"C1JO*DXW7Q2XO;
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MSL#I]-QL#_V->$WO4NM/U55 8H"K:)VS2-,3!9/ ^F9T&_.Q &9Y?@"<J(?
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MQQF3H7 SY0OM16K?M?&'ON_W$&6RO^^[>M^785\4)X&;N1ES0KKOF61)$L>
M GU?P"9S);R=NN][R^6/&&VRKZNUKZNU4Y$J>_GS$/+GSQ6\Z6N=!%[L,$\Y
M&>.>%$Q(Z;'42T#!B%40^?Q^VY?LBQ7NF>J>J3Y*',R>J3X,4UT&]:ZC(^U$
M#G-#+V7< 7X:1S)CRA&<BTC&6>C=K^-IQ^H4VD4-%V.X0M+\&PD_GRQ(N^S
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M*!CE2.3CLB?.13XIYW";QG"M9"Y&5#_K? K"<#*&K\,?9N)*%V6_E^;3V84
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M*O16NWI#8=VC(4I"%YF]/,W-LH9_^W=8$H@I5A/';#K1%&34R;#!G!BM['5
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M'.$(WU=^*CDHG:"I.JZ;IAX,X7$9_#",RE(05OBH)/13Y%%=!:>P6-HLS9;
MT :)EE4>%6 )^X^)-/E1\SK;R92C()![J3%=Q *IFXM68%3_UD%KE M >3H&
MG@"SRO*1X37*Y@-B-$A!:=0F(J3Z;AO)FV6J9GG+8&X&3!2_?M [6C?M:AZV
M7 F.F(OS"3!@>%%[H0; G6/D"U8IH5 14,OZ/0FS)DQ:SA?J"D:>+V9]!%\Y
M)G;;!8T%<DU,Y,9D#+L9R\.7BQF&M?5[KQ>B4(+LY!AI3Q]6?SL>OCIY,P E
MM%T@I%I&607J=_=E;9V3_^Y6..GW/H%*DBU&< RC9DJ@6^E)^^26 CE--;W1
M5:6SE8TJV!1=89CW>'6K0C*5WG(Q+2ESTA)614?&,FO^B!&HH%,MZ.DY*@-=
M6OT>-6F>9,#7FZJJS)+I@51**@ S'>&M:RY):=);,UW88,RZF$V_RJ<T6?^4
MDU+H;$19)39+LN6H;"NL"#_H6Q3;B;K_?%0A% R=IKP7JZ1-2]VBP%>';W_K
M';Y]T3N=SN":AD[8KXLQ?6^!<N,6FSM0@1*KH[VH]^Z!YWSC#)?*0?0RN+RP
M2CT#U@6LUYQDS59L1/I5Q4.J,D%55D9%#_V5;[:]YM,4J-]XA*KLI&J@_HJU
MI9U031'S_2K)>.,W*JB\X9W]MA9^358B>TQ(^62Y$_0E0XS R^&Y,B/5>\.8
M![M:!.R.]+I99._H^FZ-@VK^M@8*E<+X;=",N $)F>M1R_@.WZN*D:W(+!!C
M2"=%):[Z%L!4LH8N (64-'++V"$Q+=(6':CS1G :EE4C/# L<G9Q5>8@2B?
M#@=826#C_#&.Q<3 IU=K%D(CE].1T1^G"WA5[[+(0:,$IGY>:#)?_0IKNX3=
M*[J1*BTC>F77- YAPQOTE[RL8WWAE]67=\%$E?8"PVD!HKE]/+0):&Y;'<4$
M9)/2C1AGM.G^'_3^JC1D3,R95=FFU?&-\G$^;\T?M?45TR4<X:*@@4V =-$N
MU]8YWTO*%%C/IT"@4BA^GTRLHOU6^XTZ@)HVL0;%JT,A>=)NK6P_S7?-@;>2
ME+!(@ZG0TY;22P98F]%;UF4=5I_HD>?4\%X@T0PT[JF!R,)&%51?-Z.TJAX5
M.A^GBZ*L3>_B:X#C\FUJ4."GR?32Y%D#;<E\9K.JVR\UU9:L:36SIETKGUHS
MQ;EUM\:"?)OL56<^5UB(<(VMZM2,V-J@N3FY)IO%1*DU?@M;B(^J2#3EH4AX
M4D5CNA%8XHC(S;2L1C9G&(&5AG6!IKRL@MK40>^W:747JH\KCTZY2$OD&9-Y
M,Y3UB,$YV]MBC4MV/!IH80+0L/4.==&!YS\NU+E)1I^TW]5*\]Y 3S27&?I)
M.M_&+Z%' D9$NB\7L'NWH6$!>/[JVCJ,-FUJ;08SP'2%3.SA&&J&<0L:KS&[
M-02P85'U56V1@-USE6< KM$#M>2%L:5M% I40ZS3UHLJB48A(-OGW@E_-'33
M+CM0Y.4G_-TZ&*O!\;\%\.)EK+.O<7V7J)Y@']7SZ%/YCE$]6Z-TEDRM7N8D
MW//B-,T$=^,@C2,L::G=6(>>=*)-(=3;3;3=]_ H=+63)2%/'9YZKLA$P*4C
M>,#C-$SC73+BWE[#1J18WF#/-$:&&TKR(@ANI&YOHL^G<U,JQ:"L&;)7A*#
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MSTE<GV<)7 D=:]=)'2>1D9!Z#U!VC*N]70$HD:>S,/,Y*%L9-G!S Y9&<8H
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MIS>$EE?Z<9G(PF=-B1>:TFP<7JC)\%Q-FA>1P &L,G U?%]1Q#8;1X-X9,'
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MV,W]K9HZ'F^X> C3M'HZ='NB"Y>>>TF&2ZD!;Z\7TA[H@,O3!P0#J-,9[H'
MQNBQ"],^#SHH ,P47PWG]0*!H;%=/ZED<CS,8]QWT,X*M:<3H@\>=F9K&,;)
M)<>]N8ORQ(21N&@>3)E^1MNS3%ZX=_ZL3J\:H$QJY@9]&\9#.LP*/69)&MZ%
M(ZDV8_1G-3%) S4^'O>S+"M &E;*7Q&R331TK'EC_?5YUZQ:2RXK4U[*EE<"
M%"2P,9DUU:()*MIK5-^-W2LR5MJ,,1=SJ-F(G>KJT($Y.P*8S$+J3?]J-H;'
M%>XT_G-%N%F4PP[TQ0ZN%^2O,S=T>N?#<-Z*7G\T&:)?\]WC5D\FZS5-S=<
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MB$9:Z;V@HI9'B H:%33Z80XN#9@01B/Q@G.JC#+1$26L)"$E7 RD^D!2>\9
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MGUV3U+5KTN^=GNWYCNTV_NQ8U^E6VU)OKH^G/_7QA?*,)WI&R?:^I07W#JZ
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M"D9))9#&Q %^.(TL# <*03L&PZ6)!<^1K\YS_"XC?I1)\9-)D9][]IELKF]
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M3]"MS?2IZM0YA"#ZVC!D_RUNG[6^M\X.:&O_@+5/=DC0U(%MBG V1+BC&KE
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M=<A5/A%^02?RF&;JK.5T/8/V5=>[,?6]S_FT3V]-IOU3*9N+,TY7S@G\]"3
MO*R>YEC-[21X*77@W;6LRL\VF>]RVJ+>,LX1Q-AHP75[P\;[7HYO5WOZ#4::
MLX=4G@BR[C[=RS@LX8+P<L8NQ\?JJBNWD/?2"9O=0M@_[^VK$MESS<^%X-)L
MW/,'!8:>$:IN\9RZ(L =N_%")+<T:R81M_&BZH<[_SSNV>/0&<7PK^<RV9=6
M=%7V=_\8'A&&=Y+>DQ7E,4_ W&ENQ;[P^T72R(3)I.'B;J?7RWYW/TV.,CR@
M=M7+(7*^G4"7DL?Y=EV["Y=<,$DX[844E@=O#>;6:TH]Q]8EQ:O\/_)SIH[S
MW:#612;2E\YH;V[G9WAUZV=X=:/H/&YTAVR-Y2;X^!O:\?ZD=78 UQ[@]M9'
MUOKR7N3VM;8^BZ_K?T/[#N"Y'\_F"#Z^;.#6UMNSS:T# N\B[77_?7NKNP_]
M^-[>ZAZTO_R]MPEM_+K>3NT.IIG<H_47IB"+T];N#A-)N5R&&(8ZT]!%CXQV
M%@EA6))*"JWLRIK239BJ-2)Z?CJ#J$!D@<@,D8H;$JCUAEO,M8S:2^&B8SH(
M8ZD-MR4S*A!9=XC\WGHWPX$D$_4J&90\!8Q,2B,KN$%6!RUAA?22Q_IQX1<X
M*W!V,YPQZ@,%/%-$)<ZUS\4>L***&(6]CL7B>T%PUIF!,X)-Q#8AE@0'D\\8
MY"+12&E.8'T+E'&WLL::DHK:P]G2!<OJU^!R94VGRFVKU8P777/-JCL;LZK3
M6K71\P-8,JH#_)>.0MUFO^O>Q<'IW61[K3FSS(N^9XG(H*C%L-HS[US 5D0B
M<VDZKP2?,*:1*6/:["'@A:W^-RS^_SX>^#V8$\-,SC;<& Z/\WG!X5]Q-.J.
M&4!>.'OVTQ@%F^_FPD#4$^<\N#A>:)8Y"S1R1'F43,RSPR5!W:+)LY?+*BBH
M<W77YBYG_1S5(F1J1AJX,TP[YX157! BHC7JVF,&5V$G$[_ ;S7 GX(S=\&9
M:V(I6 AM-#*"ILS2+Y%13J (OB<L.)@DYL'YN";8_*_ZX$O!@GN''931# ?)
M.<^$$U:G)"TED7BIDQ9ZV2R0$IMX(#S,Q"9,KK:2(@502 IQKA72D0A$4_1$
M1D<P4RMKM,G,HNCFE\L**;&)<F69*N7*.EU9LK1ND:45<ZF#Y\_/^F%QE9LK
MJ[R"7;Z%2.:EF.D^NA23P]%IQ2UE6K!((]>.8FF"G]1K?CSKO.P./HD%WLJ6
M]XP%3AB6-%/68VT,..@Z()L9@+0AF"<?I>1DP0EABU"]^ION!<L+EC\'EH=$
M(G4BZ<0M5\[;K,>8$B^QYUKB&PA?"Y8O'Y;#M7E3!_!\F[?6-TYW/,?<RF20
MHB(B^$,@YVA$ K/(I4[>:IXSU\C",M?JA^4%=PON/@?NDJ 8UBSBZ %WF37*
M:JR\%1X'*@PM-O0+PMV-J[@KL54F6H$,IV!$)VN15DD@2;5,..A I<VXB\FB
M4NSJA[LU#52=UW4]IZV\5+?NUCQBK&[T:M/">5-VZ.NJO(XKDO2JL<Q3HUT5
M [4W53=I_KB\R17N:7JU8LI\89[KW]W)19<ZF0>N>]JP*8TKOKC3ZO)<R#0?
M:ZS*1,Y7TLQ59OI9UGU_<*DNZP7A:Z:T'E;56W*-O^:$/78PJ"C*?]*PT(<?
MN?S@(*9N58UR;UKQMGKN:N.O*4>LJAM'['ITH^>DAAT7PLVXDO&LHNT;+S9Y
MP9P699K0_=YBDLP0S3XNG>5UE>]>,2\E;7_<"=CFLTX*15C"$.>"(NV<1C*Z
MY+0R-&G\<G@IAQ?$E)?QI@KCJU^'XQ)@N8@O3-JJ)-D%\E0,DC,UKB?W99)T
MF--G546$82[7!XOX< CFXR#F*EGP^:[M]*[[O M_3\N-GA<KNU";84;+JZ6F
MSZN&>KAVMS\XO2=7IAB3CRP-,29>550NGA21KFI.EX7!L33V,1LK;O78AW)^
M4+)L'(>SOO/U1!_G)&^-.6*KQ=&D+ /5VNW$]?9\R7@'2\9#>, N=_U5B?!#
MM9A^OEA,/\ B6R2Y"$G^"7\72=Y#DN_/C;@J2Z2*QEV'A=-F+98);HEYT5[:
M*Q=H)BR5 CP65=K2RJ/6_&=CMG'"5L7BD^E^[J6SRF[L]^+I-/B6H+?7I\_=
M12C/O/WV\XXO+U/%+?MVAXTT0V62TO/$@^?&*8LQB8;PO+OF"5.W36!X9X=[
M;WLA__/^(H#S=O1N$A-^-1MCG\^V#S^?5H4 ]S^2K_L?3]L?/D';-NCV5CC<
M_/ 9P_TG7[]LG,YMC&VU.U^W-DXWMSQMK_]]"/? LS=P:__K7IMN\Z];GSJ;
M6[]UM_?_2.V_QHEEETZ9:J9M--HCK7E$W B"K(T:<>Z-RN.K0EQ9$[S)]'SU
MTKI13[QD)IT"4,\!4&^_V4XW1TY_[P_R^;.\D7.Q#?'6^^/#XVKWI/+&+IRQ
M[-7^%@&WXI;]_L)/R#\9=IW-8)<@+-,D)20D9XC;A)&FQB'"C*'86!F)6-@)
M^0)>!;Q>"7CE0%(!KP6#%YD!+QZ)U%%0Q&.TB L;D XF(JQYL"I&*BPMX%7
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M\.&B<EB^X-.2X5.A*:H1=,W1%%%I(R<5L9I$W%J,;&0),0Q#SHA2+/+"]%'
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MP9_]WFX<%.MK@0 VQ_XL=&32*$1B/F7M8T(N28)P##1R[%ER865-&-S4?/Y
M2C&_"I05\^L.6#9G?A5H6QBTS5%&<YXXMAP1[@+B6 0PRRA#3' ?#*,X&@6.
M99,85LRS@FG%//O1F9V"5 M$*C'+;HJ3,,8;I*3$B&=+3!,N$#-8)JN,8MB
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MY- \?:AVG 0(:+O-6^L;ISM$:N.B(4B$$!"WFH(=2RF*1CIG@XE:DX<GT=0
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M@@$;0UK!%?:.F10BV!42!L81L]*(@%M', ZCP3$HZ(7H&V/9-V%BC2J3=#I
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MI:1"RE+PT37\9*-T*'FL"+4$1RSRXHOK%Q_FMG%V%.'__1@;)[#.1X-&[ :
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MOIY[Y_(/#*I_^67K#]HZ 0CX^.EX]^/V):@A7/_I>.<8QEI^AK#T>/^B=7Z
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M87]0#A&[X0">,!@T1^1IN1U]!O?RWZE^][G3OXO3U'RV, K$BH7.=VS[I!I
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M5S46W[(UA@>%-7V_FW!\47BOMC2J2A! \NO?NN#XN^VMYI7[- OCFR-G\+8
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M9Q)>?2&'K@LYGGPHCUC(<;.'\-">\R@)L9L*OOYZ 6'A8/"*_65^H*7T*M"
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M_[QU"O@%)Y1^DN1W*K-T>/33F+Q9Q&I[)%7;W;GD;YUB6ADR+[:?2;G#J.6
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M;8(UTYX<@PT-FM/3 S+XR#YBH.MIKYGCN3+'[M:W0T,SKF&;?",C[E,:86,
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M=_<^!YTMN&<+WG>Y0SM[V^>['[[T=[=VXH4ZA"V8#]DG[>/O>?O#=MS9^AR
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MAO=$5WI%2IIXDI@S]T2G="/QF)EZB*$Y'9H2Y$5I-_$4GEMH)X/P[UJF6GI
MX3!L/J#P)%PR'I4CD$M6HH%XFJ4V)W?Q464.X@RD%'S8-Z,NO.5_'*!:13_]
M7/NG10Z22YK1F3'NTY^NG[PC3'R\%<?83-,1/EIHJ!G'0'/XTG^@_&IPA-<5
M2+\#U1LCK=J)(4DW50;,R Q57AJOF\/GPPM/%[#F@V($W%&@-06B>FA$60QL
M&3L,&R8Y/H4['2_ 0M0:8G9Y-YXHD=R5[J>9!T]T8M=.XQ/0]A WRQ%.']2D
MLF:V)2809DAHMQ&H-TL\O&17C0K4[K3E@5? O'R A#@PSM>8 #+L?-IMX2_
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M(3J(,A+Z!OOV4I%$OA"@!0E+9!J9B <I74D+/@7"61M/#TTV/%0B8B'S.8O
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MXU@(ADF5K!6$]V3UW&-X;,W##X_/NN;A)\?#\]:2$@%AB:+ M,1:2\0'']6
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M)M9,OX O1Z"$[7'N!G+$]&569=93].TCJJ'#@XS7%3^;81=8RYX W=*%Y?@
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M.\X$'V=;.J!!462^Y;Z\+T#>'6UX.V"&:5T%XFKBUK!6/3 FIT/W/HB>.+\
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MV^FQ&5;DA6=NY& "F2N1+E#>5^8OU<0N<UWRJ#"=R8%2! 38XGXT<T<EQK;
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MH!18.0)P($]--PN1 EFL(F&+7\-Y1H1_+6 @1-4+OE[ZA>CF(2$XX!N+F<]
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M(1N&X5D&W-;F'F;\27$L*LX"K.$/E)R,C,X<4C^[2#1-7U8'% F7D#I(!=A
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M11@107$")!_WL%1D,OP5B +#.7',XICFX'M?F>_-0L[C\JP4GN"(,$ER2]&
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M1>9N.-Y,?CX K>-TBL<3OA0D9LX8UWTKPQ3D%)7R/(Q(5P:&94MK*MOII .
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MS"V&IM682<,)?4!2S8K5"!SY]:,7!]VH4G$\QOV.E'!74EC?*^E\V^;.=98
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MR,YTP_N +Y .++5+#YAM'G9EXK*+>V#NQ=C8JMRTK4"GL<Q%NR/T>W[(X8I
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M&J Q+_+6\.;ZU[I8F?J(>/ 1\<;Q)ZG//5R_>L%7;-][C .CIG:G'N-\QVB
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M9.U=;7/;N!'^?K\"56<ZUYDHMN27).XY'=F.<^HXML=V<NVG&XB$)#0DH -
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MBITA&5/FVTX[!D9&1#+>=\0Q--T7/$&*:8MP>D >#/?5Q?R)03D5.WHKM#I
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M;_.ZGZ(A^-KF.%DS7:*54EH>+SD].>U*&)MLT]\]H,5K*V,@DUQ/TS)=3\A
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M2$N4K'8K7-6U,P;ND#.>Z_TYPE'*@-RQHB.J*#E":KW]OYZ2(=U]T!LJ]M5
MS\'P:QC/NW%#OY-U.YU?G*F].9@(IOEWF/]%$6!<'5EX\1=Y-OU07ZNWZKV$
MQ7CW*+E'6MJ$SX<25JNXNNL<N2*Z3@J8S"H5Y+2LKX56AJ+.ETIUVGK0F0$*
M\"I!QM)ZCO2=Q.Q_L",NK^5\^8@1-\J($%E.SC'M-05O.4F&T0N(3I$%;MV(
MO9:004713?#P_4&-?>7?\VR\=0R#4,E;BRP8GHF\I%EP%-L[;H*.6D%J/CAB
M8^(&%5+W IE^]-0,1NOL]\IF$OIH!&K#HNLFEG/+0'G!K TY%T?,Q]8YV/T4
M#2JZ[@4P#372#"4KH>(Z=A4W&3T90+1(-&DEF0^&TD3MK%64)I;0>I;2_10=
M;J;/]:BT ,!5H/"V")",HMO$@G(D$^D$1;VIY$><S[/5S+M#^>B&J-I]OLYN
M"AQNIK+9NQXC;]F.LD?/8O80Y/[-S#<#S=NC]"_BB35C=<_WI^J>QX)<A2K)
MH<M,AGKIH#>&!1L4\^2# I G<N+A+KD6E.Q=W+FUZBV:KO?MNGWBFQ- SCNR
MZKWWRGDCZO"K@)KLB4J"D2LEIRRM3SD""-O:0#<A?"A=TP?'Y'<5IH/#H%UY
M<D?2:V_7->DBRZ0D)[\D'"?A.4]4*V1:.INR31!3Z^N,FQ ^A"SO*0-X=Q0T
MZ1O]?G8\">DF[5=^=@0!N?+(F1?<UQLQ@87D*:CRV:G(0TQ@'W0Z6RTYA)3P
M,='5JXH.90%7I= 5BT>8G? $:)9LK:I9BL2]A\(P>*VT4BFW']"[)8W#B&N"
M%#9BC(PK059 ><4B*D[F(: 44@AKFS>6_3!QS4'@V4\@LXW>!Q;(8(E%(Z7:
MM9^ Z: 49?4&F3.\V%BRD++YIOV/$L@\*<3NKO;>$'OS3LZ56^E<R4::F!F:
M0/(QQ;)0DB7Y2 \B*\&A>0/>AK0-(<09!.Z:*._ ]U,%DU$D2C.EK=?2N5*O
MP./ C$%)X98L&%MG;3O<3_58T8OWSM@(GBE=KZ%&IRD8387%Y*35P@J7^G[J
MGG[TTAZ(_80LVRA[8"&+\ (C4C[FA!;UNO3:*ZLTDS74*L'FW+QG^8<+688+
MT]UU_0@-'5$ 1W*=3 $WY%!-O2PO.19Y+"#  F#KIL:F#1V'BE3ZAUL_.AON
MYN+'=(SY=(*S<O/1>3];C"MAUYP_PO[BUL0]^A;C?N)LU#EY?]UR/6$4T_/L
M"+J,%T&./"$Y<D%?N(M) QC/9>L[5W>ALVV_Y>TUSSL*3F>GB_6KO\7%XM,Q
M3(7\G=YY3$F*5=)P9QF9ENZJ4V24]4:60XG.ZD0)L3BHU+;E8$C=([WC]O[F
MSX."H>%D^'UXN*3]W?SM;'J$\U$=TJ=BT<R9*DZ?-0/C,H,4N#">7NQAAGQ+
M#H84'3\Q0.\%A@,!>CWE*VE -U1=*A4A0&#U] O3P246.)<,M*>G,$*6MO5.
M4P.RA^7;;LO4>J>%"89ERRF%4J4VTP7+@!(HJ62BT'I8EN$!AIZZY]L'\_TZ
MPGV0,U"_>)LEX:24M?^;QQ29CC$P<%ZRI+FU0:.&U/K*N5X9>NI><S@/0TOD
M]%PV>%,'41V-ZRCP[MS#'U@'4_UK-LM?QY/)=2I[^WWQ[-4$]AB"W&C=-LE^
M'T+8OUOX]FI=<?/--$U.\WAZ=$G=R&;M,B RE44=+5HD658;F>-"&Z^M0F7N
MU\7&:^UKCU^/I_38OQU_J5/(URPXLAA=E*6P%+.B[*DX%B4&IC3E53H6573K
M5/HAFH80(O0#AMLVKZEVFOGP*]:$HH3(4!)4 M2#(P+J8$W*L8MU$NH>4VE]
MZ\QZW#]:I^L!,+"3M)OI^AX$UC%@"4PVY,(9&MM1PEF=?DENTSJO2W;N]GS<
M/JU#@W&%#SYQP:'!G L3W#CB.!#'*.OA42XA1"4CM&XR> KVL >\;&T,MU'-
M(1Z0E1CSQ@6#GBM7,IGJ7&*]V,/:>A)9UJLJP4BCP/C69G-[*@<UBO!Q4-5"
M?PVOX?F.[S5^1H8H<Q',)%6+E,DP,"27;&1!;H-UHO7)JTWHVNMFJXT<K-%1
M2R4I#N(\UKUEQ;Q1F:$V&IT7"57L)>)^7&O;'!0W+JIJ+OG'-+H&97&<0C C
MDV0:;&#!YSJ_5-$_S66.K=O?GKC1[0U<!]+BDRC3C&ZE9X<KU-#*0RK5W!9$
MHZ:+C4!LDBW!1PH<(6$=I*=9T AUZ+72%E+0MV\Y&;3;W#!J,MDZ8W5BF.LV
M8I"11>")";2"9\I/.;8NEF^3NST!S[H-;K8P?MLJIWUA)R:KP23-G,[$&&1:
M/82ZS8P*,J^-%*W3^B$5=@X&@IT$/A"_]OIT>3K'5>_<^\[#W4L>UI-MR'HC
M%_: I2@>1+)1DGWP=90H&N8EY:5*B#I+5"3@K9W7HY7@5D5^,43^ Y[ F*0\
M?U=>CQ>D_/^#,!]ERR.:8.L!*$K1LY+T4!9)SRCGW %$85NW338@>T@.L"'J
MMHG[^U#P0=+.[PG_@Y[_3U]Q\@4O&A'10[9&.5:<YV3D"[)8;XT2$+@I0OBB
M#OBD;D#QD'SQ8/"XEUH?"8KUD?GT=3:*FOLDI:VQ"J7/KG8.RMK\0T\,UHD4
M2;0^#KX3H4,ZW#(8X.VBQ,?$&P$(1SK7N?22J -T3.ML6<P&F E%><=E\<W/
M+^Q(ZI &QP\+<ULK\A%1]WIV.J]=$=E;Z1DE3_2$2!Y9\"[5.?N@%$4(PARP
MLG$/I9M@SOS_B+FMU=AB_M9V9':WDE[1JBAY]\HXYNI4<LV-820OS4J40A@7
M@\L/W\F]!P&;(,D^720=4#L]EU=J&^OUA6BS\FHV_8)$?7=><3J>S?^8+?<8
M&[O=Q[<IF^S!4J,22>WI_83SDTK)2*-0/'#/'%I2-M0;<9*(3*@,.87(>6EM
M_5?7;]$A_V:Z6,Y/ZP'7UY!JH>FT#B1W,I5@%4-9-(&X3JOCBAPRY]9EL$7(
MUN/'[J)E2(6*G76_KL%\;\$W/"A1<#['3&:O7J18I_R<6T]9._^*8:5P<H5%
M6^:=,RQRP[4+OIC4.H6[@Y1!;58W1,'^<N_9A71WQJV<:;^^3.YRQ/KOL-QW
M_O@NB[1Q)WNSU\JI( 47>,=-?>_AK)L_\.LII490*'"A6"84R6MT6EB4RK/B
M8L(<D9O<^EJ@36G;^SZ*3=997Z'U-B8A*7"O\S@H>I>%>4%1G_;<*AN%Y:'U
MS=Z[4SLHA]8'[FZ;N0,IMMW%*!L*Y;OJ;/8H54J6I6[0KQ22L@WRY4&G)(2,
M%K'UK62[TCJD<OMP0+BO4@\.P<LZ+42%)2=/86.JYVLSUHO)!?-*>44AH_3-
M3V9O2>*0RNR# MPN*GP<G'6UV2"LXIE,,,>Z \4!*"Q5F5DG3)'9"NM:YP1;
M$SFD\OKPL+:U&A\%;5TM360A; Z%I7KP04?(S*.O5]>FDI*F9*CY*)IM:1Q2
M67UP6-M:B2U*ZYL2>+-L*XOS&>J],=E1?,F58<$+S:*6UN@8A"ZWH+:FJ+[3
MTD,JI_>*H(/H9GCUD%W:[G=;YM%J(CTUU&^,1H<(7&3-K*9 7;OL"2"@F<2@
MC0M90//! 8.HBOPYS90KU\(QYM^^)7KK11E9B9#!:Y)%]?':(ME<+8&E%#2W
M@"[YUB>'=R+T2=9"MD';5MZSB3J;16MW$#F2/J=0R/0+5:^J A591&(_6PZA
M7E:"NO61XCM(>9)%C'W0TT(E&SK(B]?KETAK_?-O_P]02P,$%     @ "(BI
M5B^&^A" :0  8A<% !,   !G:"TR,#(S,#,S,5]D968N>&UL[+U9<UM)DB[X
MWK\B)^_K>&?L2UM77].2RM*8,J61E%5WGF"Q>)#H) $5 "I3_>O' ^ F$""Q
MQ % $E95*@H"S_G"_8L(]PA?_O-__W5^]L-7'(W[P\'??N3_SG[\ 0=IF/N#
MD[_]^/OG-^!^_-__]6__]I__%\#_>?GQW0^OA^GB' >3'UZ-,$PP__!G?W+Z
MPS\SCO_XH8R&YS_\<SCZH_\U /S7])=>#;]\&_5/3B<_"";D_+^._D-CY)X;
M TX+"2KJ $%'!3+;:(RQ3''[?Y_\!]HH="X"0C(,%*8,427ZK:0CST)K)>7T
MH6?]P1__4?^(88P_T. &X^E?__;CZ63RY3]^^NG//__\][_BZ.S?AZ.3GP1C
M\J>K;_]X^?6_[GS_3SG]-O?>_S3]U^NOCON+ODB/Y3_]GU_??4JG>!Z@/QA/
MPB#=O(!>GR?7OW@;C?YI]H_TU7'_/\;3WW\W3&$R5<^#0_AAZ3?JW^#J:U _
M BY \G__:YQ__*]_^^&'F>3"*(V&9_@1RP^7/_[^\>U=I/W!Y*?</__I\CL_
MA;,S0CQ]PN3;%_S;C^/^^9<SO/KL=(1E*?JK(5=0NL+Y7_5I/VV-Z92 C-)%
M1*!/<5 )WA#CHJ=OC_GZ69"QA(NS24/$=Y_=%._P//1;"OC.HQN@G3X(SO$\
MXJ@EU.^>>POG%<AYA"<7893#8'**X6QR^N]I>/[3%."KX2#3H#'3#^/A63_7
M%?;3A/ZL2^YX6#Y-ANF/T^%9I@7[-99^ZD]^_M=%?_+M8A N<I^^_?"P3DZA
M+L5,SB;__VKQTEMC)G+U!_VZ7KVCOUZ^N8YN]Z/'OR9(CZ1/^_EO/_8+9I.T
MTC%+K91(/B#)@&5,KDAK3:\%@"J(*U&<#=-W>,[J0CZ\9MY9B'@V_;1W,8:3
M$+[TKE]&LL.W]..XYXU#ETH$)K0#);V#$%/]PR##)%1*^BYOQU?SH(1QG#+W
M\A7$8"%^PK/)^.J3R@8Q9<)R%#,%;SZNMX-$YL(87^/L_]\.;HMR)L./P[.S
M-\/1GT2.'L8DG$X1LDP)5$ +/M">SZ/Q#+/5/I3&@UX3XO<2N2']B]&5;"Y7
MG0V7I6I+->7&9+@[E<QH0>/[\8?AB![WMQ_9M@SZ=!I&.'Y_,:FF5+5.>UA2
M,%8(,$AVH0K.@5-" \LL1RN2%3JVGACS(';/@D[5-FPI\[LDX%N3X,Y0>XSK
M9(J(Q'D>R7\H#"+G :2)PJI,CH&US9?'>11/G ;;2?TN#T03'KP=CR\PO[X8
M$3$_X*@_S#.^3O_Q_9<J__'/?Y&1WJ<=O6<"#3,["3Y;<B!34N"R8Z %856,
M,Q[:;Z/KHGP&/.I.:W=Y)COBV3_"V04N 2Q%5-8;<*5D4)H3].@\*)]2,D+F
MDLQN:+8<Y+-D62.=W269ZG0Q^XCCR:B?IGX(?>U%%<]O.'E?2%0%^Y,+^DXO
M<6FLMQX,3QR4, *\YH8V:>.=I.68X8Y(MSKH9TG"CG1ZEY1Z4U*>G-X[@:XF
MS?ORSS :D0\_[D55LA%:@BU%@3(%(3I:HJ7E:*37DLS"^P\@UG[GT^1.MZ*_
MRQ&S[<+U(O_WQ7@R/1KYB&?UK.3S\'/XZY_]R6D5#,$G<4PI_S),#U7.O^!@
M/#W*[CF-:*/FD'0F1P*1@3>9 ]J0O%(IN-+:;-\"[M,DW*[U>)>"MB$%/P]?
MY#S52CC[$/KY[>!5^-*?A+,I\CB/_".2#,?]"7["T==^PME,^XAI>#+3[732
M]73B5CBF(622IG+,0G"1K%#K>').9.2Y.YYV,J9G0^;],^(NX]VVC'\_.<51
MA3W"TWH_\I6DF8;G^&XX'D^-")JYO>"-$$@F ]><C >) D*P"7S!*)A5G%SW
MQJQ=!=?39EYSS=QEC]^6/83C!E0O%1MRR1ZRSDCV R,P:!TD:UTVBH486Y^R
M?P?@:?-A<UDO.#GMX/Q<.W)NM8L@HG2@E%7@&6,031!>6>:29+L]/V]R(&SJ
M\2,CGRD:<I>4]@JB-)&,XF",SX[D[W=\(+S%/>#G$,^PET3F:(4DLRI&4!8]
M.8-&02$G,3C)0S'-5?4=@H8S]5:H2.=W7%N(<='MQ0^SB___2&=#LAW^]N-D
M=($W'PX'$_QK\O/9](5_^W&,)_6'9DR8$:ON+\-!M6Y>_-4?]X2,R"UM(CEZ
M!DK0'Z[H#$1S=+2FI*Q:FZ?W FK(DWO"=^[AS0:*7L:9K07>P078'*;7TUUO
M)5"]N8"B1FQ8"*CEOKXL(.H>#FRON&%74M\9)8IFT6G'H60,M L6<E B3U <
MXRSYQ"5KO0OND K?Q9KMGPGK"+L#!A"<\^',D/UU:O^2L>F92F30&>G);-7U
MVBRA!ATP23* %)FUC;5_!\3NC?L&RAFVE&P'43!+#C0NP466HB]D\"8M!9 =
MG.NI1 ;T5CDAD7&4S0^K[@'T%"C03N(=S/P7*5V<7TR/;)>=/EP!Q:!\R0*L
M3^1^\F+ 2?)&"6WRD4FN3//S]E7!/0F:=**)#D)G/N*$QHKYYS :D ,^OD3E
M4 @1Z[D4#S1V80-$;A.X'!2/W&5G>&-^+$;R%,C00,9+@UG^\Z<YP9"G_,?F
M$>>?+L[/P^C;L'SJGPSZI9_H.\3EX<5@4J\?AV?]U,?Q;_7&<4),?EU'=C9>
M/\A\P_<TB2MO,<;Y4'+%BJ7_\"*<LL5'X6T2P0L4J*5GO0W?N:TA>$:?#F>/
M?%$OB4]FD>LO!OFW(2U"B__Y,_TT#FD:%7-S[F*\9$G&0'L9*Z!,=A!5860U
MDUZ3H#]UZZ"2EOBW7R>O@C1>A?%ICW.7,LL:G""33R4LX)A6$'.VSF5-'H5J
MOC[>1K#[=7%O;+J[G&ZLB@Y,\-EV\0G3Q8@4@.,W7W_K]R2:X'AT(*25H%C*
MX$VP$(.,VG.. 4,G[O;W.)XQ2;962T/S_.3T>SC?WOSCM[=OS[^$_J@._GWY
M<#%*IV&,'VMB[+AGM17!H@-?&#F5@AR(4(0&X7T1PFL7F+I_>UWSC<^0)UWJ
MI*&9_A#,T7?Q#:_(?OA&]L0L,J$R/1#E(6I'SJCU""$+229KX+9H9[74V]'H
MGK<?*=69KAH&MA/D5\/!9$3COPAG'S%A_VN],1F_Q#(<X8NSL^&?-5/]S7#T
M:H2Y/YG>72-MN9HS#3;7'3>4"%X+!8'&P+,3L3#W(+'6?^_SI%3'^FD8P+X4
M[&<<G?<8,I'))0(G@P&54X$H688B1?*$MJBP*6GJ\X_DV$+>;0/&/XR&"3&/
MWY#(%@+L1:Z=3X&!]TBKG;2,L*4$3OLL"[(HA'R0"P^^YGE2HJWT&X:)+Z7K
MS<KU\U\U^A(_8BU $\ZJR"Y&(Y)03Q?.E6823- 9% H!@1D.B3.G7'3%^DU7
MCQ5>_SR9M!MM=1 %?@6\1JR_(HMK>(ZC%^,Q3G[#28^IY,.T5)!,$92N2:MD
MOH/U)5N-T0C=.G;J/CS/D%K-U=1!6/7;P80&WB?"3Q'5@-V?_TIG%S5(\9?A
M,/_9/SOK$9ZZKPH@;M/@M940./.@HC52FB*C:WVMO@JN9TRIYFKK(.;Z354'
MOB-1Y#FXOX^Q7)R]ZQ?L\8C:<52@ T^@N-= MKN R%"'Z!6/S2/V5\'UC*G5
M7&U=1'7_=E&E^;Z\_X)5)(.33[.HTW&O9@,:70RP0HZA,H*33Y@]6"Z"9LJ0
M5["@W-5VL?W+P#QC%K51T +J;!T[<K4\S@ZL,-^*8+@YPYH>+SC)'*_1M*H>
M6"F7.-0X.3+QH@E%1V5\ZVUO97#/F%K=*' !U;8YS/XP'$]>I%EB'0V]FH T
M"0A8+;'6S]-),1Q<>A:]I*3VGH1@BPIU3@APV6B(EB7,.0L;S8->WUJO?(;\
MZ50K"^BS=16617[#NWZ(_;.:[R.STT4E"P)%+1%3 G@C,A@NHV=,V5!VX=]=
M WJ&C&JOJ 4TVKK.RKWH;AUF1*M$- S!F9JIESG]%+P%&9$^Y4(IF79)J&=]
M+-6E\A:0;.-C\)5PUI.SP05>II3_#^8>)N0&O2#7 2.HDA,XESQ(;YS0)68=
M6D=LKX?P2+DN5+F >5M78[E&5*4\*QU3AJ/S>EOX/I[U3Z9;^JSV53C[^2\\
M_S(K>G#Y]=<7LTV_%Z10S-.ZG*TBBS%9K-6PR,--T@:G%+.A==Q?(^C/F*O[
M4/X"$F]]DE\+YN>+,WQ?&HAVE@N*/M3B"HSV@41F!RL<(N8 63.G!$FVF.;%
MT9J/8E?YUP=#Z#T3X5"ROY<?0HY??OLU_/=P].HLC&=YC2E;ICE/8&S40'-5
MDGW-:_4#+C/G5BK?VFY= ][>,L/W3*253Y6W4V@'R67W0+T!^ELXQ\N,F57@
M=I2%OB;4_>2G=Z;ZU2G63&\'0#?F/9/!&["\EJ#6+(/S)H+V.JKH@N"B=4;C
M0=#L@=SW0V79.NKJ@%UO!],XJ7$MOHKTY%-:]%^3T7PV_%(7^<L,/:65X36$
MA2!5BT5K<%(GP%!4L#6]*[?>0E<"MGO/IE/UWKG$;ZV;AFD_X]&D][': M,9
MXY*RVDL-O-9P4Z8$"-%+<%ER19Y^5F&E>COTU%ODH+_=$..[%SYSJVESX3=,
MR;@&<97&NP*,=>R<5;C0?AEXV&[90OCSZMM"<@WW@GDXQB6CDDV0<C:@2BV
M1QL?<).%B+JP4E;*>=^W I=8!.WUMX[ &NOM5Y+4^<7Y)1 6R%@1M()HJRN0
MY,EP4866EFR"1E,*KA3<\H#FOGOI[O;@K<0^;"&SQOOGK^&O6T"$3RK4TDOT
M]EK03]!&[M"!0&F-T_6?5^K$\I#R;K_T$2IO8YEU8#VO=+Q<PP5JDO;G_CE]
MY7WY1)^.R\P&^#0)H\GK,)FM1=S[PIS@X*++H#@G%G)#1IV/SI6819K/)]O-
M%</*(WCF9MD!T.*PZZ/TYK;![BJD]/@^:Z3,CW.N2HK.5EH?(\M6J^1KRK1F
M+$5A<G4.RX954NBMQSHIQSHIQSHIQSHIQSHIQSHIQSHIQSHIQSHICYA2QSHI
MQSHIQSHIQSHIQSHIQSHIQSHIQSHIA\ZD8YV48YV48YV48YV41T2I8YV48YV4
M8YV48YV4@V71L4[*L4[*L4[*L4[* ?'G6"?E6"?E6"?E6"?EZ5#K6"?E6"?E
M6"?E6"?E^7+U6"?E6"?E6"?E6"?E6"?EP%-+CG52CG52#JR"Q;%.RJ.BV;%.
MRK%.RK%.RK%.RG.PFHYU4HYU4HYU4HYU4HYU4HYU4HYU4K:MD[*7$A)7EL20
M+(E!PGJE,CUZ[H__N"Q[\#WN=B4E5GCS#DM,K"N'N9(3C$GC"A*9M% Q!(]6
M6R6R3T($Q>**)2=60+'U_>?WC[TY#M8FD ;K N04&8 &R124/D/0,FHIG K-
M+Y:6HVEPS_O]DS^0<4T?A!/D/<F4E]P'*#[6=(CH(=B$D)B,@79;B:F#D)2E
M>/9Q+]:$!0MN9-L(O8.R$'>PS;P>S[7QI230/"90P3L(F=QDISWA]<K&TCGI
M=WR#M!O5KR_>?=_IS';U>G9R&4PP.X3SJ63/B:A1!58C-!6X)"R8Z(SV&<V=
MX@\;FD/S;][7V4(+50Z;B;2QGU*/Q-Z7[S!=GI"M JKAL<%2(+L_1-A60\.N
MQ+L[W3OK1<B"G #ER0DHU>VB#4I$#,F0:2M*"W]UQSJ_Y]QA-RI?0ZIMJ_M<
M9R]>NF<Z<1DT)R>/V5K7#Q-XH6AG8UFP;+US\N&X];F'[M9E;23E81,1-33/
M;B%Y>8G$&VU-D#7_ST<R%+V&6(HFM]RBRU9J;^+*RGKYI)2UB8BZF5FO+I'D
M8IR//( OTM9B;Q:BLQFRRCH7;93+*]0!^/ZA3T19FXBH;:6JZ_%<G74%FLBB
MT/L+(R3%*)KC,@%/+CE5A!,IK*RLUT]*69N(J&'=IZ6V]\MOG^E7IQMT09YS
M% F,%[R&Z]&D9XQ#LCY$XZ*VHG-7]0;.$_!.6@N]X>1=/EKZQ4O&KP*MHWBN
M>V#M)W:KF0H?/-;83OX=1,[<!S$PKXP5!21S-"M2K!!U!#22%U7+OIC6,5@[
MI\8#\5;[8,8Z8N^"$5<&R#S$RSU.)A]I9 X0 VV5RD7PF!4DGAEG05OO6Y<>
M> #2 9R ;ZJ^>5HTE/TN3L%??GN)@W1Z'D9_3*>$X=8%%B,4LH0(GS 0K'1@
M;4E.&,6*6RF :CLCXSM,3]O2V%S\.S$_K]!=3HU5\.W*YIC#=C"&QQ8:?9 N
M#=2Q"Q-D'B<O)B>3#.AI27BF:]8ORV"E0)UH2=6Y>]=E%W19WQC9(5O6T4('
M+/D4SG!\F0CY&UZ%#6.0M+F:#"Y*&G%0BGZ*!7P6)JD0G+>M"VLM!'( )LA6
M^IK/S]M:V!U8'Y?Q+N.;ZI67N&S10EEC:4]%&BG/]>XA2Z!]53MDAJ6\4J3G
M&B18AN6)\:")R'<5L?;_#$F$_R!97(QPX^"S10]I$D?V(+JYD##A68XJD6A1
MJJ)+4)%TIV*P)@=N16_1 UNE9\\*W_^*D]-A?COXBI=E[M]=!WMP[D(]U 03
M:ZG%0$R(RF7@6$IP1J -S=?=E=&UZ0$S__SW?PYP-#[M?[D)2^JY'$K6*=*,
MD@*4\ *BI661U;J!//"2;&O+9&5PNU^*.N+/XEXPK=73]E9R,<:K<H&?,$S&
M/X=T^B&,)M_^/CS+X_>#SZ?X<DAK1X_&3FLI2G#<!D(= S@3.6 210;::;&L
MVB]F(P!/CC@[U$<G[M'Y>>TY.$Q_O I?^I-P]NDTC'":3C?ZBOG-</3FHFX"
M;\?CBUH2I$?;@]*Y%*B-(T!)Q2!J58">780I!F5H;0^M#?+)D6PWZNK@DNA-
MZ(^F76M^Q3 F7%46M2C2[X-AK)"KU?=V\.5B:@62L=D_Z\]LS=H69]0?G+P,
MX_[XNG32)YQ,9B&5),>HA19<06:6Y,A9!.^RK:Y#,%EFUOZHN+O1/%G&'@@!
M.CB0;#RRJQYBXZE[?#5_Q[<'+$1PS&0/F$,]_$\6@E$"O$Q>219R^_.(G0_R
M.!'V0I>&K9U6ENOLSH(7H7*-.9)&NEIU,='>I#4$J;F/GB6;6Y<Q7 W9KK(>
M=L2_#M1Q"%D1#PWK[J>(-5)K>J1MC0HL%H2"K!YI.P/11 -"%^^Y\L*(E:J3
M/Q!;O0W&_5=Q:$>7X1[4UCA.?QFNR^/059 U3-2X'\WNLS5VI]5AIRK9+6E,
M#C8(@Q"X+Z!*=.!%YK3(%UZLY4SP\DC)<D^:QR%R91U-M(U=_^7R8/_OTX/]
M%[_^_.+M(%T%:7M'JZP*D%V-RR&/'KPW'ES0*J(B)Z@\W 'QGA?L-DRZI0J&
MS>77P<WBITF83.V=:=VK]V5Z>C-E<2A)&N$*2*_(;8TJ0O1)@==6!Q-E)+.N
MM>F[#,P3M#/:*J"+".I;>*[B^U9 U%40TQTT^PE;:J2N^9/3-K+NX@C^+C+N
M<O(^)^"Y%ERRN39EIC^$3D1])A-Y>H]4^P]$(>U,^>N(N+-[ERFNJ\0Y\MV#
MCY)!,K7=$F<&?/*QEM4,)4KTC+O62K^#8@\A)EOJ9N$-R<:"[6#__W 6!M>&
MJQ)>%4^V"/$U@C*^AK:P (ZA2%QHZ58K8+6&DF^__PGO\AN+N8.K@2LLEWQ>
M!4U'F_KW2/:SH6^NF24JWD*L'2SE<ZA<85%GS)"$J<F>*,!;04ZJ<]9H(Q53
M_A$J^8%]NRL=KR/-MAYY]2%)TJP"NMI(HK,E2 XQSSJVUJ@-[B&%C,A=4'Z^
M@N\"1_SN<W>_YVXCY&$K"76PU5[?L;W\=OWCW_LXHI><?GM7RT)?UBXO2LG,
MH$B9:EU%7CO52-!>L:*+LZEY6_?5D#WA[;D#U71P9[GHDG9\%^]U]X.'P7;5
MM6(=H'OJ6=&!QE>X4V^KKBZ:5:P%FB>=C<D"2BBF!M@7<.@R1&FUX!EU#*W/
M" ^ 6P\UJC@T:JVCI2XI-0L@F4I 7F[))0>M+6&QJ=;.MU+6VI;D6P=NDV4F
MRM#Z6.$>.'OH1M&=(I=19DLM=&L8W1+#FQ'^ZP('Z=MLMF#VN98^U62_@PJU
M%A"KIRZ,+'8K#8_-CR96@/4\3*(F2KG+FZU;TBZ:/-< K[;5%2#NT J:@[=W
MVZ>-:E?8G5KH94?FSCS4K -'86A[5L'4]MX(P9,7B<%@3,YP8YJW']P7=58W
M;?;&G'74L2L#^3H,]BI=V$3O9!&0N:,--8I:N<XX2"D:Z26R@JW34%;!=1CV
MS58*7<40WD8;79@W_4$8I'XX>SL83T87%>)LH@2=T7D-2=04/<L9A.P2..8"
M"[)8B<U-FL50GK(9TT#X=SFQ=4_S:1>Q4BL(#_(G''WM)Z+K^[( [;C65QHO
M_J>KO72%L71DX[0<Q]Z:EVY/D.&!:;>#?:_IF'R(S/,<@-D8ZXKLP2EE@3FE
M&8^<L=QZZ3M\IC[<__2PB;J.4MO>ADW;-0XF)%#ZQY.W@PF.: >YSD:Z- .X
M50JC]""3XZ P"8@B%9!H>(C*<Y[F[/@%%V0KO6KW=M;^%#GL4 M+C;'&Y5->
M#0>99B%F^F$\/.OG,,'\,IS5I+5/IXB35\/S+\-!%=&'T9 ,G,FW>JTX"8-<
M#9=I,]>-RZZT?'F3<BV=26.^\Y=GW&IKH[=%9>]BEB9X5)Q[4W0JO99 MHRB
MN/WX%[<>_^XZ^TU*%X(2G"R.6(U42UY,L0E$]B&7VM/,MW;Y'D:U=?3(LC?\
M,AJ.QST6I4[!,K E:QIS[;Q8)W0NA5PJADFGE3+46HQYBF@/P0IMF7$GX*2=
M KHI2W9Q?G%6I^5K_#+"-$L*II_/<"KV07YQ/AQ-^O\S_7SI8'K*Z:R<EQ +
MH5>)&8@R)# !M2?Y2=F\F5@K[$^.<GM1:A>1;\N _8:3GA8INLP=).(%*,,<
MQ-I#.,0@)5,R"]<ZAOT^/$^.1,V$WT%BR\VITU*4LW,GJ1RWTGG0M>ZTLDJ"
M#R(!*JU%/5(4JC5)5L6VJ_3_CFG2B2KVG?C_H.QN%=*7QEO%LX6 -!_(O;)
MDR!!3H+IF LOJO7&MP*L_9\'MZ3#JDO3AFK9Y=9UJ];^*A"["MM_&-Z>8OE;
MJW95ZFRIESU1J!95M3D5B+H6-<[D1T3+/>1@,]EFQGC7ND;9WJCS4(;  3!G
M'75TP)A?0SJE37WT[3:\J^8;*CD=' ?A<P&%V8 SKE[6FF"]9C[,MX'<FBGW
MP#D@:WE3]0V[D7T'/OX[#&,\'9[EM^=?1L.OLQOVJ[A!%((SLOJTQ "*105.
M!@LL<,]5]*+HU@;R/7">'BU:R;Z;%.$O%Q,<S;.5"Y&%)E>_<.=JB&J P*NA
MYK+4C#N=7.OLE250GAX=6LB\BT(1P^D-4JK"?5O/@TY&.+ZBJ0\>O78,3/82
ME(P&?'$1)!-1>TW_2RLU@5^+#\OQ/$52-))^%T5(+T8DWHL1TKC?]/^J/UTO
M7RX7R<F$LE;1D#47$(I2$)AUWEL7N6F=B+H<S=-C12/)=U%X<U@F?X8IL*L?
M7]=<A.%T^*^&X^L=COB9A6 *N&/UF%#1LE88[762>YW(%%>^]=*Q,KBGQYAN
M]+(TZK_Q#?[".-!787Q:Q?0UG-6_AD'^-8S^P$D]0OI48T3IQ75:3'\CSQ>S
MW?A"OT,L3>[W=R6KN>M^%-J9J(.U.M3*9LYPVIND(]LEFY)P<2QO&UR-0KY?
MC,<XJ2$V5T$MMU[]_N;5](7?AH/17&GDZ_-RGJ(PT@(7D::/+I+\.9&AJ%A[
M6"I6FM]U-AW UN8B:91>,*?8:XBO^^-Z2$^(>B*S8!S+9,CJ2)+R%AQ/Y CS
M4+13DMC3O-WJJN#V&$J_<Q;>,3D[T6 '9Q>O,4YN%HE7)(AZ+XTF.S)[.'E*
MR58#J$"00@(FX\@PUB+)UIU:%P)YSA3:7C.=G(#>W5EJ4.,ENJ),=#1H0&;(
MVC$B@O,YTU\Q92TC64/M#T'O0_2<"=105QT<B<S$LVA%9*QVMO,:A+.R'MM)
M\,Y92,9S,MW1.-,ZX7TIF.?,GS8:ZN#,Y.7%F 8X'K\:GL?^8!IB]6HXF-#H
MIV[88-RG]X29W7\96=WC4I=8!<&R5Z"$K@6G::^U$DU@)*446J],&\!\SG3K
M6JL='-3<$M6B:6)9,JP8!"L*[=6<YHK/VD'1N7 9>8G-KP3O1_2<Z=505UW6
M:=A"3K.X'\S%ILP$>%-O.HJU$&5B()F.M+USY4MG54"V!;^KD+W#8>5^]'XH
MX7^KU$K@B=9PA1$T&:6TQ(<RK?L+-I6$)'?-;&=U @ZOJLV>^+)!X9MU]+:G
MJB6K0#P6OME2M1N4+]E$+WNBD)?9&S&M2V=X=:(]1&9K'TL1<D3K16F=WO68
M"]]TS9QUU+&OPC><R<RU8;62'/DL2#Z+\YZ#+MF7(%A.O+/+C4=7^&8MA6Y2
M^&8=;71P_+[XGF#6+T/)D*=5H2P2,I,T>.8T8!&%:Y<]KM;;<.NKG:.]TTA+
M'9RB?L3Q9-1/$\R+,2[^])+[JV#OR/[9!O=^#*-6'!CN68$=;'M;C8'QI&QT
M""'77@.LIL"*HB#+$K(1)3+6NG3@X9'O =/J$+FWCMZZN(@<#O#;[(;KS<4@
M7Z%R*FMGK8%4ZFVZRAF\$!I*T)8E9H+FK</M%R/9O3FU.VW.WS-NKXH.+*O?
M/_TR_(JCP:S"R>VK]$M\4<F")A8H,B&H^@<-/I!5@,+DXJ3+K</P'\+TC$C3
M5#U=N')+2HEE8V5FY"^P( A69@5<';C5V2=ABHRRN<-_6!4I#\,D;Z&?#JZF
MFQ896V4LQZ*5RVC:@B!=U@+<1+N'7K12)&:5*@RT"K0C!!G 6:D@!EZ;0&NT
M*CX[IFY8M/)@B+J.4CL@Z(.60M9(R&I-3ZLXJ,@-!%=/"TO-U+$8-+8^4#T\
M0VY_&E_7L%M'7?MK,1>=S&B3 F.K^<F]@YAT H621>9XSKFSC@8'V6+N0,R^
M]MK;>Q>Z5< >N]"UU/A6K<(V4=?>N]"AU2ZB3&"-KL>$3$*0M@ B"FEK$4RV
MDTO'Q]B%;G?46D=+.^I"QZ_.>KQ2.;( 4J&@1;L$B):6[^ 2MT%8$V1KR_X>
M.(=Q6=U(D2MTH=M$"UW:3K>@B:N[J,P%.MK&>4VG5II !N=K&YEBH_31*]W9
M"G,7SG,CR"9:V-$*<M5!45E6L$B$&"TMHZ$68LY*07$EA)B*9KRS1JB/KX]E
M:X)LHH6E\0J'4YG@MS"J.2%?<1^E".Z\?-^U!^Z7QERQ 9-K=%/4!6-6QDM:
M&KB5,1A4/LO,MRDV< ?(_K,CWEW'Z]>6+Y;17(HIUNPU$R$63!!S+ $Y>GZ0
M&1+OMJTN<'+:^Q1JY=A/DV'ZXQW][_<O'W#4'^:>=HP5JR64F"V)I-"JX#B#
M; /*D*0*]N&^+TL>_MB3CM:ARZU6+RU$W8$)]T!2<.91Q)@L\%1HL(YL2Y]H
M%S("!2:7M BMZTD\[03N3=C3@:XZL/4VR==,J3@OM0;NE0$ER)4.H7!R8H+B
MM)B0^=&ZI-DSS,+=AG-=:[6#&-@-(-^:18$94T(2-(M,O68S&0** CH$9,JI
M+%3K$FI; 3Z2<Q>:[B TY/O+L(]D]??_!_,OI(%WM4]14%(Q'@-$^@F4-;4.
MD R +&FI55+"MJYZ<3^BYTRTAKKJX'KI>W0OOI*'58V$-\-1-3I?G)T-_ZS]
MW^COKTA@_4G%/+,^WP[2J!9,?HVS_^\Y&7TV-!V2Q0*J&%9;$3GZ0P3O<O*J
MN2_4#OV1H3OG0 >E#Q99N;^3S.;G7*9)I6L#$R]I]4Z6A!6Y J=E,$QRX7CK
M?7HU9,^9A1WH[B[#-NXD3E[X/\*H7^%=M5K]F:R%R;?/1)!Q+1I/,R*1:1!.
MR%6_ENKGTS!Y2X[6.[(TZ.?!]'<'X>QCF-#7/N+D8C3H$6CKBR_ 7,V[4%*3
M_"RK%=DBEN13U ^?F'2%[CE2\E"4?9>_=OO\JHQX7D>VN']P/8^=?*O?.O]2
MU3P=6"]*R7Q=QY.<FKLBUS/_  X-UZY4<[=U#<>-@#Y'LNY.LW?IZ ZG5E$(
M6EJ+'$PNHL89:@B,?HI(&X-7'M&& SR)?\2UBK8AZW[T?H"UBNX+%DJ<!V.,
MALQI6BK#:H2&H)VC"$X#*X:[#LL5/>FXT;58LUG<Z#K:VWM,WRI@CW&C+36^
M57#?)NK:.\=D*#;H((!C(7LWA50+;!;0VFCZR+"4.]NA'WO<Z.ZHM8Z6=APW
MFEEMJ>0B"8'7"JVT7@?FV73^UF9L0L1CW.AFBEPC;G0=+>PH;O0J(,V8P)U-
M!$W3'XI;"T$I ]8R5HJ-]9[F&!;8%4$VT4*7*\@]M>.""\R9PH'Y6.KUG8-@
M, #*XM'(XH+J,"/KZ18";616-]%;!]$!JU296P7BL1#HEJK=H)SC)GK94R%0
MQ=&;["V@=1X4XPY<3!JLC,AU-EQWEQ_S" N!=LV<==2QKT*@-=(SZJ#!65>C
M"&CA]\$YX-XY*0B@BJTC/AYO(="U%+I)(=!UM-'01!Z/)KU/Z13S10T7GIWW
M_XJ3TWI/_Q7'DXKU[J>(OX5SG,XDS616*5K@H;::M"@A<D,3RS+A$)U@JU4\
M(R"W&$1_NV'/MAB?IXVT4\TVC%>KN)?ANIR,JR!;QUYZ@'OWH]FM>;1;K0X[
M54G#C6\%A%+$R(QEX&TPH+RK59RS!EEH:34E6RPK!? <(%F6&$2'RI5U--&0
M(R>GE\"N(/VS/SE]^^']Y0:<N"W6*R1 GG;XP!-$Q36-.)E49!16SN4&+(BH
MN><%N[-K6JM@V%Q^#0T80O7+92;CWZ>9C"]^_?G%VT&Z2DB.O*2@&-GX,1&T
MP.NFJ<FVDM%$VE>CLP]J]9X7/ 6MMI)?P[F:L=][AR?A;!9#-;O/0)T%1P59
M*_+90K9 MH\%AP12>.N2E_<LX&-,_WXR_/H3/7JV?M,/-TOW@A<^3[-Q6\DW
MC#>O4&8HKJXP5\"Q@MWW,!-NOW6W]MW6XA\VE%WC"?T]'F]0UQ14852U+1CY
MN\XD$,A*\D1,]/<5LCT$'2XQN[I3X1HB:VLW?1J6R<LP^..ZB$/2BBD%7B-M
M]9*V!U_00A%,Q>28BTH\N*E^_\S=[:/;B7780B9+S9_#*6SQ(DWZ7Z>VWNR>
M[G:1QCV4NE@!SKZ+7ZPKL?ER&#Y:&[,T*F>EG(]1F.IL"4/4D4%O4PYC!6C[
M#\E]=QTDRD,V5A@/,EFR.8L3X'UB@,BB1LV4B9V5<MIG@8P[8.[','WI[X-A
M'./HZRSOX,O%A/YY.$CT6[/TU'"6+LZF/WX<GIV]&8[^).+WA"Y2)\ZA:*MI
ML4)#VQ%9AQ*C$9J,1<_O,Z6WDG!7@WKL<?SKL'[I#<-!,*;+")Y;BU\]?K@S
MF/'WHQE_G)/V95KV+)&!2511VT(BYS6;QLF:$H80O91)Z9Q,=R$=+0>R1^H?
M!N%6N'#;+5MV=*>[RJ"6C.G#Q2B=AC&.:[[N^.UX?%'S=<>?<#*992Z,>R86
MY-9QL%C3)J7F$&)08'0,)A3&6?M>([L>Y''J/":6[2@^:_NU0EO/L\\"=&:Z
M-IK-$%A&8$P&9LD7E*EUH:$=["S[S-5S:)6K%?N=$K*VHT ((6E("GWTGI-4
MC[EZAV>0[E3O!Y.KMZ2EBDK%:>Y3M2 4C<45<))KP)"$$P$QIV/SKBYXL6+S
MKG7T<^BMD%89R[%YUS*:MB!(ESV1-M'NH3.6.>%-K-T-; ED,_$,D?,$05D4
MLF3.8^O:GX?/U V;=QT,4==1:ML[J\45+:[-VZO$HQ0UKW&V)<7:#8KY:J@K
M0*U*RHX):>;RY1=<9:WTJD?>DVLM10X[U$+;V*$E]1LO<0E%AH0(K":CU1*W
MM2J9X@C1(,HL@C?B87;<^XKGR8IV4M]3,F!RWBI4Y-I;6XBP04/@.0 OD6?I
MZ3^BL]R)IYP,N)55WUAO>TH&7 7B,1EP2]5ND-*UB5[VE PH%/?9&0^,TTZJ
MC/5D_3D-5IN4:HO#T+Q6Y6-.!NR:.>NH8U_)@(P[&V-A9($96GB%)ADD+L 3
MYIQMB3GMI-#*HT@&7$NAFR0#KJ.-_?6H+5Z+C(:V:*?(R4PI@]?9@(B,)2<9
MU[JS1C9/O-98(SNHE?8Z*$>_7MV15< >:XVUU/A6!:$V4=?>:XU%%20OP4,V
MQM"<2QR\4@5,1%.LS\5U5SKQL=<:VQVUUM'2CCM,2L]\L"J 98R@H<\0=;20
MA)%",,^,:'V _8A+2:VER#5*2:VCA4<0B+_:M_81D[\>LGV'YV\AQ[E(_2"T
MD5ZG;#T1MO8\KHZBY[D0PZ+#;2+UUT.YW5)VDQH^W[[CYDWOKJ-!E)$\R2!
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MOA8,O""C-'K,BGL>K&[MCJZ*[2D3J1/]M&T\64D^;VL.\O?PKIG?JU8^1F$
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M&2*/"3+A+#R5$"/OU"I\2IO^EO+MW!&XE0J["J[G6A1@+9VMF@R^B<!W613
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M'&)/2('H P/OZ_V,] Z")V-7AEAD#4*.I77X?E=CV6FGQ(/AVKIGP;L@2ML
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MW4B1)$)BMAC(ML9@UPR]X$DI3C/T/J$SS1VB@QG\LYE%!R?YM6BW8 +NI1K
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M0W2%DA)+$+3UD*0+QG-CVN^/QZ.W@UHP'IS:#J%VS$8.3SK^9<6<R#R#\+H
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MF% :T\'<6S><]Q$MM,DU??HEVE9-CVJI/KX,V"P(*QU9I2TPRL52">0!,Q?
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M$G@_M2H2_>ZL^W\HK8:RX.C$<94,QES7<P:%PD(0%  9D71.Y"!:5_KIA^P
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M/:U69O\[E68+*B*&(,*80I)E%.;2[% %PG$4ITF<T=C%?W:Q)&-SJ+V9+8S
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M!QCY'JJLXV^*K8HNV<8#OS^.AP/C?BOZ/G-PR#EV33E^WWZI]A*--VB %AS
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MJ'7FI/:N'>9VTP7%"CZL9D)-)=$XYXI I;2"1,0<<JTDS%(JTSSGG&;<NZI
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M#IE9XP54L)P:MU$'SJ;Q@F(_C\;O]F[L]%$5AN;$O3$"6Z9APX!304F*491
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M112Q),VAC'/3P5)PB(L"0<044B*.)"Z0'^_)43D^'\ X'"?FN+@YR;\/53/
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M=A/!+:OXNK03MR]T(^=9D608<0)YQ!5$,HT@2Q6'>H%/J$2*4+]&ND,I.K4
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M3U&<Y7[GNKVD3VW8W:FHXUZMN#V':;)WVJ5@T1;A6"JFU?+<\C> :]P3!X,
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MG>KU_G0+-N-Z:92TU MBT_WB=-9X9>\4\(>U!0S2S3T<M*$H2J]7:%SNT6
M'I"*AGORE7O#]7[S!\OKQC(JXR*#*$KT5"HVW".T2"!B,4M$5A L]%3*9,P]
M=X;W,KPBZD[2D)/[J@+&\6#UV)P\\YQ?'0/2<TNX'SRC;0B[U>KTWP\^-#_T
M;G!'PFWV@@]-/+D3?.32?E^X?M#:["J_D?5_WR_?+Y_T(+1:E[*:$R)RGA0<
MQ@76DZV8*8C3(H9QCAE3D22%U^ZND]")[MFV&O[H<8#F/,AN<>!ZS,:)"*V>
MX)=6T[^879:.LN&"@Q,F@<+$>5FC!@PGLU^&#K>;O(M)CM(Z:EF+K>G<\.MJ
M)?Y1+A9S%5&"!"-0L,*<PD,*4ED(F,9*)DI*DB;89=+@+'%J4XCZW.SKEN+U
MSH/BU1WE\Y%D$.P&CR;'>5W!+SNM0:NV>W&%(YS.V^WA81UI(ST,O#Y[XWY0
MG=SU=GS,6/O9?E9U=JH];PPUQ_N\EH^T%&^DDNNU%$U)X=VRKC2N59E'D4*1
MS#$D$>80B51 ';PY+")99$0HB54?-HM^VDQT5MBHWE8*5[;N:V6/,O#MVE;:
M]SYVW=-M?:>3P;QPTWEFZY!&?>N/^FC)A6V1 )-/'P0'FY4Z*7'CZ:H/4)?G
ML5Y/ZQ=!7Z\>'IITF\W$59^VFTI';A.DYUBE*4M$ 944"**<4T@R06 2DT+0
M1+&4QCX[$N>$36VOH=:U+H&=-46N8+77MW^GMK.0N\6X4$ .',D:#+_6&-::
MSD!'UW QRP610)'IK*A1XX^+T2^CC-,]_6+);GF1)EQ&.8L@3_)4KXFYA)@7
M"*J(RY3%*BIRK[C1:^D[QFF'1B^_[]]Q47N-\0-_UQ?M]OY\CR^/KOY4QUTN
MG3+FY2<8:/'SJFX9^O6[E)LOTAZG?%-6?+&JMMK9=ZS:K"G?S(L<)1E-&50H
MP1#%>K%#"I1!%C&"4HY2RJ@7]ZR3V*E]JHW6P*H-&KU!1W'P1ZNZ9[,01S>X
M?>SAP1TX% 3!U9^$U0NF4!RJ;D+'I4#U N* P=3O[GYAJF4R+66U(ZW82YG'
M%$LALPCB.,HAHGD&J8Q,$2.5F21)3G'AL^E^7MS4DN?ORJ7V0$D7=CF_7"W5
M[@>+O2&S+E&4V!GC%Z<N^,$M/H5#=^"X]*&+7H=XY\UE]+RCD1LH@:+0!6&C
M1A\WPU]&'<>[^D6;SVM3R++Y\5F_#9N[I>TG\%@?C/JFGVC[=A6%DK&("Y@1
M1?7R)$>0)0S!!,L$<28C510^,R('F5.;#K4JSX!5VD:?G=HS8-3NU3G-!7ZW
M2!,8U*'#S6IYWS1L_/9LWREXPS0/7 )%'!>)HX8=#PA>QAZ?6[TK!N[^]O9.
MHQ>9AS<'#J(L%P2G"D9"1QF4H0+2/"T@3G$A**&YC)W(9HX^?6I!Q6@(C(HV
MJ#CO61^![7R(N!J,@8/!<QPN']AP ,1YP_XZ8$;:G'=\47QVWT_;?7*G_<@M
M8^VJG]:VLX-^YB)_9AQJ:ZU-UO>#_O]OC_4Y\+E(%,X-30J*"8:H(#HT14)/
MA1#+]&3(G"F3KC0IQT5,+4A]L)0FCX:(5VOGSG9Q L"+D2H + .'*Z,A^*3:
M;1H+T&^/#7O$U0"Y,WM<#]18)!V] //BV3B/Q6G*C!/WC<9^<5[O+I'%A2M[
MGHP5_[VM-K;/SK?5%VD4+A?RH]SLJ\J_K5[3ZKN>!SZ50HI7/WZK3 ?O7?EY
M<]BD[&1NN11YHA*3G.(91#)F>@X78Y@4:9ZFA"5%[M5G80@EIQ9E.S8::LYU
M:Z6I%0(+4X>G?VK^SK6=8&O.BY7+]@S*\A[0G87_YGG<=X@WP&W%>FN_#CVK
M?>[2G8% 6_C\C(SYM;$3M(8:QJ)??JN=_!>P/UFSMW>078(A'1+J?/00*HY[
MSGI D _.:P\IZ[J:A[NE>%GQNL]I[L\$XSSE3,H,JBS7\VTE4CV6" Y)H5)*
MB,)<>34"]1,_M5'B2)&V"28F&7E=:86C-]SB^G 8#QRQ6\4MH =8=[9"P!^#
MG+_N!US@T@]'X3<I$/$#YE09B>=3>E?:ZPC[C?[9%*&^DDNIRLU<B"RA+*-0
M<AW+$$Z4*:K',,LB+'""E4#$)Z"=D#.UR&4'F,KPF*G5&OS":BWM26I3K&TG
M0QOZYYDC@5XHNP6J -@-')&:::)6<5?&_DNC9<"3U1=P"%>@?E3*V!7HYTP]
M4F)^]G*_V%"M-_.O\M[,QWZ5J_LU??Q><KIXLWJ@Y7(N2(:)Q+EI=\XAB@B&
M!!<1S"B2,E*(%JE3W=E9*5.+"UT-P1^UCHZ)__-HGH\ P3 :>D;B!8_SA^]D
M_KG/7C^@\\GK?^T_]_//'N5C=S*O_=3=+KZ6Y.KU:J%_L3*+JB?9;6^M)R,?
MM34G?FW9*4UN9[6L+)W+/%<IEXASF!-,())9 ?6\@<&(HJQ(]*(HB;RJ4\.K
M.+40\\RN9[S09IK?_7=].LPV$GQ^4TVZY%G:,8#SW:8UMW7IP!%Q!&]>P9L5
M&O#@/%K!%+P1KU9H@$_S; 67U+<^KSG,:+=^/M/UI_77C2D\MF6 G^7:'DJ:
MIRH79@\:"L64GCRR'&+%"11(IEF"<(Z(U[+23>S40OU.Z_88XB-MJX#-Z<-M
M9?O)UJ<0/0\A.OK!+4*'1W?@J+L'MMG#U3KKUQC46C>EPEKO^LQBR.(]'Z""
MU>\Y"1VYA,\'B,,J/J^[>YY;D%4EY?,.56WI\H^&W+)ZLY7_)>GZG7XSYUR8
M]!<14"0QAHCG#.(H)9"@2!5ZM2MPG/C$+%\%IA:]](M8>!Y1\(7<+3P-">3
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M>6]>IB_RT9!'&GEJM7ZP[]:K'\TOO\D_-Z^T57^?%P07#+,,JH11B&)$H%X
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M::(@06D,A4BH(%G*,^9$"'25%E.;Z[S4= ;H8K'Z!]6O"5"K->#6)K#01LW
M\C)S5D!_G8]IHWEAZ)56AT^D8\4,U': #Q;Y0S<YL)@%](5/I^X1?#)>(^^A
M?./9\_M*3,^U!._[Z!$[AE]I_?.&XM<^K&_+ #T(KM:/J[5]KN$=EZ_-9'#]
MX_5*R#FCE$2TH-I#U)35X1S2**4PIS&A"=>_$DY-]1SE36T8JE4&SW2>63I\
MO9I<@T9S8%3W;29P'O?S@\P : X\G(0 LD>; 2=XKN@V</[Y(S<=<#+VL/>
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M7+C5)O20/;7P8M4W>:F] >"/6E7'A5P?!YP/- /#.G#HZ86H5S^"GMA<T:/
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M<_-FX1$1$"5I;%XS.D\3X=5#?$^ U\M@O :75LO*-[4GS*S*>%:-QKZ][_8
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MYAG4!&&($\H@27@,41YEN:8T(BCU6:3'Q4QMN6Y;.CW5:GHG=1V#TG''=S%
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MEB]JM6UG'$MNBT)R2#BV+3\2"5F<2HB8UE'$1)92IR(Y!R-/C\R,<B[=C,\
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MR)@:(]3)/NNJK?(WM2B6*_!YN?9-?3@&IALU7 C1P)10G[XTU0D'K5+8@4/
M(J5O6I6PP\1C14K#5"'<MFCX3:T?EK)NU& ]C<_/ED1N]3?%UN4')AZ^V#9;
M_[:<R_)V<?>@?EFRE9QAK6(6&S(@9D\'L6 *LH1S*#.LB<01Q[$3(URFQM1(
MHU;:.OZE5=NSU4J_F>BFD_'P'9AQFM8LM1E@9\<5:$"_U:"R!5AC0&4-J,P!
MMPM@# *51:-,B6=WG,&G9MSN.8--D7^SG8N0/=.,I]_8XS;KN<C^@V8^EXW6
MHY_%\VIEQ'PL2L'F-A3UPT*^MPE1/,]EPE &::)2B),\@IRK"&:11(HD6<QS
MIPN#+B%3>[4T>H):T3J@VJ@*WCLGK'5"VOT6"074P.^(7ACY]<0X T*_]ABG
M!AVO4\89LUXUS3CW["7%\D_$I?^^D$;<\GFQ5O+#=V$>O7ZT?YLIIE&&#1,@
MF=N"BDJ:+6H20XJ2/">4,**B'@'BO91Q6@CC1X=;6_X5%(]/SS;D>Y/HVJ?\
MON_DN&UTA\-Z.CE*;3- ;0>H#0E=SK\GCD$+_?OJ\ 8M 'K"=+PY0-_!O#?L
MKUN4M$ZH?F/?B\?GQR_*?*>-FW^O;O67U5(^B_6M_L3*IDZ7DM_87'U9%4)=
M+^2NFDV59)[&)!.4)=#\/X?8MB0G#)O]?8)U1+.<9*EKE:T!U9R:5_9;L; 6
M@:>M27;S+UKM%<&3-02L5\7]O4="Z)!3??;$8"(3.,(99JO!4G6=NS'T"C2F
M@IVM=OO:6&M_M/:"C<' 6@PJDX&Q&;2*;756#QASVIU/)28R_2.=6DSA:^!S
MLC'"[)P\^1A2]E@G(R/@USHY&4-:SPA,910S;RIEN]1?O[!B7A7X7;8ZEC:I
M(N^+N=T[S'(J*<$1ASS1D=EL:04)D@SRF&+*HAPQOX0.;PVF]O8W!H"YT?T*
MR%I!SXA.[QEPVU$-BNO +V4+::T\^,FJ_S/8&F"3FMN=DQL;KL#[,^#[1Y+V
M!3!4O*FW_'&C4OO"<Q"[VGN@?I3W-U56Q8IM.H2@N=(YY5!K)6R""8>$)AE,
M(YDPD2J4$Z^0AM;84Z.I1K5>J21MR-S8IR<0 _.*(P;>5''$VD DT!YYU.5]
MQ*3]A7OLD9[QB&8#O5:?BA<E;XP;M+BWOM%U6:IU^:E8J)NU>BQG,A&YBI(<
M9G&&(=:9@$SD&NI4,IW0.*+$JRF B]"I+>):9U@I#79:@UIM\(=5'%2:>ZYP
MIQEP6_JA<1V8$T) ZA_>Z(%1J#A'%Y'C!CQZ@' 0^>CSV7ZD](&M%H;>2K,Y
MJZIT;-QOQ83@6D2051GMB::0$2K,!HB+.,H$DH+Y\- ).5.CGLTVQYYRUB6%
MMAL>\%.Q ,^EW/W3SW[L<PKJ!".%6"IA%!$-<6IVG<06#\!292D7J::8^Y4\
M#P#V.)7.#^$&P^/M1O !,!R8TS<:V@.[NM32 /O#,S $HNU34D9EZC.F[I/S
MN<?[\?$^SYL5\N&[F#_;2DJ_+I?RSV(^G^4BT3C.)!3(=HYBMC\"9PD4.F8J
M(UJBR(N<781.C:E;3@RKE+ZR9>#\&,();#>Z" WAP-QQX )> <O%/VUU!ANE
M3Y.N-Y?X8!2(6)Q$CLHR/B#L4X[79X.6\K?%F>]6;"$>5*MWD, L4TD&%=.V
MF$$DC7N(4ICF5(A<4H$B%: H_S'94V.C1C\0 PC^'Y1&.Z<E2(7]H_"[$=-
MH [,3V?;E&X =VJ'%:IP?1=HPY:@/RIY"L7DNR!Q+ O?.<3(#4FJ/YHCO[KS
M%9HE9LN+H]QL@(4R^S,E""0LCF&64)V11"G,\E%ZCQQ1;FH\^!M;_4.MFW[2
MNYJ[X*4YDWZJU!ZIZ\BQR;R(- >?HA%9M6<OD>H_8'/%\*5[.L=K&-*!^UOW
M!CFFVA28^R)0@W7\Z)+1D_NW/:*K6]5??KR;FPWB+B>92!UE4<WDF?%:.8(L
MIF8'+?(XPFF24N+GM7;+FQI#;]2UP9N5PG;!5RI[LO(9F!V)-AQX0W/G2=S
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MR8]9DM@N51&!++45E-(DAS3'%,:&3C,<941*Y+5I[J_+U#AUJR:86SW;UZ*
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M52M6+]EX]C5,9Y6S5XOE!W*I_CI?DA<V_2>157LF+[85]Q>2O>%CRX+11H;
M6*W 0.MK5UL!S%HG$S,BLN8]RMN1/^X3]\'0.I:"^PVB[A^7>VB<M->G/LG
MWP&CG<>-9G71>)&"ARQ$G;=&WJ6OHUFU=A34\Y*U:QW^/.G8W\OTPZOI?+HF
MQ^0KWEKVQA9B6C/G<@2GL?:.BXFVLE3 BTIHR?<VL;5,#B#S1QH _!B4W9U
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M\^M%TTO.7:B#<\"0^,A;-N1?*(K:.982G!%H0_->UWM3-VXW@:<HCAE&41U
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M.=.\_G5W\GIY26V+D&_K^0915]](O&7LM_ );[;YV:)880&R8*5NBB![%L)
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M4$_8.%29\\$DVX&#J=/TZ*=]JJ*J"W;6!J2$%#:24 I;U]+1[YS'#-PX)IS
M7%+KH^@Q.L8?LM[R,#I:TAVB96M.7%&Z)T,"Z>NR]I0E>)4B&%%"QE!2-JU?
MTA^G9%QW<[R&7X#, >+N #1WO&9E9.LGO<F9A2@A%1[)3W(%(?L,UEK%E"V^
MV-:)WZ.$] 690S3\<*O]T>+N8N; G0-VRX)D2A,/'+RO.ZJ#971>8P3!E6;,
M./2F=>OM-T2,>R0-@);CQ#QNH'O_A-[@?EE54?VN5]$[) ZDMW5^D+?@$DI@
MEA>')HABU(L1[G.?,/[&C!;124LQ]HF&K9$8H7,LOC8A&1).<(X KC*%Z5Z'
ME)U.[N57I><_8YRCI*D&7T;% >+L(1VNI+_%Q72>W\SPQM-)Y[DE;QE%G2&:
MDP1'&H=@9;'"VQ*L>!$23_[X[M!PB.8>YK['BK$O*+S_]WS+@XX)%;,1)-;Q
MV25;"$%Q,%Y[B0I9#FQO*'S]\>-$#2>#PF%B[ P*M1QHRX6KHP<Y*Q!+CIM5
MKDY+ UG5\7#U B>^W"7\S >,$SF<#@X'BK*#5/4?X>IZK8CU(+?I_UQO<OB0
ME92EM@N%2!XN,>(B> 2TKC!+YZMO/ISV<4K&+>=K?2/60-I=8F9K3J@EYZ[.
M]<N%U>V&L:YDR! HZO)8E)6L]2WJ4[2,>\G10L\O0N< H7< GE_#XE^X>O7G
MGXMY2!^_Y6KK1E,.&+23H'R=#2@HFG?!&?*EP2"+4AG5NH!S-\IZ ]8A*)@/
MKI(>@(:AUE]4Q_UZ]N?U[?TT^6TGK";">2)1V42NW*$%;600VD7I97-H/4'+
MN-6_K4^W)A+O%#DWHW(IX;."G+<-2.*)]9F394?!GA5*^Z"5:OWN\S0UX[JB
M-MK> 4('B+Y#$/U_U_,5YK>+:;KQIY1S))VYK*/>-?E332Y;6PF,EV)3C$$T
M[U%XD:C^('6(]E\ U7&JZ !;]QWW+U]'#ADGO/"4<;+B$B@>R 9+W1-DB^<:
MUV\9@Y9(_;+7#.K!.@J&K:H[3-[=P>:GD.HHA^O9:D(FY;)"!H+2D_IB'\BX
M8H#D>' 4Y]6+GD%Q<TM+3^53!RKZ6? <*/7NT/-Z1C\9EZMW886_K^H0X+>X
M2%57'W 2@M4Q\@3H:M<65S4"\!ZR%R7*R .:84LUGZ.NIQJK(1#63#,]/6[^
M&OZ:?KK^=(^W/S%-P]7=+]UAM-@2C':"LN! \A2%@R,"(?#L,3"'.3Z8%/WB
MX^>^-/3T7'X<T$ZKCNY\W9WZHGK3O_PXO[IC4V_*[ZMY^M<ZG'R_F'[X0/$D
M"IVRB<2N3 *4YEB7[=2N,:L%ES)&W3JT/Y+DGN[9A_"*P^KP+"#[?A'J_- ?
MPI?E),@<+>I:Z%17_GAAP?O$B<W";.0VNM1ZD/Y>!/9T,78J.!ZJG[, 'WUM
MB>FZ]ES>X9-/4MT Q$UEE-=2"D5IF=$:LC+,!BN3E*T?&@\FMJ>D]E2@;*&W
MG@+).SQN@YB[I\#;Q3Q?I]6;\DN@$ ;_G"\H?*XKZ=<GPZM9OGWYKP'.1!6N
M//,,T&"M,48+,2D&6A=;35BK^'(1S8 $CMM:/V@(.IXB>_:W]]B:SOD$B0LF
MR$Z%X0&4C!3%Z&A!ZA#H'$%$WWIGQ,[$[81.=P[H'%8OYP&XM67Q"8M,\"(#
M,+(H8LQG\$IGLJG(<D8?.6N]%'%GXG8"G+\PP!V@E^X ]U.8+FI= DY,4JX(
M@5"2KR\U)*S(M <;3?'>V5)RZQ6(3Y"RVTTU.U\T'2;TGH*]AP]_/^!L_FDZ
MJ_]\4G<]:30>I#>6Y*05Q(QD'G3B2^M0!/W"D)I]/FXWL)S%N\9@4N[ Z]R?
M=/\3,3%+E/)\/U^NEA.&D3DF%$BLU7N2.8@Z^UH$E6*)7!8<=O_ ?7IV@]19
M/60T$W\'4'KZ4>;'4C#5A/K._;ASA5/$ET$X05)#$IWWMBY%QN1SDB&5(89"
M[4S@;F [B\>,X1740Y_'UV[H_\;\ 7]?+:;_VN2^$V.LDAPSD' 4*)<M.*L#
M91XH;+9<<[MKX\^3'[(;7,[B.:&Q1#O$QD>2Z9J1MW2(3^_>HTQ83D997N^=
MD8[O4 *0#13@Q@O4$5-X6-"_*U:>_M#=L',6=_\#2[R#4^Z6E4DP4J>D&1A?
MZNI,6<< *023"^?664->LO$1=OOINX'FK.[F#Q3MN [F5?X_U\M5%<+R_?Q5
MSM.J@G#U-DSSZ]GWX<_I*ES]^#_7T]67[^>?_IS/Z!O?E,=L9#D11>DL*<OT
M*KFZWE!"P"" /*HHA<P =[A;;T?/;@@[E[OTD?34[_JORM!75I?SN[S>'7QV
MS$#;W7]\PTFW!_(T[ A<$:,MTC&PP1!D/$L$6HJ:5.3*)E-,%D,,_CS-"%RM
M'$_>* @ZU^WB+H,OI8!(*>BB@E=ZV!?M?D?@[J/W74;@[B/J#H*E1Z>E,<6X
MSE@@,%6'E5@%7@@%FI>8C0\R\]9AT\&3!T\Z!G<OY>XR>7 ?27>(EIO15YA*
M"L9#]+80%XJ#KXL\D^;"\V1-9*UO(<]F\N!>&MYQ\N >XNX -(^/P@N<E>B8
M@ZPW8RZ("<<])*9CX8JYP%L?26<T>7 ?#>\T>7 ?<7> F4?F27LK@A0F@,Y%
M@4HI0^0Q02:^"D\EQ,@'C6'Z'(9[S)%TI)2[P\F=V=+.96LHS0/+;:@Y*(>0
M)$FI",F+X%;Q_]C)['OI>-?)[/L(O)L+YR?GAY,,A/24$&A9URLI#!!+09!,
MA)*\4"AV'3YUCI/9]U+F?I/9]Y%L=P[F]HZ+CF>53"9G*SF%=2$1&Q3- 5/<
M9F6B3&78;II?]FIK/ND$U'9'TF'R[@XV=QIL'1H>B^3 40E04@AP-B-8F07F
M%$MJOF'WO-J:]U+TKFW-^TB]B[G;/VP_>%-O@NMJD[J0+:!*EE%.$.D(!^4I
MFW1*9D#,3B5$ZT+[:0J/DM)3)-P*/<?+?'_P^ UX9OBAMD6_;WI5\WZ;64Y,
M5MYS74!:GL@C,X2 (D+,@D) KZ-.IC%L[GY^3T=4&ZP<+-U^MR3^@F&)R^/W
M)#[Q<QJ]'^U"9:.'HLU'W:[9-,P$SPI8H3)I.9."94D@"J52I*<24NN([SX%
M1WL$7"X1US_S!URFQ?3/]42]=<AF;-T^D0V$S&W=:<P@JESJ&! N"\$ZN-8M
M.<^0,_*=W.%Z_\9--!+YB!'M<K&:O NS#YO;[)QR=,D90+6YF$3R<LP!#UB;
MA#2%7#OU:--/O8,1^M,M/NY]X-A(:*2^^;&R[ $ -X/FB[*.60Y)2U$K"VMU
MAU<@@N(F<^FUV^FA?!<(C'E)<H2R'JK[ ,F-K/!?I[/:OKHEW/J4@Y(*,-BZ
M!CIFB+XP8%D'&Z,3FNUTF?J"RN]]Z,A*/T1E\Q;R&UOQF[[E+>%TN+'@)0/I
MZHB<1#)PZ!-(4U3F+-:%$RT4?_=#QTDLFRG^8/EU<&OU^'EWFS&Q%!U'2GV3
M"%C/O/I 23[1:H^<U[VNK'D:^3Q)(V\":QP?#*&';F#UYD^L.=OLPYJOFCRO
MJS<W03:2E$SV#K(MQ)&S!KP@#UF#;Q58C$FV?MQ]F:H>@\\#0? HP)III .,
MW>?EQ[_^Q-D2)VBX-I(%X#9J\K^A+C<P&82P7H<BI2NM1V,_2DB/;JH-DHZ7
M>[_UUYN+@/6OKV=EOOBT_IE'7HP]]>.:WH_M1/- UV3,)>UK2VR])%%<"8@V
M)O!!^&2EDUXTKQUM>DUV']'_Q.F'CRO,KS[35S\0?.K[^%V7R2>ZH/=>1 H5
M,Z/44%-T7ZLK4O")N2"M$:U+3?:E<>R3[&"$/.]N&BNGNV/L 7^U>KT^9]Z9
M8SK102,Q9( Y*VJGBX=0'Z=\X%D*AY9S=4KP/4+CV(??:<!WK')Z/P9_3Q\Q
M7U_AO-R*81KB]&JZ^O)K6%TOIJOI$<U(AWQ(TR/S"/Z&.4@#NL@I3@(M*8M4
M*$2=3!Q!1.O1RV1T:3T ?XCWIOM&\U6D;\.7=:??QF>3"ZBS-98I7/UO#(N)
MCSIDK1.P$(AW:2GO\$J!R%)G56J#8?NWMD.I[>IPW0<UNV2% RBL@V-V)TY_
MN,;?R+3?_QNO/N.OE!=_7$[J_%L?7 (M9%VMNO;HW$&0B1O#?0F^=9?@H;1V
M=>P.#LMCE75&H*P&]_[?\XG,-J=,G'&VWFD5%,2"!5+A(3F)$LLP;_8[DSAN
MW<\($#Q$->>&O+I7>))XB%+F#"$Q#8HQ#H$%!SQR[I1*);)3W-<^2^2XZP/&
M0M_>ZCDS_/TTOUY,2M:2!XHO9.2L#@ZUX+(G1Z\YTRP5&?)8Q_ -C>-N"Q@)
M?7LK9]Q.H%U9>U7HX[[R9U0D\TD6HC,%E$B&8ETD7^]0Y&R<USL,@3GHH\<=
M]M\ 4R>1^1DYM(DWP7)N"T@5R59X]+45SY*M6"<5)DJDVM^6[T;;N'/Z1W!@
M>RFC61WW0"#[8Y:W%Y*8?_PKT;?>;/@SN1CO5=VVAB3)&""2%"&Q+(I6@9O4
M^K7B($+''<1_*O@U45,_32=/<$G<.!-EW<PBZ^H@JSTXE"3)$(/R3GH^\#O\
M5U+&';??$%8M1-VPU:V'5X?)@YQFH'>'"1_QY>$ACU_?'O[K<%%_/__T:;H9
MO!?66V@J"3A+Q[SG[/ S&PEQ7^H;O=;<^=A7#S_VVRECH?""CCLPK$A0#A/X
M(FI6KE(=GVJM:?U,NQ>!1SM^4LOBSB=N:B"]]XREG(!^L12U.XK?E>>U&SS1
M;U00H76]Z*.$C/M",QQ2OCD3CM;"R-7GOY"K^[!6S/?D&=>-%W1$FN2\A> M
MG6*N&*"P*$$J(04>K&5AI]#AA1+T;S]Y7- T4.6\F5R[0L6=,5DQ.^<+Q<=,
MU$T>C&4(3E#4P[.QRC$F]$[^92]LC#UMKH4^GX3&@<(=]QKO_;^GL]_)>\[R
M=]/YDOSJC!(I<K5_S*;K?5.K+V_*/\/R([G=U7SVC^7/VTCBO]>1Q.M9VG9K
M))58D,6"K:L45+VS="IZ\);K(A7RN,-D^4;$](*M0P$Q'U4['5P!/G3@O]R.
MQY:>Q6!T3>@],2+I=XE^T5Q%],*PI%OO57F2F'&+!-H=<FVEW@%\?B:+NPT5
MO[P-JW7\>'6%'S!??7D]*XOZ5_F//^>SWZ[7!N(C)?ZYCG5#C:"B8>!=$H""
M(DICF&38.L?8G\J^HJH#X3$_J:[ZK0RMDIS/UFOJC[HH>/ S&EX,/$==HXN
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M*37?0/0M%2-7YK51[[RIK'M R_S3I_ELS<=W-T_#B7E>-\VG:!0HD\C%!HG
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M?23_>(>=P*+R7&C@#.LN7^+$):U!>_H+"O"<2"]/I-GED\:M'&T$A]82[>"
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MBH4E%!N14DKZQ1EFH&0C@Q%"V^;U"L=1?+3C;;9.*6HA-8\<G)624HN@P)>
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M,2YH=&U02P$"% ,4    "  (B*E6Y:4*0T (   U*   &0
M@ %\"   9V@M,#,S,3(P,C-X,3!Q>&5X,S$R+FAT;5!+ 0(4 Q0    (  B(
MJ58@6RI+2 @  )TH   9              "  ?,0  !G:"TP,S,Q,C R,W@Q
M,'%X97@S,3,N:'1M4$L! A0#%     @ "(BI5O/MC0B7!0  $A<  !D
M         ( !<AD  &=H+3 S,S$R,#(S>#$P<7AE>#,R,2YH=&U02P$"% ,4
M    "  (B*E6.@;<"Y8%   4%P  &0              @ % 'P  9V@M,#,S
M,3(P,C-X,3!Q>&5X,S(R+FAT;5!+ 0(4 Q0    (  B(J58(UK#YGP4  #T7
M   9              "  0TE  !G:"TP,S,Q,C R,W@Q,'%X97@S,C,N:'1M
M4$L! A0#%     @ "(BI5C>5NU#X- (  JT8  \              ( !XRH
M &=H+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    (  B(J597H,.0;Q(  ,C6   /
M              "  0A@ @!G:"TR,#(S,#,S,2YX<V102P$"% ,4    "  (
MB*E6:FLGH,(B  #%7P$ $P              @ &D<@( 9V@M,C R,S S,S%?
M8V%L+GAM;%!+ 0(4 Q0    (  B(J58OAOH0@&D  &(7!0 3
M  "  9>5 @!G:"TR,#(S,#,S,5]D968N>&UL4$L! A0#%     @ "(BI5C($
M2EM0" $ ORH+ !,              ( !2/\" &=H+3(P,C,P,S,Q7VQA8BYX
M;6Q02P$"% ,4    "  (B*E6ZJWR04^D  !\I@< $P              @ ')
L!P0 9V@M,C R,S S,S%?<')E+GAM;%!+!08     #  , "@#  !)K 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
